true
0001419051
POS AM
P1Y
0001419051
2023-01-01
2023-09-30
0001419051
dei:BusinessContactMember
2023-01-01
2023-09-30
0001419051
2023-09-30
0001419051
2022-12-31
0001419051
us-gaap:NonrelatedPartyMember
2023-09-30
0001419051
us-gaap:NonrelatedPartyMember
2022-12-31
0001419051
us-gaap:RelatedPartyMember
2023-09-30
0001419051
us-gaap:RelatedPartyMember
2022-12-31
0001419051
2021-12-31
0001419051
us-gaap:NonrelatedPartyMember
2021-12-31
0001419051
us-gaap:RelatedPartyMember
2021-12-31
0001419051
2023-07-01
2023-09-30
0001419051
2022-07-01
2022-09-30
0001419051
2022-01-01
2022-09-30
0001419051
2022-01-01
2022-12-31
0001419051
2021-01-01
2021-12-31
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001419051
us-gaap:CommonStockMember
2021-12-31
0001419051
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001419051
TSOI:SharesToBeIssuedMember
2021-12-31
0001419051
TSOI:SubscriptionReceivableMember
2021-12-31
0001419051
us-gaap:RetainedEarningsMember
2021-12-31
0001419051
us-gaap:NoncontrollingInterestMember
2021-12-31
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-06-30
0001419051
us-gaap:CommonStockMember
2022-06-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001419051
TSOI:SharesToBeIssuedMember
2022-06-30
0001419051
TSOI:SubscriptionReceivableMember
2022-06-30
0001419051
us-gaap:RetainedEarningsMember
2022-06-30
0001419051
us-gaap:NoncontrollingInterestMember
2022-06-30
0001419051
2022-06-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-12-31
0001419051
us-gaap:CommonStockMember
2022-12-31
0001419051
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001419051
TSOI:SharesToBeIssuedMember
2022-12-31
0001419051
TSOI:SubscriptionReceivableMember
2022-12-31
0001419051
us-gaap:RetainedEarningsMember
2022-12-31
0001419051
us-gaap:NoncontrollingInterestMember
2022-12-31
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-06-30
0001419051
us-gaap:CommonStockMember
2023-06-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001419051
TSOI:SharesToBeIssuedMember
2023-06-30
0001419051
TSOI:SubscriptionReceivableMember
2023-06-30
0001419051
us-gaap:RetainedEarningsMember
2023-06-30
0001419051
us-gaap:NoncontrollingInterestMember
2023-06-30
0001419051
2023-06-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2020-12-31
0001419051
us-gaap:CommonStockMember
2020-12-31
0001419051
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001419051
TSOI:SharesToBeIssuedMember
2020-12-31
0001419051
TSOI:SubscriptionReceivableMember
2020-12-31
0001419051
us-gaap:RetainedEarningsMember
2020-12-31
0001419051
2020-12-31
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-01-01
2022-09-30
0001419051
us-gaap:CommonStockMember
2022-01-01
2022-09-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-09-30
0001419051
TSOI:SharesToBeIssuedMember
2022-01-01
2022-09-30
0001419051
TSOI:SubscriptionReceivableMember
2022-01-01
2022-09-30
0001419051
us-gaap:RetainedEarningsMember
2022-01-01
2022-09-30
0001419051
us-gaap:NoncontrollingInterestMember
2022-01-01
2022-09-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-07-01
2022-09-30
0001419051
us-gaap:CommonStockMember
2022-07-01
2022-09-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2022-07-01
2022-09-30
0001419051
TSOI:SharesToBeIssuedMember
2022-07-01
2022-09-30
0001419051
TSOI:SubscriptionReceivableMember
2022-07-01
2022-09-30
0001419051
us-gaap:RetainedEarningsMember
2022-07-01
2022-09-30
0001419051
us-gaap:NoncontrollingInterestMember
2022-07-01
2022-09-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-01-01
2023-09-30
0001419051
us-gaap:CommonStockMember
2023-01-01
2023-09-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-09-30
0001419051
TSOI:SharesToBeIssuedMember
2023-01-01
2023-09-30
0001419051
TSOI:SubscriptionReceivableMember
2023-01-01
2023-09-30
0001419051
us-gaap:RetainedEarningsMember
2023-01-01
2023-09-30
0001419051
us-gaap:NoncontrollingInterestMember
2023-01-01
2023-09-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-07-01
2023-09-30
0001419051
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001419051
TSOI:SharesToBeIssuedMember
2023-07-01
2023-09-30
0001419051
TSOI:SubscriptionReceivableMember
2023-07-01
2023-09-30
0001419051
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001419051
us-gaap:NoncontrollingInterestMember
2023-07-01
2023-09-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2021-01-01
2021-12-31
0001419051
us-gaap:CommonStockMember
2021-01-01
2021-12-31
0001419051
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-12-31
0001419051
TSOI:SharesToBeIssuedMember
2021-01-01
2021-12-31
0001419051
TSOI:SubscriptionReceivableMember
2021-01-01
2021-12-31
0001419051
us-gaap:RetainedEarningsMember
2021-01-01
2021-12-31
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-01-01
2022-12-31
0001419051
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001419051
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0001419051
TSOI:SharesToBeIssuedMember
2022-01-01
2022-12-31
0001419051
TSOI:SubscriptionReceivableMember
2022-01-01
2022-12-31
0001419051
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2022-09-30
0001419051
us-gaap:CommonStockMember
2022-09-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2022-09-30
0001419051
TSOI:SharesToBeIssuedMember
2022-09-30
0001419051
TSOI:SubscriptionReceivableMember
2022-09-30
0001419051
us-gaap:RetainedEarningsMember
2022-09-30
0001419051
us-gaap:NoncontrollingInterestMember
2022-09-30
0001419051
2022-09-30
0001419051
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2023-09-30
0001419051
us-gaap:CommonStockMember
2023-09-30
0001419051
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001419051
TSOI:SharesToBeIssuedMember
2023-09-30
0001419051
TSOI:SubscriptionReceivableMember
2023-09-30
0001419051
us-gaap:RetainedEarningsMember
2023-09-30
0001419051
us-gaap:NoncontrollingInterestMember
2023-09-30
0001419051
2007-08-06
2023-09-30
0001419051
2021-08-03
2021-08-04
0001419051
TSOI:ResNovaBioIncMember
2023-09-30
0001419051
srt:MaximumMember
2022-12-31
0001419051
us-gaap:LandMember
2023-09-30
0001419051
us-gaap:LandMember
2022-12-31
0001419051
us-gaap:VehiclesMember
2023-09-30
0001419051
us-gaap:VehiclesMember
2022-12-31
0001419051
us-gaap:ComputerEquipmentMember
2023-09-30
0001419051
us-gaap:ComputerEquipmentMember
2022-12-31
0001419051
TSOI:OfficeFurnitureAndEquipmentMember
2023-09-30
0001419051
TSOI:OfficeFurnitureAndEquipmentMember
2022-12-31
0001419051
TSOI:ShippingAndOtherEquipmentMember
2023-09-30
0001419051
TSOI:ShippingAndOtherEquipmentMember
2022-12-31
0001419051
us-gaap:LandMember
2021-12-31
0001419051
us-gaap:VehiclesMember
2021-12-31
0001419051
us-gaap:ComputerEquipmentMember
2021-12-31
0001419051
TSOI:OfficeFurnitureAndEquipmentMember
2021-12-31
0001419051
TSOI:ShippingAndOtherEquipmentMember
2021-12-31
0001419051
TSOI:ExclusivePatentLicenseAgreementMember
TSOI:ConvertiblePromissoryNoteMember
2022-02-21
2022-02-23
0001419051
TSOI:ExclusivePatentLicenseAgreementMember
TSOI:ConvertiblePromissoryNoteMember
2022-02-23
0001419051
TSOI:AssetsTransferAndLicenseAgreementMember
2022-03-24
2022-03-25
0001419051
TSOI:AssetsTransferAndLicenseAgreementMember
TSOI:InitialPaymentMember
2022-03-24
2022-03-25
0001419051
TSOI:AssetsTransferAndLicenseAgreementMember
TSOI:SecondPaymentMember
2022-03-24
2022-03-25
0001419051
TSOI:OfficersAndDirectorsMember
2023-09-30
0001419051
TSOI:OfficersAndDirectorsMember
2022-12-31
0001419051
TSOI:OfficersAndDirectorsMember
2023-01-01
2023-09-30
0001419051
TSOI:OfficersAndDirectorsMember
2022-01-01
2022-09-30
0001419051
TSOI:ConvertiblePromissoryNoteMember
2023-09-30
0001419051
TSOI:ConvertiblePromissoryNoteMember
2023-01-01
2023-09-30
0001419051
us-gaap:DerivativeMember
2023-01-01
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputSharePriceMember
srt:MinimumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputSharePriceMember
srt:MaximumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputExpectedDividendRateMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2023-09-30
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputExpectedTermMember
2023-01-01
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
2023-01-01
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
srt:MinimumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
srt:MaximumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedDividendRateMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2023-01-01
2023-09-30
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2023-01-01
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
2023-01-01
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExercisePriceMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedDividendRateMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2023-01-01
2023-09-30
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2023-01-01
2023-09-30
0001419051
TSOI:ConvertiblePromissoryNoteMember
2023-01-01
2023-09-30
0001419051
TSOI:ConvertiblePromissoryNoteMember
2022-01-01
2022-09-30
0001419051
TSOI:ConvertiblePromissoryNoteMember
2023-09-30
0001419051
TSOI:ConvertiblePromissoryNoteMember
2022-12-31
0001419051
TSOI:ConvertiblePromissoryNoteMember
2022-01-01
2022-12-31
0001419051
TSOI:ConvertiblePromissoryNoteMember
2021-12-31
0001419051
TSOI:ConvertiblePromissoryNoteMember
2021-01-01
2021-12-31
0001419051
TSOI:ConvertiblePromissoryNoteMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:ConvertiblePromissoryNoteMember
srt:MaximumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
2022-01-01
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputSharePriceMember
srt:MinimumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputSharePriceMember
srt:MaximumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputExpectedTermMember
2022-01-01
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
2022-01-01
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
srt:MinimumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
srt:MaximumMember
2022-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:ConvertibleNotesPayableMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2022-01-01
2022-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2022-01-01
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
2022-01-01
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExercisePriceMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedDividendRateMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2022-01-01
2022-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2022-01-01
2022-12-31
0001419051
us-gaap:DerivativeMember
2021-01-01
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputSharePriceMember
srt:MinimumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputSharePriceMember
srt:MaximumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputExpectedDividendRateMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2021-12-31
0001419051
us-gaap:DerivativeMember
us-gaap:MeasurementInputExpectedTermMember
2021-01-01
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
2021-01-01
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
srt:MaximumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedDividendRateMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:MaximumMember
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2021-01-01
2021-12-31
0001419051
TSOI:ConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2021-01-01
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
2021-01-01
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputConversionPriceMember
srt:MaximumMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputSharePriceMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedDividendRateMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MinimumMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputPriceVolatilityMember
srt:MaximumMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MinimumMember
2021-01-01
2021-12-31
0001419051
TSOI:RemainingConvertibleNotesMember
us-gaap:MeasurementInputExpectedTermMember
srt:MaximumMember
2021-01-01
2021-12-31
0001419051
us-gaap:ConvertibleNotesPayableMember
2022-01-01
2022-12-31
0001419051
us-gaap:ConvertibleNotesPayableMember
2021-01-01
2021-12-31
0001419051
us-gaap:ConvertibleNotesPayableMember
2022-12-31
0001419051
us-gaap:PrivatePlacementMember
2022-01-01
2022-12-31
0001419051
TSOI:ConsultingServicesMember
2022-01-01
2022-12-31
0001419051
TSOI:ConsultingServicesMember
2023-01-03
2023-01-03
0001419051
TSOI:SalariesMember
2022-01-01
2022-12-31
0001419051
us-gaap:LicenseMember
2022-01-01
2022-12-31
0001419051
TSOI:PrepaidFeesMember
2022-01-01
2022-12-31
0001419051
us-gaap:ConvertibleNotesPayableMember
2023-01-03
2023-01-03
0001419051
us-gaap:PrivatePlacementMember
2023-01-01
2023-09-30
0001419051
TSOI:ConsultingServicesMember
2023-01-01
2023-09-30
0001419051
TSOI:SalariesMember
2023-01-01
2023-09-30
0001419051
us-gaap:ConvertibleNotesPayableMember
2023-01-01
2023-09-30
0001419051
TSOI:LandDevelopmentMember
2023-01-01
2023-09-30
0001419051
TSOI:LandDevelopmentMember
2023-01-01
2023-09-30
0001419051
2022-08-04
2022-08-04
0001419051
2022-08-09
0001419051
us-gaap:PrivatePlacementMember
2021-01-01
2021-12-31
0001419051
TSOI:ConsultingServicesMember
2021-01-01
2021-12-31
0001419051
TSOI:SalariesMember
2021-01-01
2021-12-31
0001419051
TSOI:LandDevelopmentMember
2021-01-01
2021-12-31
0001419051
TSOI:ConsultingServicesMember
us-gaap:SubsequentEventMember
2023-01-03
2023-01-03
0001419051
us-gaap:ConvertibleNotesPayableMember
us-gaap:SubsequentEventMember
2023-01-03
2023-01-03
0001419051
us-gaap:SubsequentEventMember
TSOI:ConsultingServicesMember
2023-10-02
2023-10-02
0001419051
us-gaap:SubsequentEventMember
us-gaap:PrivatePlacementMember
2023-10-05
2023-10-05
0001419051
srt:MinimumMember
2023-10-13
0001419051
srt:MaximumMember
2023-10-13
0001419051
2023-10-13
0001419051
us-gaap:SubsequentEventMember
us-gaap:ConvertibleNotesPayableMember
2023-10-13
2023-10-13
0001419051
us-gaap:SubsequentEventMember
TSOI:AccruedSalariesMember
2023-10-16
2023-10-16
0001419051
us-gaap:SubsequentEventMember
TSOI:ConsultingServicesMember
2023-10-16
2023-10-16
0001419051
us-gaap:SubsequentEventMember
us-gaap:PrivatePlacementMember
2023-10-25
2023-10-25
0001419051
us-gaap:SubsequentEventMember
2023-01-03
2023-01-03
0001419051
us-gaap:SubsequentEventMember
2023-01-03
0001419051
us-gaap:ConvertibleNotesPayableMember
us-gaap:SubsequentEventMember
2023-01-04
2023-01-04
0001419051
us-gaap:SubsequentEventMember
TSOI:AccruedSalariesMember
2023-01-09
2023-01-09
0001419051
us-gaap:SubsequentEventMember
2023-01-09
2023-01-09
0001419051
us-gaap:SubsequentEventMember
2023-01-09
0001419051
us-gaap:SubsequentEventMember
us-gaap:ConvertibleNotesPayableMember
2023-02-06
2023-02-06
0001419051
us-gaap:SubsequentEventMember
us-gaap:ConvertibleNotesPayableMember
2023-02-07
2023-02-07
0001419051
us-gaap:PrivatePlacementMember
us-gaap:SubsequentEventMember
2023-02-21
2023-02-21
0001419051
us-gaap:PrivatePlacementMember
us-gaap:SubsequentEventMember
2023-02-21
0001419051
us-gaap:SubsequentEventMember
us-gaap:PreferredClassAMember
srt:DirectorMember
2023-03-21
2023-03-21
0001419051
us-gaap:SubsequentEventMember
TSOI:CampbellNeurosciencesIncMember
2023-03-21
2023-03-21
0001419051
us-gaap:SubsequentEventMember
2023-03-21
2023-03-21
0001419051
us-gaap:SubsequentEventMember
TSOI:CampbellNeurosciencesIncMember
2023-03-21
0001419051
2023-03-22
0001419051
2023-03-22
2023-03-22
0001419051
TSOI:NotesPayableOneMember
us-gaap:RelatedPartyMember
2022-12-31
0001419051
TSOI:NotesPayableOneMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:NotesPayableTwoMember
us-gaap:RelatedPartyMember
2022-12-31
0001419051
TSOI:NotesPayableTwoMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:NotesPayableThreeMember
us-gaap:RelatedPartyMember
2022-12-31
0001419051
TSOI:NotesPayableThreeMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:NotesPayableFourMember
us-gaap:RelatedPartyMember
2022-12-31
0001419051
TSOI:NotesPayableFourMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:NotesPayableFiveMember
us-gaap:RelatedPartyMember
2022-12-31
0001419051
TSOI:NotesPayableFiveMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:ScientificAdvisoryBoardMember
TSOI:NotesPayableOneMember
2022-12-31
0001419051
TSOI:ScientificAdvisoryBoardMember
TSOI:NotesPayableOneMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:ScientificAdvisoryBoardMember
TSOI:NotesPayableOneMember
2022-01-01
2022-12-31
0001419051
TSOI:ScientificAdvisoryBoardMember
TSOI:NotesPayableOneMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001419051
srt:ChiefExecutiveOfficerMember
TSOI:NotesPayableTwoMember
srt:MinimumMember
2022-12-31
0001419051
srt:ChiefExecutiveOfficerMember
TSOI:NotesPayableTwoMember
srt:MinimumMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
srt:ChiefExecutiveOfficerMember
TSOI:NotesPayableTwoMember
srt:MaximumMember
2022-12-31
0001419051
srt:ChiefExecutiveOfficerMember
TSOI:NotesPayableTwoMember
srt:MaximumMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
srt:ChiefExecutiveOfficerMember
TSOI:NotesPayableTwoMember
2022-01-01
2022-12-31
0001419051
srt:ChiefExecutiveOfficerMember
TSOI:NotesPayableTwoMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001419051
srt:ChiefFinancialOfficerMember
TSOI:NotesPayableFourMember
2022-12-31
0001419051
srt:ChiefFinancialOfficerMember
TSOI:NotesPayableFourMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
srt:ChiefFinancialOfficerMember
TSOI:NotesPayableFourMember
2022-01-01
2022-12-31
0001419051
srt:ChiefFinancialOfficerMember
TSOI:NotesPayableFourMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001419051
TSOI:BusinessAdvisoryBoardMember
TSOI:NotesPayableFiveMember
srt:MinimumMember
2022-12-31
0001419051
TSOI:BusinessAdvisoryBoardMember
TSOI:NotesPayableFiveMember
srt:MinimumMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:BusinessAdvisoryBoardMember
TSOI:NotesPayableFiveMember
srt:MaximumMember
2022-12-31
0001419051
TSOI:BusinessAdvisoryBoardMember
TSOI:NotesPayableFiveMember
srt:MaximumMember
us-gaap:RelatedPartyMember
2021-12-31
0001419051
TSOI:BusinessAdvisoryBoardMember
TSOI:NotesPayableFiveMember
2022-01-01
2022-12-31
0001419051
TSOI:BusinessAdvisoryBoardMember
TSOI:NotesPayableFiveMember
us-gaap:RelatedPartyMember
2021-01-01
2021-12-31
0001419051
srt:OfficerMember
2019-12-31
0001419051
srt:OfficerMember
2018-12-31
0001419051
TSOI:OneOfficersMember
us-gaap:RestrictedStockMember
TSOI:AccruedSalariesMember
2021-01-01
2021-12-31
0001419051
TSOI:OneOfficerAndOneDirectorMember
us-gaap:RestrictedStockMember
2021-06-17
2021-06-18
0001419051
TSOI:FourOfficerAndOneDirectorMember
us-gaap:RestrictedStockMember
2021-11-30
2021-11-30
0001419051
TSOI:OneOfficersMember
us-gaap:RestrictedStockMember
TSOI:AccruedSalariesMember
2022-01-01
2022-12-31
0001419051
TSOI:FourOfficerAndOneDirectorMember
us-gaap:RestrictedStockMember
2022-04-05
2022-04-05
0001419051
TSOI:OneOfficerAndOneDirectorMember
us-gaap:RestrictedStockMember
2022-09-08
2022-09-08
0001419051
TSOI:FourOfficerOneDirectorMember
us-gaap:RestrictedStockMember
2022-11-02
2022-11-02
0001419051
TSOI:FourOfficerAndOneDirectorMember
us-gaap:RestrictedStockMember
2022-12-30
2022-12-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
utr:sqft
United
States
SECURITIES AND EXCHANGE COMMISSION
POST-EFFECTIVE
AMENDMENT NO. 1
to
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Therapeutic
Solutions International, Inc.
(Exact
name of Registrant as Specified in Its Charter)
Nevada |
|
2833 |
|
45-1226465 |
(State
or other jurisdiction of
incorporation or organization) |
|
(Primary
Standard Industrial
Classification Code Number) |
|
(I.R.S.
Employer
Identification No.) |
701
Wild Rose Lane
Elk
City, Idaho 83525
760-295-7208
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
EastBiz.com,
Inc.
5348
Vegas Dr.
Las
Vegas, NV 89108
Phone:
(702) 871-8678
Email:
info@incparadise.com
(Name,
address, including zip code, and telephone number including area code, of agent for service)
Copies
to:
H.D.
Kelso & Associates
Hugh D. Kelso III, Esq, Managing Attorney
8799 Balboa Avenue, Suite 155 San Diego, CA 92123
Ph: 619-840-5056
Email:
hdklawfirm@yahoo.com
Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☒
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
THE
REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE
REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE
IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE
AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(A), MAY DETERMINE.
EXPLANATORY
NOTE
We
initially registered on Form S-1 (File No. 333-268070) (i) the issuance and sale of up to 555,000,000 shares of our Common Stock, par
value $0.0001 per share (“Common Stock) offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933 and pursuant to a securities purchase agreement which provides the right to an aggregate gross proceeds of up to $10.0 million
from the sale of our Common Stock to the selling shareholder, GHS Investments, LLC (“GHS”) (the “GHS Purchase Agreement”)
entered into on September 19, 2022. The S-1, as amended, became effective February 15, 2023.
As
of the date of this filing, GHS has been issued 541,632,207 shares of Common Stock vis-à-vis 12 noticed Puts so that 13,367,703
shares remain available as registered under the effective S-1 of Common Stock, and the total value of the remaining shares is $11,763.58
(at current market price) so that $9,219,567.99 remains available under the GHS Purchase Agreement.
This
Post-Effective Amendment No. 1 to Form S-1 (“Post-Effective Amendment No. 1”), is being filed to, (i) pursuant
to Rule 462(b) under the Securities Act of 1933, as amended, for the purpose of increasing the aggregate number of shares of common stock
offered by Therapeutic Solutions International, Inc. (Registrant) by 300,000,000 additional shares of Common Stock by this Post-Effective
Amendment No. 1 to 313,367,703 shares available for sale to selling shareholders. The information set forth in the Prior Registration
Statement and all exhibits thereto are hereby incorporated by reference in this filing; and (ii) include an updated prospectus to include
relevant Exchange Act reports, specifically the Annual Report for FY 2022 ending December 31, 2022, filed on Form 10-K on 3/29/2023,
and the Quarterly Report filed on form 10-Q for FY 2023 for quarter ending September 30, 2023, filed on 11/14/2023 and after the effective
date of the Form S-1 relating to the offering and sale of Common Stock that was registered for resale by the selling stockholder named
in the prospectus to this Post-Effective Amendment No. 1.
Accordingly,
this Post-Effective Amendment No. 1 is filed to:
1.
continue the registration of 13,367,703 shares of the registrant’s Common stock that was originally registered under and issued
pursuant to the Registration Statement filed on Form S-1, as amended, and which became effective February 15, 2023; and,
2.
300,000,000 additional shares of Common Stock by this Post-Effective Amendment No. 1 for an aggregate of 313,367,703 shares available
for sale to selling shareholders.
All
applicable registration fees were paid at the time of the original filing of the Prior Registration Statements.
The
required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
PROSPECTUS
THE
INFORMATION IN THIS PROSPECTUS MAY NOT BE COMPLETE AND MAY BE CHANGED. WE AND THE SELLING STOCKHOLDERS MAY NOT SELL THESE SECURITIES
UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL
THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.
SUBJECT
TO COMPLETION, DATED JANUARY 3, 2024
THERAPEUTIC
SOLUTIONS INTERNATIONAL, Inc.
Up
to 300,000,000 Additional Shares of Common Stock
Total
Registered Shares up to 313,367,703
This
prospectus (the “Prospectus”) relates to the additional sale by the selling shareholder named in this Prospectus of Therapeutic
Solutions International, Inc. (the “Company” and/or “TSOI”) of up to 300,000,000 additional shares of common
stock, par value $0.001 per share, in addition to the remaining registered shares of 13,367,703 for a total of 313,367,703 shares to
be registered under this Statement and Prospectus. We will not receive proceeds from the sale of the shares by the selling Shareholder.
However, we may receive aggregate gross proceeds of up to $10.0 million from the sale of our common stock to the selling shareholder,
pursuant to a securities Purchase Agreement, entered into with GHS Investments, LLC (“GHS”) on September 19, 2022 (the “GHS
Purchase Agreement”), a copy being attached hereto as Exhibit 1.1. For a full discussion of the terms, and conditions of the purchase
of the securities and more information about how the selling stockholder may sell its Purchase Shares see the “Description of the
Securities Purchase Agreement,” beginning on page 6, and the “Plan of Distribution,” beginning on page 49 of this Prospectus.
The
GHS Purchase Agreement provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company may
sell to GHS, in the Company’s discretion, up to $10,000,000 of shares (“Purchase Shares”) of the Company’s common
stock. The Purchase Agreement permits TSOI to issue Purchase Notices to GHS for up to Ten Million Dollars ($10,000,000) in shares of
our common stock through the earlier of 24 months from the date of the Purchase Agreement (circa 9/19/2024) or until $10,000,000 of such
shares have been subject of a Purchase Notice.
The
selling stockholder will sell its Purchase Shares at prevailing market prices or in privately negotiated transactions. We provide more
information about how the selling stockholder may sell its Purchase Shares in the section titled “Plan of Distribution” beginning
on page 49.
As
described in the Explanatory Notes above, to date GHS has been issued 541,632,207 shares of Common Stock vis-à-vis 12 noticed
Puts so that 13,367,703 shares remain available as registered under the effective S-1 of Common Stock, and the total value of the remaining
shares is $11,763.58 (at current market price) so that $9,219,567.99 remains available under the GHS Purchase Agreement.
GHS
is an underwriter within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and any broker-dealers or agents
that are involved in selling the shares may be deemed to be “underwriters” within the meaning of the Securities Act in connection
with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares
purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. We will bear all costs, expenses
and fees in connection with the registration of the common stock. The selling stockholder will bear all commissions and discounts, if
any, attributable to its sales of our common stock.
We
are not selling any shares of Common Stock under this Prospectus and will not receive any of the proceeds from the resale of the Common
Stock by GHS (referred to sometimes herein as the “Selling Shareholder”). We will pay for expenses of this offering, except
that the Selling Shareholder will pay any broker discounts or commissions or equivalent expenses and expenses of its legal counsel applicable
to the sale of its shares. There are no arrangements to place the funds received in an escrow, trust, or similar arrangement and the
funds will be available to us following deposit into our bank account.
The
Common Stock is quoted on the OTC Markets, under the symbol “TSOI.” On December 29, 2023, the last reported sale price of
the Common Stock on the OTC Markets was $0.001 per share.
Investing
in our securities involves certain risks. See “Risk Factors” beginning on page 21. We urge you to carefully read this
Prospectus and its exhibits describing the terms of these securities before investing. Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.
Our
independent registered public accounting firm has included a “going concern” paragraph regarding our consolidated financial
statements.
The
date of this Prospectus is January 3, 2024.
TABLE
OF CONTENTS
ABOUT
THIS PROSPECTUS
This
Prospectus is part of a post-effective registration statement that we have filed with the Securities and Exchange Commission (the “SEC”)
to amend our registration on Form S-1 (File No. 333-268070) to add 300 million additional shares of common stock to which the Selling
Shareholder named herein may, from time to time, offer and sell or otherwise dispose of the securities covered by this Prospectus. You
should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front
cover of this Prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the
document incorporated by reference, when permitted by the Act, even though this Prospectus is delivered or securities are sold or otherwise
disposed of on a later date. It is important for you to read and consider all information contained in this Prospectus, including any
information incorporated by reference herein, in making your investment decision. You should also read and consider the information in
the documents to which we have referred you under the captions “Where You Can Find More Information” in this Prospectus.
Neither
we nor the Selling Shareholder have authorized any dealer, salesman or other person to give any information or to make any representation
other than those contained or incorporated by reference in this Prospectus. You must not rely upon any information or representation
not contained or incorporated by reference in this Prospectus. This Prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any of our securities other than the securities covered hereby, nor does this Prospectus constitute an offer to sell
or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or
solicitation in such jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are
required to inform themselves about, and to observe, any restrictions as to the offering and the distribution of this Prospectus applicable
to those jurisdictions.
We
further note that the representations, warranties and covenants made in any agreement that is filed as an exhibit to any document that
is incorporated by reference in the accompanying Prospectus were made solely for the benefit of the parties to such agreement, including,
in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.
Unless
the context otherwise requires, references in this Prospectus to “TSOI,” the “Company,” “we,” “us,”
and “our” refer to Therapeutic Solutions International, Inc., a Nevada corporation.
PROSPECTUS
SUMMARY
The
following is a summary of what we believe to be the most important aspects of our business and the offering of our securities under this
Prospectus. We urge you to read this entire prospectus, including the more detailed financial statements, notes to the financial statements,
exhibits, and other information incorporated by reference, if any, from our other filings with the SEC. Each of the risk factors could
adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our
securities.
The
Securities Purchase Agreement
On
or about September 19, 2022, GHS LLC, a Nevada limited liability company (“GHS” and/or “Selling Shareholder”),
and Therapeutic Solutions International, Inc. (“TSOI” and/or “Company”), a Nevada corporation, entered in a securities
Purchase Agreement (the “Purchase Agreement”), wherein the terms and conditions of the equity financing transaction provide
that, upon effectiveness of a registration statement on Form S-1 (the “Registration Statement”) filed with the U.S. Securities
and Exchange Commission (the “Commission”), the Company shall have the discretion to deliver puts to GHS and GHS will be
obligated to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) based
on the investment amount specified in each put notice. TSOI has the right to sell to GHS, and the GHS has the obligation to purchase
from TSOI put common stock pursuant to a Purchase Notice common stock (“Purchase Shares”) from time to time, to purchase
a minimum of ten thousand dollars ($10,000.00) and up to a maximum of: (1) five hundred thousand dollars ($500,000.00) and two times
(2x) the average daily dollar trading volume for the Company’s stock during the relevant Valuation Period all subject to the Available
Amount. Each Purchase Notice will set forth the Purchase Price and number of Purchase Shares in accordance with the terms of the PA,
as follows:
Notwithstanding
the foregoing dollar limitations, the Company and the Investor may, from time to time, mutually agree (in writing) to waive the aforementioned
limitations for a relevant Purchase Notice, which waiver, for the avoidance of doubt, shall not exceed the Beneficial Ownership Limitation
contained herein. The Company may not deliver more than one Purchase Notice to the Investor every ten (10) Business Days unless, from
time to time, TSOI and GHS mutually agree to different timing of the delivery Purchase Notices.
Settlement
for Purchase Shares. On each Settlement Date, for each Purchase hereunder, the Company shall deliver a number of Purchase Shares equal
to 100% of the aggregate Purchase Amount for such Purchase divided by the Purchase Price per share for such Purchase, against payment
by the Investor to the Company of the Purchase Amount with respect to such Purchase (less documented deposit and clearing fees, if any),
as full payment for such Purchase Shares via wire transfer of immediately available funds. The Company shall not issue any fraction of
a share of Common Stock upon the any Purchase.
Beneficial
Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall not issue or sell, and
the Investor shall not purchase or acquire, any shares of Common Stock under the PA which, when aggregated with all other shares of Common
Stock then beneficially owned by GHS and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated
thereunder), would result in the beneficial ownership by the Investor and its affiliates of more than 4.99% of the then issued and outstanding
shares of Common Stock (the “Beneficial Ownership Limitation”).
Discount
Price. With respect to a Purchase made pursuant to Section 2(a) hereof, 80% of the lowest traded price of the Common Stock during the
Valuation Period (the ten (10) consecutive Business Days immediately preceding, but not including, the Settlement Date).
For
example, on November 28th, 2022, the lowest traded price of the Company’s common stock during the ten (10) consecutive
trading day period immediately preceding the filing of this Registration Statement was $.0102. At that price we would be able to sell
49,019,607 shares to GHS under the securities Purchase Agreement at the discounted price of $0.00816. At that discounted price, the put
amount of $500,000 worth of shares registered for issuance to GHS under the securities Purchase Agreement would, if sold by us to GHS,
would result in an aggregate number of additional shares of 12,254,902. There is no assurance the price of our common stock will remain
the same as the market price, increase or decrease.
The
securities Purchase Agreement (section 1(u)) also contains a provision for a discount rate different from above in the event we were
to uplist to a National Exchange, as that meaning is defined in the Act. The Company has no plans to uplist in the foreseeable future,
if ever.
As
aforementioned, this prospectus (the “Prospectus”) pursuant to the filing of the Form S-1 Post-Effective Amendment No. 1,
relates to the additional sale by the selling shareholder named in this Prospectus of Therapeutic Solutions International, Inc. (the
“Company” and/or “TSOI”), of up to 300,000,000 additional shares of common stock, par value $0.001 per share,
in addition to the remaining registered shares of 13,367,703 for a total of 313,367,703 shares to be registered under this Statement
and Prospectus. We will not receive proceeds from the sale of the shares by the selling Shareholder. However, we may receive aggregate
gross proceeds of up to $10.0 million from the sale of our common stock to the selling shareholder, pursuant to a securities Purchase
Agreement, entered into with GHS Investments, LLC (“GHS”) on September 19, 2022 (the “GHS Purchase Agreement”),
a copy being attached hereto as Exhibit 1.1. Currently, $9,219,567.99 remains available under the GHS Purchase Agreement. The Purchase
Agreement permits TSOI to issue Purchase Notices to GHS for up to Ten Million Dollars ($10,000,000) in shares of our common stock through
the earlier of 24 months from the date of the Purchase Agreement (circa 9/19/2024) or until $10,000,000 of such shares have been subject
of a Purchase Notice. The selling stockholder will sell its Purchase Shares at prevailing market prices or in privately negotiated transactions.
For
a full discussion of the terms, and conditions of the purchase of the securities and more information about how the selling stockholder
may sell its Purchase Shares see the “Description of the Securities Purchase Agreement,” beginning on page 6, and the “Plan
of Distribution,” beginning on page 49 of this Prospectus.
THE
OFFERING
Common
stock offered by selling stockholders: |
|
Up
to 313,367,703 shares of Common Stock consisting of 300,000,000 shares of additional registered Common Stock and 13,367,703 shares
of remaining Common stock. |
Offering
Price Per Share: |
|
The
Selling Shareholder identified in this prospectus may sell all or a portion of the shares being offered under the Financing Agreement
at fixed prices and prevailing market prices at the time of sale, at varying prices or at negotiated prices. |
|
|
|
Common
stock outstanding: |
|
|
Before
offering |
|
3,802,666,978 |
After
offering fully executed |
|
(TBD) |
|
|
|
Use
of proceeds: |
|
We
will not receive any proceeds from the sale of the shares of our common stock by the selling shareholder. However, we will receive
proceeds from our initial sale of shares to GHS vis-à-vis Puts pursuant to the securities Purchasing Agreement. The proceeds
from the initial sale of shares will be used for the purpose of working capital. |
OTC
Pink Marketplace symbol: |
|
Shares
of our common stock are currently quoted on the OTC Pink Marketplace under the symbol “TSOI.” |
Risk
Factors: |
|
This
investment involves a high degree of risk. See “Risk Factors” for a discussion of factors you should consider carefully
before making an investment decision. |
COMPANY
OVERVIEW
Therapeutic
Solutions International, Inc. Therapeutic Solutions International, Inc. (“TSOI” or the “Company”), was organized
August 6, 2007, under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011, the
Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions,
Inc., a California corporation.
Business
Description
Currently
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate(make more active) or downregulate (make less active) one’s immune system.
Activating
one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.
TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.
Nutraceutical
Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechin-3-gallate, and thymoquinone. QuadraMune® has been shown to increase
Natural Killer Cell activity and healthy Cytokine production.
Regenerative
Medicine – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
The
stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of (a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal-like
stromal cells.
Immunotherapies
- TSOI has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to Parkinson’s Disease
developed on our StemVacs™ platform.
Investigational
Drug Applications (IND)
Treatment
of Metastatic Breast Cancer by StemVacs-V Cancer Immunotherapeutic (IND transferred to subsidiary Res Nova Bio, Inc.)
The
Primary Objective is safety and feasibility of StemVacs-V administration at 12 months as assessed by lack of adverse medical events.
The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.
Safety,
Feasibility, and Immunomodulatory Activities of StemVacs™ in Patients with Advanced Solid Tumors
The
Primary Objective is safety and feasibility of StemVacs™ administration at 12 months as assessed by lack of adverse medical events.
The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.
ARDScell
Umbilical Cord-derived Mesenchymal Stem Cells for Patients with Acute Respiratory Distress Syndrome (ARDS)
The
overall objective of this protocol is to confirm safety and determine effectiveness of Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
infusions in subjects with ARDS.
The
primary objective is to assess effectiveness of UC-MSC treatment on proportion of patients alive and free of respiratory failure at Day
60 after randomization. The secondary objectives will be to assess all-cause mortality at Day 60, survival at day 31, number of subjects
experiencing serious adverse events (SAEs) by day 31, SAE-free survival, time to recovery (evaluated until day 60), and time to oxygen
requirement equal or below 40% oxygen.
CTEcell
Investigation of Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Chronic Traumatic Encephalopathy (CTE) Patients (transferred
to subsidiary CTE Biologics, Inc.
Primary
Objective is to determine safety and efficacy of 100 million intravenously administered CTEcell™ allogeneic umbilical cord mesenchymal
stem cells. Efficacy will be determined by behavioral scores, brain imaging, and reduction in inflammatory markers. Toxicity of treatment
was evaluated for the duration of the study and will be graded according to the criteria of the World Health Organization.
COPDcell
Therapy (IND transferred to subsidiary Breathe Biologics, Inc.)
To
determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients
with moderate-to severe chronic obstructive pulmonary disease (COPD). The Primary Endpoint, which is toxicity, will be assessed by number
of adverse events (AEs). The Secondary Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.
Orphan
Drug Designation
Rare
diseases affect patients and their families. Over 7,000 rare diseases affect more than 30 million people in the United States. Many rare
conditions are life threatening and most do not have treatments. The FDA works to enhance to the availability of treatments for rare
diseases by evaluating information from product sponsors to determine if drugs meet the criteria for certain incentives and administering
grants to provide funding for research on rare diseases.
The
Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet certain criteria. Orphan drug
designation provides incentives including:
●
|
Tax
credits for qualified clinical trials |
●
|
Exemption
from user fees |
●
|
Potential
for seven years of market exclusivity after approval |
On
June 26, 2023, the Company applied for Orphan Drug Designation Using JadiCell Adult Stem Cells for Treatment of Acute Respiratory Distress
Syndrome (ARDS).
On
July 12, 2023, the Company applied for Orphan Drug Designation Using JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia.
Nutraceutical
Division (TSOI)
|
● |
ProJuvenol®
is a patented, (US No.: 9,682,047) and powerful synergistic blend of complex anti-aging ingredients in capsules. |
|
|
|
|
● |
NanoStilbene®
is an easily absorbed nanoemulsion of nanoparticle pterostilbene derived from the ‘047 patent. |
|
|
|
|
● |
DermalStilbene
is a topical form of pterostilbene delivered via spray application onto skin, derived from the ‘047 patent. |
|
|
|
|
● |
IsoStilbene
an injectable formulation of pterostilbene is available by prescription only, derived from the ‘047 patent. |
|
|
|
|
● |
NeuroStilbene
is an intranasal form of pterostilbene delivered via spray application inside the nostril, derived from the ‘047 patent. |
|
|
|
● |
NanoPSA
is a blend of NanoStilbene® and Broccoli Sprout Extract (BSE) providing 74mg of BSE and 125mg of our patented NanoStilbene®,
a proprietary formulation of nanoparticle pterostilbene. |
|
|
|
|
● |
NLRP3
Trifecta is a two-product combo and consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. |
|
|
|
|
● |
QuadraMune™
is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquinone. |
Patents
On
September 29, 2023, the Company filed a patent application titled “Immunological Enhancement of Transplanted Dopaminergic
Cells by Administration of Donor Derived Neutrophil Progenitors” which disclosed compositions of matter, protocols and therapeutic
means to enhance engraftment and viability of pluripotent stem cell derived dopaminergic cells by simultaneously administering donor
derived neutrophils or neutrophil progenitors. In one embodiment said neutrophil progenitors are engineered to express tolerogenic molecules
such as Fas Ligand. In another embodiment pluripotent stem cells are cultured in BMP4 containing media to generate embryoid bodies which
are subsequently dissociated and treated with G-CSF and interleukin 10.
On
July 18, 2023, the Company filed a patent application titled “Compositions for Preserving and/or Augmenting T and NK
Cell Immunity in Cancer Patients” which discloses compositions of matter useful for preserving and/or augmenting T and NK cell
immunity through prevention of T cell receptor zeta chain loss. In one embodiment a cancer patient is treated with a combination of pterostilbene
and RU486 at a sufficient concentration and frequency to reduce loss of T cell receptor zeta chain caused by cancer. In one embodiment
said RU486 and pterostilbene combination is administered together with one or more immunotherapeutic agents. In one embodiment said immunotherapeutic
agents are activators of one or more toll like receptors.
On
May 01, 2023, the Company filed a patent application titled “Aneurysm Treatment by Exosomes” which provides
means of inhibition and/or treating aneurysms and other degenerated blood vessels through administration of regenerative cell derived
exosomes, and/or regenerative cell derived apoptotic bodies. In one particular embodiment vessel regeneration is increased through administration
of stem cell exosomes/or stem cell apoptotic bodies. Other embodiments include regeneration of vessels prone to aneurysms, repairing
aneurysms of vessels, or acceleration of endothelialization after stent placement. Provided within the invention are methods of rejuvenating
properties of said vessels associated with physiological health, examples of which include appropriate production of anti-coagulating/clotting
factors, control of angiogenesis, and appropriate revascularization of injured tissue.
On
March 13, 2023, the Company filed a patent application titled “Generation and Utility of B Cell Subsets for Treatment
of Chronic Obstructive Pulmonary Disease” which disclosed are B cell subsets, generation of B cell subsets and utilization
of B cell subsets for treatment of Chronic Obstructive Pulmonary Disease (COPD). In one embodiment B cells possessing a B regulatory
phenotype are generated in vivo by administrating of mesenchymal stem cells. In another embodiment B regulatory cells are utilized to
treat COPD in an interleukin-35 dependent manner. In another embodiment B regulatory cells possess the marker CD5 and produce interleukin-10.
On
February 14, 2023, the Company filed a patent application titled “Enhancement of Anti-Angiogenic Cancer Immunotherapy
by Abortogenic Agents” which discloses the parallels between pregnancy and cancer that have been historically made, however,
the ability to leverage abortogenic immunity against neoplasia has not been widely examined. The current invention provides means of
suppressing tumor associated immune inhibition through administration of progesterone and/or glucocorticoid receptor antagonists such
as RU-486. In one embodiment the invention provides the concurrent utilization RI-486 and antiangiogenic immunotherapy. In another embodiment,
abortogenic inhibitors of immunity such as indolamine 2,3 dioxygenase are administered together with RU-486 and/or anti-angiogenic immunotherapy.
Various antiangiogenic agents can be utilized in the practice of the invention including the ValloVax immunotherapy and/or the StemVacs-V
therapy.
On
January 09, 2023, the Company filed a patent application titled “Prediction of Stem Cell Therapy Responsiveness by Quantification
of Pre-Existing B Regulatory Cells” which disclosed novel means of stratifying patients into potential of positive response
to mesenchymal stem cell therapy based on quantification of pretreatment levels of B regulatory cells. In one embodiment quantification
of cells concurrently expressing CD5 and CD19. In another embodiment B regulatory cells are CD19+CD39–IL10+. In one embodiment
the selection of B regulatory cells is quantified by flow cytometric means and patients possessing more than 7 % IL-10 secreting CD19
cells are chosen for stem cell therapy. In some embodiments numbers of B regulatory cells are increased prior to treatment by administration
of various interventions including providing GM-CSF, microbiome alteration or manipulation of oxidative stress.
On
January 04, 2023, the Company filed a patent application titled “Enhanced Efficacy of Tolerogenic Vaccination”
which disclosed means, methods, and compositions of matter useful for induction of antigen specific suppression of immunity and/or tolerogenesis
through administration of tolerogenic agents together with antigens and/or modified antigens delivered via multiple intradermal injections.
In one embodiment the invention teaches the use of a tattoo gun or a similar device to administer over an extended area of skin a compound
which induces a tolerogenic microenvironment and subsequently administration of said antigen in the artificially created microenvironment.
The essence of the disclosed invention is the superior tolerogenic effects observed when tolerogenic stimuli and antigen are administered
over an extended area of skin through the use of a tattoo gun or similar device.
On
November 14, 2022, the Company filed a patent titled “Treatment of Chronic Obstructive Pulmonary Disease with Myeloid
Derived Suppressor Cells” which discloses compositions of matter, protocols, and treatment means for prevention and/or reversing
Chronic Obstructive Pulmonary Disease (COPD) using myeloid derived suppressor cells as a monotherapy or adjuvant therapy. In one embodiment
umbilical cord low density myeloid cells are expanded using interleukin-3 and GM-CSF and administered in an allogeneic manner to a mammal
suffering from COPD. In some embodiments combinations of myeloid derived suppressor cells and mesenchymal stem cells are disclosed.
On
October 24, 2022, the Company filed a patent application titled “Mesenchymal Stem Cell Therapy of Epilepsy and Seizure
Disorders” which discloses novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through
administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes. In one embodiment umbilical
cord mesenchymal stem cells are administered to a patient suffering from epilepsy at a concentration and frequency sufficient to inhibit
neuronal hyperactivation and/or reduce neuroinflammatory status of the patient.
On
October 03, 2022, the Company filed a patent application titled “Stimulation of Pulmonary Regenerative Exosomes by Mesenchymal
Stem Cells and Derivatives Thereof” which discloses therapeutic means for pulmonary degenerative conditions through the administration
of mesenchymal stem cells in order to induce regenerative exosomes from dendritic cells expressing CD103. In one embodiment cultures
of mesenchymal stem cells with dendritic cell progenitors are disclosed wherein said mesenchymal stem cells induce a modulation of STAT3
signaling in said dendritic cell endowing a regenerative property to said dendritic cells and exosomes derived from said cells.
On
September 19, 2022, the Company filed a patent application titled “Treatment of Bipolar Disorder Using Mesenchymal Stem
Cells and Modification of Mesenchymal Stem Cells” that discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal
stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem
cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated with
carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering
from bipolar disorder.
On
September 12, 2022, the Company filed a patent application titled “Treatment of COPD by Stimulation of Stem Cell Mobilization”
which discloses means of inducing pulmonary regeneration and/or protection from oxidative stress by stimulation of endogenous stem cell
mobilization together with one or more inhibitors of NF-kappa B and/or one or more inhibitors of oxidative stress. The invention discloses
the unexpected finding that G-CSF administration enhances oxidative stress and pulmonary damage, however, coadministration with pterostilbene,
results in synergistic suppression of COPD pathology.
On
August 29, 2022, the Company filed a patent application titled “Gene Silencing Therapy of Acute Respiratory Disorder”
that teaches treatment means, compositions of matter and protocols useful for suppression of acute respiratory disorder (ARDS) through
induction of RNA interference in the pulmonary microenvironment alone and/or in conjunction with mucolytic and/or DNA disrupting agents.
In one embodiment short interfering RNA (siRNA) is prepared which targets complement receptors C3R and/or C5R together with TNF-receptor,
IL-6 receptor and/or TLR4 and TLR9. In some embodiments NanoStilbene is utilized as a delivery vehicle for siRNA delivery.
On
August 12, 2022, the Company filed a patent application titled “Treatment of Chronic Obstructive Pulmonary Disease by
Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof” that discloses means, treatments and compositions of matter
useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of
mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse reduction
in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction
of pulmonary regeneration directly or indirectly.
On
July 29, 2022, the Company filed a patent application titled “Gene Modified iPSC Derived Cellular Compositions for Regeneration
and Immune Modulation” that disclosed cells and cellular compositions useful for treatment of degenerative and/or autoimmune
diseases derived from gene edited/gene modified pluripotent stem cells. In one embodiment pluripotent stem cell such as inducible pluripotent
stem cells are gene modified to express tissue associated transcription factors such as pdx-1 if endodermal tissue is desired and cells
are differentiated into regenerative-type cells such as along the mesenchymal lineage. In one embodiment the invention teaches transfection
with IL-27 to induce expression of coinhibitory molecules for suppression of autoimmunity. In some embodiments the invention provides
generation of iPSC derived MSC which cannot stimulate inflammation due to gene-editing based removal of inflammatory associated transcription
factors.
On
May 12, 2022, the Company filed a patent application titled “Inhibition and Reversion of Chronic Obstructive Pulmonary
Disease (COPD) by Endothelial Cell Regeneration” that teaches means, treatment methods, and compositions of matter useful for
prevention and/or reversion of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration
of mesenchymal stem cells and exosome thereof as a means of augmenting endogenous endothelial regeneration and/or endothelial regeneration
stimulated by exogenous means. In some embodiments the invention provides administration of allogeneic mesenchymal stem cells together
with autologous endothelial progenitor cells and/or mobilization of said autologous endothelial progenitor cells.
On
March 7, 2022, the Company filed a patent application titled “Treatment of Trauma Associated Cognitive Dysfunction Using
Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof” which teaches means, treatments and compositions of matter
useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration
of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse
cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization
of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.
On
February 7, 2022, the Company filed a patent application titled “Treatment of COVID-19 Associated Cognitive Dysfunction
by Nutraceutical Preparations” that teaches means and methods of treating cognitive dysfunction associated with COVID-19 and/or
other associated with inflammatory conditions. In one embodiment treatment of COVID-19 cognitive dysfunction performed by administration
of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation
of endogenous neural progenitor cells and/or protect cells from inflammatory damage. In one embodiment said nutraceuticals are comprised
of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiments nutraceutical compositions
are utilized to overcome treatment resistant of currently used antidepressants.
On
November 1, 2021, the Company filed a patent application titled “Induction of Concurrent Pulmonary Immune Modulation
and Regeneration by Protein Mediated Conjugation of Immune Regulatory Cells with Endogenous Progenitor Cells” that discloses
means, methods and compositions of matter useful for treatment of inflammatory pulmonary diseases such as COVID-19 through administration
of agents that facilitate interaction between immune modulatory cells and endogenous pulmonary progenitor cells. In one embodiment a
bispecific antibody capable of facilitating the interaction between CD25 on T regulatory cells and CD47 on pulmonary epithelial stem
cells is described.
On
October 11, 2021, the Company filed a patent application titled “Umbilical Cord Derived Regenerative and Immune Modulatory
Stem Cell Populations” which provides universal donor cellular populations derived from umbilical cords possessing ability
to elicit immune modulation and evoke regeneration when administered into a mammalian host. Generation of cellular products for clinical
use are provided including methodologies of expansion, characterization, and means of therapeutic implementation.
On
October 4, 2021, the Company filed a patent application titled “Reduction of Neutrophil Extracellular Trap formation
by Mesenchymal Stem Cells and their Exosomes” that disclosed methods of reducing lung inflammation in acute respiratory distress
syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration
of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps
by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal
stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.
On
September 22, 2021, the Company filed a patent application titled “Stimulation of Mesenchymal Stem Cell Therapeutic Activities
by T Regulatory Cells” teaches novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia,
production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments
the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation
of mesenchymal stem cell activity in a GITR dependent manner.
On
September 16, 2021, the Company filed a patent application titled “Ivermectin Compositions for Treatment of COVID-19”
that discloses novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic
activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane.
In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive
mechanisms.
On
August 23, 2021, the Company filed a patent application titled “Umbilical Cord Mesenchymal Stem Cells for Treatment of
Chronic Obstructive Pulmonary Disease and Lung Degeneration” that discloses means of treating lung degenerative diseases including
chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as JadiCells alone, and/or using said cells
under conditions that are activated in order to endow enhanced regenerative activity. In one embodiment said activation of said mesenchymal
stem cells is performed through stimulation with a toll like receptor agonist at a concentration and duration sufficient to induce a
>50% increase in keratinocyte growth factor expression from said stem cells. In another embodiment the invention provides the use
of JadiCells as a means of producing exosomes, wherein said exosomes possess therapeutic properties capable of reducing inflammation,
fibrosis and degeneration associated with COPD, as well as stimulation of regenerative activity. In some JadiCells are activated by a
treatment with Activated Protein C.
On
August 18, 2021, the Company filed a patent application titled “Enhancement of Umbilical Cord Mesenchymal Stem Cell Therapeutic
Activity by Stimulators of T Regulatory Cells and/or Cells Expressing CD73” that teaches compositions of matter and protocols
useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing
CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed
to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or
activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells
are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed
with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.
On
August 11, 2021, the Company filed a patent application titled “Induction of Neurogenesis using Umbilical Cord Derived
Mesenchymal Stem Cells and Derivatives Thereof” that disclosed compositions of matter and protocols useful for treatment of
neurological dysfunctions through stimulation of adult neurogenesis using administration of umbilical cord derived mesenchymal stem cells
such as JadiCells. In one embodiment viral induced neuropathy is reduced by administration of JadiCells to stimulate neurogenesis. In
another embodiment the neurogenic activity of selective serotonin reuptake inhibitors is enhanced by administration of JadiCells. In
some embodiments administration of JadiCell exosomes, conditioned media, microvesicles and/or apoptotic bodies is utilized to stimulate
neurogenesis.
On
July 28, 2021, the Company filed a patent application titled “Neuroprotection and Neuroregeneration by Pterostilbene
and Compositions Thereof” with new data demonstrating that the blueberry derived compound pterostilbene possesses numerous
brain protective and potentially brain regenerative activities. The data disclosed by the Company indicates: a) pterostilbene suppresses
inflammatory cytokines TNF-alpha, IL-1 beta and IL-6; b) pterostilbene inhibits death of neurons caused by inflammatory mediators; c)
pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1, and FGF-2; and d) pterostilbene
allows/enhances proliferation of endogenous brain stem cells.
Granted
on November 23, 2022.
On
July 6, 2021, the Company filed a patent application titled “Treatment of Parkinson’s Disease by Immune Modulation
and Regenerative Means” in which we describe and disclose means, methods and compositions of matter for treatment Parkinson’s
Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson’s Disease is treated by augmentation
of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine
secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose
naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means
utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.
On
May 24, 2021, the Company filed a patent application titled “Immunotherapies for Targeting of Tumor Vasculature”
that disclosed novel means, protocols, and compositions of matter for creating targeted immune responses and/or induction of immunological
memory towards the tumor vasculature. In one embodiment pluripotent stem cells are transfected with one or more genes capable of eliciting
immunity, induced to differentiate into endothelial-like cells which resemble the tumor endothelial cells, and utilized as a vaccine.
In some embodiment’s genes are engineered under control of specific promoters to allow for various specificities of activity. In
one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α- Gal epitope
(Galα1,3Galα1,4GlcNAc-R). Addition of adjuvants to enhance antigen presentation of the vaccine composition, as well as means
of stimulating systemic enhancement of circulating endothelial specific T cells are also disclosed.
Published
on November 24, 2022.
On
May 21, 2021, the Company filed a patent application titled “Lithium as a Monotherapy and/or Stem Cell Adjuvant Therapy
for Pulmonary Fibrosis” that disclosed compositions of matter, therapeutics, and protocols useful for reduction and/or reversion
of pulmonary fibrosis. In one specific embodiment lithium chloride is administered together with a regenerative cell in a patient suffering
from, or at risk of pulmonary fibrosis. In one embodiment said lithium chloride is administered as an adjuvant to a regenerative therapy,
wherein said regenerative therapy is a gene therapy, a protein therapy, a cell therapy, or a tissue transplant. In one embodiment lithium
chloride, or a salt thereof is utilized alone, or with a regenerative means, to evoke preservation and/or elongation of telomere length
in pulmonary tissue. In one embodiment the invention teaches administration of umbilical cord mesenchymal stem cells (MSC) and/or products
derived from said cells in order to induce an inhibition of natural or pathological reduction of telomere length, to preserve telomere
length or to enhance telomere length. In one embodiment the MSC described in the invention as useful are umbilical cord derived MSC.
Published on November 24, 2022.
On
May 17, 2021, the Company filed a patent application titled “Treatment of Major Depressive Disorder by Low Dose Interleukin-2”
which teaches methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration
of low dose interleukin- 2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement
of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard
antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as
a treatment of major depressive disorder.
On
April 13, 2021, the Company filed a patent application titled “Amelioration and Treatment of Opioid Addiction”
that discloses compositions of matter, protocols and treatment means for reducing and/or preventing opioid addiction. In one embodiment
the invention teaches intranasal administration of umbilical cord blood plasma, or extracts thereof, together with pterostilbene or pterostilbene
containing nanoparticles, and/or oxytocin, and/or human chorionic gonadotropin.
On
March 29, 2021, the Company filed a patent application titled “Compositions Capable of Stimulating Immunity Towards Tumor
Blood Vessels” which discloses novel means, protocols, and compositions of matter for eliciting an immune response against
blood vessels supplying neoplastic tissue. In one embodiment pluripotent stem cells are transfected with one or more genes capable of
eliciting immunity. In some embodiments such genes are engineered under control of specific promoters to allow for various specificities
of activity. In one specific embodiment pluripotent stem cells engineered to endow properties capable of inducing expression of the α-Gal
epitope (Galα1,3Galα1,4GlcNAc-R).
On
March 23, 2021, the Company filed a patent application titled “Chimeric Cells Comprising Dendritic Cells and Endothelial
Cells Resembling Tumor Endothelium” which disclosed are means, methods and compositions of matter useful for induction of immunological
responses towards tumor endothelial cells. In one embodiment the invention teaches fusion of dendritic cells and cells resembling tumor
endothelial cells and administration of such chimeric cells as an immunotherapy for stimulation of tumor endothelial cell destruction.
In other embodiments pluripotent stem cells are utilized to generate dendritic cells, wherein said dendritic cells are fused with pluripotent
stem cell derived endothelial cells created in a manner to resemble tumor endothelial cells.
On
March 16, 2021, the Company filed a patent application titled “Pluripotent Stem Cell Derived Dendritic Cells and Engineered
Dendritic Cells for Cancer Immunotherapy” which disclosed are populations of dendritic cells generated from stem cells capable
of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem
cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist
immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem
cell antigens such as BORIS and/or NR2F6.
On
March 4, 2021, the Company filed a patent application titled “Therapeutic Monocytes for Prevention of Suicidal Ideation”
that discloses compositions of matter, protocols, and therapeutic means for treatment of suicidal ideations and/or suppression of suicidal
attempts. In one embodiment the invention provides the use of umbilical cord derived monocytes as a means of treatment. In another embodiment,
monocytes are de-differentiated from adult monocytes using reprogramming means to create monocyte capable of producing anti-inflammatory
as well as regenerative properties useful in reducing suicidal ideations and/or attempts. Published on September 8, 2022.
On
February 2, 2021, the Company filed a patent application titled “Ex Vivo Generation of Immunocytes Recognizing Brother
Of The Regulator of Imprinted Sites (BORIS) Expressing Cancer Stem Cells” that discusses means, methods and compositions of
matter useful for induction of immunity towards cancer stem cells by providing a dendritic cell, wherein said dendritic cells express
BORIS and/or peptides derived from BORIS, wherein said dendritic cell is cultured in the presence of one or more immunocytes. In one
embodiment said dendritic cells are derived from umbilical cord blood sources and allogeneic to T cells, which are expanded ex vivo and
used for the purposes of immunotherapy.
Published
on August 25, 2022.
On
February 8, 2021, the Company filed a patent application titled “Stimulation of Natural Kill Cell Memory by Administration
of Dendritic Cells” which disclosed means, methods and compositions of matter useful for induction of natural killer cell memory
by administration of dendritic cells and/or exosomes thereof. In one embodiment a mammal suffering from cancer is administered allogeneic
cord blood derived dendritic cells that are not pulsed exogenously. In one embodiment the dendritic cells are stimulated to possess chemotactic
activity towards the tumor by culture of dendritic cell progenitors in hypoxia. Natural killer cell memory is induced, in part, by triggering
of upregulation of cytokines associated with homeostatic expansion such as interleukin 7 and interleukin 15. Published on August 11,
2022.
On
January 26, 2021, the Company filed a patent application titled “Stimulation of Dendritic Cell Activity by Homotaurine
and Analogues Thereof” which discloses means, methods, and compositions of matter useful for enhancement of dendritic cell
activity. In one embodiment the invention provides the use of GABA agonists such as homotaurine for stimulation of dendritic cell activity.
In one embodiment said dendritic cell activity is enhancement of natural killer cell activity and/or of T cell activity. In one embodiment
NK cell activity is ability to induce cytotoxicity in neoplastically transformed cells, whereas T cell activity is either cytokine production
for CD4 cells or cytotoxicity for CD8 cells.
Published
on July 28, 2022.
On
December 21, 2020, the Company filed a patent application titled “Immunotherapy for Opioid Addiction” which
teaches means, methods and compositions of matter useful for reduction of brain inflammation and prevention of opioid addiction and/or
tolerance. In one embodiment the invention provides utilization of platelet rich plasma (PRP), alone, or admixed with regenerative/anti-inflammatory
adjuvants, for reduction of neural inflammation. In one embodiments PRP is admixed with oxytocin and administered intranasally in a patient
at risk of opioid addiction. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil, and/or pterostilbene
and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed
with regenerative/anti-inflammatory adjuvants.
Published
on June 23, 2022.
On
December 8, 2020, the Company filed a patent application titled “Treatment of Major Depressive Disorder and Suicidal
Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches” that teaches means and methods
of treating major depressive disorder and/or other disorders that predispose to suicide by administration of nutraceutical means, wherein
said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor
cells. In one embodiment said nutraceuticals are comprised of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or
sulforaphane. In some embodiment’s nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.
Published on June 9, 2022.
On
November 24, 2020, the Company filed a patent application titled “Stimulation of NK Cell Activity by QuadraMune Alone
and together with Metformin” that disclosed means, compounds, and compositions of matter useful for stimulation of natural
killer cell activity. In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising
of metformin, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal in need of natural killer
cell immune modulation. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected
with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters
observed in patients with COVID-19.Published on May 26, 2022.
On
October 27, 2020, the Company filed a patent application titled “Protection/Regeneration of Neurological Function by
Endothelial Protection/Rejuvenation” using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy
and Schizophrenia” which therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions.
In one embodiment the invention teaches the treatment of chronic traumatic encephalopathy (CTE) through protecting/regenerating the endothelial
by administration of cells such as stem cells. In one embodiment stem cells are administered in order to protect the endothelium from
apoptosis and to preserve the blood brain barrier. In another embodiment stem cells are administered together with endothelial progenitor
cells in order to regenerate neural endothelium. In other embodiments preservation of brain integrity in conditions of degeneration is
accomplished by administration of stem cells and/or endothelial cells. Published on April 28, 2022.
On
October 18, 2020, the Company filed a patent application titled “Nutraceutical Reduction Prevention and/or Reversion
of Multiple Sclerosis” that discloses compositions of matter, protocols, and treatment means for preventing and/or reversing
multiple sclerosis in a mammal. In one embodiment administration of compositions containing pterostilbene, and/or nigella sativa, and/or
sulforaphane, and/or epigallocatechin-3-gallate (EGCG) are provided. Published on June 23, 2022.
On
September 24, 2020, the Company filed a patent application titled “Personalized Immunotherapies for Reduction of Brain
Inflammation and Suicide Prevention” that discloses means, methods and compositions of matter useful for reduction of brain
inflammation and prevention of suicidal ideations and suicidal attempts. In one embodiment the invention provides utilization of autologous
platelet rich plasma, alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiment
autologous PRP is admixed with oxytocin and administered intranasally in a patient at risk of suicidal ideation. In another embodiment,
PRP is admixed with fortified and non-fortified nigella sativa oil and administered intranasally. Other embodiments include utilization
of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants. Published on March
24, 2022.
On
September 14, 2020, the Company filed a patent application titled “Immunotherapy of Schizophrenia and Schizophrenia Associated
Suicidal Ideation/Suicide” Disclosed are methods, means, and protocols of modifying the immune system so as to induce an immunologically
tolerant state insofar as T regulatory cell number and/or activity is augmented in a patient suffering from schizophrenia. In one embodiment
T regulatory cells are administered to the patient from exogenous sources, be they allogeneic or autologous. In other embodiments, T
regulatory cells are generated endogenously through administration of immature dendritic cells, mesenchymal stem cells, and/or pharmaceutical
means.
On
August 28, 2020, the Company filed a patent application titled “Upregulation of Therapeutic T Regulatory Cells and Suppression
of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline”
which discloses compositions of matter, treatments and protocols useful for induction of T regulatory cells in response to inflammation,
as well as inhibition of suicidal ideations and/or neuroinflammation. In some embodiments the invention teaches the administration of
a therapeutic combination of ingredients comprising of minocycline, pterostilbene, nigella sativa, sulforaphane, and epigallocatechin-3-gallate
(EGCG) to a mammal undergoing upregulation of inflammatory mediators. Published on March 3, 2022.
On
August 21, 2020, the Company filed a patent application titled “Methods of Determining Risk of Suicide and/or Suicidal
Ideation by Immunological Assessment” which discloses means and methods of identifying risk of suicide and/or suicidal ideation
by assessment of immunologically related cytokines and cells. In one embodiment, a score, termed the “Campbell Score” is
devised based on assessment of serum cytokines, ability of immune cells to make cytokines when stimulated ex vivo, and ability of immune
cells to produce neurotransmitters when stimulated ex-vivo. In one embodiment the concentration of interleukin-6 is utilized as a means
of assessing suicidal propensity along, and/or in combination with metabolites of the enzyme indolamine 2,3 deoxygenase.
On
August 05, 2020, the Company filed a patent application titled “Prevention of Neuroinflammation associated Memory Loss
Using Nutraceutical Compositions” which discloses means, methods, and therapeutic compositions for prevention of memory loss
during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients
comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation
in order to preserver memory function.
Published
on February 10, 2022.
On
July 22, 2020, the Company filed a patent application titled “Additive and/or Synergistic Combinations of Metformin with
Nutraceuticals for the Prevention, Inhibition and Treatment of SARS-Cov-2 and Associated COVID-19” showing potent synergy between
QuadraMune™ and the antidiabetic drug metformin in treating COVID-19 associated lung damage models. It was discovered that the
ability of QuadraMune™ to protect the lungs from inflammation that resembles coronavirus-induced pathology is markedly amplified
by concurrent administration of metformin. At a mechanistic level, it was shown that metformin increased the ability of QuadraMune™
to a) increase the number of “healing macrophages” (“M2” macrophages); b) augment production of anti-inflammatory
and regenerative proteins; and c) suppress production of pathological inflammatory proteins. Published on January 27, 2022.
On
July 13, 2020, the Company filed a patent application titled “Prevention of Pathological Coagulation in COVID-19 and
other Inflammatory Conditions” s directed to the utilization of pterostilbene, and/or nigella sativa extract, and/or sulforaphane,
and/or Epigallocatechin gallate (EGCG) alone or in combination, for the prevention of pathological coagulation. In on embodiment a composition
containing all four ingredients is administered to a patient at risk of hypercoagulation in order to prevent aberrant expression of pro-coagulation
molecules and/or induce expression of molecules known to suppress coagulation. In one embodiment the invention teaches administration
of pterostilbene, thymoquinone, sulforaphane, and EGCG as a means of decreasing expression of tissue factor. Published on May 12, 2022.
On
June 30, 2020, the Company filed a patent application titled “Augmentation of Natural Killer Cell Activity and Induction
of Cytotoxic Immunity Using Leukocyte Lysate Activated Allogeneic Dendritic Cells: StemVacs™” which describes the process
of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions
that would benefit from NK activation such as cancer and COVID-19. Published on March 31, 2022.
On
June 22, 2020, the Company filed a patent application titled “Treatment of SARS-CoV-2 with Dendritic Cells for Innate
and/or Adaptive Immunity” that disclosed means, methods, and compositions of matter for prophylaxis and/or treatment of SARS-CoV-2
by administration of dendritic cells in a manner and frequency sufficient to induce activation of innate and/or adaptive immune responses.
In one embodiment the invention teaches administration of dendritic cells pulsed with one or more innate immune stimulants in a manner
endowing said dendritic cell with ability to induce augmentation of natural killer (NK) cell number and/or activity. In another embodiment
the invention teaches the use of dendritic cells stimulated with innate immune activators in a manner to allow for uptake of viral particles
and presentation of viral epitopes to T cells in order to stimulate immunological activation and/or memory responses. Published on December
23, 2021.
On
June 15, 2020, the Company filed a patent application titled “Nutraceuticals for Suppressing Indolamine 2,3 Deoxygenase”
from new data showing QuadraMune™ significantly inhibited inflammation associated with memory impairment, as well as reduced levels
of kynurenine. Elevation of kynurenine is associated with activation of indolamine 2,3 deoxygenase, an enzyme associated with inflammation
and depression. Granted on January 25, 2022.
On
June 11, 2020, the Company filed a patent application titled “Nutraceuticals for Reducing Myeloid Suppressor Cells”
which disclosed compositions of matter, treatments and protocols useful for reduction of number and/or activity of myeloid suppressor
cells (MSC). In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene,
Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at possessing an increased number and/or activity of
said MSC in which reduction of number and/or activity is desired. In another embodiment, the invention teaches administration of said
therapeutic combination to a mammal infected with viral and/or bacterial infections and/or neoplasia. In some embodiments dosage of said
therapeutic combination is based on inflammatory and/or immunological parameters observed in patients. Published on December 16, 2021.
On
May 11, 2020, the Company filed a patent application titled “Treatment of COVID-19 Lung Injury Using Umbilical Cord Plasma
Based Compositions” which disclosed means, methods, and compositions of matter useful for the treatment of lung inflammation
associated with viral and bacterial infections, as well as with systemic inflammation, through the administration of umbilical cord blood
derived plasma-based compositions. In one embodiment the invention teaches administration of umbilical cord blood plasma together with
pterostilbene, and/or sulforaphane, and/or thymoquinone, and/or Epigallocatechin gallate (EGCG) and/or n-acetylcysteine in an aerosolized
manner to patients suffering from COVID-19 associated pulmonary deficiencies. In another embodiment, umbilical cord blood plasma is administered
with immune-stimulatory agents in order to concurrently inhibit propagation of viral load in the lung while suppressing pulmonary deficiencies.
On
May 4, 2020, the Company filed a patent application titled “Nutraceuticals for the Prevention, Inhibition and Treatment
of SARS-Cov-2 and Associated COVID-19” which teaches compositions of matter, treatments and protocols useful for prevention
of SARS-CoV-2 infection, as well as inhibition of viral propagation and acceleration of viral cure. In some embodiments the invention
teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, nigella sativa, sulforaphane, and
epigallocatechin-3-gallate (EGCG) to a mammal at risk of infection with SARS-CoV-2. In another embodiment, the invention teaches administration
of said therapeutic combination to a mammal infected with said SARS-CoV-2. In some embodiments dosage of said therapeutic combination
is based on inflammatory and/or immunological parameters observed in patients with COVID-19. Granted on March 8, 2022.
On
November 4, 2019, the Company filed a patent application titled “Cellular, Organ, and Whole-Body Rejuvenation Utilizing
Cord Blood Plasma and Pterostilbene” that disclosed methods, means, and protocols for stimulation of rejuvenation in single
cells, organs, and organisms by administration of cord blood derived plasma, cord blood plasma concentrates, and cord blood derived exosomes
together with pterostilbene. The invention describes the previously unexpected finding that addition of pterostilbene to cord blood enhances
the rejuvenation properties of cord blood. Said rejuvenation properties include telomere preservation, reduction in beta galactosidase,
and retention of cellular activities.
Published
on May 6, 2021.
On
September 9, 2019, the Company filed a patent application titled “Pterostilbene and Formulations Thereof for Protection
of Hematopoiesis from Chemotherapy and Radiation” which disclosed compositions of matter useful for treatment and/or prevention
of hematopoietic injury using pterostilbene and formulations thereof. In one embodiment nanoparticle delivered pterostilbene is administered
subsequent to chemotherapy induced neutropenia in order to accelerate recovery of the hematopoietic compartment. In another embodiment,
pterostilbene is provided concurrently with chemotherapy in order to concurrently assist the neoplasia killing action of the chemotherapy
while protecting the bone marrow from suppression. In contrast to conventionally used agents that protect from neutropenia such as G-CSF
and GM-CSF, the products disclosed can be chronically administered, thus allowing for concurrent use with chemotherapeutic or radiotherapeutic
agents.
On
January 21, 2019, the Company filed a patent application titled “Prevention and Reversion of Chronic Traumatic Encephalopathy
through Administration of “Educated” Monocytes and Progenitors Thereof” that provides means of preventing and/or
reversing chronic traumatic encephalopathy in a patient through the modulation of monocytes as well as monocytic progenitors. In one
embodiment the invention teaches administration of monocytes that have been previously “educated” by exposure to mesenchymal
stem cells in order to endow onto said monocytes properties associated with stimulation of neuroregenerative properties. In some embodiments
monocytes are educated by treatment of monocytic progenitors with conditions capable of endowing anti-inflammatory and regenerative conditions,
said conditions include culture with epigenetic modifying agents. In other embodiments, the invention teaches the manipulation of cord
blood derived monocytes as a starting population of cells for education by culture with mesenchymal stem cells.
On
January 21, 2019, the Company filed a patent application titled “Autologous Neurogenic Cells and Uses Thereof for Professional
Athletes at Risk of Chronic Traumatic Encephalopathy” which disclosed are means, compositions of matter and methods of business
for treating Chronic Traumatic Encephalopathy (CTE) using autologous primary cells and modified cells of autologous origin which have
been banked. In one embodiment of the invention autologous dedifferentiation cells are generated and stored for future administration
in patients which have suffered CTE. In other embodiments, dedifferentiated cells are differentiated into neurons or neuronal progenitor
cells and subsequently administered locally or systemically or in a combination. In other embodiments autologous cells are maintained
in an undifferentiated manner and/or neurologically differentiated state and utilized as a conditioning source in an extracorporeal circulatory
system replicating clinical stage extracorporeal liver perfusion (ECLP) with substitution of autologous dedifferentiated, neurologically
differentiated or a combination of said cells instead of hepatic cells.
On
December 18, 2018, the Company filed a patent application titled “Treatment of Chronic Traumatic Encephalopathy via RNA
Administration” which disclosed are protocols, treatment means, and compositions of matter useful for treatment of Chronic
Traumatic Encephalopathy through administration of RNA or modified RNA molecules. In one embodiment said RNA is generated to activate
various toll like receptors (TLR), of which said activation leads to production of cytokines which paradoxically lead to protection from
Chronic Traumatic Encephalopathy, wherein said protection constitutes a) reduction in glial cell activation, b) neuronal apoptosis due
to excitotoxicity; and c) stimulation of endogenous regenerative processes including endothelial progenitor cell mobilization, proliferation
of neuronal progenitor cells in the dentate gyrus and subventricular zones. In one particular embodiment targeting of RNA molecules is
performed to specific brain cells including pyramidal neurons through the use of liposomes, exosomes, apoptotic bodies, nanoparticles
and shark or cameloid antibodies is disclosed.
On
September 25, 2018, the Company filed a patent application titled “Pterostilbene and Formulations Thereof for Treatment
of Pathological Immune Activation” that teaches treatments, protocols, and compositions of matter are described for reduction
of pathological immune system activation. In one embodiment, pterostilbene and/or formulations thereof are administered in a patient
suffering from cytokine release syndrome at a concentration and frequency sufficient to reduce abnormal cytokine production and thus
treat the cause of said cytokine release syndrome. Formulations of pterostilbene are disclosed for rapid release, enhanced biodistribution,
and targeting to cytokine releasing effectors are disclosed for use in the practice of the invention.
On
September 17, 2018, the Company filed a patent application titled “Pterostilbene and Compositions Thereof for Prevention
and Treatment of Chronic Traumatic Encephalopathy” that teaches means, methods, and compositions of matter useful for prevention
of chronic traumatic encephalopathy. In one embodiment of the invention, disclosed is utilization of pterostilbene and/or pterostilbene
based compounds for prevention and/or treatment of chronic traumatic encephalopathy. In one embodiment, the invention teaches administration
of pterostilbene and/or pterostilbene based compounds for reduction of taupathy associated with chronic traumatic encephalopathy.
On
August 13, 2018, the Company filed a patent application titled “Enhancement of Ozone Therapy using Pterostilbene”
that disclosed methods, means and compositions of matter using pterostilbene for enhancing therapeutic efficacy of ozone therapy in the
field of oncology. The invention provides previously unknown synergies between ozone administration together with pterostilbene at inducing
direct and indirect cytotoxicity to cancer cells. The invention provides means of delivery, administration, and therapeutic protocols
for treatment of cancer patients. In one embodiment combination of ozone therapy together with pterostilbene is utilized to overcome
drug resistance.
On
October 08, 2017, the Company filed a patent application titled “Synergistic Inhibition of Glioma Using Pterostilbene
and Analogues Thereof” that teaches methods, means and compositions of matter for utilizing pterostilbene and analogues thereof
for suppression of viability, metastasis and proliferation of glioma cells alone, or together with immunotherapy, chemotherapy, or radiotherapy
means. In one embodiment said pterostilbene augments immunogenicity of glioblastoma cells so as to enhance killing by immune cells or
complement subsequent to damage of said glioblastoma cells by chemotherapy, radiotherapy, or immunotherapy.
On
April 26, 2017, the Company filed a patent application titled “Augmentation of Stem Cell Activity using Pterostilbene
and Compositions Containing Pterostilbene” that disclosed means of augmenting circulating endogenous stem cells through administration
of an effective amount of pterostilbene or derivatives thereof. In one embodiment a patient with reduced levels of circulating endothelial
progenitor cells is treated with pterostilbene at a concentration and frequency sufficient to restore, and/or enhance levels of circulating
endothelial progenitor cells (EPC). In another embodiment endogenous levels of stem cells are restored or enhanced by administration
of pterostilbene, said endogenous stem cells comprising cells of the dentate gyrus, subventricular zone, hepatic stem cells, cardiac
stem cells, and hematopoietic stem cells.
On
March 29, 2017, the Company filed a patent application titled “Stimulation of Immunity to Tumor Stem Cell Specific Proteins
by Peptide Immunization” that discloses treatment of cancer is disclosed through administration of proteins or specific peptides
found on tumor stem cells in vivo, in a matter eliciting monocyte or dendritic cell migration in order to allow uptake of said administrated
proteins or peptides, followed by administration of a maturation signal in vivo. The invention provides for treatment of cancer through
induction of anticancer immunity and/or immunity towards tumor initiating stem cells.
On
March 29, 2017, the Company filed a patent application titled “Targeting the Tumor Microenvironment through Nutraceutical
Based Immunoadjuvants” that disclosed compositions useful for the treatment of cancer which modulate tumor associated immunosuppression,
thus acting as immunoadjuvants. In one embodiment a composition containing apigenin, is provided, said composition useful for inhibition
of tumor associated immune suppression mediated through the molecule indolamine 2,3 deoxygenase (IDO). In another embodiment, liposomal
apigenin is administered as a means of decreasing IDO expression.
On
March 29, 2017, the Company filed a patent application titled “Activated Leukocyte Extract for Repair of Innate Immunity
in Cancer Patients” that disclosed are compositions, methods of use, and pharmaceutical preparations useful for modulation
of immune responses. In one embodiment a composition is extracted polyvalently activated peripheral blood mononuclear cells through dialysis.
Said immune modulator is useful for treatment of cancer and alleviation of cancer associated immune depression. In one embodiment, said
immunomodulator acts as a costimulatory of T cell activation by modulation of cytokine production. In one embodiment said immune modulator
is concentrated for miRNA species capable of activating innate immune cells.
On
March 29, 2017, the Company filed a patent application titled “Augmentation of Anti-Tumor Immunity by Mifepristone and
Analogues Thereof” which relates to compositions of matter and methods useful for improving a treatment outcome and/or an alteration
of immunity in a condition that benefits from immune stimulation. In particular, one embodiment of the invention teaches administration
of sufficient doses of mifepristone or a derivative, alone, or in combination with an immunotherapeutic such as, but not limited to,
an antibody, a vaccine, a cytokine, or a medicament whose therapeutic activity is associated with immune modulation.
On
March 29, 2017, the Company filed a patent application titled “Methods of Re-Activating Dormant Memory Cells with Anticancer
Activity” that disclosed methods, protocols, and compositions of matter useful for stimulation of anticancer immune responses.
In one embodiment of the invention culture of buffy coat cells is performed in an environment resembling non-physiological conditions.
Buffy coat derived products are subsequently harvested, concentrated, and added to a culture of monocytes and lymphocytes. Conditioned
media from said second culture is subsequently utilized as an injectable solution for stimulation of anticancer immunity.
On
March 29, 2017, the Company filed a patent application titled “Modulation of Oral Microbiome for Treatment of Periodontitis”
that disclosed methods, means, and compositions of matter useful for inhibition of, reduction in progression and reversion of periodontitis.
In one embodiment the invention provides prebiotic and/or probiotic compositions which modulation the oral microbiome in order to ameliorate,
prevent or reverse periodontitis. In one embodiment a composition is administered into the oral cavity containing Actinomyces naeslundii,
Actinomyces odontolyticus, Streptococcus thermophilius, Lactobaccilus brevis and Lactobacilius plantarum. Administration may be performed
using various means including a mouthwash, a patch, a toothpaste, or in a preferred embodiment said prebiotic and/or probiotic compositions
are delivered via a mouth tray.
On
July 20, 2016, the Company filed a patent application titled “Prevention of Pregnancy Complications by Probiotic Administration”
which disclosed methods, protocols and compositions of matter for the treatment of pregnancy complications through immune modulation
of a mammal in need. In one embodiment the invention provides probiotic compositions for immune modulation to decrease risk of pregnancy
complications. Pregnancy complications include recurrent spontaneous abortions (RSA), preterm birth, pre-eclampsia including hemolysis
elevated liver enzymes low platelets (HELP), premature rupture of the membrane, Antepartum hemorrhage including placental abruption,
chorioamnionitis, Intrauterine growth restriction, placenta pravaevia, sequalae of intraamniotic infection. Published on January 26,
2017.
On
July 20, 2016, the Company filed a patent application titled “Exosome Mediated Innate and Adaptive Immune Stimulation
for Treatment of Cancer” that teaches means of stimulating innate and/or adaptive immunity to cancer by administration of exosomes.
Stimulation of innate immunity involves modifying exosomes by chemical addition of innate immune stimulators, whereas stimulation of
adaptive immunity involves pulsing dendritic cells generating exosomes with antigens, in some cases, pulsing with Brother of the Regulator
of Imprinted Sites (BORIS) proteins, peptides, or altered peptide ligands thereof.
On
July 8, 2015, the Company filed a patent application titled “Augmentation of Oncology Immunotherapies by Pterostilbene
Containing Compositions” that disclosed compositions of matter and methods useful to augmentation of immune responses to tumors.
In one embodiment, a pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency
to induce de-repression of tumor targeting immune responses. In one specific embodiment of the present invention, pterostilbene enhances
antibody dependent cellular toxicity (ADCC) and in turn augments efficacy of FDA approved antigen specific immunotherapeutics such as
trastuzumab (Herceptin) and other monoclonal antibody therapies used for treating cancer.
Issued
and Granted Patents:
On
June 20, 2017, the US Patent and Trademark Office issued and granted U.S. Patent No.: 9,682,047 titled “Augmentation
of oncology immunotherapies by pterostilbene containing compositions” that discloses compositions and methods useful to enhancing,
improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer
patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances
antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other
monoclonal antibody therapies useful for treating cancer.
On
January 25, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,229,674 titled “Nutraceuticals
for suppressing indolamine 2,3 deoxygenase” which disclosed are compositions of matter, treatments and protocols useful for
reduction of expression and/or activity of indolamine 2,3 deoxygenase (IDO). In some embodiments the invention teaches the administration
of a therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate
(EGCG) to a mammal at possessing an increased expression and/or activity of said IDO in which reduction of number and/or activity is
desired. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with viral
and/or bacterial infections and/or neoplasia. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or
immunological parameters observed in patients.
On
March 08, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,266,707 titled “Nutraceuticals
for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19” that disclosed methods of treating or
preventing complications associated with a SARS-CoV-2 infection, comprising: administration of a combination comprising: a) Green Tea
and/or extract thereof; b) Blueberry and/or extract thereof; c) Nigella sativa and/or extract thereof; and d) broccoli and/or extract
thereof in an amount and frequency sufficient to treat or prevent complications associated with said SARS-CoV-2 infection.
On
November 23, 2022, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,504,410 titled “Neuroprotection
and Neuroregeneration by Pterostilbene and Compositions Thereof” with new data demonstrating that the blueberry derived compound
pterostilbene possesses numerous brain protective and potentially brain regenerative activities. The data disclosed by the Company indicates:
a) pterostilbene suppresses inflammatory cytokines TNF-alpha, IL-1 beta and IL-6; b) pterostilbene inhibits death of neurons caused by
inflammatory mediators; c) pterostilbene stimulates production of regenerative factors from cells in the brain such as BDNF, NGF, FGF-1,
and FGF-2; and d) pterostilbene allows/enhances proliferation of endogenous brain stem cells.
On
September 19, 2023, the US Patent and Trademark Office issued and granted U.S. Patent No.: 11,759,495 titled “Upregulation
of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical
Compositions Alone or Combined with Minocycline” which discloses compositions of matter, treatments and protocols useful for
induction of T regulatory cells in response to inflammation, as well as inhibition of suicidal ideations and/or neuroinflammation. In
some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of minocycline, pterostilbene,
nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal undergoing upregulation of inflammatory mediators.
*The
data provided here is partial and does not contain all materials submitted for publication and is preliminary until peer review is complete.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure,
or prevent any disease.
Aneurysm
Treatment by Exosomes
On
May 1, 2023, the Company announced launching VasoSome Vascular Inc., based on successful treatment of Aortic Aneurysms using patent pending
exosome therapy.
At
present there is no treatment available for Aortic Aneurysms other than open surgical or endovascular repair, both of which carry significant
risks. The Company is currently at an early stage of development but seeks to be first-in-man clinical trials.
Abdominal
Aortic Aneurysms (AAA)
An
AAA is a localized dilation or “ballooning” of the abdominal aorta. Prevalence approaches 5% in men over 60 years and increases
with age. About 7.5% of men over 65 years are affected. Aneurysm disease currently affects about 1.7m individuals in the United States.
The prevalence is expected to exceed 3m by 2025 with the “baby boomers” reaching their seventh decade.
The
natural history of AAA is progressive growth, leading to rupture and death. The growth rate is about 0.3cm per year and the rate of growth
accelerates as the aneurysm gets bigger. Most AAA’s are asymptomatic and remain undetected — until they rupture.
More
than 80% of patients who suffer a ruptured AAA don’t survive long enough to reach a hospital and 50-70% of those who do reach a
hospital don’t survive treatment. The likelihood of rupture increases dramatically as the AAA grows. At 5.5cm, the one year incidence
of rupture is about 9%, rising to 33% as the aneurysm grows to 7cm. Ruptured AAA’s are a leading cause of death in the USA, and
are the 10th leading cause of death for men over 55 years. In the US, 1-2% of all male deaths in the over 65 years cohort are due to
AAA. Only 10% of patients with AAA are still alive 8 years after diagnosis compared to 65% of a similar normal population. Those who
die lose an average of nine years of life.
Technology
VasoSome’s
product VSX-001 is a proprietary nanoparticle derived from specialized stem cells that can be utilized in a “universal donor”
manner, meaning it does not have to be matched with the donor. The product possesses numerous properties of stem cells, including inhibition
of inflammation, suppression of damage to blood vessels, and ability to regenerate damaged tissue. Advantages of administering VSX-001
compared to stem cells include: a) VSX-001 is substantially smaller in size than stem cells, allowing for superior distribution; b) VSX-001
does not multiply, thus possessing a superior long-term safety profile; and c) VSX-001 can be manufactured more economically as compared
to stem cells.
Acute
Respiratory Distress Syndrome (ARDS)
On
April 20, 2023, the Company filed with the USFDA an Investigational Drug Application (IND) to initiate a Phase III Clinical Trial for
Acute Respiratory Distress Syndrome. ARDS is a condition in which lung injury causes fluid to leak into the spaces between the capillaries
and the alveoli. Pressure on the alveoli increases and eventually fluid accumulates. Fluid in the lungs causes the alveoli to collapse,
leading to a series of cascading problems, each further decreasing the lungs’ capacity to move oxygen into the blood, and directly
impacting the body’s tissues and organs. ARDS afflicts approximately 190,000 Americans a year and is expected to reach a 19.5 billion
dollar a year market by 2029.
Chronic
Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI)
On
December 10, 2018, Therapeutic Solutions International, Inc., announced the signing of an agreement between TSOI and Jadi Cell LLC for
licensing of the JadiCells universal donor adult stem cell, as covered in US Patent No.: 9,803,176 B2, for use in Chronic Traumatic Encephalopathy
(CTE), and Traumatic Brain Injury (TBI).
On
December 17, 2020, the Company filed an Investigational New Drug (IND) application seeking permission from the Food and Drug Administration
(FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy
(CTE) patients with JadiCells™.
On
May 25, 2023, the Company announced the creation of CTE Biologics, Inc., as a subsidiary company dedicated to commercializing the JadiCells™
adult stem cell platform for treatment of chronic traumatic encephalopathy.
On
July 05, 2023, the Company signed license agreements with CTE Biologics, Inc., for the exclusive use of US Patent Publication No.: 20220125852
titled as: “Protection and Regeneration of Neurological Function by Using Stem Cells” as well as the sale and transfer of
Investigational New Drug Application titled as: “Investigation of Umbilical Cord derived Mesenchymal Stem Cells for the Treatment
of Chronic Traumatic Encephalopathy Patients.”
Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and
is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression,
depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal lobe.
Traumatic
brain injury (TBI) is an insult to the brain, not of a degenerative or congenital nature, but caused by external physical force that
may produce a diminished or altered state of consciousness, which results in an impairment of cognitive abilities or physical functioning.
CTE
represents a significant unmet medical need which we believe is amenable to stem cell intervention. We are eager to accelerate treatments
and potential cures for debilitating conditions such as CTE and traumatic brain injury and plan to leverage New regulatory pathways such
as the recently approved “Right to Try” Law to deliver these medicines as soon as possible to patients which currently have
no other options.
Schizophrenia/Suicide
Clinical Programs
On
October 29, 2020, the Company announced publication on the NIH clinical trials website of its newly initiated trial aiming to validate
a blood-based diagnostic for predicting suicide risk and is listed as NCT04606875.
The
Campbell Score™, which is a patent-pending method of quantifying inflammatory-associated biological markers, has previously been
shown in pilot investigator-initiated studies to correlate with propensity for suicide. Based on positive feedback from collaborators,
the Company decided to initiate a formal clinical trial to validate correlations between the Campbell Score™ and established psychiatric
assessment tools of suicidal propensity. Currently the only means of quantifying predisposition to suicide is based on psychological,
question-based techniques.
On
December 31, 2020, the Company signed license agreements with Campbell Neurosciences Inc., a partially owned company, for access to the
9 patents filed related to the previous Campbell Neurosciences Division. The patents are:
1. |
63/128759
Immunotherapy for Opioid Addiction |
|
|
2. |
63/122862
Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based
Approaches |
|
|
3. |
63/105964
Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment of Conditions
such as Chronic Traumatic Encephalopathy and Schizophrenia |
|
|
4. |
17/030416
Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention |
|
|
5. |
63/077723
Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide |
|
|
6. |
63/071381
Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration
of Nutraceutical Compositions Alone or Combined with Minocycline |
|
|
7. |
63/068388
Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment |
|
|
8. |
63/061202
Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions |
|
|
9. |
63/057315
Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof |
|
|
10. |
Application
Serial No. 63/174291 filed by Licensor and titled as: Amelioration and Treatment of Opioid Addiction. |
|
|
11. |
Patent
Application Serial No. 63/189630 filed by Licensor and titled as: Treatment of Major Depressive Disorder by Low Dose Interleukin-2. |
Additionally,
Campbell Neurosciences Inc. has entered into purchase agreements with Therapeutic Solutions International ensuring a continued supply,
at a discounted rate, of nutraceuticals which are being explored for anti-inflammation/suicide prevention activity.
Treatment
of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells
On
October 7, 2022, the Company formed Breathe Biologics, Inc., and licensed to them a patent application titled “Umbilical Cord Mesenchymal
Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease and Lung Degeneration” that discloses means of treating lung
degenerative diseases including chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as COPDcells.
In
addition, the Company has transferred ownership of the filed investigational drug application titled “JadiCell Therapy for COPD”
to determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients
with moderate-to-severe COPD. The Primary Endpoint, which is toxicity, will be assessed by number of adverse events (AEs). The Secondary
Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.
COPD
is a consistently progressive, ultimately fatal disease for which no treatment exists capable of either reversing or even interrupting
its course. It afflicts more than 5% of the population in many countries, and it accordingly represents the third most frequent cause
of death in the U.S., where it accounts for more than 600 billion in health care costs, morbidity, and mortality.
COPD
possesses several features making it ideal for stem cell-based interventions: a) the quality of life and lack of progress demands the
ethical exploration of novel approaches. For example, bone marrow stem cells have been used in over a thousand cardiac patients with
some indication of efficacy. Adipose-based stem cell therapies have been successfully used in thousands of race-horses and companion
animals without adverse effects, as well as numerous clinical trials are ongoing and published human data reports no adverse effects.
Mesenchymal
Stem Cells (MSCs) are potent immunomodulatory cells that recognize sites of injury, limit effector T cell reactions, and stimulate regulatory
cell populations (i.e., T-regs) via growth factors, cytokines, and other mediators. Simultaneously, MSCs also stimulate local
tissue regeneration via paracrine effects inducing angiogenic, anti-fibrotic and remodeling responses. Consequently, MSCs-based therapy
represents a viable treatment option for autoimmune conditions and other inflammatory disorders, yielding beneficial effects in models
of autoimmune Type 1 Diabetes, Systemic Lupus Erythematosus, Autoimmune Encephalomyelitis, Multiple Sclerosis, cardiac insufficiency,
and organ transplantation. MSCs have been reported to inhibit inflammation and fibrosis in the lungs, have shown safety in clinical trials
for ARDS, and have been recently suggested as useful to treat patients with severe COVID-19 based on their effects preventing or attenuating
the immunopathogenic cytokine storm.
Unfortunately,
evaluation of stem cell therapy in COPD has lagged behind other areas of regenerative investigation; b) the underlying cause of COPD
appears to be inflammatory and/or immunologically mediated. The destruction of alveolar tissue is associated with T cell reactivity,
pathological pulmonary macrophage activation, and auto-antibody production. Mesenchymal stem cells have been demonstrated to potently
suppress autoreactive T cells, inhibit macrophage activation, and autoantibody responses. Additionally, mesenchymal stem cells can be
purified in high concentrations from adipose stromal vascular tissue together with high concentrations of T regulatory cells, which in
animal models are approximately 100 times more potent than peripheral T cells at secreting cytokines therapeutic for COPD such as IL-10.
Additionally, use of adipose derived cells has yielded promising clinical results in autoimmune conditions such as multiple sclerosis;
and c) Pulmonary stem cells capable of regenerating damaged parenchymal tissue have been reported. Administration of mesenchymal stem
cells into neonatal oxygen-damaged lungs, which results in COPD-like alveoli dysplasia, has been demonstrated to yield improvements in
two recent publications.
Based
on the above rationale for stem cell-based COPD treatments, we are proposing a 10 patient Phase I safety trial to assess ability of our
COPDcell, a type of umbilical cord derived stem cells to improve objective and quality of life parameters in patients with moderate to
severe COPD.
MSCs
can be derived in large number from the Umbilical Cord (UC). COPDcell’s are a type of UC-MSCs, which can be utilized in the allogeneic
setting and have demonstrated safety and efficacy in clinical trials for a number of disease conditions including inflammatory and immune-based
diseases. UC-MSCs have been shown to inhibit inflammation and fibrosis in the lungs.
Breast
Cancer Immunotherapy
Recently
the Company announced the formation of a subsidiary intended as a Spin-Off Company, Res Nova Bio, Inc. (“Res Nova Bio”),
which is dedicated to the development of cancer inhibiting anti-angiogenesis immunotherapies. Res Nova Bio has licensed from Therapeutic
Solutions International intellectual property covering StemVacs-V, which is an iPSC derived platform technology announced by the Company
in May of 2021. The technology utilizes pluripotent stem cells called iPSCs in order to generate new cells which resemble tumor blood
vessels that are made to act as a “therapeutic vaccine.” Specifically, the administration of StemVacs-V stimulates the immune
system to selectively kill blood vessels that feed the tumor but not healthy blood vessels. It is believed that for every 1 tumor blood
vessel cell that is killed, 200-300 tumor cells are also killed as a result.
In
addition to the license, the Company has transferred ownership of the IND titled “Treatment of Metastatic Breast Cancer
by StemVacs-V Cancer Immunotherapeutic” to Res Nova Bio with the primary objective being safety and feasibility of StemVacs-V administration
at 12 months as assessed by lack of adverse medical events. The secondary objective is efficacy as judged by tumor response, time to
progression, and immunological monitoring.
Cellular
Manufacturing and Cell Banking
On
October 18, 2021, the Company announced the formation of Allogen Biologics Inc, a wholly owned subsidiary of TSOI. Allogen Biologics
will house intellectual property and Standard Operating Procedures related to generation of the Company’s existing and anticipated
cellular therapeutics. In addition, Allogen will house and maintain all relevant cell banks.
On
May 10, 2022, Allogen Biologic, Inc, and Therapeutic Solutions International Inc, entered into an Exclusive Patent License Agreement
(EPLA) for Patent Application Serial No. 63/254,469, filed by Licensor and titled as: Umbilical Cord Derived Regenerative and Immune
Modulatory Stem Cell Populations.
On
August 16, 2023, TSOI issued this press release “Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully
Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial”.
Now
that we have established our own Master Cell Bank with corresponding biomarker assays of CD73, CD90, CD105 >90%, and CD14, CD34, CD45
<10%, these aliquots, which are in process of 3rd party validation will remain in cryopreservation to age the cells for purposes of
required immuno-assays to clear phase 3 in the future when cells reach acceptable age to satisfy FDA. MCB was established in August 2023
and our estimate is next August 2024 we will have adequately aged the cells to obtain clearance for phase 3 IND.
RISK
FACTORS
Risks
Associated with Our Business and Industry
This
prospectus contains forward-looking statements concerning our future programs and cash needs as well as our plans and strategies. These
forward-looking statements are based on current expectations, and we assume no obligation to update this information, except as required
by applicable laws and regulations. Numerous factors could cause actual results to differ significantly from the results described in
these forward-looking statements, including the following risk factors.
We
have identified material weaknesses in our internal control over financial reporting.
We
are required to comply with the provisions of Section 404 of the Sarbanes-Oxley Act of 2002, which require us to maintain an ongoing
evaluation and integration of the internal controls of our business.
There
were no changes in our internal control over financial reporting that occurred during our fiscal quarter ending September 30, 2023 that
materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.
Our
management, including the Chief Executive Officer assessed the effectiveness of our internal control over financial reporting as of September
30, 2023. In making our assessment, we used the framework and criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (“COSO”) (2013). Based on that assessment, our management has identified certain material weaknesses
in our internal control over financial reporting. Our management concluded that as of September 30, 2023, our internal control over financial
reporting was not effective, and that material weaknesses existed in the following areas as of September 30, 2023.
(1)
we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding
certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will
continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;
(2)
we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process,
transaction or account changes, and the performance of account reconciliations and approval;
(3)
we have ineffective controls over the period end financial disclosure and reporting process caused by insufficient accounting staff.
Under
Section 404 and the SEC’s rules, a company cannot find that its internal control over financial reporting is effective if any “material
weaknesses” exist in its controls over financial reporting.
Our
liquidity and capital resources are very limited.
Our
ability to fund operating activities is also dependent upon our ability to access external sources of financing and our ability to effectively
manage our expenses in relation to revenues. Our ability to fund working capital and anticipated capital expenditures will depend on
our future performance, which is subject to general economic conditions specific to the health, supplements and nutrition products industries,
consumer demand for our products, competition and other factors that are beyond our control. There can be no assurance that our operations
and access to external sources of financing will continue to provide resources sufficient to satisfy our liabilities arising in the ordinary
course of business.
We
will require significant additional external financing to implement our business plan.
We
will require external financing to sustain our operations, support our expansion, achieve or maintain profitability, or, should we become
subject to unforeseen events or circumstances, continue as a going concern. There can be no assurance that we will be able to secure
any such external financing, or, if we are able to secure such external financing, that it will be on terms favorable, or even acceptable,
to us. Any inability to achieve or sustain profitability or otherwise secure external financing would have a material adverse effect
on our business, financial condition, and results of operations, raising substantial doubts as to our ability to continue as a going
concern, and we may ultimately be forced to seek protection from creditors under the bankruptcy laws or cease operations, which may result
in a substantial or complete loss of your invested capital.
We
may not be able to effectively manage our potential growth and the execution of our business plan.
Our
potential growth and the execution of our business plan together are likely to place significant strain on our managerial, operational
and financial resources. To effectively manage our potential growth and execute our business plan, we will need to, among other things:
|
● |
retain
additional personnel across several departments in the Company; |
|
● |
develop
strong customer loyalty for new products in a crowded competitive marketplace; |
|
● |
continue
to establish and continue to increase awareness of our brands; |
|
● |
price
our products and services at points which will allow us to maximize sales while at the same time maximizing gross profit margins; |
|
● |
establish,
maintain, expand and manage multiple relationships with various vendors, strategic partners, licensees and other third parties, including
suppliers of the products we sell on our website and elsewhere, warehousing distributors, shipping companies and others; |
|
● |
rapidly
respond to competitive developments, particularly when new high-demand products become available; |
|
● |
build
an operations structure to support our business and provide efficient and effective customer service and support; |
|
● |
expand
our IT infrastructure to respond to increasing customer traffic to our website, demand for content from site users and to manage
growing e-commerce transactions; |
|
● |
establish
and maintain effective financial and management controls, reporting systems and procedures; |
|
● |
control
our expenses; |
|
● |
provide
competitive employee salaries and benefit packages; and, |
|
● |
avoid
lawsuits and other adverse claims. |
There
can be no assurance that we will be able to accomplish any or all of the above goals. If we prove unable to effectively execute our business
plan or manage our growth, it is likely to have a material adverse effect on our business, financial condition, including liquidity and
profitability, and our results of operations.
If
our proposed product sales model does not successfully operate at a profit our growth strategy may be impeded.
To
effectively expand and meet our growth objectives our products sales model must be executed upon in a profitable manner. Profitability
is dependent upon a variety of factors, some beyond our control, including, but not limited to the amount of traffic we can consistently
attract to our brand, to retail sales in “brick and mortar” retailers, to our website, and our ability to stock or otherwise
make available products that our customers purchase, our ability to stock or otherwise make available the best new products as they enter
the market, our ability to provide consistent and superior customer service, the general economic conditions, particularly in the U.S.,
that could impact the amount of money customers spend collectively on the products we sell, and/or that could reduce the amount of money
our average customer spends, and/or could reduce the number or frequency of repeat orders for products, and/or could result in customers
finding products in other venues if they can find those products for a lower price. Other factors that could impact our ability to execute
on our business model in a profitable manner include, but are not limited to, competition in our markets, recruiting, training and retaining
qualified personnel and management, maintenance of required local, state and federal governmental approvals and permits, costs associated
with principal component products and supplies, delivery shortages or interruptions, consumer trends, our ability to finance operations
externally, changes in supply or prices of the products we sell and disruptions or business failures among our product suppliers, distributors,
warehouses or shippers. Any failure to operate in a profitable manner could hurt our ability to meet our growth objectives by attracting
licensees, and our business, financial condition, including liquidity and profitability, and our results of operations would be negatively
affected.
If
we cannot stock, warehouse or otherwise provide product to customers in a consistent, reliable and cost-effective manner our growth strategy
may be impeded.
As
our growth strategy depends to a large extent on our ability to sell various products to consumers on our website and in traditional
“brick and mortar” retailers, if we cannot supply those products in a consistent, reliable and cost-effective manner, we
may lose customers. To accomplish a consistent, reliable and cost-effective method for supplying product to customers, we must successfully
engage with suppliers at a number of levels, including warehousing agreements, stocking agreements and other forms of distribution. Our
ability to conclude such arrangements with specific product suppliers may involve the need for trade finance, purchasing agreement finance
and other capital. In addition, we may encounter problems in fulfilling orders due to business conditions among the products companies
themselves, many of which problems are beyond our control. If we are unable to establish and continue such agreements and structures
with products companies, our growth strategy may be impeded, which could negatively affect our business, financial condition, including
liquidity and profitability, and our results of operations.
We
face significant competition for our products.
The
markets in which we operate are intensely competitive, continually evolving and, in some cases, subject to rapid change. Our competitors
include:
|
● |
traditional
and well-established companies with recognized and well patronized brands in the nutritional supplements and health products industry
segment; |
|
● |
entrenched
nutritional supplements and health products companies with well-known customer on-line services and portals and other high-traffic
web sites that provide sales access to healthcare and nutritional supplements and related products; and |
|
● |
companies
that focus on providing on-line and/or off-line healthcare related content, including some that promote competitor brands. |
Many
of our competitors have greater financial, technical, product development, marketing and other resources than we do. These companies
may be better known than we are and have more customers than we do. We cannot provide assurance that we will be able to compete successfully
against these companies or any alliances they have formed or may form. If we are unable to compete with one or more of our competitors,
our growth strategy may be impeded, which could negatively affect our business, financial condition, including liquidity and profitability,
and our results of operations.
Product
revenue.
Although
we intend and continue to develop and introduce new nutraceutical products, we currently market and sell encapsulated ProJuvenol®,
DermalStilbene, IsoStilbene, and NeuroStilbene, NanoStilbene®, NLRP3 Trifecta, and QuadraMune® are all
powerful antioxidants. We currently do not have a broad portfolio of other products completed that we could rely on to support our operations
if we were to experience any difficulty with the manufacture, marketing, sale, or distribution of our current products.
Government
regulation could adversely affect our business.
Our
products and their associated component ingredients are subject to existing and potential government regulation. Our failure, or the
failure of our business partners or third-party providers, to accurately anticipate the application of laws and regulations affecting
our products and the manner in which we deliver them, or any failure to comply, could create liability for us, result in adverse publicity,
or negatively affect our business. In addition, new laws and regulations, or new interpretations of existing laws and regulations, may
be adopted with respect to consumer protection and other issues, including pricing, products liability, copyrights and patents, distribution
and characteristics and quality of products and services. We cannot predict whether these laws or regulations will change or how such
changes will affect our business. Any of this government regulation could impact our growth strategy, which could negatively affect our
business, financial condition, including liquidity and profitability, and our results of operations.
The
Company’s success may depend upon its ability to protect its patents and proprietary technology.
The
Company owns patents for several of its products and relies upon the protection afforded by its patents and trade secrets to protect
its technology. The Company’s success may depend upon its ability to protect its intellectual property. However, the enforcement
of intellectual property rights can be both expensive and time consuming. Therefore, the Company may not be able to devote the resources
necessary to prevent infringement of its intellectual property. Also, the Company’s competitors may develop or acquire substantially
similar technologies without infringing the Company’s patents or trade secrets. For these reasons, the Company cannot be certain
that its patents and proprietary technology will provide it with a competitive advantage.
Third
parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expense
or be prevented from providing certain services, and which may otherwise harm our business.
We
could be subject to claims that we are misappropriating or infringing intellectual property, trade secrets or other proprietary rights
of others. These claims, even if not meritorious, could be expensive to defend and divert management’s attention from our operations.
If we become liable to third parties for infringing these rights, we could be required to pay substantial damage awards and to develop
non-infringing products, obtain a license or cease selling the products that use or contain the infringing intellectual property. We
may be unable to develop non-infringing products or obtain a license on commercially reasonable terms, or at all. Any claims against
our company for infringement could impede our growth strategy, which could negatively affect our business, financial condition, including
liquidity and profitability, and our results of operations.
We
may be subject to claims brought against us as a result of product liability claims.
The
Company presently does not carry products liability insurance covering its development, marketing and sale of the products it intends
to sell. However, the Company intends and expects to acquire adequate and reasonable products liability insurance after the business
is funded. There is no guarantee that the amount of funds raised by virtue of this offering will be adequate to acquire or maintain such
insurance. Should the Company not acquire adequate funding to obtain products liability insurance, its uninsured operations would expose
the Company and its shareholders to material risks should products liability claims arise. Any claims can be costly to defend, and any
successful products liability claim against the Company could materially impact the ability of the Company to continue as a going concern
and therefore place your total investment in the Company at risk of being a complete loss.
We
may be subject to claims brought against us as a result of product associated content we provide.
Consumers
are reasonably expected to access health-related information regarding our products through our on-line web site. If our content, or
content we obtain from third parties, contains inaccuracies, it is possible that consumers or others may sue us for various causes of
action. Although our planned web site contains terms and conditions, including disclaimers of liability, that are intended to reduce
or eliminate our liability, the law governing the validity and enforceability of on-line agreements with consumers that provide the terms
and conditions for use of our public or private portals are unenforceable. A finding by a court that these agreements are invalid and
that we are subject to liability could harm our business and require costly changes to our business. We have planned editorial procedures
in place to provide quality control of the information that we publish or provide. However, we cannot assure you that our editorial and
other quality control procedures will be sufficient to ensure that there are no errors or omissions in particular content. Even if potential
claims do not result in liability to us, the fact that we would need to investigate and defend against these claims could be expensive
and time consuming and could divert management’s attention away from our operations. In addition, our business is in part based
on establishing a reputation amongst consumers that our portals as trustworthy and dependable sources of healthcare information. Allegations
of impropriety or inaccuracy, even if unfounded, could therefore harm our reputation and business, which could negatively affect our
business, financial condition, including liquidity and profitability, and our results of operations.
Changes
in commodity and other operating costs or supply chain and business disruptions could adversely affect our results of operations.
Changes
in product costs are a part of our business; any increase in the prices that suppliers charge for their products could adversely affect
our operating results. We remain susceptible to increases in prices as a result of factors beyond our control, such as general economic
conditions, seasonal fluctuations, weather conditions, demand, safety concerns, product recalls, labor disputes and government regulations.
We rely on third-party distribution companies to deliver ingredients to our manufacturers and ultimately our products to customers. Interruption
of distribution services due to financial distress or other issues could adversely affect our operations.
We
face substantial competition in attracting and retaining qualified senior management and key personnel and may be unable to develop and
grow our business if we cannot attract and retain such senior management and key personnel.
As
an early-stage company, our ability to develop and grow our business, to a large extent, depends upon our ability to attract, hire and
retain highly qualified and knowledgeable senior management and key personnel who possess the skills and experience necessary to satisfy
our business needs. Our ability to attract and retain such senior management and key personnel will depend on numerous factors, including
our ability to offer salaries, benefits and professional growth opportunities that are comparable with and competitive to those offered
by more established companies operating in our marketplace. We may be required to invest significant time and resources in attracting
and retaining additional senior management and key personnel as needed. Moreover, many of the companies with which we will compete for
any such individuals have greater financial and other resources, affording them the ability to undertake more extensive and aggressive
hiring campaigns, than we can. The normal running of our operations may be interrupted, and our financial condition and results of operations
negatively affected, as a result of any inability on our part to attract or retain the services of qualified and experienced senior management
and key personnel, or should our prospective key personnel refuse to serve, or, once appointed, leave prior to a suitable replacement
being found.
Risks
Associated with This Offering and Our Securities
Trading
on the OTC Markets may be volatile and sporadic, which could depress the market price of our common stock and make it difficult for our
stockholders to resell their shares.
Our
common stock is quoted on OTC Markets. Trading in stock quoted on OTC Markets is often thin and characterized by wide fluctuations in
trading prices due to many factors that may have little to do with our operations or business prospects. This volatility could depress
the market price of our common stock for reasons unrelated to operating performance. Moreover, OTC Markets is not a stock exchange, and
trading of securities on the OTC Markets is often more sporadic than the trading of securities listed on a quotation system like NASDAQ
or a stock exchange like the American Stock Exchange. Accordingly, our shareholders may have difficulty reselling any of their shares.
Our
stock is a penny stock. Trading of our stock may be restricted by the SEC’s penny stock regulations and FINRA’s sales practice
requirements, which may limit a stockholder’s ability to buy and sell our stock.
Our
stock is a penny stock. The Securities and Exchange Commission has adopted Rule 15g-9 which generally defines “penny stock”
to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per
share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements
on broker-dealers who sell to persons other than established customers and “accredited investors”. The term “accredited
investor” refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000
or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a
transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared
by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer
also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its
salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer’s
account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer
orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s
confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these
rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and
receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the
level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny
stock rules may affect the ability of broker-dealers to trade our securities. We believe the penny stock rules discourage investor interest
in, and limit the marketability of, our common stock.
FINRA
sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.
In
addition to the “penny stock” rules promulgated by the Securities and Exchange Commission (see above for a discussion of
penny stock rules), FINRA rules require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds
for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional
customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status,
investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that
speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers
to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect
on the market for our shares.
Our
management will have substantial discretion over the use of proceeds of this Offering and may not apply them effectively.
Our
management will have significant flexibility in applying the net proceeds of this Offering and may apply the proceeds in ways with which
you do not agree. The failure of our management to apply these funds effectively could have a material adverse effect on our business
and our results of operations. The proposed allocation of the net proceeds of this Offering represents our management’s best estimate
of the expected use of funds to finance our activities in accordance with our management’s current objectives and overall market
conditions. See “Estimated Use of Proceeds”.
Our
existing stockholders may experience significant dilution from the sale of our common stock pursuant to the GHS securities Purchase Agreement.
The
sale of our common stock to GHS Investments LLC in accordance with the securities Purchase Agreement may have a dilutive impact on our
shareholders. As a result, the market price of our common stock could decline. In addition, the lower our stock price is at the time
we exercise our put options, the more shares of our common stock we will have to issue to GHS in order to exercise a put under the Purchase
Agreement. If our stock price decreases, then our existing shareholders would experience greater dilution for any given dollar amount
raised through the offering.
The
perceived risk of dilution may cause our stockholders to sell their shares, which may cause a decline in the price of our common stock.
Moreover,
the perceived risk of dilution and the resulting downward pressure on our stock price could encourage investors to engage in short sales
of our common stock. By increasing the number of shares offered for sale, material amounts of short selling could further contribute
to progressive price declines in our common stock.
The
issuance of shares pursuant to the GHS Financing Agreement may have a significant dilutive effect.
Depending
on the number of shares we issue pursuant to the GHS securities Purchase Agreement, it could have a significant dilutive effect upon
our existing shareholders. Although the number of shares that we may issue pursuant to the securities Purchase Agreement will vary based
on our stock price (the higher our stock price, the less shares we have to issue), there may be a potential dilutive effect to our shareholders,
based on different potential future stock prices, if the full amount of the Financing Agreement is realized. Dilution is based upon common
stock put to GHS and the stock price discounted to GHS’s purchase price of 80% of the lowest trading price during the pricing period.
GHS
Investments LLC will pay less than the then-prevailing market price of our common stock which could cause the price of our common stock
to decline.
Our
common stock to be issued under the GHS securities Purchase Agreement will be purchased at a twenty percent (20%) discount, or eighty
percent (80%) of the lowest trading price during the ten (10) consecutive trading days immediately preceding our notice to GHS of our
election to exercise our “put” right. GHS has a financial incentive to sell our shares immediately upon receiving them to
realize the profit between the discounted price and the market price. If GHS sells our shares, the price of our common stock may decrease.
If our stock price decreases, GHS may have further incentive to sell such shares. Accordingly, the discounted sales price in the Financing
Agreement may cause the price of our common stock to decline.
We
may not have access to the full amount under the Financing Agreement.
Our
ability to draw down funds and sell shares under the securities Purchase Agreement with GHS requires that the registration statement
of which this prospectus forms a part to be declared effective and continue to be effective. The registration statement of which this
prospectus forms a part registers the resale of 555,000,000 shares issuable under the securities Purchase Agreement with GHS, and our
ability to sell any remaining shares issuable under the investment with GHS is subject to our ability to prepare and file one or more
additional registration statements registering the resale of these shares. These registration statements may be subject to review and
comment by the staff of the Securities and Exchange Commission and will require the consent of our independent registered public accounting
firm. Therefore, the timing of effectiveness of these registration statements cannot be assured. The effectiveness of these registration
statements is a condition precedent to our ability to sell all of the shares of our common stock to GHS under the Financing Agreement.
Even if we are successful in causing one or more registration statements registering the resale of some or all of the shares issuable
under the Financing agreement with GHS to be declared effective by the Securities and Exchange Commission in a timely manner, we may
not be able to sell the shares unless certain other conditions are met. For example, due to the floating offering price, we are not able
to determine the exact number of shares that we will issue under the securities Purchase Agreement. Consequently, if the price per share
does not rise adequately, we might have to increase the number of our authorized shares in order to issue the shares to GHS to gain access
to the full $10,000,000.00 under the securities Purchase Agreement. Increasing the number of our authorized shares will require board
and stockholder approval, who may determine the dilution effect to be too great to justify authorization of additional shares. Accordingly,
because our ability to draw down any amounts under the securities Purchase Agreement with GHS is subject to a number of conditions, as
outlined herein, there is no guarantee that we will be able to draw down all of the $10,000,000.00 provided by the equity finance agreement
with GHS.
Unless
an active trading market develops for our securities, investors may not be able to sell their shares.
We
are a reporting company, and our common shares are quoted on OTC Markets (OTC Pink) under the symbol “TSOI”. However, there
is a very limited active trading market for our common stock; and an active trading market may never develop or, if it does develop,
may not be maintained. Failure to develop or maintain an active trading market will have a generally negative effect on the price of
our common stock, and you may be unable to sell your common stock, or any attempted sale of such common stock may have the effect of
lowering the market price, and therefore, your investment may be partially or completely lost.
Since
our common stock is thinly traded it is more susceptible to extreme rises or declines in price, and you may not be able to sell your
shares at or above the price paid.
Since
our common stock is thinly traded its trading price is likely to be highly volatile and could be subject to extreme fluctuations in response
to various factors, many of which are beyond our control, including (but not necessarily limited to):
● |
the
trading volume of our shares; |
● |
the
number of securities analysts, market-makers and brokers following our common stock; |
● |
new
products or services introduced or announced by us or our competitors; |
● |
actual
or anticipated variations in quarterly operating results; |
● |
conditions
or trends in our business industries; |
● |
announcements
by us of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; |
● |
additions
or departures of key personnel; |
● |
sales
of our common stock; and |
● |
general
stock market price and volume fluctuations of publicly-traded, and particularly microcap, companies. |
Investors
may have difficulty reselling shares of our common stock, either at or above the price they paid for our stock, or even at fair market
value.
The
stock markets often experience significant price and volume changes that are not related to the operating performance of individual companies,
and because our common stock is thinly traded it is particularly susceptible to such changes. These broad market changes may cause the
market price of our common stock to decline regardless of how well we perform as a company. In addition, there is a history of securities
class action litigation following periods of volatility in the market price of a company’s securities. Although there is no such
litigation currently pending or threatened against us, such a suit against us could result in the incursion of substantial legal fees,
potential liabilities and the diversion of management’s attention and resources from our business. Moreover, and as noted below,
our shares are currently traded on the OTC Link (OTC Pink tier) and, further, are subject to the penny stock regulations. Price fluctuations
in such shares are particularly volatile and subject to potential manipulation by market-makers, short-sellers and option traders.
There
is currently no liquid trading market for our common stock and we cannot ensure that one will ever develop or be sustained.
The
trading market for our common stock is currently not liquid. We cannot predict how liquid the market for our common stock might become.
Our common stock is quoted in OTC Markets under the symbol “TSOI.”
The
elimination of monetary liability against our directors and officers under Nevada law, and the existence of indemnification rights to
our directors, officers and employees, may result in substantial expenditures by the Company.
Pursuant
to Nevada Revised Statutes Section 7502, a Nevada corporation may indemnify any person who was or is a party or is threatened to be made
a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative,
except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts
paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he:
(a)
Is not liable pursuant to NRS 78.138; or
(b)
Acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and,
with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any
action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, does not,
of itself, create a presumption that the person is liable pursuant to NRS 78.138 or did not act in good faith and in a manner which he
reasonably believed to be in or not opposed to the best interests of the corporation, or that, with respect to any criminal action or
proceeding, he had reasonable cause to believe that his conduct was unlawful.
A
corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement
and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit
if he:
(a)
Is not liable pursuant to NRS 78.138; or
(b)
Acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification
may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after
exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and
only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application
that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the
court deems proper.
To
the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of
any action, suit or proceeding referred to in subsections 1 and 2, or in defense of any claim, issue or matter therein, the corporation
shall indemnify him against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection with the
defense.
These
provisions and resultant costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their fiduciary
duties even though such actions, if successful, might otherwise benefit us and our stockholders.
Public
company compliance may make it more difficult to attract and retain officers and directors.
The
Sarbanes-Oxley Act and related rules implemented by the SEC have required changes in corporate governance practices of public companies.
As a public entity, these rules and regulations increase compliance costs and make certain activities more time consuming and costly.
As a public entity, these rules and regulations also make it more difficult and expensive for us to obtain director and officer liability
insurance and we may be required to accept reduced policy limits and coverage. As a result, it may be more difficult for us to attract
and retain qualified persons to serve as directors or as executive officers.
We
do not plan to pay any cash or stock dividends in the foreseeable future.
The
payment of dividends upon our capital stock is solely within the discretion of our future board of directors and is dependent upon our
financial condition, results of operations, capital requirements, restrictions contained in our future financing instruments and any
other factors our board of directors may deem relevant. We have never declared or paid any cash or stock dividends on our capital stock
and we currently anticipate that we will retain earnings, if any, to finance the development and expansion of our business and, as such,
do not intend on paying any cash or stock dividends in the foreseeable future.
Best
Efforts Offering.
The
Securities are being offered by the Company on a “best efforts” basis. There is no firm commitment by any person to sell
any of the common stock and there is no assurance that any common stock offered will be sold. There is no minimum number of common stock
required to be sold in this offering.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus and the information incorporated by reference in this prospectus contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”). These statements are therefore entitled to the protection of the safe harbor
provisions of these laws. These statements may be identified by the use of forward-looking terminology such as “anticipate,”
“believe,” “budget,” “contemplate,” “continue,” “could,” “envision,”
“estimate,” “expect,” “forecast,” “guidance,” “indicate,” “intend,”
“may,” “might,” “outlook,” “plan,” “possibly,” “potential,” “predict,”
“probably,” “pro-forma,” “project,” “seek,” “should,” “target,”
“will,” “would,” “will be,” “will continue” or the negative of or other variation on
these words or comparable terminology.
We
have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these
expectations, assumptions, estimates and projections are reasonable, these forward-looking statements are only predictions and involve
a number of risks and uncertainties, many of which are beyond our control. These and other important factors may cause our actual results,
performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking
statements.
Management
cautions that the forward-looking statements contained in this prospectus and the information incorporated by reference are not guarantees
of future performance, and we cannot assume that such statements will be realized, or the forward-looking events and circumstances will
occur.
The
risks, uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking
statements include, but are not limited to, those set forth in the “Risk Factors” section below.
Some
of the factors that could cause actual results to differ from our expectations are:
● |
the
state of the Company’s development; |
●
|
the
Company’s ability to continue as a going concern; |
●
|
the
Company’s ability to compete in an unproven market; |
●
|
resistance
by potential customers to new technologies; |
● |
performance
issues with the Company’s products; |
●
|
uncertainties
related to estimates, assumptions and projections relating to unpaid losses and loss adjustment expenses and other accounting policies; |
● |
reliance
on key personnel; |
● |
introduction
of competing products by other companies; |
●
|
inflation
and other changes in economic conditions, including changes in the financial markets; |
●
|
security
breaches and other system disruptions; |
● |
legislative
and regulatory developments, especially in the gathering and use of information about private citizens; |
●
|
weather
conditions and natural disasters (including, but not limited to, the severity and frequency of storms, hurricanes, tornados and hail);
and |
●
|
acts
of war and terrorist activities, among other man-made disasters. |
Given
these risks and uncertainties, you are cautioned not to place undue reliance on any forward-looking statements. The forward-looking statements
included or incorporated by reference into this prospectus and in the information incorporated by reference are made only as of the date
of this prospectus. Except as required by applicable law, including the securities laws of the United States and the rules and regulations
of the SEC, we do not undertake and specifically decline any obligation to update or revise any forward-looking statements in this prospectus
after we distribute this prospectus, or publicly announce the results of any revisions to any such statements to reflect future events
or developments, whether as a result of any new information, future events or otherwise.
USE
OF PROCEEDS
We
will not receive any proceeds from the sale of the common stock by the selling stockholders.
The
Company will retain broad discretion over the use of the net proceeds from the sale of the securities to purchaser. We currently intend
to use the net proceeds for working capital, capital expenditures, extinguishment of debt or other liabilities, and general corporate
purposes. We may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary
to our own, although we have no current commitments or binding agreements with respect to any acquisitions as of the date of this prospectus.
Market
for Our Common Stock
Market
Information
Our
common stock is quoted on the OTCQB under the symbol “TSOI.” The table below sets forth for the periods indicated the quarterly
high and low bid prices as reported by OTC Markets. Limited trading volume has occurred during these periods. These quotations reflect
inter-dealer prices, without retail mark-up, mark-down, or commission and may not necessarily represent actual transactions.
| |
Quarter | | |
High | | |
Low | |
FISCAL QUARTER ENDING SEPTEMBER 30, 2023 | |
| Third | | |
$ | 0.0018 | | |
$ | 0.0014 | |
| |
Quarter | | |
High | | |
Low | |
FISCAL YEAR ENDING DECEMBER 31, 2022 | |
| First | | |
$ | 0.0257 | | |
$ | 0.0241 | |
| |
| Second | | |
$ | 0.022 | | |
$ | 0.0199 | |
| |
| Third | | |
$ | 0.014 | | |
$ | 0.0121 | |
| |
| Fourth | | |
$ | 0.0063 | | |
$ | 0.0055 | |
| |
Quarter | | |
High | | |
Low | |
FISCAL YEAR ENDING DECEMBER 31, 2021 | |
| First | | |
$ | 0.0859 | | |
$ | 0.0668 | |
| |
| Second | | |
$ | 0.044 | | |
$ | 0.040 | |
| |
| Third | | |
$ | 0.052 | | |
$ | 0.050 | |
| |
| Fourth | | |
$ | 0.0319 | | |
$ | 0.0274 | |
Our
common stock is considered to be penny stock under rules promulgated by the Securities and Exchange Commission (the “SEC”).
Under these rules, broker-dealers participating in transactions in these securities must first deliver a risk disclosure document which
describes risks associated with these stocks, broker-dealers’ duties, customers’ rights and remedies, market and other information,
and make suitability determinations approving the customers for these stock transactions based on financial situation, investment experience
and objectives. Broker-dealers must also disclose these restrictions in writing, provide monthly account statements to customers, and
obtain specific written consent of each customer. With these restrictions, the likely effect of designation as a penny stock is to decrease
the willingness of broker-dealers to make a market for the stock, to decrease the liquidity of the stock and increase the transaction
cost of sales and purchases of these stocks compared to other securities.
We
have granted registration rights only to the selling investor shareholder herein. We have not proposed to publicly offer any shares of
our common stock in a primary offering.
Availability
of Rule 144. Rule 144 is not available for the resale of securities issued by companies that are, or previously were, shell companies,
such as our company. Paragraph (i) of Rule 144 prohibits the use of the rule for resale of securities issued by any shell companies (other
than business combination related shell companies) or any issuer that has been at any time previously a shell company, except where the
following conditions are met:
|
● |
the
issuer of the securities that was formerly a shell company has ceased to be a shell company; |
|
● |
the
issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
|
● |
the
issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding
12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on
Form 8-K; and |
|
● |
at
least one year has elapsed from the time that the issuer filed current comprehensive disclosure with the SEC reflecting its status
as an entity that is not a shell company. |
Holders.
As of the close of business on November 10, 2023, we had approximately 213 holders of our common stock. The number of record holders
was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in
the names of various security brokers, dealers, and registered clearing agencies. We have appointed New Horizon Transfer 215-515 West
Pender Street, Vancouver, BC V6B 6H5, 604-876-5526, to act as transfer agent for the common stock.
Dividends
We
have not declared or paid any cash dividends on our common stock during the two fiscal years ended December 31, 2021 and December 31,
2022, respectively, or in any subsequent period. We do not anticipate or contemplate paying dividends on our common stock. The only restrictions
that limit the ability to pay dividends on common equity, or that are likely to do so in the future, are those restrictions imposed by
law.
Securities
Authorized for Issuance under Equity Compensation Plans
The
following table sets forth as of the most recent fiscal year ended December 31, 2022, certain information with respect to compensation
plans (including individual compensation arrangements) under which our common stock is authorized for issuance:
Plan
Category |
|
(a)
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
|
(b)
Weighted Average Exercise Price of Outstanding Options, Warrants, and Rights |
|
(c)
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column
(a) and (b)) |
Equity
compensation plans approved by security holders: |
|
0 |
|
0 |
|
0 |
Equity
compensation plans not approved by security holders: |
|
0 |
|
0 |
|
0 |
Total: |
|
0 |
|
0 |
|
0 |
Dilution
If
you invest in shares of our common stock in this offering, your investment will be immediately diluted to the extent of the difference
between the initial public offering price per share of common stock and the net tangible book value per share of common stock after this
offering. Dilution results from the fact that the per share offering price of the shares of common stock is substantially in excess of
the net tangible book value per share attributable to the shares of common stock held by existing owners.
Our
net tangible book value as of September 30, 2023, was $0.001 per share of common stock. We calculate net tangible book value per share
by taking the amount of our total assets, reduced by the amount of our total liabilities, and then dividing that amount by the number
of shares of common stock outstanding.
[Balance
of Page Intentionally Left Blank]
Management’s
Discussion and Analysis of
Financial
Condition and Results of Operations
You
should read the following discussion of our financial condition and results of operations in conjunction with financial statements and
notes thereto included elsewhere in this prospectus. The following discussion contains forward-looking statements that reflect our plans,
estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that
could cause or contribute to these differences include those discussed below and elsewhere in this prospectus, particularly in the section
labeled “Risk Factors.”
This
section of the prospectus includes a number of forward-looking statements that reflect our current views with respect to future events
and financial performance. Forward-looking statements are often identified by words like “believe,” “expect,”
“estimate,” “anticipate,” “intend,” “project,” and similar expressions, or words that,
by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as
of the date of this prospectus. These forward-looking statements are subject to certain risks and uncertainties that could cause actual
results to differ materially from historical results or our predictions.
General
Our
principal executive office is located at 701 Wild Rose Lane, Elk City, Idaho, 83525, with an additional satellite office located at 4093
Oceanside Blvd. Suite “B”, Oceanside, California, 92056; our telephone number is (760) 295-7208, and our website is www.therapeuticsolutionsint.com.
The reference to our website does not constitute incorporation by reference of the information contained on our website.
We
file our quarterly and annual reports with the Securities and Exchange Commission (SEC), which the public may view and copy at the SEC’s
Public Reference Room at 100 F Street, N.E. Washington D.C. 20549, on official business days during the hours of 10 a.m. to 3 p.m. The
public may obtain information on the operation of the SEC’s Public Reference Room by calling the SEC at 1–800–SEC–0330.
The SEC also maintains an Internet site, the address of which is www.sec.gov, which contains reports, proxy and information statements,
and other information regarding issuers which file electronically with the SEC. The periodic and current reports that we file with the
SEC can also be obtained from us free of charge by directing a request to Therapeutic Solutions International, Inc., 701 Wild Rose Lane,
Elk City, Idaho 83525, Attn: Corporate Secretary.
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS
On
January 3, 2019, the Board of Directors engaged Fruci & Associates II, PLLC (“Fruci”), as the Company’s independent
registered public accounting firm for the year ending December 31, 2018. The Company filed a Form 8-K on January 7, 2019, in regard to
this change. Fruci has acted as the Company’s independent registered public accounting firm for the years ending December 31, 2019,
2020, 2021, and 2022, as well. There currently are no disagreements between Fruci and the Company.
INFORMATION
WITH RESPECT TO THE REGISTRANT
CURRENT
BUSINESS OPERATIONS DESCRIPTION
Overview
As
stated more fully above under Business Description (beginning page 8), currently the Company is focused on immune modulation for the
treatment of several specific diseases. Immune modulation refers to the ability to upregulate(make more active) or downregulate (make
less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce
recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital
for reducing inflammation, autoimmune disorders and allergic reactions.
TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.
Nutraceutical
Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechin-3-gallate, and thymoquinone. QuadraMune® has been shown to increase
Natural Killer Cell activity and healthy Cytokine production.
Regenerative
Medicine – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
The
stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of (a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal-like
stromal cells.
Immunotherapies
- TSOI has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to Parkinson’s Disease developed
on our StemVacs™ platform.
Investigational
Drug Applications (IND)
Treatment
of Metastatic Breast Cancer by StemVacs-V Cancer Immunotherapeutic (IND transferred to subsidiary Res Nova Bio, Inc.)
The
Primary Objective is safety and feasibility of StemVacs-V administration at 12 months as assessed by lack of adverse medical events.
The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.
Safety,
Feasibility, and Immunomodulatory Activities of StemVacs™ in Patients with Advanced Solid Tumors
The
Primary Objective is safety and feasibility of StemVacs™ administration at 12 months as assessed by lack of adverse medical events.
The Secondary Objective is efficacy as judged by tumor response, time to progression, and immunological monitoring.
ARDScell
Umbilical Cord-derived Mesenchymal Stem Cells for Patients with Acute Respiratory Distress Syndrome (ARDS)
The
overall objective of this protocol is to confirm safety and determine effectiveness of Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
infusions in subjects with ARDS.
The
primary objective is to assess effectiveness of UC-MSC treatment on proportion of patients alive and free of respiratory failure at Day
60 after randomization. The secondary objectives will be to assess all-cause mortality at Day 60, survival at day 31, number of subjects
experiencing serious adverse events (SAEs) by day 31, SAE-free survival, time to recovery (evaluated until day 60), and time to oxygen
requirement equal or below 40% oxygen.
CTEcell
Investigation of Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Chronic Traumatic Encephalopathy (CTE) Patients (transferred
to subsidiary CTE Biologics, Inc.
Primary
Objective is to determine safety and efficacy of 100 million intravenously administered CTEcell™ allogeneic umbilical cord mesenchymal
stem cells. Efficacy will be determined by behavioral scores, brain imaging, and reduction in inflammatory markers. Toxicity of treatment
was evaluated for the duration of the study and will be graded according to the criteria of the World Health Organization.
COPDcell
Therapy (IND transferred to subsidiary Breathe Biologics, Inc.)
To
determine safety and efficacy of intravenously administered allogeneic JadiCell umbilical cord blood mesenchymal stem cells in patients
with moderate-to severe chronic obstructive pulmonary disease (COPD). The Primary Endpoint, which is toxicity, will be assessed by number
of adverse events (AEs). The Secondary Endpoint, which is efficacy will be evaluated at baseline and days 30, 60, and 90.
Orphan
Drug Designation
Rare
diseases affect patients and their families. Over 7,000 rare diseases affect more than 30 million people in the United States. Many rare
conditions are life threatening and most do not have treatments. The FDA works to enhance to the availability of treatments for rare
diseases by evaluating information from product sponsors to determine if drugs meet the criteria for certain incentives and administering
grants to provide funding for research on rare diseases.
Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and
is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression,
depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment
to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021, the Company received an IND Serial # 27377 for a clinical
trial of 10 patients with CTE.
On
August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal trial for
registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated lung failure under
IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including
bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective in saving the lives of
COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the ICU on a ventilator. In
patients over the age of 85 the survival rate was 91%.
In
addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™
resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK
cells.”
The
Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells
called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells. Most recently the Company announced
filing of a patent for a new hybrid cell created by the Company capable of training the immune system to kill blood vessels feeding cancer
but sparing healthy blood vessels. These discoveries are an extension of previous findings from the Company showing that StemVacs is
capable of suppressing new blood vessel production.
On
May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.
Critical
Accounting Policies and Estimates
The
discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these unaudited
condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We
base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results
of which form the basis for making judgments about the carrying values of assets and liabilities that re not readily apparent from other
sources. Actual results may differ materially from these estimates under different assumptions or conditions.
Recent
Accounting Pronouncements
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
In
August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
(“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models
for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result,
more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion
features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use
of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using
either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller
reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those
fiscal years. The accounting guidance has been adopted with no significant financial statement impact.
Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company’s financial statement presentation or disclosures.
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
1)
Identify the contract with a customer.
2)
Identify the performance obligations in the contract.
3)
Determine the transaction price.
4)
Allocate the transaction price to the performance obligations in the contract.
5)
Recognize revenue when (or as) the entity satisfies a performance obligation.
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
Revenue is adjusted based on an estimate of the expected returns based on historical rates. Our estimate of the provision for returns
is based upon our most recent historical experience of actual customer returns. Additionally, we consider other factors when estimating
our current period return provision, including levels of inventory in our distribution channel as well as significant market changes
which may impact future expected returns, and make adjustments to our current period provision for returns when it appears product returns
may differ from our original estimates. These returns have not been significant to the Company’s revenues in the accompanying financial
statements.
Wholesale
policies.
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Seller’s listed retail price. Seller
will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any balances not
paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the aggregate of
$500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five
Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned
products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the
aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense.
Retail
policies of e-commerce.
Shipping.
Shipping Time - Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or shipped
on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit time
offered to the customer by this site or other parties only as an estimate. We encourage the customer to order in a timely fashion to
avoid delays caused by shipping or product availability. Fulfillment mistakes that may be made which result in the shipment of incorrect
products to the customer will also be accepted for return.
Out
of Stock. We will ship the customer’s product as it becomes available. Usually, products ship by the next business day. However,
there may be times when the product the customer had ordered is out-of-stock, which will delay fulfilling the customer’s order.
We will keep the customer informed of any products that the customer had ordered that are out-of-stock and unavailable for immediate
shipment. The Customer may cancel their order at any time prior to shipping.
Cash
and Cash Equivalents. The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance
to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2023 and December
31, 2022 and 2021, the Company had $0 and $0 in excess of the FDIC insured limit.
Inventories.
Inventories are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of
purchased materials and assembly items.
Depreciation
and Amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Amortization
is computed using the straight-line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022
and 2021 was $10,946 and $6,772, respectively.
Depreciation
expense for the nine months ended September 30, 2023, and 2022 was $8,161 and $3,489, respectively.
Intangible
Assets. Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual
assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with
finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances
indicate that the carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685
and $11,295, respectively.
Amortization
expense for the nine months ended September 30, 2023, and 2022 was $222,581 and $191,192, respectively.
Long-lived
Assets. In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets
is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment
when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any,
are measured as the excess of the carrying amount of the asset over its estimated fair value.
Research
and Development. Research and Development costs are expensed as incurred. Research and Development costs are expensed as incurred.
Research and Development expenses were $1,441,128 and $794,750 for the years ended December 31, 2022 and 2021, respectively.
Research
and Development expenses were $410,146 and $1,177,123 for the nine months ended September 30, 2023, and 2022, respectively.
Income
Taxes. The Company accounts for income taxes under ASC 740 “Income Taxes,” which codified SFAS 109, “Accounting
for Income Taxes” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No.
109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities
of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred
tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
Stock-Based
Compensation. Compensation expenses for stock issued to employees is determined as the fair value of consideration or services received
or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB)
issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public
companies is for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities,
the effective date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018, for
which there was no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which
are restricted and nonrefundable shares.
Leases.
On February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on
their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions.
ASU 2016-02 became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis
for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements.
The Company recorded a Right-of-use asset and a Lease Liability of $131,818 as of September 30, 2023.
Derivative
Liabilities. A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a
future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments
embedded in other contracts and for hedging activities.
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company
entered into certain debt financing transactions in fiscal 2021 and 2022, as well as 2023, as disclosed in “Convertible Notes”
below, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative
instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle
instruments indexed to our common shares on a first-in-first-out basis.
The
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number
of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented
an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability
is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes
in the derivative liability fair value are reported in operating results each reporting period.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $531,525
and $202,144 at December 31, 2021 and 2022, respectively.
For
the notes issued during the nine months ended September 30, 2023, the Company valued the conversion feature on the date of issuance resulting
in an initial liability of $628,437. Since the fair value of the derivative was in excess of the proceeds received, a full discount to
convertible notes payable and a day one loss on derivative liabilities of $78,868 was recorded during the nine months ended September
30, 2023. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $0.0008 to $0.0034, the closing stock price of the Company’s common stock on the date of valuation
ranging from $0.0011 to $0.006, an expected dividend yield of 0%, expected volatility ranging from 124% to 160%, risk-free interest rate
ranging from 4.67% to 5.46%, and an expected term of one year.
During
the nine months ended September 30, 2023, convertible notes with principal and accrued interest balances totaling $338,577 were converted
into 218,504,885 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated
with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the fair value of
the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative liability as compared to the portion
of the convertible note converted was recorded as a loss or gain on derivative liabilities. During the nine months ended September 30,
2023, the Company recorded $100,807 to gain on derivative liabilities in connection with these conversions. The derivative liabilities
were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0008 to
$0.004, the closing stock price of the Company’s common stock on the date of valuation ranging from $0.001 to $0.006, an expected
dividend yield of 0%, expected volatility ranging from 110% to 193%, risk-free interest rates ranging from 4.55% to 5.37%, and expected
terms of 0.48 to 0.50 years.
On
September 30, 2023, the derivative liabilities on the remaining convertible notes were revalued at $292,699 resulting in a gain of $93,836
for the nine months ended September 30, 2023, related to the change in fair value of the derivative liabilities. The derivative liabilities
were revalued using the Black- Scholes option pricing model with the following assumptions: exercise prices of $0.0008, the closing stock
price of the Company’s common stock on the date of valuation of $0.002, an expected dividend yield of 0%, expected volatility ranging
from 157% to 175%, risk-free interest rate of 5.46%, and an expected term ranging from 0.53 to 1 years.
The
Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to
the effective interest method. During the nine months ended September 30, 2023, and 2022, the Company amortized $299,268 and $461,058
to interest expense, respectively. As of September 30, 2023, discounts of $157,861 remained which will be amortized through September
2024.
Fair
Value of Financial Instruments. The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible
notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term
nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of September 30, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative
liabilities. The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the three months ended September 30, 2023:
Balance, December 31, 2022 | |
$ | 202,144 | |
Issuance of new derivative liabilities | |
| 328,433 | |
Conversions | |
| (331,714 | ) |
Change in fair market value of derivative liabilities | |
| 93,836 | |
Balance, September 30, 2023 | |
$ | 292,699 | |
Use
of Estimates. Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals.
Actual results could differ materially from those estimates.
Comprehensive
Loss. Comprehensive loss for the periods reported was comprised solely of the Company’s net loss.
Non-Controlling
Interests. Non-controlling interests disclosed within the consolidated statement of operations represent the minority ownership’s
32% share of net losses of Res Nova Bio, Inc., incurred during the nine months ended September 30, 2023.
Net
Loss Per Share. Basic loss per share is computed by dividing net income available to common stockholders by the weighted average
number of common shares outstanding during the period of computation. Diluted loss per share is computed similar to basic loss per share
except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential
common shares had been issued, if such additional common shares were dilutive. Since we had net losses for all the periods presented,
basic and diluted loss per share are the same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential common shares, consisting of shares underlying
outstanding convertible notes payable were excluded as their inclusion would be antidilutive.
As
of September 30, 2023, and 2022, a total of 1,259,591,300 and 211,919,728, respectively, potential common shares, consisting of shares
underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.
Convertible
Notes Payable. At various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with
principal amounts totaling $544,000 with third parties for which the proceeds were used for operations. The Company received net proceeds
of $505,000, and a $39,000 original issuance discount was recorded. The convertible promissory notes incur interest at a rate of 10%
per annum and mature on dates ranging from January 1, 2023 to December 5, 2023. The convertible promissory notes are convertible to shares
of the Company’s common stock 180 days after issuance. The conversion price per share is equal to a percentage of 63% of the average
of the three (3) lowest trading prices of the Company’s common stock during the fifteen (15) trading days immediately preceding
the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading
market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties
ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes
include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and
accrued interest increasing by 150%. The Company was required to reserve at December 31, 2022 a total of 267,136,056 common shares in
connection with these promissory notes.
At
various times during the nine months ended September 30, 2023, the Company entered into convertible promissory notes with principal amounts
totaling $283,250 with a third party for which the proceeds were used for operations. The Company received net proceeds of $250,750,
and an $32,500 original issuance discount was recorded. The convertible promissory notes incur interest at 10% per annum and mature on
dates ranging from April 11, 2024, to September 29, 2024. The convertible promissory notes are convertible to shares of the Company’s
common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices
of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay
the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the
default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company
was required to reserve at September 30, 2023 a total of 1,259,591,300 common shares in connection with these promissory notes.
Derivative
liabilities
These
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number
of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented
an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability
is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes
in the derivative liability fair value are reported in operating results each reporting period.
For
the notes issued during the nine months ended September 30, 2023, the Company valued the conversion feature on the date of issuance resulting
in an initial liability of $628,437. Since the fair value of the derivative was in excess of the proceeds received, a full discount to
convertible notes payable and a day one loss on derivative liabilities of $78,868 was recorded during the nine months ended September
30, 2023. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $0.0008 to $0.0034, the closing stock price of the Company’s common stock on the date of valuation
ranging from $0.0011 to $0.006, an expected dividend yield of 0%, expected volatility ranging from 124% to 160%, risk-free interest rate
ranging from 4.67% to 5.46%, and an expected term of one year.
Unregistered
Sales of Equity Securities and Use of Proceeds
|
● |
On
January 3, 2023, we issued 4,054,054 shares of common stock for the partial conversion of $15,000 for convertible note dated June
27, 2022. |
|
● |
On
January 3, 2023, we issued 17,000,000 shares of common stock, valued at $0.006 per share, for consulting services. |
|
● |
On
January 4, 2023, we issued 10,052,083 shares of common stock for the complete conversion of $36,187 for convertible note dated June
27, 2022. |
|
● |
On
January 9, 2023, we issued 4,081,132 shares of common stock for $20,000 of accrued salaries. |
|
● |
On
January 9, 2023, we issued 4,000,000 shares of common stock, valued at $0.0049 per share, for consulting services. |
|
● |
On
February 6, 2023, we issued 6,060,606 shares of common stock for the partial conversion of $20,000 for convertible note dated August
2, 2022. |
|
● |
On
February 7, 2023, we issued 11,386,719 shares of common stock for the complete conversion of $36,437 for convertible note dated August
2, 2022. |
|
● |
On
March 21, 2023, we issued 60,224,825 shares of common stock, valued at $0.00216 per share, for an investment in the Company’s
Private Placement. |
|
● |
On
March 28, 2023, we issued 14,705,882 shares of common stock for the partial conversion of $25,000 for convertible note dated September
27, 2022. |
|
● |
On
April 3, 2023, we issued 21,308,333 shares of common stock for the complete conversion of $31,962 for convertible note dated September
27, 2022. |
|
● |
On
April 6, 2023, we issued 40,959,979 shares of common stock for an investment in the Company’s Private Placement of $75,.366. |
|
● |
On
April 20, 2023, we issued 25,000,000 shares of common stock, valued at .0024 per share, for consulting services. |
|
● |
On
April 24, 2023, we issued 89,639,965 shares of common stock for an investment in the Company’s Private Placement of $150,595. |
|
● |
On
April 28, 2023, we issued 20,000,000 shares of common stock for the partial conversion of $30,000 for convertible note dated October
26, 2022. |
|
● |
On
May 3, 2023, we issued 17,975,000 shares of common stock for the complete conversion of $26,963 for convertible note dated October
26, 2022. |
|
● |
On
May 10, 2023, we issued 16,500,000 shares of common stock for the complete conversion of $82,500 for convertible note dated November
29, 2016. |
|
● |
On
May 10, 2023, we issued 27,500,000 shares of common stock for the complete conversion of $110,000 for convertible note dated April
20, 2017. |
|
● |
On
May 10, 2023, we issued 13,750,000 shares of common stock for the complete conversion of $27,500 for convertible note dated May 23,
2019. |
|
● |
On
June 5, 2023, we issued 33,988,466 shares of common stock for an investment in the Company’s Private Placement of $59,820. |
|
● |
On
June 6, 2023, we issued 21,428,571 shares of common stock for the partial conversion of $30,000 for convertible note dated December
5, 2022. |
|
● |
On
June 7, 2023, we issued 11,758,929 shares of common stock for the complete conversion of $116,463for convertible note dated December
5, 2022. |
|
● |
On
June 21, 2023, we issued 45,278,200 shares of common stock for an investment in the Company’s Private Placement of $72,445. |
|
● |
On
July 7, 2023, we issued 16,542,544 shares of common stock for an investment in the Company’s Private Placement of $26,468. |
|
● |
On
July 12, 2023, we issued 11,538,462 shares of common stock for the partial conversion of $15,000 for convertible note dated January
10, 2023. |
|
● |
On
July 13, 2023, we issued 21,843,750 shares of common stock for the complete conversion of $26 213 for convertible note dated January
10, 2023. |
|
● |
On
July 25, 2023, we issued 59,085,509 shares of common stock for an investment in the Company’s Private Placement of $70,903. |
|
● |
On
August 9, 2023, we issued 15,873,016 shares of common stock for the partial conversion of $15,000 for convertible note dated February
8, 2023. |
|
● |
On
August 10, 2023, we issued 16,233,766 shares of common stock for the partial conversion of $15,000 for convertible note dated February
8, 2023. |
|
● |
On
August 11, 2023, we issued 35,135,932 shares of common stock for an investment in the Company’s Private Placement of $40,758. |
|
● |
On
August 14, 2023, we issued 14,285,714 shares of common stock for the complete conversion of $12,000 for the convertible note dated
February 8, 2023. |
|
● |
On
August 31, 2023, we issued 20,175,569 shares of common stock for an investment in the Company’s Private Placement of $17,755. |
|
● |
On
September 6, 2023, we issued 20,000,000 shares of common stock for an investment in the Company’s Private Placement of $10,000. |
|
● |
On
September 20, 2023, we committed to issue 2,500,000 shares of common stock, valued at $0.0015 per share, for consulting services,
which were subsequently issued on October 3, 2023. |
|
● |
On
September 19, 2023, we issued 24,149,625 shares of common stock for an investment in the Company’s Private Placement of $23,184. |
|
● |
On
September 20, 2023, we issued 61,757,394 shares of common stock, valued at $0.0016 per share, for consulting services. |
|
● |
On
January 4, 2022, we issued 1,034,482 shares of common stock for $30,000 of accrued salaries. |
|
● |
On
January 14, 2022, we issued 4,158,759 shares of common stock for the complete conversion of $56,975 for convertible note dated July
12, 2021. |
|
● |
On
February 4, 2022, we issued 4,778,689 shares of common stock for the complete conversion of $58,300 for convertible note dated August
2, 2021. |
|
● |
On
February 14, 2022, we issued 24,500,000 shares of common stock, valued at $0.01 per share, for an investment in the Company’s
Private Placement. |
|
● |
On
February 24, 2022, we issued 10,000,000 shares of common stock, valued at $0.01 per share, for an investment in the Company’s
Private Placement. |
|
● |
On
February 23, 2022, we issued 149,402,390 shares of common stock, valued at $0.0208 per share, for a license. |
|
● |
On
March 31, 2022, we issued 10,000,000 shares of common stock, valued at $0.01 per share, for an investment in the Company’s
Private Placement. |
|
● |
On
April 4, 2022, we issued 6,786,585 shares of common stock for the complete conversion of $83,475 for convertible note dated October
1. 2021. |
|
● |
On
April 5, 2022, we issued 9,000,000 shares of common stock, valued at $0.0251 per share, for consulting services. |
|
● |
On
May 2, 2022, we issued 7,000,000 shares of common stock, valued at $0.026 per share, for consulting services. |
|
● |
On
May 2, 2022, we issued 3,571,994 shares of common stock for the complete conversion of $56,438 for convertible note dated November
2, 2021. |
|
● |
On
May 3, 2022, we issued 2,000,000 shares of common stock, valued at $0.0254 per share, for consulting services. |
|
● |
On
May 4, 2022, we issued 2,000,000 shares of common stock, valued at $0.0259 per share, for consulting services. |
|
● |
On
May 24, 2022, we issued 2,000,000 shares of common stock, valued at $0.02261 per share, for consulting services. |
|
● |
On
June 16, 2022, we issued 2.919.708 shares of common stock for the partial conversion of $40,000 for convertible note dated December
15, 2021. |
|
● |
On
June 17, we issued 1,951,993 shares of common stock for the complete conversion of $26,938 for convertible note dated December 15,
2021. |
|
● |
On
July 13, 2022, we issued 2,777,778 shares of common stock for the partial conversion of $35,000 for convertible note dated January
12, 2022. |
|
● |
On
July 15, 2022, we issued 1,701,389 shares of common stock for the complete conversion of $21,438 for convertible note dated January
12, 2022. |
|
● |
On
July 25, 2022, we issued 4,095,000 shares of common stock for the complete conversion of $51,188 for convertible note dated January
21, 2022. |
|
● |
On
August 4, 2022, we issued 5,000,000 shares of common stock, valued at .02 per share, for consulting services. |
|
● |
On
August 9, 2022, we issued 2 shares of preferred shares, valued at 0.001 per share. |
Defaults
Upon Senior Securities
None.
Results
of Operations
We
had a net loss of approximately $3.7 million in 2022 compared to a net loss of approximately $3 million in 2021.
Net
sales increased $60,811 from $145,956 to $206,767, for the years ended December 31, 2021 and 2022, respectively. This increase was mainly
due to an increase in sales of the Company’s nutraceutical line of products.
Cost
of goods sold increased $36,896, from $42,544 to $79,440, for the years ended December 31, 2021 and 2022, respectively. This increase
was mainly due to higher net sales of the Company’s new nutraceutical line of products in 2022 vs 2021.
Operating
expenses for the years ended December 31, 2022 and 2021 were approximately $3.2million and $2.5 million, respectively, an increase of
$700,000. This increase was mainly due a combination of increased general and administrative expenses, an increase in consulting fees,
an increase in legal and accounting fees, and an increase in research and development.
Cost
of goods sold increased $36,896, from $42,544 to $79,440, for the years ended December 31, 2021 and 2022, respectively. This increase
was mainly due to higher net sales of the Company’s new nutraceutical line of products in 2022 vs 2021.
Operating
expenses for the years ended December 31, 2022 and 2021 were approximately $3.2million and $2.5 million, respectively, an increase of
$700,000. This increase was mainly due a combination of increased general and administrative expenses, an increase in consulting fees,
an increase in legal and accounting fees, and an increase in research and development.
General
and administrative expenses increased approximately $355,000, from $139,000 to $494,000, for the years ended December 31, 2021 and 2022,
respectively. This increase was mainly due to an increase in amortization, marketing and travel during the year.
Salaries,
wages and related expenses increased approximately $8,000, from $437,000 to $445,000, for the years ended December 31, 2021 and 2022,
respectively. This increase was mainly due to an increase in salaries.
Consulting
fees increased approximately $167,000 from $265,000 to $432,000 for the years ended December 31, 2021 and 2022, respectively, due to
an increase in overall consulting services during 2022.
Legal
and professional fees decreased approximately $376,000, from $773,000 to $397,000 for the years ended December 31, 2021 and 2022, respectively,
due to a decrease in overall patent and general counsel services.
Research
and development costs increased approximately $696,000 from $795,000 to $1,441,000, for the years ended December 31, 2021 and 2022, respectively.
This increase was mainly due to research and development expenses related to the Company’s nutraceutical line of products.
Total
loss from derivatives liabilities decreased approximately $405,000 from $539,000 to $134,000 for the years ended December 31, 2021 and
2022, respectively. This decrease was due to a derivative liability expense from certain convertible notes in 2022 compared to 2021.
Net
interest expense increased approximately $34,000 from $612,000 to $646,000 for the years ended December 31, 2021 and 2022, respectively.
This increase was mainly due to increased debt balances.
Results
of Operations for the Nine Months Ended September 30, 2023, and 2022
You
should read the following discussion of our financial condition and results of operations together with the audited financial statements
and unaudited financial statements included in this prospectus. This discussion contains forward-looking statements that reflect our
plans, estimates and beliefs. Our actual results may differ materially from those anticipated in these forward-looking statements.
We
had net loss of $1,743,194 for the nine months ended September 30, 2023, compared to a net loss of $2,737,342 for the nine months ended
September30, 2022, a decrease of $994,148. This decrease was mainly due to decreases in consulting and research and development expenses.
The Company has concentrated on Patents this year instead of consulting. Research and Development decreased because one of the contractors
finished his term. Net sales decreased $123,207, from $198,188 to $75,161, for the nine months ended September 30, 2022, and 2023, respectively.
Sales have declined because of the economic factors.
Cost
of goods sold decreased $7,220 from $33,437 to $26,217, for the nine months ended September 30, 2022, and 2023, respectively. These decreases
were mainly a result of decreases in net sales for products in 2023.
Operating
expenses for the nine-month periods ended September 30, 2023, and 2022 were $1,478,652 and $2,486,052, a decrease of $1,007,400. This
decrease was mainly due to decreases in consulting and research and development expenses.
General
and administrative expenses decreased $28,613, from $388,561 to $359,948 for the nine months ended September 30, 2022, and 2023, respectively.
This decrease was mainly attributable to a decrease in marketing, advertising and selling expenses during the nine months ended September
30, 2023.
Salaries,
wages, and related expenses decreased $1,227, from $336,926 to $335,699 for the nine months ended September 30, 2022, and 2023, respectively.
This decrease was mainly due to a decrease in wage related expenses as we weren’t manufacturing our own product in-house for the
nine months ended September 30, 2023.
Consulting
fees decreased $174,377 from $317,284 to $142,907 for the nine months ended September 30, 2022, and 2023, respectively, due to a decrease
in overall consulting services. Prepaid consulting services were expensed over either a year or two years and have expired which led
to a decrease in consulting services. We had an increase in patent expense which doesn’t use consulting services.
Legal
and professional fees decreased $36,206 from $266,158 to $229,952 for the nine months ended September 30, 2022, and 2023, respectively,
due to decrease in legal expense for patents.
Research
and development decreased $766,977, from $1,177,123 to $410,146 for the nine months ended September 30, 2022, and 2023, respectively,
due to a decrease in research and development due to a contractor completing his term of research. The company has concentrated on Patents
this year to date.
Liquidity
and Capital Resources
We
have experienced recurring losses over the past years which have resulted in accumulated deficits of approximately $19.4 million and
a working capital deficit of approximately $1.9 million at September 30, 2023. These conditions raise significant doubt about the Company’s
ability to continue as a going concern. The Company’s ability to continue as a going concern is contingent upon its ability to
secure additional financing, increase sales of its products and attain profitable operations. It is the intent of management to continue
to raise additional capital. However, there can be no assurance that the Company will be able to secure such additional funds or obtain
such on terms satisfactory to the Company, if at all.
There
is no guarantee we will receive the required financing to complete our business strategies, and it is uncertain whether future financing
will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop
or expand our operations.
Off
Balance Sheet Arrangements
We
currently do not have any off-balance sheet arrangements.
Quantitative
and Qualitative Disclosures about Market Risk
As
a Smaller Reporting Company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled
disclosure reporting obligations and therefore are not required to provide this information requested by this item.
Controls
and Procedures
Disclosure
Controls and Procedures
As
required by Rule 13a-15(b) under the Securities Exchange Act of 1934, or Exchange Act, our principal executive officer and principal
financial officer evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of September
30, 2023. Based on this evaluation, these officers concluded that as of the end of the period covered by this Quarterly Report on Form
10-Q, these disclosure controls and procedures were not operating effectively to ensure that the information required to be disclosed
by the Company in reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC and include controls and procedures designed to ensure that such information is accumulated
and communicated to our management, including our principal executive officer, to allow timely decisions regarding required disclosure.
Because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues,
if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can
be faulty and that breakdowns can occur because of simple error or mistake.
Changes
in Internal Control over Financial Reporting
There
were no changes in our internal control over financial reporting that occurred during our fiscal quarter ended September 30, 2023 that
materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.
Our
management, including the Chief Executive Officer assessed the effectiveness of our internal control over financial reporting as of September
30, 2023. In making our assessment, we used the framework and criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (“COSO”) (2013). Based on that assessment, our management has identified certain material weaknesses
in our internal control over financial reporting.
Our
management concluded that as of September 30, 2023, our internal control over financial reporting was not effective, and that material
weaknesses existed in the following areas as of September 30, 2023.
|
(1) |
we
do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding
certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will
continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions; |
|
|
|
|
(2) |
we
have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process,
transaction or account changes, and the performance of account reconciliations and approval; |
|
|
|
|
(3) |
we
have ineffective controls over the period end financial disclosure and reporting process caused by insufficient accounting staff. |
Legal
Proceedings. From time to time, claims are made against us in the ordinary course of business, which could result in litigation.
Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages,
fines, penalties, or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of
an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future
periods.
However,
as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a
material adverse effect on our financial condition or results of operations.
Risk
Factors. No material changes to risk factors have occurred as previously disclosed in Item 1A of our Annual Report on Form 10-K for
the year ended December 31, 2022, which was filed with the SEC on March 29, 2023.
PROPERTIES
On
December 17, 2020, Therapeutic Solutions International, Inc. Board of Directors made a decision to move our corporate headquarters to
Elk City, Idaho 83525 and has purchased real property at 701 Wild Rose Lane and 50 Bullock Lane, Elk City Idaho 83525.
The
Company continues to maintain a leased satellite office at the current address of 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056.
GOVERNMENT
REGULATION
The
Company’s business is subject to varying degrees of regulation by a number of government authorities in the United States, including
the United States Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and the Consumer Product Safety Commission.
The Company will be subject to additional agencies and regulations if it enters the manufacturing business. Various agencies of the state
and localities in which we operate and in which our products are sold also regulate our business, such as the California Department of
Health Services, Food and Drug Branch. The areas of our business that these and other authorities regulate include, among others:
|
● |
product
claims and advertising; |
|
● |
product
labels; |
|
● |
product
ingredients; and |
|
● |
how
we package, distribute, import, export, sell and store our products. |
The
FDA, in particular, regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of vitamins
and other nutritional supplements in the United States, while the FTC regulates marketing and advertising claims. The FDA issued a final
rule called “Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body,”
which includes regulations requiring companies, their suppliers and manufacturers to meet Good Manufacturing Practices in the preparation,
packaging, storage and shipment of their products. Management is committed to meeting or exceeding the standards set by the FDA.
The
FDA has also issued regulations governing the labeling and marketing of dietary and nutritional supplement products. They include:
|
● |
the
identification of dietary or nutritional supplements and their nutrition and ingredient labeling; |
|
● |
requirements
related to the wording used for claims about nutrients, health claims, and statements of nutritional support; |
|
● |
labeling
requirements for dietary or nutritional supplements for which “high potency” and “antioxidant” claims are
made; |
|
● |
notification
procedures for statements on dietary and nutritional supplements; and |
|
● |
pre-market
notification procedures for new dietary ingredients in nutritional supplements. |
The
Dietary Supplement Health and Education Act of 1994 (DSHEA) revised the existing provisions of the Federal Food, Drug and Cosmetic Act
concerning the composition and labeling of dietary supplements and defined dietary supplements to include vitamins, minerals, herbs,
amino acids and other dietary substances used to supplement diets. DSHEA generally provides a regulatory framework to help ensure safe,
quality dietary supplements and the dissemination of accurate information about such products. The FDA is generally prohibited from regulating
active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cure or prevent
an illness, disease or malady, trigger drug status.
The
Company is also subject to a variety of other regulations in the United States, including those relating to taxes, labor and employment,
import and export, and intellectual property.
Legal
Proceedings
During
the past ten years there have been no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders
or decrees material to the evaluation of the ability and integrity of any of the persons nominated to become directors or executive officers
upon closing of the Merger Agreement, and none of these persons has been involved in any judicial or administrative proceedings resulting
from involvement in mail or wire fraud or fraud in connection with any business entity, any judicial or administrative proceedings based
on violations of federal or state securities, commodities, banking or insurance laws or regulations, or any disciplinary sanctions or
orders imposed by a stock, commodities or derivatives exchange or other self-regulatory organization.
From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However,
litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may
harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the
aggregate, a material adverse effect on our business, financial condition or operating results.
MANAGEMENT
OF THE COMPANY
The
name of the officers and directors of the Company as of December 20, 2023, as well as certain information about them, are set forth below:
Name |
|
Position |
|
Age |
Executive
Officers: |
|
|
|
|
Timothy
G. Dixon |
|
President
and Chief Executive Officer |
|
65 |
Famela
Ramos |
|
Vice
President |
|
46 |
James
Veltmeyer, MD |
|
Chief
Medical Officer |
|
58 |
Feng
Lin, MD, PhD |
|
Chief
Scientific Officer |
|
53 |
Directors: |
|
|
|
|
Thomas
E. Ichim, PhD |
|
Director |
|
48 |
Timothy
G. Dixon |
|
Chairman |
|
65 |
Background
of Officers and Directors
Timothy
G. Dixon, CEO, President, and Chairman
Mr.
Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. He also currently
serves as Chairman of Campbell Neurosciences, Inc., Allogen Biologics, Inc., Res Nov Bio, Inc., VasoSome Vascular, Inc., CTE Biologics,
Inc., and Breathe Biologics, Inc., all subsidiaries of TSOI. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006
to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011. Mr. Dixon also has extensive experience in dealing with corporate
compliance matters with the U.S. Food and Drug Administration (FDA), as well as many international regulatory bodies. Mr. Dixon is inventor
and co-inventor of 75+ patents and patents pending.
James
Veltmeyer, MD – Chief Medical Officer
Dr.
Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of
Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing
36 doctors.
Dr.
Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his
colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the most prestigious honor
awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians who was chosen four of
the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department
of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.
Feng
Lin, MD, Ph.D., – Chief Scientific Officer
Dr.
Lin has a stellar track record of drug development in the area of immunology and immuno-oncology having worked with the public company
Inovio Pharmaceuticals, where he developed technologies for gene delivery and therapeutic DNA vaccines against cancer and infectious
diseases in both R&D and clinical settings. Subsequently, Dr. Lin served as Director of Chinese Operations for MediStem Inc, which
was acquired by Intrexon in May 2014. It was the rapid clinical translation model developed by Dr. Lin at MediStem that resulted in the
company’s accelerated FDA clearance to begin clinical trials, which resulted in the sale of the company.
Dr.
Lin received his postdoctoral training at the Sanford-Burnham Medical Research Institute and his MD and Ph.D. at the Xiangya Medical
School of Central South University, China. He has authored over 20 peer-reviewed scientific publications, including several in top journals
such as Science, Cell, and Cancer Cell. He holds several patents.
Famela
Ramos – Vice President Business Development
Famela
Ramos is a Nurse, a Researcher, and a Politician. Ms. Ramos has run for Congress in the 53nd Congressional District. Ms. Ramos came to
the United States from the Philippines at the age of two, when her father joined the United States Navy. Her parents worked tirelessly
to support the family of 5 children, all of which became successful entrepreneurs and Government Employees. As a nurse, Ms. Ramos has
experience from the beginning of life, having practiced in pediatric nursing, to the end of life, having worked as a hospice nurse.
Her
excellence in nursing and research is attested by 7 peer reviewed publications that she collaborated with Academy and Industry in advancing
cutting edge research in immunology and regenerative medicine. The first paper, was a collaboration with the Moores Cancer Center and
several biotechnology companies, describing the state of the art in cancer immunotherapy, and proposing future directions. The second
paper discussed the possibility of stimulating regeneration of injured lung stem cells using specific types of laser and light based
interventions, this was a collaboration between the University of Utah and the University of California, San Diego. The third paper,
a collaboration between a nutraceutical company and Indiana University, demonstrated the beneficial effects of a nutritional supplement
on circulating stem cells in healthy volunteers. The fourth publication was the first successful use of two different types of stem cells
in a patient with heart failure, which resulted in a profound improvement. The fifth publication is a report of 114 patients that were
treated with umbilical cord blood stem cells and demonstrated safety and signals of efficacy in collaboration with a Chinese Biotech
company. The sixth publication was successful treatment of a spinal cord injury patient with stem cells. The seventh publication was
the basis for an investigational new drug (IND) application to the FDA, describing use of fat stem cells to treat aplastic anemia. Ms.
Ramos has established the Right to Try Foundation, which assists companies in utilizing this new law that allows for accelerated patient
access to experimental medication. Through this Foundation Ms. Ramos facilitated the first utilization of a cancer vaccine in the United
States and has been assisting both public and private companies. Most recently the Foundation has collaborated on filing new patents
for means of implementing the Right to Try Law.
Ms.
Ramos is a board member of Silent Voices, a Pregnancy Resource Center that provides counselling to woman in emergency pregnancies, alternatives
to abortion, and for woman that do choose abortion, post abortion support. Ms. Ramos has been endorsed by business and community leaders
as well as nationally known athletes including Dr. Peter Farrell, founder of Resmed, a $18 billion company, and Wes Chandler, an NFL
Hall of Fame San Diego Charger.
Thomas
E. Ichim, Ph.D., Director
Dr.
Ichim was appointed to the Board of Directors on January 22, 2016. Dr. Ichim also served as Chief Executive Officer and Director of Allogen
Biologics, Inc., a subsidiary of TSOI. Dr. Ichim also serves as Director of Res Nova Bio, Inc. and Breathe Biologics, Inc, also subsidiaries
of TSOI.
Dr.
Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies
including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech, Inc, bioRASI, and OncoMune LLC. To date he has published 121 peer-reviewed
articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology
Text Book.” Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr. Ichim is inventor on over 135 patents and patent
applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways.
Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell,
the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical
trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.
Dr.
Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University
of Western Ontario, London, Ontario, Canada and a Ph.D. in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.
Scientific
Advisory Board
Dr.
Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair, Department of Translational Neuro-Oncology
and Neurotherapeutics, John Wayne Cancer Institute.
Dr.
Kesari is also Director of Neuro-Oncology, Providence Saint John’s Health Center and Member, Los Angeles Biomedical Research Institute.
He is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally
recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. Dr. Kesari is on the advisory
board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against
Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. Dr.
Kesari is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences biotech startups.
Dr.
Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to
treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding
of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and
novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain
tumors and eradicate the disease.
Dr.
Francesco Marincola joined Kite in 2021 as Global Head of Cell Therapy Research. Before joining Kite, Francesco was President and
Chief Scientific Officer at Refuge Biotechnologies where responsible for the development and implementation of research and clinical
development strategies for adoptive cell therapy products and lead therapeutic programs based on nuclease deactivated CRISPR circuits.
He is also a National Institutes of Health (NIH) tenured senior investigator in cancer immunotherapy and biomarker research, and spent
23 years at the NIH, including 15 years as the Chief of the Infectious Disease and Immunogenetics Section at the NIH Clinical Center.
Previously, he also served as a distinguished research fellow in immune oncology discovery at AbbVie and as Chief Research Officer at
Sidra Research in Doha, Qatar.
The
former President of the Society for Immunotherapy of Cancer (SITC; 2013-2014), Francesco currently serves as Editor-in-Chief for several
prominent peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications and Immunotherapy,
and is the author of more than 600 peer-reviewed publications. He has edited several books including the SITC-affiliated Cancer Immunotherapy
Principles and Practice Textbook.
Dr.
Donald Banerji is a Clinical development professional with 33 years of global clinical research and development experience (Phase
I-IV) in the pharmaceutical industry. Recently retired from Novartis as Global Clinical Development Head of Respiratory and Allergy Medicine.
Recognized by peers and external scientific community as an expert in pulmonary and allergy drug development bringing several iconic
brands to market with millions of patients benefitting from treatment through improving care and outcomes for patients with respiratory
diseases. Managed multidisciplinary teams in the filing of several new drug applications. Responsibilities included strategic and tactical
planning, regulatory interactions with global health authorities, appropriate resource and budgetary management and timely execution,
approval of high-quality large drug development programs and delivery of groundbreaking data. These global programs over a span of 3
decades resulted in the approval and competitive labeling of 14 innovative medicines, including 3 inhaled steroids for asthma, a triple
combination of 2 bronchodilator and an inhaled steroid for asthma, 3 non-steroidal inhaled controller drugs for asthma, 3 intranasal
steroids for allergic rhinitis and 4 bronchodilator drugs for COPD. Signature achievements at Novartis included first to market with
the development and approval of the first to market inhaled dual combination medicine in COPD (Ultibro) and the first to market triple
combination medicine in asthma (Enerzair). With reimagining medicine as a core driver, these treatments changed the practice of medicine
and were incorporated in global treatment guidelines for COPD and asthma. Recipient of numerous corporate awards including the highest
scientific award of Distinguished Scientist 2016 for pioneering work in COPD. Published over 400 primary manuscripts and abstracts, including
the landmark study FLAME in NEJM.
Dr.
Boris Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic
viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development,
having worked closely on the development of the first cancer vaccine to be approved by a regulatory body (Melacine). Dr. Minev has also
extensive expertise in immunotherapy clinical trial designs, logistics, and regulatory issues. He has a considerable supervision &
management experience in industrial and academic settings and has excellent skills in biotech business development, communication, and
collaboration. Previously he held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where
he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology.
Dr.
Minev is also an adjunct professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director,
Laboratory of Tumor Immunology and Immunotherapy where, for more than 15 years, his research has been focused on the discovery of new
target antigens for immunotherapy of cancer and the development of optimized cancer vaccines. Prior to that, Dr. Minev worked in Dr.
Steven Rosenberg’s Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.
Dr.
Minev is an Advisory Board Member of the European Society for Translational Medicine (EUSTM). He is a member of the Scientific and Clinical
Advisory Boards of several biotechnology companies and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey
Consulting and Thomson Current Drugs, among others. He is the recipient of the European Association of Cancer Research Fellowship and
the Fogarty International Fellowship.
Dr.
Pablo Guzman is a cardiologist in Fort Lauderdale, Florida where he is on staff at Holy Cross Hospital. He received his medical degree
from University of Puerto Rico School of Medicine and his Cardiology Fellowship at The Johns Hopkins Hospital where he then spent the
first part of his career continuing his basic science and clinical research along with his clinical duties. His CV includes over 25 papers
published in peer-reviewed journals and more than 15 abstracts.
He
is a Fellow of the American College of Cardiology and practiced for more than 30 years. Dr. Guzman is well experienced in basic and clinical
research, having participated in many clinical trials. He is also the acting Chief Medical Officer of Variant Pharmaceuticals, a Specialty
Pharma company developing treatments for kidney diseases.
Dr.
Juergen Winkler is presently practicing at Quantum Functional Medicine in Carlsbad, CA, which he founded in July of 2012. In 2005
he was the co-founder of Genesis Health Systems (Integrative Cancer and Medical Treatment Center) located in Oceanside, CA. He has been
a featured speaker for: the NSCC Women’s Health Seminar, Annual IPT/IPTLD Integrative Cancer Care Conference (Multiple years),
Health Freedom Expo 2011 & 2012, the Japanese Society of Oxidative Medicine in Osaka Japan, ACOSPM 2010 & 2011 conferences, NSCC
Health and Wellness Series 2013, and various other events. He is the physician author of Chapter 5 in the Defeat Cancer book and has
been a featured physician in the Townsend Letter.
Dr.
Nassir Azimi is a cardiologist in La Mesa, California and attended Dartmouth Medical School and completed his residency at the University
of Colorado. He finished his four year fellowship in Cardiovascular and Peripheral Interventions at Yale University in New Haven. Dr.
Azimi has been in private practice for over 13 years establishing a thriving clinical practice for cardiac patients as well as treating
patients for peripheral vascular disease. He is active in Interventional Cardiology and Peripheral Interventions. Dr. Azimi is the director
of La Mesa Cardiac Center’s Nuclear Cardiology Laboratory. He is also an investigator in multiple clinical research studies for
various cardiac and peripheral diseases. He has been recognized as San Diego’s Top Interventional Cardiologists by San Diego Magazine
2013,2014,2016, 2017 and also by Castle Connoly for 2013, 2014, 2015,2016, 2017, and 2018. He is a former chief of biomedical ethics
(6 years), former chief of Medicine and former chief of Endovascular Medicine as well as Vice Chief of Cardiology at SGH. He is on the
board of directors of the California ACC where he serves as chair of the public relations committee. He is on Editorial Review Board
for multiple medical journals. He is a national speaker on various topics in cardiology and internal medicine.
Dr.
James Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University
School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency,
overseeing 36 doctors. Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014,
2016, and 2017) by his colleagues in the San Diego County Medical Society as a “Physician of Exceptional Excellence,” the
most prestigious honor awarded to a “Top Doctor” in San Diego County. He is among a select group of San Diego physicians
who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently
the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.
Dr.
Barry Glassman, DMD, DAAPM, DAACP, FICCMO, Diplomate ABDSM, FADI, is a Diplomate of the American Academy of Craniofacial Pain and
the American Academy of Pain Management, as well as a Fellow of the International College of Craniomandibular Orthopedics and the Academy
of Dentistry International, he is also on staff at the Lehigh Valley Hospital where he serves as a resident instructor of Craniofacial
Pain and Dysfunction and Dental Sleep Medicine.
Dr.
Glassman is a Diplomate of the Academy of Dental Sleep Medicine. He is on the staff at the Sacred Heart Hospital Sleep Disorder Center,
as well as serving as the Chief Dental Consultant to three other sleep centers in the Lehigh Valley. A popular and dynamic speaker, Dr.
Glassman lectures internationally, as well as throughout the United States. In addition to his extensive schedule which includes guest
lecture appearances and in-depth courses on joint dysfunction, chronic pain, headache, sleep disorders, and migraine headache, Dr. Glassman
is a frequent speaker at major chronic pain and joint dysfunction professional conferences. A graduate of the University of Pittsburgh:
Bachelor of Science 1969, Pittsburgh, Pennsylvania University of Pittsburgh School of Dental Medicine; D.M.D. 1973, Pittsburgh Pennsylvania
Post Graduate Hours in Craniomandibular Dysfunction and Sleep Disorders: Over 2500
J.
Christopher Mizer founded Vivaris in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses
in a broad range of industries that are leaders in their market niches. Mr. Mizer serves as the chairman of each of the portfolio companies
and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies
are going through periods of ownership succession and new management team members are being assembled.
Mr.
Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition,
and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs. Prior to joining Key Corp., he was Consultant
in the Capital Markets practice with Ernst & Young. He began his career as a Research Assistant with The Center for Economic Issues,
a think-tank focused on economic development. He earned the B.S. (biology, applied math), B.A. (economics), M.S. degrees (biology –
neurogenetics), and MBA (finance, accounting) degrees from Case Western Reserve University. Mr. Mizer has taught business strategy, finance
and entrepreneurship at the graduate level at Case Western Reserve University, John Carroll University, and the University of California,
San Diego and at the undergraduate at San Diego State University.
Howard
Leonhardt is an inventor and serial entrepreneur. He has 21 U.S. patents with over 100 patent claims for products for treating cardiovascular
disease and has over 40 new patent claims pending. His TALENT (Taheri-Leonhardt) stent graft developed in the early 1990′s holds
a leading world market share for repairing aortic aneurysms without surgery.
His
inventions have treated over 500,000 patients in 60 countries. In early 1999 Leonhardt founded Bioheart, Inc. www.bioheartinc.com a leader
in applying adult muscle stem cells to treat heart failure.. Leonhardt holds a Diploma in International Trade from Anoka Technical College.
He attended the University of Minnesota,Anoka Ramsey College and UCLA Extension. He holds an honorary Doctorate in Biomedical Engineering
from the University of Northern California and is an honorary alumnus of the University of Florida and Florida International University.
He is co-leader of Startup California and Founder and Chairman of The California Stock Exchange TM (Cal-X) preparing to be the first
social good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund powered by Motif Investing- www.calstockexchange.com
– He founded Cal-X Crowdfund Connect www.calxcrowdfund.com a crowdfunding campaign management co. and Cal-X Stars Business Accelerator,
Inc.www.calxstars.com a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations.
There
are 30 regenerative medtech and regenerative economy startups in the current portfolio class. His Leonhardt Ventures angels network has
raised and put to work over $145 million in 32 companies to date, most of them founded by Leonhardt. BioLeonhardt www.bioleonhardt.com
is developing the first implantable programmable and re-fillable stem cell pump. He leads CerebraCell for brain regeneration. EyeCell
for eye regeneration and AortaCell for aorta regeneration and number of other organ regeneration spin offs from his patented core technologies.
Leonhardt serves as state spokesperson in California for the JOBS ACT and Crowdfunding for Startup California and has given over 40 speeches
on the subject. He has operated Leonhardt’s Launchpads NorCal at the University of Northern California Science & Technology
Innovation Center in Rohnert Park, CA since 2008 and recently opened Leonhardt’s Launchpads Utah in Salt Lake City just off the
campus of the University of Utah. He has served on the Board of Directors of the University of Northern California, a private biomedical
engineering school, since 1999.
Family
Relationships. There are no family relationships between any director or executive officer.
Information
with Respect to Our Board of Directors. The following is a brief description of the structure and certain functions of our Board
of Directors. Each of the current directors is serving until his respective successor is duly elected, subject to earlier resignation.
We do not have standing audit, compensation or nominating committees of our Board of Directors. However, the full Board of Directors
performs all of the functions of a standing audit committee, compensation committee and nominating committee.
Audit
Committee Related Function
We
do not have a separately designated standing audit committee in place. Our full Board of Directors currently serves in that capacity.
This is due to the small number of members of our Board of Directors, the small number of executive officers involved with our company,
and the fact that we operate with few employees. Our Board of Directors will continue to evaluate, from time to time, whether a separately
designated standing audit committee should be put in place. We do not have an audit committee charter.
The
Board of Directors reviews with management and the Company’s independent public accountants the Company’s financial statements,
the accounting principles applied in their preparation, the scope of the audit, any comments made by the independent accountants upon
the financial condition of the Company and its accounting controls and procedures and such other matters as the Board of Directors deems
appropriate. Because our common stock is traded on the OTC Markets Pink Sheet, we are not subject to the listing requirements of any
securities exchange regarding audit committee related matters.
The
Board of Directors consists of two directors, Mr. Timothy G. Dixon and Dr. Thomas Ichim. Because we do not have an audit committee at
all, we disclose that we do not have any “audit committee financial expert” serving on an audit committee.
Compensation
Committee Related Function
We
do not currently have a standing compensation committee, and do not have a compensation committee charter. The full Board of Directors
currently has the responsibility of reviewing and establishing compensation for executive officers and making policy decisions concerning
salaries and incentive compensation for executive officers of the Company.
The
Company’s executive compensation program is administered by the Board of Directors, which determines the compensation of the Chief/Executive
Officer/President and the Chief Financial Officer of the Company. In reviewing the compensation of the individual executive officers,
the Board of Directors considers the recommendations of the Chief Executive Officer, other market information and current market conditions,
as well as any existing employment agreements with them.
Nominating
Committee Related Function
We
do not currently have a standing nominating committee. We have not adopted procedures by which security holders may recommend nominees
to serve on our board of directors.
Director
Independence. We do not have standing compensation, nominating, or audit committees of the board of directors, or committees performing
similar functions. We intend to form these committees in the near future.
Certain
Relationships and Related Transactions. Our Board of Directors currently consists of two directors, one of whom is an officer of
the Company. As of December 31, 2022, we disclose that we had no independent directors.
In
general, it is our policy to submit all proposed related party transactions (those of the kind and size that may require disclosure under
Regulation S-K, Item 404) to the Board of Directors for approval. The Board of Directors only approves those transactions that are on
terms comparable to, or more beneficial to us than, those that could be obtained in arm’s length dealings with an unrelated third
party. Examples of related party transactions covered by our policy are transactions in which any of the following individuals has or
will have a direct or indirect material interest: any of our directors or executive officers, any person who is known to us to be the
beneficial owner of more than 5% of our common stock, and any immediate family member of one of our directors or executive officers or
person known to us to be the beneficial owner of more than 5% of our common stock.
Section
16(a) Beneficial Ownership Reporting Compliance. Section 16(a) of the Exchange Act requires our directors and executive officers,
and persons who own more than 10% of a registered class of our equity securities, to file with the SEC initial reports of ownership and
reports of changes in ownership of common stock and other of our equity securities. Officers, directors and greater than 10% stockholders
are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.
To
our knowledge, based solely on a review of the copies of such reports furnished to us during the fiscal year ended December 31, 2021,
all Section 16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial owners were complied with.
Code
of Ethics. We have adopted a Code of Ethics for our principal executive and financial officers. Our Code of Ethics was filed as an
Exhibit to our Annual Report on Form 10-K for fiscal year 2010. We hereby undertake to provide a copy of this Code of Ethics to any person,
without charge, upon request. Requests for a copy of this Code of Ethics may be made in writing addressed to: Therapeutic Solutions International,
Inc., 4093 Oceanside Blvd, Suite B, Oceanside, California, 92056, Attn: Corporate Secretary.
EXECUTIVE
COMPENSATION
Summary
Compensation Table
The
following table summarizes the compensation paid, with respect to years ended December 31, 2022 and 2021 for services rendered to us
in all capacities, to each person who served as an executive officer of the Company:
| |
| | |
| | |
| | |
| | |
| | |
Nonequity | | |
| | |
| |
Name and | |
| | |
| | |
| | |
Stock | | |
Option | | |
Incentive Plan | | |
All Other | | |
| |
Principal | |
| | |
Salary | | |
Bonus | | |
Awards | | |
Awards | | |
Compensation | | |
Compensation | | |
Total | |
Position | |
Year | | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | | |
($) | |
Timothy G. Dixon | |
| 2022 | | |
| 240,000 | (1) | |
| | | |
| 140,800 | | |
| | | |
| | | |
| | | |
| 380,800 | |
President, CEO and CFO | |
| 2021 | | |
| 227,000 | (2) | |
| | | |
| 367,600 | | |
| | | |
| | | |
| | | |
| 594,600 | |
| |
| 2020 | | |
| 195,000 | (3) | |
| | | |
| 411,900 | | |
| | | |
| | | |
| | | |
| 607,400 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Dr. James Veltmeyer | |
| 2022 | | |
| | | |
| | | |
| 25,100 | | |
| | | |
| | | |
| | | |
| 25,100 | |
Chief Medical Officer | |
| 2021 | | |
| | | |
| | | |
| 32,000 | | |
| | | |
| | | |
| | | |
| 32,000 | |
| |
| 2020 | | |
| | | |
| | | |
| 129,100 | | |
| | | |
| | | |
| | | |
| 129,100 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Feng Lin | |
| 2022 | | |
| | | |
| | | |
| 25,100 | | |
| | | |
| | | |
| | | |
| 25,100 | |
Chief Scientific Officer | |
| 2021 | | |
| | | |
| | | |
| 32,000 | | |
| | | |
| | | |
| | | |
| 32,000 | |
| |
| 2020 | | |
| | | |
| | | |
| 125,600 | | |
| | | |
| | | |
| | | |
| 125,600 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Famela Ramos | |
| 2022 | | |
| | | |
| | | |
| 25,100 | | |
| | | |
| | | |
| | | |
| 25,100 | |
Vice President | |
| 2021 | | |
| | | |
| | | |
| 79,300 | | |
| | | |
| | | |
| | | |
| 79,300 | |
|
(1) |
$120,000
was accrued and $67,400 paid with stock as of December 31, 2022 |
|
(2)
|
$120,000
was accrued and paid with stock as of December 31, 2021 |
|
(3) |
$60,000
was accrued and unpaid as of December 31, 2020 |
Outstanding
Equity Awards. We have no outstanding equity awards.
Employment
Agreements. We do not have any employment agreements as of September 30, 2023.
Director
Compensation. When our employees serve on our Board of Directors, we do not give them any additional compensation in respect of such
Board service. Directors currently serve without compensation.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND
RELATED STOCKHOLDERS MATTERS
The
following table sets forth, as of December 18, 2023, information regarding the ownership of the Company’s outstanding shares of
common stock by (i) each person known to management to own, beneficially or of record, more than 5% of the outstanding shares of our
common stock, (ii) each director of the Company, (iii) each executive officer of the Company, and (iv) all directors and executive officers
as a group. As of December 18, 2023, a total of 3,802,666,978(2) shares of our common stock were outstanding.
Name of Beneficial Owners(1) | |
Amount and Nature of Beneficial Ownership | | |
Percent of Shares Outstanding | |
Timothy G. Dixon (i) | |
| 358,993,103 | | |
| 9.44 | % |
Thomas E. Ichim (ii) | |
| 142,000,000 | | |
| 3.73 | % |
John Peck | |
| 227,283,333 | | |
| 5.98 | % |
All directors and executive officers as a group (2 persons) i)(ii), (iv) | |
| 500,993,103 | | |
| 13.17 | % |
(1) |
Under
SEC rules (i) a person is deemed to be the beneficial owner of shares if that person has, either alone or with others, the power
to vote or dispose of those shares. The persons named in the table have sole voting and dispositive power with respect to all shares
shown as beneficially owned by them, subject to community property laws where applicable. |
(2) |
Issued
and outstanding increased from registration date to the date of this prospectus due to end of 3rd Quarter accounting ending 9/30/2023
including Tim Dixon Board authorized conversion of $105,000.00 in past 90 days accrued salary into 70,000,000 shares; and Board authorized
grant award of common stock to Dr. Ichim of 4,000,000 shares; Board grants a Stock Award to Mr. Dixon and Dr. Ichim, of 4,000,000
shares each; and 12,000,000 shares for Dr. Lin; 35,000,000 shares for Dr. Veltmeyer for intellectual property development; and 5,000,000
shares to Mr. Kelso; and 2,000,000 shares for Ms. Barnes for professional services. |
SELLING
STOCKHOLDERS
The
table below sets forth information concerning the resale of the shares of common stock by GHS, the Selling Stockholder. We will not receive
any proceeds from the resale of the common stock by the Selling Stockholders. None of the Selling Stockholders are registered broker-dealers.
The following table also sets forth the name of each person who is offering the resale of shares of common stock by this Prospectus,
the number of shares of common stock beneficially owned by each person, the number of shares of common stock that may be sold in this
offering and the percentage each person will own after the offering, assuming they sell all of the shares offered:
Name | |
Amount Beneficial Ownership Before Offering1 | | |
Percentage of Common Stock Owned Before Offering1 | | |
Amount to be Offered for the Security Holders’ Account | |
Amount to be Beneficially Owned After Offering | |
Percentage of Common Stock Owned After Offering2 |
GHS | |
| 5,000,000 | | |
| 0.013 | % | |
$10,000,000 (total on Effective Date) | |
| |
TBD% |
| |
| | | |
| 0.0 | % | |
$9,219,567.99 (currently available) | |
| |
TBD% |
TOTAL | |
| 5,000,000 | | |
| 0.013 | % | |
| |
| |
|
(1)
The number and percentage of shares beneficially owned is determined in accordance with Rule 13d-3 of the Exchange Act and the information
is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any shares
as to which the selling shareholder has sole or shared voting power or investment power and also any shares that the selling shareholder
has the right to acquire within 60 days. The 5,000,000 shares were acquired by GHS on 9/20/2022 as commitment shares for entering into
the securities Purchase Agreement.
(2)
Assumes that all of the Purchase Shares held by the selling stockholder covered by this prospectus are sold and that the selling stockholder
acquires no additional shares of common stock before the completion of this offering. However, as the selling stockholder can offer all,
some, or none of their Purchase Shares, no definitive estimate can be given as to the number of Purchase Shares that the selling stockholders
will ultimately offer or sell under this prospectus. In addition, as the number of shares per put is determined by current market price,
not definitive estimate can be given as to number of shares ultimately owned by GHS or their percentage of beneficial ownership.
DESCRIPTION
OF CAPITAL STOCK
General
This
Prospectus describes the general terms of our capital stock. The following description is not complete and may not contain all the information
you should consider before investing in our capital stock. For a more detailed description of these securities, you should read the applicable
provisions of Nevada law and our amended and restated certificate of incorporation, as amended, referred to herein as our certificate
of incorporation, and our amended and restated bylaws, referred to herein as our bylaws. When we offer to sell a particular series of
these securities, we will describe the specific terms of the series in a supplement to this Prospectus. Accordingly, for a description
of the terms of any series of securities, you must refer to both the prospectus supplement relating to that series and the description
of the securities described in this prospectus. To the extent the information contained in the prospectus supplement differs from this
summary description, you should rely on the information in the prospectus supplement.
As
of December 18, 2023, our authorized capital stock consists of an aggregate of 5,505,000,000 shares, comprised of 5,500,000,000 shares
of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time
to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of December
18, 2023, we have 3,802,666,978 shares of Common Stock and 2 Series A Preferred shares issued and outstanding.
Common
Stock
Holders
of shares of our common Stock are entitled to one vote for each commons share held on all matters submitted to a vote of our security
holders and do not have cumulative voting rights. Accordingly, holders of a majority of the shares of our common stock entitled to vote
in any election of directors may elect all of the directors standing for election. Subject to preferences that may be applicable to any
shares of preferred stock outstanding at the time, holders of shares of our common stock are entitled to receive dividends ratably, if
any, as may be declared from time to time by our board of directors out of funds legally available.
Upon
our liquidation, dissolution or winding, holders of shares of our common stock are entitled to receive ratably, our net assets available
after the payment of:
|
● |
all
secured liabilities, including any then outstanding secured debt securities which we may have issued as of such time; |
|
● |
all
unsecured liabilities, including any then outstanding unsecured debt securities which we may have issued as of such time; and |
|
● |
all
liquidation preferences on any then outstanding preferred stock. |
Holders
of shares of our common stock have no preemptive, subscription, redemption or conversion rights, and there are no redemption or sinking
fund provisions applicable to our common shares. The outstanding shares of our common stock are, and the shares offered by us in this
Offering will be, when issued and paid for, duly authorized, validly issued, fully paid and non-assessable. The rights, preferences and
privileges of holders of shares of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares
of any series of preferred stock that we may designate and issue in the future.
The
payment of dividends upon our shares of our common stock is solely within the discretion of our board of directors and dependent upon
our financial condition, results of operations, capital requirements, restrictions contained in our current or future financing instruments
and any other factors our board of directors may deem relevant. We have never declared or paid any dividends on our common shares. We
currently intend to retain our future earnings, if any, to finance the development and expansion of our business and do not intend on
paying any dividends in the foreseeable future.
Dividend
Policy. We have never declared or paid any cash dividends on our common stock.
Transfer
Agent and Registrar. The transfer agent and registrar for our common stock is New Horizon Transfer, Inc., located at 202-515 West
Pender Street, Vancouver, BC V6B 6H5, (604) 876-5526.
Listing.
Our common stock is not listed on a national securities exchange but is quoted for trading on the OTC Pink Sheets operated by OTC
Markets Group, Inc., at the OTCPK tier under the symbol “TSOI.” We have not applied to list our common stock on any other
exchange or quotation system.
Limitations
on Directors’ Liability
Our
articles of incorporation and bylaws contain provisions indemnifying our directors and officers to the fullest extent permitted by Nevada
law. Section 78.7502 of the Nevada Revised Statutes provides in part that a corporation shall have the power to indemnify any person
who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than
an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent
of another corporation or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in
a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action
or proceeding, had no reasonable cause to believe her conduct was unlawful.
The
effect of these provisions is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages
against a director for breach of the director’s fiduciary duty as a director, except that a director will be personally liable
for:
●
|
any
breach of his or her duty of loyalty to us or our stockholders; |
●
|
acts
or omissions not in good faith which involve intentional misconduct or a knowing violation of law; |
●
|
the
payment of dividends or the redemption or purchase of stock in violation of state or federal law; or |
●
|
any
transaction from which the director derived an improper personal benefit. |
This
provision does not affect a director’s liability under the federal securities laws. To the extent that our directors, officers
and controlling persons are indemnified under the provisions contained in our articles of incorporation, bylaws or Nevada law against
liabilities arising under the Securities Act, we have been advised that in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is therefore unenforceable.
Provisions
of our Certificate of Incorporation, Bylaws and Nevada Law that May Have an Anti-Takeover Effect
Certain
provisions set forth in our articles of incorporation and bylaws, as well as Nevada statutes could have the effect of discouraging potential
acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider
favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.
Articles
of Incorporation and Bylaws. In particular, articles certificate of incorporation and bylaws, among other things:
|
●
|
authorize
our board of directors to designate and issue, without further action by the stockholders, up to 5,000,000 shares of undesignated
preferred stock; |
|
●
|
provide
that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum, or by the
sole remaining director; and, |
|
●
|
provide
the board of directors with the ability to alter the bylaws without stockholder approval. |
Nevada
Anti-Takeover Laws. As a Nevada corporation, we are subject to certain anti-takeover provisions that apply to public corporations
under Nevada law. Pursuant to Section 607.0901 of the Nevada Business Corporation Act, or the Nevada Act, a publicly held Nevada corporation
may not engage in a broad range of business combinations or other extraordinary corporate transactions with an interested shareholder
without the approval of the holders of two-thirds of the voting shares of the corporation (excluding shares held by the interested shareholder),
unless:
|
●
|
the
transaction is approved by a majority of disinterested directors before the shareholder becomes an interested shareholder; |
|
●
|
the
interested shareholder has owned at least 80% of the corporation’s outstanding voting shares for at least five years preceding
the announcement date of any such business combination; |
|
●
|
the
interested shareholder is the beneficial owner of at least 90% of the outstanding voting shares of the corporation, exclusive of
shares acquired directly from the corporation in a transaction not approved by a majority of the disinterested directors; or |
|
●
|
the
consideration paid to the holders of the corporation’s voting stock is at least equal to certain fair price criteria. |
An
interested shareholder is defined as a person who, together with affiliates and associates, beneficially owns more than 10% of a corporation’s
outstanding voting shares. We have not made an election in our amended Articles of Incorporation to opt out of Section 607.0901.
In
addition, we are subject to Section 607.0902 of the Nevada Act which prohibits the voting of shares in a publicly held Nevada corporation
that are acquired in a control share acquisition unless (i) our board of directors approved such acquisition prior to its consummation
or (ii) after such acquisition, in lieu of prior approval by our board of directors, the holders of a majority of the corporation’s
voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting
of voting rights as to the shares acquired in the control share acquisition. A control share acquisition is defined as an acquisition
that immediately thereafter entitles the acquiring party to 20% or more of the total voting power in an election of directors.
Preferred
Stock
Our
articles of incorporation, and its amendments, empowers our board of directors, without action by our shareholders, to designate and
issue up to 5,000,000 shares of preferred stock from time to time in one or more series, which preferred stock may be offered by this
Prospectus and supplements thereto.
Nevada
law provides that the holders of preferred stock will have the right to vote separately as a class on any proposal involving fundamental
changes in the rights of holders of that preferred stock. This right is in addition to any voting rights provided for in the applicable
certificate of designation.
We
will fix the rights, preferences, privileges and restrictions of the preferred stock of each series in a certificate of designation relating
to that series filed with the State of Nevada. We will file as an exhibit to the registration statement of which this Prospectus is a
part or will incorporate by reference if so entitled, from a current report on Form 8-K that we file with the SEC, the form of any certificate
of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of
preferred stock. This description will include any or all of the following, as required:
|
● |
the
title and stated value; |
|
●
|
the
number of shares we are offering; |
|
●
|
the
liquidation preference per share; |
|
●
|
the
purchase price; |
|
●
|
the
dividend rate, period and payment date and method of calculation for dividends; |
|
●
|
whether
dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; |
|
●
|
any
contractual limitations on our ability to declare, set aside or pay any dividends; |
|
● |
the
procedures for any auction and remarketing, if any; |
|
●
|
the
provisions for a sinking fund, if any; |
|
●
|
the
provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase
rights; |
|
●
|
any
listing of the preferred stock on any securities exchange or market; |
|
●
|
whether
the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated,
and the conversion period; |
|
●
|
whether
the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated,
and the exchange period; |
|
●
|
voting
rights, if any, of the preferred stock; |
|
●
|
preemptive
rights, if any; |
|
●
|
restrictions
on transfer, sale or other assignment, if any; |
|
●
|
whether
interests in the preferred stock will be represented by depositary shares; |
|
●
|
a
discussion of any material or special United States federal income tax considerations applicable to the preferred stock; |
|
●
|
the
relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our
affairs; |
|
●
|
any
limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock
as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and |
|
●
|
any
other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. |
If
we issue shares of preferred stock under this prospectus, after receipt of payment therefor, the shares will be fully paid and non-assessable.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the
voting power or other rights of the holders of our common stock. Preferred stock could be issued quickly with terms designed to delay
or prevent a change in control of our Company or make removal of management more difficult. Additionally, the issuance of preferred stock
could have the effect of decreasing the market price of our common stock.
Existing
Preferred Stock. The Company currently has one classes or series of preferred stock designated: the Series A Preferred Stock. As
December 18, 2023, two shares of Series A Preferred Stock are outstanding leaving 4,998,000 treasury preferred. No other shares of preferred
stock are issued or outstanding.
Series
A Preferred Stock
On
August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to
Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall
be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on
all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all
issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination,
on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock
shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall
vote together with the holders of Common Stock as a single class.
PLAN
OF DISTRIBUTION
This
Post-Effective Amendment No. 1 and its Prospectus relates to the resale of up to 313,367,703 aggregate shares of Common Stock, which
includes 300,000,000 additional shares of common stock and 13,367,703 shares of Common Stock that are continuing to be registered, issuable
to GHS, the Selling Stockholder, pursuant to a “Purchase Notice” under an securities Purchase Agreement, dated September
19, 2022, that we entered into with GHS. The agreement permits us to issue Purchase Notices to GHS for up to ten million dollars ($10,000,000)
in shares of our common stock for 24 months or until $10,000,000 of such shares have been subject of a Purchase Notice. $9,219,567.99
continues to be available under the Purchase Agreement. GHS may sell all or a portion of the shares being offered pursuant to this prospectus
at fixed prices, at prevailing market prices at the time of sale, at varying prices or at negotiated prices.
The
purchase price of the common stock is set at eighty percent (80%) of the VWAP (volume weighted average price) of the common stock during
the ten (10) consecutive trading day period immediately preceding the date on which the Company delivers a put notice to GHS, not including
settlement date. In addition, there is an ownership limit for GHS of 4.99%.
The
selling shareholder may, from time to time, sell any or all of shares of our common stock covered hereby on the OTC Markets, or any other
stock exchange, market or trading facility on which the shares are traded or in private transactions. A selling shareholder may sell
all or a portion of the shares being offered pursuant to this prospectus at fixed prices, at prevailing market prices at the time of
sale, at varying prices or at negotiated prices. A selling shareholder may use any one or more of the following methods when selling
securities:
|
● |
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
|
● |
block
trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction; |
|
● |
purchases
by a broker-dealer as principal and resale by the broker-dealer for its account; |
|
● |
an
exchange distribution in accordance with the rules of the applicable exchange; |
|
● |
privately
negotiated transactions; |
|
● |
in
transactions through broker-dealers that agree with the selling stockholder to sell a specified number of such securities at a stipulated
price per security; |
|
● |
through
the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
|
● |
a
combination of any such methods of sale; or |
|
● |
any
other method permitted pursuant to applicable law. |
The
selling stockholder may also sell securities under Rule 144 under the Securities Act of 1933, if available, rather than under this prospectus.
Broker-dealers
engaged by the selling stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or
markdown in compliance with FINRA IM-2440.
In
connection with the sale of the securities or interests therein, the selling shareholder may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The selling shareholder may also sell securities short and deliver these securities to close out its short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The selling shareholder may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
GHS
is an underwriter within the meaning of the Securities Act of 1933 and any broker-dealers or agents that are involved in selling the
shares may be deemed to be “underwriters” within the meaning of the Securities Act of 1933 in connection with such sales.
In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act of 1933. We are required to pay certain fees and expenses
incurred by us incident to the registration of the securities.
The
selling shareholder will be subject to the prospectus delivery requirements of the Securities Act of 1933 including Rule 172 thereunder.
The
resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws.
In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.
Regulation
M. Regulation M is intended to preclude manipulative conduct by persons with an interest in the outcome of an offering. Under applicable
rules and regulations under the Securities Exchange Act of 1934, any person engaged in the distribution of the resale securities may
not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined
in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholder will be subject to applicable provisions
of the Securities Exchange Act of 1934 and the rules and regulations thereunder, including Regulation M, which may limit the timing of
purchases and sales of securities of the common stock by the selling stockholder or any other person.
In
general, Rule 101 of Regulation M prohibits distribution participants and their affiliated purchasers from bidding for, purchasing, or
attempting to induce any person to bid for or purchase, a covered security during a specified period (restricted period). Consequently,
Regulation M may prohibit GHS and any other distribution participants that are participating in the distribution of the Company’s
securities from purchasing shares in the open market during the time period the equity line financing provided by GHS through the securities
Purchase Agreement is in effect.
We
will make copies of this prospectus available to the selling stockholder and will inform it of the need to deliver a copy of this prospectus
to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act of 1933).
LEGAL
MATTERS
Rule
415. Certain securities being registered on this Form are to be offered on pursuant to the securities Purchase Agreement (“PA”)
(See Exhibit 1.1). The common stock registered hereunder may be sold by us or any of the selling stockholders, separately, or in combination
with us, at various times within the Commitment period under the securities PA, which terminates September 19, 2024 (the “Maturity
Date”).
Rule
144 Shares. Currently, none of our securities may be resold pursuant to Rule 144 unless an exemption from registration exists.
The
securities sold in this offering can only be resold through registration under Section 5 of the Securities Act of 1933, Section 4(1),
if available, for non-affiliates or by meeting the conditions of Rule 144(i). A holder of our securities may not rely on the safe harbor
from being deemed statutory underwriter under Section 2(11) of the Securities Act, as provided by Rule 144, to resell his or her securities.
“Form 10 information” is, generally speaking, the same type of information as we are required to disclose in this Prospectus,
but without an offering of securities.
Hugh
D. Kelso III, Esq., has opined on the validity of the shares of common stock being offered hereby (see Exhibit 5.1).
Instruction
1 to Item 509 of Regulation S-K requires disclosing whether the interest of any expert or counsel named in the Prospectus exceeds $50,000.
The interest of any expert or counsel named in the Prospectus does not exceed $50,000 according to Instruction 1 Item 509 of Regulation
S-K.
EXPERTS
Our
financial statements for the year ended December 31, 2021, and the year ended December 31, 2022, were audited by Fruci & Associates
II, PLLC and are included in reliance upon such reports given upon the authority of Fruci & Associates II, PLLC, as experts in accounting
and auditing (see Index to Financials, F1. Consent to use for this S-1 received. (see Exhibit 23.1).
DISCLOSURE
OF COMMISSION POSITION ON INDEMNIFICATION
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling
the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is therefore unenforceable.
ADDITIONAL
INFORMATION
Upon
the effective date of the registration statement of which this prospectus is a part, we will be required to file reports and other documents
with the SEC. You may also read and copy any materials we file with the SEC at the public reference room of the SEC at 100 F Street,
NE., Washington, DC 20549, between the hours of 10:00 a.m. and 3:00 p.m., except federal holidays and official closings, at the Public
Reference Room. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Our SEC
filings are also available to you on the Internet website for the SEC at http://www.sec.gov.
INDEX
TO FINANCIAL STATEMENTS
F-1 |
Interim Condensed Consolidated Balance Sheets for September 30, 2023 |
F-1 |
|
|
|
F-2 |
Interim Condensed Consolidated Statements of Operations (Unaudited) for September 30, 2023 |
F-2 |
|
|
|
F-3 |
Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) for September 30, 2023 |
F-3 |
|
|
|
F-4 |
Interim Condensed Consolidated Statements of Cash Flows (Unaudited) for September 30, 2023 |
F-5 |
|
|
|
F-5 |
Interim NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS for September 30, 2023 |
F-6 |
|
|
|
F-6 |
Report of Independent Registered Public Accounting Firms |
F-18 |
|
|
|
F-7 |
Consolidated Balance Sheets as of December 31, 2022 and 2021 |
F-19 |
|
|
|
F-8 |
Consolidated Statements of Operations for two full years ended December 31, 2022 and for December 31, 2021 |
F-20 |
|
|
|
F-9 |
Consolidated Statements of Stockholders’ Deficit for two full years ended December 31, 2022 and for December 31, 2021 |
F-21 |
|
|
|
F-10 |
Consolidated Statements of Cash Flows for two full years ended December 31, 2022 and for December 31, 2021 |
F-22 |
|
|
|
F-11 |
Consolidated Notes to Financial Statements, December 31, 2022 |
F-23 |
INDEX
TO EXHIBITS
Note:
Exhibits 1.1, 3.1, 3.2, 3.3, and 107.1 are incorporated by reference from effective S-1A dated February 15, 2023.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Condensed
Consolidated Balance Sheets
| |
September 30,
2023 | | |
December 31, 2022 | |
| |
(Unaudited) | | |
| |
| |
| | |
| |
ASSETS |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 90,138 | | |
$ | 18,040 | |
Restricted cash | |
| - | | |
| 11,003 | |
Accounts receivable | |
| 21,764 | | |
| 25,398 | |
Inventory | |
| 26,418 | | |
| 42,428 | |
Prepaid expenses and other current assets | |
| 42,661 | | |
| 212,352 | |
Total current assets | |
| 180,981 | | |
| 309,221 | |
| |
| | | |
| | |
Property and equipment, net | |
| 377,076 | | |
| 273,078 | |
Right-of-use asset | |
| 131,818 | | |
| 8,612 | |
Other assets | |
| 2,784,502 | | |
| 3,014,620 | |
| |
| | | |
| | |
Total assets | |
$ | 3,474,377 | | |
$ | 3,605,531 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY |
| |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 374,459 | | |
$ | 401,992 | |
Accounts payable-related parties | |
| 7,206 | | |
| 7,209 | |
Accrued expenses and other current liabilities | |
| 601,446 | | |
| 531,783 | |
Lease liability | |
| 26,786 | | |
| 8,612 | |
Notes payable, current portion | |
| 4,638 | | |
| 4,638 | |
Convertible notes payable, net of discount of $157,861 and $175,063, at September 30, 2023 and December 31, 2022, respectively | |
| 46,139 | | |
| 65,187 | |
Notes payable-related parties, net | |
| 699,866 | | |
| 988,672 | |
Derivative liabilities | |
| 292,699 | | |
| 202,144 | |
Total current liabilities | |
| 2,053,239 | | |
| 2,210,237 | |
| |
| | | |
| | |
LONG TERM LIABILITIES | |
| | | |
| | |
Notes payable, net of current portion | |
| 6,810 | | |
| 10,507 | |
Lease liability, net of current portion | |
| 105,032 | | |
| - | |
TOTAL LIABILITIES | |
| 2,165,081 | | |
| 2,220,744 | |
| |
| | | |
| | |
Commitments and contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
Shareholders’ Equity: | |
| | | |
| | |
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 2 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | |
| - | | |
| - | |
Common stock, $0.001 par value; 5,500,000,000 shares authorized; 3,450,665,355 and 2,617,390,830 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively. | |
| 3,450,666 | | |
| 2,617,392 | |
Additional paid-in capital | |
| 17,282,608 | | |
| 16,334,129 | |
Shares to be issued | |
| 13,074 | | |
| 126,324 | |
Subscription receivable | |
| (21,000 | ) | |
| (21,000 | ) |
Accumulated deficit | |
| (19,414,380 | ) | |
| (17,672,058 | ) |
Total shareholders’ equity | |
| 1,310,968 | | |
| 1,384,787 | |
Non-controlling interest | |
| (1,672 | ) | |
| - | |
Total shareholders’ equity - Therapeutic Solutions International, Inc. | |
| 1,309,296 | | |
| 1,384,787 | |
| |
| | | |
| | |
Total liabilities and shareholders’ equity | |
$ | 3,474,377 | | |
$ | 3,605,531 | |
See
accompanying notes to condensed consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Condensed
Consolidated Statements of Operations
(Unaudited)
| |
For the Three Months Ended September 30, 2023 | | |
For the Three Months Ended September 30, 2022 | | |
For the Nine Months Ended September 30, 2023 | | |
For the Nine Months Ended September 30, 2022 | |
| |
| | |
| | |
| | |
| |
Net sales | |
$ | 25,730 | | |
$ | 74,541 | | |
$ | 75,161 | | |
$ | 198,188 | |
Cost of goods sold | |
| 7,052 | | |
| 8,790 | | |
| 26,217 | | |
| 33,437 | |
| |
| | | |
| | | |
| | | |
| | |
Gross profit | |
| 18,678 | | |
| 65,751 | | |
| 48,944 | | |
| 164,751 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
General and administrative | |
| 127,204 | | |
| 204,838 | | |
| 359,948 | | |
| 388,561 | |
Salaries, wages, and related costs | |
| 111,220 | | |
| 110,108 | | |
| 335,699 | | |
| 336,926 | |
Consulting fees | |
| 20,150 | | |
| 88,158 | | |
| 142,907 | | |
| 317,284 | |
Legal and professional fees | |
| 68,560 | | |
| 106,795 | | |
| 229,952 | | |
| 266,158 | |
Research and development | |
| 148,879 | | |
| 275,071 | | |
| 410,146 | | |
| 1,177,123 | |
Total operating expenses | |
| 476,013 | | |
| 784,970 | | |
| 1,478,652 | | |
| 2,486,052 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (457,335 | ) | |
| (719,219 | ) | |
| (1,429,708 | ) | |
| (2,321,301 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Gain (loss) on derivative liabilities | |
| (2,336 | ) | |
| (26,867 | ) | |
| 21,939 | | |
| (136,583 | ) |
Change in fair value of derivative liabilities | |
| (60,124 | ) | |
| (32,205 | ) | |
| (93,836 | ) | |
| 233,303 | |
Interest expense | |
| (83,062 | ) | |
| (167,371 | ) | |
| (327,135 | ) | |
| (512,761 | ) |
Other expense | |
| | | |
| | | |
| | | |
| | |
Gain on extinguishment of debt | |
| - | | |
| - | | |
| 85,546 | | |
| - | |
Total other income (expense) | |
| (145,522 | ) | |
| (226,443 | ) | |
| (313,486 | ) | |
| (416,041 | ) |
| |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Provision for income taxes | |
| - | | |
| 800 | | |
| 800 | | |
| 800 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss before non-controlling interest | |
| (602,857 | ) | |
| (946,462 | ) | |
| (1,743,994 | ) | |
| (2,738,142 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss attributable to non-controlling interest | |
| (816 | ) | |
| - | | |
| (1,672 | ) | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to Therapeutic Solutions International, Inc. | |
$ | (602,041 | ) | |
$ | (946,462 | ) | |
$ | (1,742,322 | ) | |
$ | (2,738,142 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share - basic and diluted | |
$ | (0.00 | ) | |
$ | (0.00 | ) | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average shares outstanding - basic and diluted | |
| 3,286,909,395 | | |
| 2,565,663,048 | | |
| 2,987,459,958 | | |
| 2,501,116,667 | |
See
accompanying notes to condensed consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Condensed
Consolidated Statements of Changes in Shareholders’ Equity (Deficit)
(Unaudited)
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| |
Series A Preferred Stock | | |
Common Stock | | |
Additional Paid-in | | |
Shares to be | | |
Subscription | | |
Accumulated | | |
Non-
controlling | | |
Total Shareholders’
Equity | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Issued | | |
Receivable | | |
Deficit | | |
Interest | | |
(Deficit) | |
December 31, 2021 | |
| - | | |
$ | - | | |
| 2,311,123,860 | | |
$ | 2,311,125 | | |
$ | 10,899,139 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (13,994,246 | ) | |
$ | - | | |
$ | (804,982 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 25,302,577 | | |
| 25,303 | | |
| 482,775 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 508,078 | |
Common stock issued for prepaid fees | |
| - | | |
| - | | |
| 11,000,000 | | |
| 11,000 | | |
| 231,320 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 242,320 | |
Common stock issued for salaries | |
| - | | |
| - | | |
| 1,034,482 | | |
| 1,034 | | |
| 28,965 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 29,999 | |
Common stock issued for cash | |
| - | | |
| - | | |
| 44,500,000 | | |
| 44,500 | | |
| 400,500 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 445,000 | |
Common stock issued for license | |
| - | | |
| - | | |
| 149,402,390 | | |
| 149,402 | | |
| 2,958,168 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,107,570 | |
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities | |
| - | | |
| - | | |
| 41,700,228 | | |
| 41,700 | | |
| 901,732 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 943,432 | |
Common stock issued for land development | |
| | | |
| | | |
| 4,000,000 | | |
| 4,000 | | |
| 46,400 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 50,400 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,738,142 | ) | |
| - | | |
| (2,738,142 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
September 30, 2022 | |
| - | | |
$ | - | | |
| 2,588,063,537 | | |
$ | 2,588,064 | | |
$ | 15,948,999 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (16,732,388 | ) | |
$ | - | | |
$ | 1,783,675 | |
| |
Series A Preferred Stock | | |
Common Stock | | |
Additional Paid-in | | |
Shares to be | | |
Subscription | | |
Accumulated | | |
Non-
controlling | | |
Total Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Issued | | |
Receivable | | |
Deficit | | |
Interest | | |
Equity | |
June 30, 2022 | |
| - | | |
$ | - | | |
| 2,552,228,460 | | |
$ | 2,552,228 | | |
$ | 15,467,138 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (15,785,926 | ) | |
$ | - | | |
$ | 2,212,440 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 9,302,577 | | |
| 9,303 | | |
| 91,575 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 100,878 | |
Common stock issued for prepaid fees | |
| - | | |
| - | | |
| 5,000,000 | | |
| 5,000 | | |
| 88,500 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 93,500 | |
Common stock issued for land development | |
| - | | |
| - | | |
| 4,000,000 | | |
| 4,000 | | |
| 46,400 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 50,400 | |
Common stock issued for conversion of convertible notes, accrued interest, and derivative liabilities | |
| - | | |
| - | | |
| 17,532,500 | | |
| 17,533 | | |
| 255,386 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 272,919 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (946,462 | ) | |
| - | | |
| (946,462 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
September 30, 2022 | |
| - | | |
$ | - | | |
| 2,588,063,537 | | |
$ | 2,588,064 | | |
$ | 15,948,999 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (16,732,388 | ) | |
$ | - | | |
$ | 1,783,675 | |
| |
Series A Preferred Stock | | |
Common Stock | | |
Additional Paid-in | | |
Shares to be | | |
Subscription | | |
Accumulated | | |
Non-
controlling | | |
Total Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Issued | | |
Receivable | | |
Deficit | | |
Interest | | |
Equity | |
December 31, 2022 | |
| 2 | | |
$ | - | | |
| 2,617,390,830 | | |
$ | 2,617,392 | | |
$ | 16,334,129 | | |
$ | 126,324 | | |
$ | (21,000 | ) | |
$ | (17,672,058 | ) | |
$ | - | | |
$ | 1,384,787 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 47,757,394 | | |
| 47,757 | | |
| 136,654 | | |
| (98,250 | ) | |
| - | | |
| - | | |
| - | | |
| 86,161 | |
Common stock issued for salaries | |
| - | | |
| - | | |
| 4,081,632 | | |
| 4,082 | | |
| 15,918 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 20,000 | |
Common stock issued for cash | |
| - | | |
| - | | |
| 445,180,614 | | |
| 445,180 | | |
| 232,198 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 677,378 | |
Common stock issued by subsidiary for services | |
| - | | |
| - | | |
| | | |
| - | | |
| 1,831 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,831 | |
Common stock issued for land development | |
| - | | |
| - | | |
| 60,000,000 | | |
| 60,000 | | |
| 36,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 96,000 | |
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | |
| - | | |
| - | | |
| 276,254,885 | | |
| 276,255 | | |
| 525,878 | | |
| (15,000 | ) | |
| - | | |
| - | | |
| - | | |
| 787,133 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,742,322 | ) | |
| (1,672 | ) | |
| (1,743,994 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
September 30, 2023 | |
| 2 | | |
$ | - | | |
| 3,450,665,355 | | |
$ | 3,450,666 | | |
$ | 17,282,608 | | |
$ | 13,074 | | |
$ | (21,000 | ) | |
$ | (19,414,380 | ) | |
$ | (1,672 | ) | |
$ | 1,309,296 | |
| |
Series A Preferred
Stock | | |
Common Stock | | |
Additional Paid-in | | |
Shares to be | | |
Subscription | | |
Accumulated | | |
Non-
controlling | | |
Total Shareholders’
Equity | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Issued | | |
Receivable | | |
Deficit | | |
Interest | | |
(Deficit) | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
June 30, 2023 | |
| 2 | | |
$ | - | | |
| 3,134,044,074 | | |
$ | 3,134,045 | | |
$ | 17,181,978 | | |
$ | 9,324 | | |
$ | (21,000 | ) | |
$ | (18,812,339 | ) | |
$ | (856 | ) | |
$ | 1,491,152 | |
Balance | |
| 2 | | |
$ | - | | |
| 3,134,044,074 | | |
$ | 3,134,045 | | |
$ | 17,181,978 | | |
$ | 9,324 | | |
$ | (21,000 | ) | |
$ | (18,812,339 | ) | |
$ | (856 | ) | |
$ | 1,491,152 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 1,757,394 | | |
| 1,757 | | |
| 1,054 | | |
| 3,750 | | |
| - | | |
| - | | |
| - | | |
| 6,561 | |
Common stock issued for prepaid
fees | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Common stock issued for salaries | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Common stock issued for cash | |
| - | | |
| - | | |
| 175,089,179 | | |
| 175,089 | | |
| 13,937 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 189,026 | |
Common stock issued by subsidiary
for services | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Common stock issued for land
development | |
| - | | |
| - | | |
| 60,000,000 | | |
| 60,000 | | |
| 36,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 96,000 | |
Common stock issued for conversion
of convertible notes, accrued interest and derivative liabilities | |
| - | | |
| - | | |
| 79,774,708 | | |
| 79,775 | | |
| 49,639 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 129,414 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (602,041 | ) | |
| (816 | ) | |
| (602,857 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
September 30, 2023 | |
| 2 | | |
$ | - | | |
| 3,450,665,355 | | |
$ | 3,450,666 | | |
$ | 17,282,608 | | |
$ | 13,074 | | |
$ | (21,000 | ) | |
$ | (19,414,380 | ) | |
$ | (1,672 | ) | |
$ | 1,309,296 | |
Balance | |
| 2 | | |
$ | - | | |
| 3,450,665,355 | | |
$ | 3,450,666 | | |
$ | 17,282,608 | | |
$ | 13,074 | | |
$ | (21,000 | ) | |
$ | (19,414,380 | ) | |
$ | (1,672 | ) | |
$ | 1,309,296 | |
See
accompanying notes to condensed consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Condensed
Consolidated Statements of Cash Flows
(Unaudited)
| |
For the Nine Months Ended
September 30, 2023 | | |
For the Nine Months Ended
September 30, 2022 | |
| |
| | |
| |
Cash flows from operating activities | |
| | | |
| | |
Net loss | |
| (1,742,322 | ) | |
| (2,738,142 | ) |
Net loss | |
$ | (1,743,994 | ) | |
$ | (2,738,142 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Stock-based compensation to consultants | |
| - | | |
| 311,078 | |
Stock-based compensation to related parties | |
| 86,161 | | |
| 197,000 | |
Loss on derivative liabilities | |
| (21,939 | ) | |
| 136,583 | |
Change in fair value of derivative liabilities | |
| 93,836 | | |
| (233,303 | ) |
Gain on extinguishment of debt | |
| (85,546 | ) | |
| - | |
Amortization of prepaid stock-based compensation | |
| 112,971 | | |
| 868,089 | |
Amortization of debt discount | |
| 299,267 | | |
| 461,058 | |
Patent amortization | |
| 222,581 | | |
| 191,192 | |
Depreciation | |
| 8,161 | | |
| 3,489 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| 3,634 | | |
| (25,769 | ) |
Inventory | |
| 16,010 | | |
| (5,126 | ) |
Prepaid expenses and other current assets | |
| 69,595 | | |
| 73,807 | |
Right-of-use asset | |
| 23,038 | | |
| 19,113 | |
Accounts payable | |
| (27,535 | ) | |
| (30,051 | ) |
Accounts payable - related parties | |
| (3 | ) | |
| (2,552 | ) |
Accrued expenses and other current liabilities | |
| 117,538 | | |
| 139,405 | |
Lease liability | |
| (23,038 | ) | |
| (19,113 | ) |
Net cash used in operating activities | |
| (849,263 | ) | |
| (653,242 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchases of property and equipment | |
| (16,158 | ) | |
| - | |
Deposits | |
| | | |
| | |
Purchase of license | |
| - | | |
| (200,000 | ) |
Issuance of note receivable | |
| (3,507 | ) | |
| - | |
Net cash used in investing activities | |
| (19,665 | ) | |
| (200,000 | ) |
| |
| | | |
| | |
Cash flows from financing activities | |
| | | |
| | |
Payments on notes payable to related party | |
| (17 | ) | |
| (2,444 | ) |
Proceeds from notes payable to related party | |
| 5,609 | | |
| - | |
Proceeds from convertible notes payable | |
| 250,750 | | |
| 415,000 | |
Payments on notes payable | |
| (3,697 | ) | |
| (3,324 | ) |
Proceeds from sale of common stock | |
| 677,378 | | |
| 445,000 | |
Net cash provided by financing activities | |
| 930,023 | | |
| 854,232 | |
| |
| | | |
| | |
Net increase (decrease) in cash, cash equivalents and restricted cash | |
| 61,095 | | |
| 990 | |
Cash, cash equivalents and restricted cash at beginning of period | |
| 29,043 | | |
| 104,259 | |
Cash, cash equivalents and restricted cash at end of period | |
$ | 90,138 | | |
$ | 105,249 | |
| |
| | | |
| | |
Supplemental cash flow information: | |
| | | |
| | |
Cash paid for interest | |
$ | 2,475 | | |
$ | 2,357 | |
Cash paid for income taxes | |
$ | - | | |
$ | 800 | |
| |
| | | |
| | |
Non-cash investing and financing transactions: | |
| | | |
| | |
Original issuance discount on convertible notes payable | |
$ | 32,500 | | |
$ | 30,500 | |
Debt discount recorded in connection with derivative liability | |
$ | 249,565 | | |
$ | 415,000 | |
Common stock issued in conversion of convertible notes payable and interest | |
$ | 787,133 | | |
$ | 943,431 | |
Property and equipment purchased with note payable | |
| | | |
| | |
Common stock issued for prepaid fees | |
$ | 1,831 | | |
$ | 242,320 | |
Common stock issued for accrued salaries | |
$ | 20,000 | | |
$ | 29,999 | |
Accrued interest added to principal | |
$ | 11,148 | | |
$ | 19,436 | |
Common stock issued for license | |
$ | - | | |
$ | 3,107,570 | |
Common stock issued for land development | |
$ | 96,000 | | |
$ | 50,400 | |
Right of use asset and lease liability | |
$ | 146,244 | | |
$ | - | |
| |
| | | |
| | |
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 90,138 | | |
$ | 94,246 | |
Restricted cash | |
| - | | |
| 11,003 | |
Total cash, cash equivalents, and restricted cash shown in
the consolidated statements of cash flows: | |
$ | 90,138 | | |
$ | 105,249 | |
See
accompanying notes to condensed consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Note
1 – Organization and Business Description
Therapeutic
Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007, under the name Friendly
Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto
Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.
Business
Description
Currently
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one’s immune system.
Activating
one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.
TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.
Nutraceutical
Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechin-3-gallate, and thymoquinone. QuadraMune has been shown to increase Natural
Killer Cell activity and healthy Cytokine production.
Regenerative
Medicine – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
The
stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal
like stromal cells.
Immunotherapies
TSOI
has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to parkinson’s disease developed on
our StemVacs platform.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Management
does not expect existing cash as of September 30, 2023, to be sufficient to fund the Company’s operations for at least twelve months
from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed
the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2023,
the Company has incurred losses totaling $19.4 million since inception, has not yet generated material revenue from operations, and will
require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue
as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as
a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its
obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating
costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings,
debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required
to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments
to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the
Company be unable to continue as a going concern.
Note
2 – Basis of presentation and significant accounting policies
Basis
of Presentation
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries,
and its 68% owned subsidiary Res Nova Bio, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
No material activity in any subsidiaries.
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
|
1) |
Identify
the contract with a customer. |
|
|
|
|
2) |
Identify
the performance obligations in the contract. |
|
|
|
|
3) |
Determine
the transaction price. |
|
|
|
|
4) |
Allocate
the transaction price to the performance obligations in the contract. |
|
|
|
|
5) |
Recognize
revenue when (or as) the entity satisfies a performance obligation. |
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
Revenue is adjusted based on an estimate of the expected returns based on historical rates. Our
estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we
consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel
as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision
for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s
revenues in the accompanying financial statements.
Wholesale
policies:
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional
Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned
products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the
aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense
Retail
policies of e-commerce:
Shipping.
Shipping Time — Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed
or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or
transit time offered to the customer by this site or other parties only as an estimate. We encourage the customer to order in a timely
fashion to avoid delays caused by shipping or product availability. Fulfillment mistakes that may be made which result in the shipment
of incorrect products to the customer will also be accepted for return.
Out
of Stock. We will ship the customer’s product as it becomes available. Usually, products ship by the next business day. However,
there may be times when the product the customer had ordered is out-of-stock, which will delay fulfilling the customer’s order.
We will keep the customer informed of any products that the customer had ordered that are out-of-stock and unavailable for immediate
shipment. The Customer may cancel their order at any time prior to shipping.
Cash
and Cash Equivalents
The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2023 and December
31, 2022, the Company had $0 and $0 in excess of the FDIC insured limit.
Inventories
Inventories
are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials
and assembly items.
Derivative
Liabilities
A
derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the
Company entered into certain debt financing transactions in fiscal 2023 and 2022, as disclosed in Note 7 containing certain
conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to
properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments
indexed to our common shares on a first-in-first-out basis.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $292,699
and $202,144 at September 30, 2023 and December 31, 2022, respectively.
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of September 30, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative
liabilities. The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the three months ended September 30, 2023:
Schedule
of Change in Derivative Liability
Balance, December 31, 2022 | |
$ | 202,144 | |
Issuance of new derivative liabilities | |
| 328,433 | |
Conversions | |
| (331,714 | ) |
Change in fair market value of derivative liabilities | |
| 93,836 | |
Balance, September 30, 2023 | |
$ | 292,699 | |
Use
of Estimates
Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.
Comprehensive
Loss
Comprehensive
loss for the periods reported was comprised solely of the Company’s net loss.
Non-Controlling
Interests
Non-controlling
interests disclosed within the consolidated statement of operations represent the minority ownership’s 32% share of net losses
of Res Nova Bio, Inc. incurred during the nine months ended September 30, 2023.
Net
Loss Per Share
Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of September 30, 2023, and 2022, a total of 1,259,591,300 and 211,919,728, respectively,
potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would
be antidilutive.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Depreciation
and Amortization
Depreciation
is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line
method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2023, and 2022 was $8,161 and $3,489,
respectively.
Intangible
Assets
Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2023, and 2022 was $222,581 and
$191,192, respectively.
Long-lived
Assets
In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.
Research
and Development
Research
and Development costs are expensed as incurred. Research and Development expenses were $410,146 and $1,177,123 for the nine months ended
September 30, 2023, and 2022, respectively.
Income
Taxes
The
Company accounts for income taxes under ASC 740 “Income Taxes,” which codified SFAS 109, “Accounting for
Income Taxes” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No.
109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided
for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
Stock-Based
Compensation
Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.
Leases
On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $131,818 as of September 30, 2023.
Recently
Issued Accounting Pronouncements
In
August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
(“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models
for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result,
more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion
features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use
of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using
either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller
reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those
fiscal years. The accounting guidance has been adopted with no significant financial statement impact.
Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company’s financial statement presentation or disclosures.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Note
3 – Prepaid expense and other current assets
Prepaid
expenses and other current assets consist of the following:
Schedule of Prepaid Expenses and Other Current Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Prepaid consulting | |
$ | 16,939 | | |
$ | 148,550 | |
Insurance | |
| 1,601 | | |
| 1,141 | |
Prepaid costs and other | |
| 24,121 | | |
| 62,661 | |
Total | |
$ | 42,661 | | |
$ | 212,352 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Note
4 – Fixed assets
Fixed
assets consist of the following:
Schedule of Fixed Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Land | |
$ | 347,381 | | |
$ | 235,223 | |
Vehicles | |
| 50,514 | | |
| 50,514 | |
Computer hardware | |
| 6,135 | | |
| 6,135 | |
Office furniture and equipment | |
| 7,912 | | |
| 7,912 | |
Shipping and other equipment | |
| 1,575 | | |
| 1,575 | |
Total | |
| 413,517 | | |
| 301,359 | |
Accumulated depreciation | |
| (36,441 | ) | |
| (28,281 | ) |
Property and equipment, net | |
$ | 377,076 | | |
$ | 273,078 | |
Depreciation
expense was $8,161 and $3,489 for the nine months ended September 30, 2023, and 2022, respectively.
Note
5 – Other assets
Other
assets consist of the following:
Schedule of Other Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Prepaid consulting | |
$ | - | | |
$ | 7,537 | |
Deposit | |
| 4,123 | | |
| 4,123 | |
Licenses, net | |
| 2,780,379 | | |
| 3,002,960 | |
Total | |
$ | 2,784,502 | | |
$ | 3,014,620 | |
As
of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December
31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy),
and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived
from US Patent No.: 9,803,176 B2.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:
Schedule of Net Licenses
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
License | |
$ | 3,261,122 | | |
$ | 3,261,122 | |
Accumulated amortization | |
| (480,743 | ) | |
| (258,162 | ) |
Licenses, net | |
$ | 2,780,379 | | |
$ | 3,002,960 | |
Amortization
expense for the nine months ended September 30, 2023, and 2022 was $222,581 and $191,192.
Note
6 - Notes Payable-Related Party
At
September 30, 2023 and December 31, 2022, the Company has unsecured interest-bearing demand notes outstanding to certain officers and
directors amounting to $694,257 and $988,672 respectively. Interest accrued on these notes during the nine months ended September 30,
2023, and 2022 was $3,956 and $12,956, respectively.
Note
7 – Convertible Notes Payable
At
various times during the nine months ended September 30, 2023, the Company entered into convertible promissory notes with principal amounts
totaling $283,250 with a third party for which the proceeds were used for operations. The Company received net proceeds of $250,750,
and an $32,500 original issuance discount was recorded. The convertible promissory notes incur interest at 10% per annum and mature on
dates ranging from April 11, 2024, to September 29, 2024. The convertible promissory notes are convertible to shares of the Company’s
common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices
of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay
the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the
default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company
was required to reserve at September 30, 2023 a total of 1,259,591,300 common shares in connection with these promissory notes.
Derivative
liabilities
These
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number
of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented
an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability
is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes
in the derivative liability fair value are reported in operating results each reporting period.
For
the notes issued during the nine months ended September 30, 2023, the Company valued the conversion feature on the date of issuance resulting
in an initial liability of $628,437. Since the fair value of the derivative was in excess of the proceeds received, a full discount to
convertible notes payable and a day one loss on derivative liabilities of $78,868 was recorded during the nine months ended September
30, 2023. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $0.0008 to $0.0034, the closing stock price of the Company’s common stock on the date of valuation
ranging from $0.0011 to $0.006, an expected dividend yield of 0%, expected volatility ranging from 124% to 160%, risk-free interest rate
ranging from 4.67% to 5.46%, and an expected term of one year.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
During
the nine months ended September 30, 2023, convertible notes with principal and accrued interest balances totaling $338,577
were converted into 218,504,885
shares of common stock. At each conversion date,
the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection
with the change in fair market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata
portion of the derivative liability as compared to the portion of the convertible note converted was recorded as a loss or gain on derivative
liabilities. During the nine months ended September 30, 2023, the Company recorded $100,807
to gain on derivative liabilities in connection
with these conversions. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $0.0008
to $0.004,
the closing stock price of the Company’s common stock on the date of valuation ranging from $0.001
to $0.006,
an expected dividend yield of 0%,
expected volatility ranging from 110%
to 193%,
risk-free interest rates ranging from 4.55%
to 5.37%,
and expected terms of 0.48
to 0.50
years.
On
September 30, 2023, the derivative liabilities on the remaining convertible notes were revalued at $292,699 resulting in a gain of $93,836
for the nine months ended September 30, 2023, related to the change in fair value of the derivative liabilities. The derivative liabilities
were revalued using the Black-Scholes option pricing model with the following assumptions: exercise prices of $0.0008, the closing stock
price of the Company’s common stock on the date of valuation of $0.002, an expected dividend yield of 0%, expected volatility ranging
from 157% to 175%, risk-free interest rate of 5.46%, and an expected term ranging from 0.53 to 1 years.
The
Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to
the effective interest method. During the nine months ended September 30, 2023, and 2022, the Company amortized $299,268 and $461,058
to interest expense, respectively. As of September 30, 2023, discounts of $157,861 remained which will be amortized through September
2024.
Note
8 – Equity
Our
authorized capital stock consists of an aggregate of 5,505,000,000 shares, comprised of 5,500,000,000 shares of common stock, par value
$0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences,
privileges, and restrictions of which shall be established by our board of directors. As of September 30, 2023, we have 3,450,665,355
shares of common stock and 2 shares preferred shares issued and outstanding.
Our
non-controlling interest’s authorized capital stock consists of an aggregate of 505,000,000 shares, comprised of 500,000,000 shares
of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time
to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of September
30, 2023, we have 18,308,333 shares of common stock and 0 shares preferred shares issued and outstanding.
In
2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.
In
2022, we issued 32,412,577 shares of common stock, valued at $691,520 for consulting services.
In
2022, we committed to issue 3,000,000 shares of common stock, valued at $18,000 for consulting services, which were issued on January
3, 2023.
In
2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.
In
2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.
In
2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.
In
2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.
In
2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $15,000, which were issued on
January 3, 2023.
In
2023, we issued 445,180,614 shares of common stock for an investment in the Company’s Private Placement of $677,378.
In
2023, we issued 47,757,394 shares of common stock, valued at $86,161 for consulting services.
In
2023, we issued 4,081,632 shares of common stock, valued at $20,000 for salaries.
In
2023, we issued 276,254,885 shares of common stock for the conversion of convertible notes of $787,133.
In
2023, we issued 60,000,000 shares of common stock, valued at $96,000 for land development.
On
August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to
Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall
be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on
all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all
issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination,
on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock
shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall
vote together with the holders of Common Stock as a single class.
On
August 9, 2022, we issued 2 shares of preferred shares, valued at 0.001 per share.
During
the nine months ended September 30, 2023, the Company’s subsidiary, Res Nova Bio, Inc., issued shares of its common stock to third
parties which represented 32% ownership of the subsidiary as of September 30, 2023. Net loss attributable to the noncontrolling interest
during the nine months ended September 30, 2023, was $1,672, which netted against the value of the non-controlling interest in equity.
The allocation of net loss was presented in the consolidated statement of operations.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Note
9 – Subsequent events
On October 2, 2023, we issued 2,500,000 valued at $0.0015 per share, for consulting services.
On
October 5, 2023, we issued 35,702,240 shares of common stock for an investment in the Company’s Private Placement of $34,274.
On
October 13, 2023, we filed an amendment of the articles of incorporation to increase the authorized shares from 4,505,000,000 to 5,505,000,000,
which include 5,500,000,000 of common stock and 5,000,000 of preferred stock.
On
October 13, 2023, we issued 46,832,386 shares of common stock for the complete conversion of $41,212 for convertible note dated April
11, 2023.
On
October 16, 2023, we issued 60,000,000 shares of common stock for $90,000 of accrued salaries.
On
October 16, 2023, we issued 65,000,000 valued at $0.0015 per share, for consulting services.
On
October 25, 2023, we issued 75,749,443 shares of common stock for an investment in the Company’s Private Placement of $78,779.
In
accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022, through the date these financial statements
were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.
Note
10 – Commitments and Contingencies
Effective
March 22, 2023, the Company entered into a sixth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists
of approximately 1,700 square feet and the amendment is for a term of 60 months and expires on April 30, 2028. Total rent expense for
the nine months ended September 30, 2023, and 2022 is $18,988 and $18,783, respectively.
The
lease will expire in 2028. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company).
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The
discussion and analysis contains forward-looking statements within the meaning of the federal securities laws. The safe harbor provided
in section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 (“statutory safe harbors”)
shall apply to forward-looking information provided pursuant to the statements made in this filing by the Company. We urge you to carefully
review our description and examples of forward-looking statements included in the section entitled “Cautionary Note Regarding Forward-Looking
Statements” at the beginning of this prospectus. Forward-looking statements speak only as of the date of this prospectus and we
undertake no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the
date of this prospectus. Actual events or results may differ materially from such statements. In evaluating such statements, we urge
you to specifically consider various factors identified in this prospectus, any of which could cause actual results to differ materially
from those indicated by such forward-looking statements. The discussion and analysis should be read in conjunction with the accompanying
financial statements and related notes, as well as the risk factors discussed herein.
PART
II - OTHER INFORMATION
Item
1. Legal Proceedings
From
time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods.
However,
as of the date of this prospectus, management believes the outcome of currently identified potential claims and lawsuits will not have
a material adverse effect on our financial condition or results of operations.
Item
1A. Risk Factors
See
“Risk Factors” beginning on Page 21 of this Prospectus.
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
On
January 3, 2023, we issued 4,054,054 shares of common stock for the partial conversion of $15,000 for convertible note dated June 27,
2022.
On
January 3, 2023, we issued 17,000,000 shares of common stock, valued at $0.006 per share, for consulting services.
On
January 4, 2023, we issued 10,052,083 shares of common stock for the complete conversion of $36,187 for convertible note dated June 27,
2022.
On
January 9, 2023, we issued 4,081,132 shares of common stock for $20,000 of accrued salaries.
On
January 9, 2023, we issued 4,000,000 shares of common stock, valued at $0.0049 per share, for consulting services.
On
February 6, 2023, we issued 6,060,606 shares of common stock for the partial conversion of $20,000 for convertible note dated August
2, 2022.
On
February 7, 2023, we issued 11,386,719 shares of common stock for the complete conversion of $36,437 for convertible note dated August
2, 2022.
On
March 21, 2023, we issued 60,224,825 shares of common stock, valued at $0.00216 per share, for an investment in the Company’s Private
Placement.
On
March 28, 2023, we issued 14,705,882 shares of common stock for the partial conversion of $25,000 for convertible note dated September
27, 2022.
On
April 3, 2023, we issued 21,308,333 shares of common stock for the complete conversion of $31,962 for convertible note dated September
27, 2022.
On
April 6, 2023, we issued 40,959,979 shares of common stock for an investment in the Company’s Private Placement of $75,.366.
On
April 20, 2023, we issued 25,000,000 shares of common stock, valued at .0024 per share, for consulting services.
On
April 24, 2023, we issued 89,639,965 shares of common stock for an investment in the Company’s Private Placement of $150,595.
On
April 28, 2023, we issued 20,000,000 shares of common stock for the partial conversion of $30,000 for convertible note dated October
26, 2022.
On
May 3, 2023, we issued 17,975,000 shares of common stock for the complete conversion of $26,963 for convertible note dated October 26,
2022.
On
May 10, 2023, we issued 16,500,000 shares of common stock for the complete conversion of $82,500 for convertible note dated November
29, 2016.
On
May 10, 2023, we issued 27,500,000 shares of common stock for the complete conversion of $110,000 for convertible note dated April 20,
2017.
On
May 10, 2023, we issued 13,750,000 shares of common stock for the complete conversion of $27,500 for convertible note dated May 23, 2019.
On
June 5, 2023, we issued 33,988,466 shares of common stock for an investment in the Company’s Private Placement of $59,820.
On
June 6, 2023, we issued 21,428,571 shares of common stock for the partial conversion of $30,000 for convertible note dated December 5,
2022.
On
June 7, 2023, we issued 11,758,929 shares of common stock for the complete conversion of $116,463for convertible note dated December
5, 2022.
On
June 21, 2023, we issued 45,278,200 shares of common stock for an investment in the Company’s Private Placement of $72,445.
On
July 7, 2023, we issued 16,542,544 shares of common stock for an investment in the Company’s Private Placement of $26,468.
On
July 12, 2023, we issued 11,538,462 shares of common stock for the partial conversion of $15,000 for convertible note dated January 10,
2023.
On
July 13, 2023, we issued 21,843,750 shares of common stock for the complete conversion of $26 213 for convertible note dated January
10, 2023.
On
July 25, 2023, we issued 59,085,509 shares of common stock for an investment in the Company’s Private Placement of $70,903.
On
August 9, 2023, we issued 15,873,016 shares of common stock for the partial conversion of $15,000 for convertible note dated February
8, 2023.
On
August 10, 2023, we issued 16,233,766 shares of common stock for the partial conversion of $15,000 for convertible note dated February
8, 2023.
On
August 11, 2023, we issued 35,135,932 shares of common stock for an investment in the Company’s Private Placement of $40,758.
On
August 14, 2023, we issued 14,285,714 shares of common stock for the complete conversion of $12,000 for the convertible note dated February
8, 2023.
On
August 31, 2023, we issued 20,175,569 shares of common stock for an investment in the Company’s Private Placement of $17,755.
On
September 6, 2023, we issued 20,000,000 shares of common stock for an investment in the Company’s Private Placement of $10,000.
On
September 20, 2023, we committed to issue 2,500,000 shares of common stock, valued at $0.0015 per share, for consulting services, which
were subsequently issued on October 3, 2023.
On
September 19, 2023, we issued 24,149,625 shares of common stock for an investment in the Company’s Private Placement of $23,184.
On
September 20, 2023, we issued 61,757,394 shares of common stock, valued at $0.0016 per share, for consulting services.
![](https://www.sec.gov/Archives/edgar/data/1419051/000149315224001075/formposam_001.jpg)
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and Shareholders of Therapeutic Solutions International, Inc.
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of Therapeutic Solutions International, Inc. (“the Company”) as
of December 31, 2022 and 2021, and the related consolidated statements of operations, changes in shareholders’ deficit, and cash
flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred to as the financial
statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2022 and 2021 and the results of its operations and its cash flows for each of the years in the two-year period ended
December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
Going
Concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the financial statements, the Company has an accumulated deficit, net losses, and negative cash flows from operations. These factors,
among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard
to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.
Critical
Audit Matters
Critical
audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be
communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and
(2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters.
/s/
Fruci & Associates II, PLLC |
|
We
have served as the Company’s auditor since 2019. |
|
|
|
Spokane,
Washington |
|
March
29, 2023 |
|
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Balance Sheets
| |
December 31,
2022 | | |
December 31,
2021 | |
| |
| | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 18,040 | | |
$ | 94,036 | |
Restricted cash | |
| 11,003 | | |
| 10,223 | |
Accounts receivable | |
| 25,398 | | |
| 16,613 | |
Inventory | |
| 42,428 | | |
| 39,817 | |
Prepaid expenses and other current assets | |
| 212,352 | | |
| 959,307 | |
Total current assets | |
| 309,221 | | |
| 1,119,996 | |
| |
| | | |
| | |
Property and equipment, net | |
| 273,078 | | |
| 284,024 | |
Right-of-use asset | |
| 8,612 | | |
| 34,184 | |
Other assets | |
| 3,014,620 | | |
| 277,571 | |
| |
| | | |
| | |
Total assets | |
$ | 3,605,531 | | |
$ | 1,715,775 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 401,992 | | |
$ | 394,035 | |
Accounts payable-related parties | |
| 7209 | | |
| 9,791 | |
Accrued expenses and other current liabilities | |
| 531,783 | | |
| 487,208 | |
Lease liability | |
| 8,612 | | |
| 25,374 | |
Notes payable, current portion | |
| 4,638 | | |
| 4,071 | |
Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively | |
| 65,187 | | |
| 79,200 | |
Notes payable-related parties, net | |
| 988,672 | | |
| 965,211 | |
Derivative liabilities | |
| 202,144 | | |
| 531,525 | |
Total current liabilities | |
| 2,210,237 | | |
| 2,496,415 | |
| |
| | | |
| | |
LONG TERM LIABILITIES | |
| | | |
| | |
Notes payable, net of current portion | |
| 10,507 | | |
| 15,532 | |
Lease liability, net of current portion | |
| - | | |
| 8,810 | |
TOTAL LIABILITIES | |
| 2,220,744 | | |
| 2,520,757 | |
| |
| | | |
| | |
Commitments and contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
Shareholders’ Equity (Deficit): | |
| | | |
| | |
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively | |
| - | | |
| - | |
Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively. | |
| 2,617,392 | | |
| 2,311,125 | |
Additional paid-in capital | |
| 16,334,129 | | |
| 10,899,139 | |
Shares to be issued | |
| 126,324 | | |
| - | |
Subscription receivable | |
| (21,000 | ) | |
| (21,000 | ) |
Accumulated deficit | |
| (17,672,058 | ) | |
| (13,994,246 | ) |
Total shareholders’ equity (deficit) | |
| 1,384,787 | | |
| (804,982 | ) |
| |
| | | |
| | |
Total liabilities and shareholders’ equity (deficit) | |
$ | 3,605,531 | | |
$ | 1,715,775 | |
See
accompanying notes to consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Statements of Operations
| |
For the Year Ended December 31, 2022 | | |
For the Year Ended December 31, 2021 | |
| |
| | |
| |
Net sales | |
$ | 206,767 | | |
$ | 145,956 | |
Cost of goods sold | |
| 79,440 | | |
| 42,544 | |
| |
| | | |
| | |
Gross profit | |
| 127,327 | | |
| 103,412 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
General and administrative | |
| 491,928 | | |
| 138,710 | |
Salaries, wages, and related costs | |
| 444,865 | | |
| 436,555 | |
Consulting fees | |
| 432,033 | | |
| 264,540 | |
Legal and professional fees | |
| 397,302 | | |
| 773,203 | |
Research and development | |
| 1,441,128 | | |
| 794,750 | |
Total operating expenses | |
| 3,207,256 | | |
| 2,407,758 | |
| |
| | | |
| | |
Loss from operations | |
| (3,079,929 | ) | |
| (2,304,346 | ) |
| |
| | | |
| | |
Other income (expense): | |
| | | |
| | |
Loss on derivative liabilities | |
| (131,475 | ) | |
| (539,006 | ) |
Change in fair value of derivative liabilities | |
| 291,123 | | |
| 494,501 | |
Interest expense | |
| (646,089 | ) | |
| (611,794 | ) |
Other expense | |
| (110,642 | ) | |
| - | |
Total other income (expense) | |
| (597,083 | ) | |
| (656,299 | ) |
| |
| | | |
| | |
| |
| | | |
| | |
Provision for income taxes | |
| 800 | | |
| 800 | |
| |
| | | |
| | |
Net loss | |
$ | (3,677,812 | ) | |
$ | (2,961,445 | ) |
| |
| | | |
| | |
Net loss per share - basic and diluted | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
| |
| | | |
| | |
Weighted average shares outstanding - basic and diluted | |
| 2,528,062,958 | | |
| 2,263,126,970 | |
See
accompanying notes to consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Statement of Changes in Sharehold’rs’ Deficit
For
the Years Ended December 31, 2022 and 2021
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Issued | | |
Receivable | | |
Deficit | | |
Deficit | |
| |
Series A Preferred Stock | | |
Common Stock | | |
Additional Paid-in | | |
Shares to be | | |
Subscription | | |
Accumulated | | |
Total Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Issued | | |
Receivable | | |
Deficit | | |
Deficit | |
December 31, 2020 | |
| - | | |
$ | - | | |
| 2,233,741,391 | | |
$ | 2,233,742 | | |
$ | 7,041,960 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (11,032,801 | ) | |
$ | (1,778,099 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 21,000,000 | | |
| 21,000 | | |
| 837,900 | | |
| - | | |
| - | | |
| - | | |
| 858,900 | |
Common stock issued for prepaid fees | |
| - | | |
| - | | |
| 20,000,000 | | |
| 20,000 | | |
| 1,452,450 | | |
| - | | |
| - | | |
| - | | |
| 1,472,450 | |
Common stock issued for salaries | |
| - | | |
| - | | |
| 8,341,723 | | |
| 8,342 | | |
| 231,457 | | |
| - | | |
| - | | |
| - | | |
| 239,799 | |
Common stock issued for cash | |
| - | | |
| - | | |
| 4,850,075 | | |
| 4,850 | | |
| 280,649 | | |
| - | | |
| - | | |
| - | | |
| 285,499 | |
Common stock issued for land development | |
| - | | |
| - | | |
| 1,500,000 | | |
| 1,500 | | |
| 57,400 | | |
| - | | |
| - | | |
| - | | |
| 58,900 | |
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | |
| - | | |
| - | | |
| 21,690,671 | | |
| 21,691 | | |
| 508,044 | | |
| - | | |
| - | | |
| - | | |
| 529,735 | |
Relief of derivative liabilities | |
| - | | |
| - | | |
| - | | |
| - | | |
| 489,279 | | |
| - | | |
| - | | |
| - | | |
| 489,279 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,961,445 | ) | |
| (2,961,445 | ) |
December 31, 2021 | |
| - | | |
$ | - | | |
| 2,311,123,860 | | |
$ | 2,311,125 | | |
$ | 10,899,139 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (13,994,246 | ) | |
$ | (804,982 | ) |
Balance | |
| - | | |
$ | - | | |
| 2,311,123,860 | | |
$ | 2,311,125 | | |
$ | 10,899,139 | | |
$ | - | | |
$ | (21,000 | ) | |
$ | (13,994,246 | ) | |
$ | (804,982 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for services | |
| - | | |
| - | | |
| 32,412,577 | | |
| 32,413 | | |
| 557,107 | | |
| 102,000 | | |
| - | | |
| - | | |
| 691,520 | |
Common stock issued for prepaid fees | |
| - | | |
| - | | |
| 11,000,000 | | |
| 11,000 | | |
| 231,320 | | |
| - | | |
| - | | |
| - | | |
| 242,320 | |
Common stock issued for salaries | |
| - | | |
| - | | |
| 4,812,259 | | |
| 4,812 | | |
| 62,587 | | |
| - | | |
| - | | |
| - | | |
| 67,399 | |
Common stock issued for cash | |
| - | | |
| - | | |
| 44,500,000 | | |
| 44,500 | | |
| 400,500 | | |
| - | | |
| - | | |
| - | | |
| 445,000 | |
Common stock issued for license | |
| - | | |
| - | | |
| 149,402,390 | | |
| 149,402 | | |
| 2,958,168 | | |
| - | | |
| - | | |
| - | | |
| 3,107,570 | |
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities | |
| - | | |
| - | | |
| 64,139,744 | | |
| 64,140 | | |
| 1,225,308 | | |
| 24,324 | | |
| - | | |
| - | | |
| 1,313,772 | |
Issuance of preferred stock | |
| 2 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,677,812 | ) | |
| (3,677,812 | ) |
December 31, 2022 | |
| 2 | | |
$ | - | | |
| 2,617,390,830 | | |
$ | 2,617,392 | | |
$ | 16,334,129 | | |
$ | 126,324 | | |
$ | (21,000 | ) | |
$ | (17,672,058 | ) | |
$ | 1,384,787 | |
Balance | |
| 2 | | |
$ | - | | |
| 2,617,390,830 | | |
$ | 2,617,392 | | |
$ | 16,334,129 | | |
$ | 126,324 | | |
$ | (21,000 | ) | |
$ | (17,672,058 | ) | |
$ | 1,384,787 | |
See
accompanying notes to consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Statements of Cash Flows
| |
For the Year Ended December 31, 2022 | | |
For the Year Ended December 31, 2021 | |
| |
| | |
| |
Cash flows from operating activities | |
| | | |
| | |
Net loss | |
$ | (3,677,812 | ) | |
$ | (2,961,445 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Stock-based compensation to consultants | |
| 380,820 | | |
| 397,750 | |
Stock-based compensation to related parties | |
| 310,700 | | |
| 461,150 | |
Loss on derivative liabilities | |
| 131,475 | | |
| 539,006 | |
Change in fair value of derivative liabilities | |
| (291,123 | ) | |
| (494,501 | ) |
Amortization of prepaid stock-based compensation | |
| 951,748 | | |
| 480,135 | |
Amortization of debt discount | |
| 593,463 | | |
| 541,612 | |
Patent amortization | |
| 233,685 | | |
| 11,295 | |
Depreciation | |
| 10,946 | | |
| 6,772 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (8,785 | ) | |
| (14,172 | ) |
Inventory | |
| (2,611 | ) | |
| (34,418 | ) |
Prepaid expenses and other current assets | |
| 174,364 | | |
| 64,777 | |
Right-of-use asset | |
| 25,572 | | |
| 24,792 | |
Accounts payable | |
| 15,166 | | |
| 91,557 | |
Accounts payable - related parties | |
| (9,791 | ) | |
| 2,581 | |
Accrued expenses and other current liabilities | |
| 169,451 | | |
| 188,979 | |
Lease liability | |
| (25,572 | ) | |
| (24,792 | ) |
Net cash used in operating activities | |
| (1,018,304 | ) | |
| (718,922 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchases of property and equipment | |
| - | | |
| (260,565 | ) |
Deposits | |
| - | | |
| 4,015 | |
Net cash used in investing activities | |
| - | | |
| (256,550 | ) |
| |
| | | |
| | |
Cash flows from financing activities | |
| | | |
| | |
Payments on notes payable to related party | |
| (2,453 | ) | |
| (4,799 | ) |
Proceeds from convertible notes payable | |
| 505,000 | | |
| 538,750 | |
Payments on notes payable | |
| (4,459 | ) | |
| (2,068 | ) |
Proceeds from sale of common stock | |
| 445,000 | | |
| 285,499 | |
Net cash provided by financing activities | |
| 943,088 | | |
| 817,382 | |
| |
| | | |
| | |
Net increase (decrease) in cash, cash equivalents and restricted cash | |
| (75,216 | ) | |
| (158,090 | ) |
Cash, cash equivalents and restricted cash at beginning of period | |
| 104,259 | | |
| 262,349 | |
Cash, cash equivalents and restricted cash at end of period | |
$ | 29,043 | | |
$ | 104,259 | |
| |
| | | |
| | |
Supplemental cash flow information: | |
| | | |
| | |
Cash paid for interest | |
$ | 3,173 | | |
$ | 3,312 | |
Cash paid for income taxes | |
$ | 800 | | |
$ | 800 | |
| |
| | | |
| | |
Non-cash investing and financing transactions: | |
| | | |
| | |
Original issuance discount on convertible notes payable | |
$ | 39,000 | | |
$ | 33,500 | |
Debt discount recorded in connection with derivative liability | |
$ | 503,726 | | |
$ | 538,750 | |
Common stock issued in conversion of convertible notes payable and interest | |
$ | 1,313,772 | | |
$ | 1,019,014 | |
Property and equipment purchased with note payable | |
$ | - | | |
$ | 21,671 | |
Common stock issued for prepaid fees | |
$ | 242,320 | | |
$ | 1,472,450 | |
Common stock issued for accrued salaries | |
$ | 67,399 | | |
$ | 239,799 | |
Accrued interest added to principal | |
$ | 25,914 | | |
$ | 25,912 | |
Common stock issued for license | |
$ | 3,107,570 | | |
$ | - | |
Common stock issued for land development | |
$ | - | | |
$ | 58,900 | |
| |
| | | |
| | |
Reconciliation of cash, cash equivalents and restricted cash to the
consolidated balance sheets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 18,040 | | |
$ | 94,036 | |
Restricted cash | |
| 11,003 | | |
| 10,223 | |
Total cash, cash equivalents, and restricted cash shown in the consolidated
statements of cash flows: | |
$ | 29,043 | | |
$ | 104,259 | |
See
accompanying notes to consolidated financial statements.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
1 – Organization and Business Description
Therapeutic
Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto
Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers,
Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.
Business
Description
Currently,
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one’s immune system.
Activating
one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.
TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
lung pathologies, and for daily health.
Cellular
Division – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
The
stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability.
Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and
is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression,
depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment
to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical
trial of 10 patients with CTE.
On
August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal
trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated
lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types
of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective
in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the
ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
In
addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™
resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK
cells.”
The
Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells
called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.
Most
recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system
to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from
the Company showing that StemVacs is capable of suppressing new blood vessel production.
On
May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Management
does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations
for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going
concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business.
As of December 31, 2022, the Company has incurred losses totaling $17.3 million since inception, has not yet generated material revenue
from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s
ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability
to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing
to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to
finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital
through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable
terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements
do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.
Note
2 – Basis of presentation and significant accounting policies
Basis
of Presentation
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any
subsidiaries.
Accounts
Receivable
Accounts
receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require
collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including
the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability
to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts
receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful
accounts.
The
Company recorded an allowance for doubtful accounts of $6,807 as of both December 31, 2022 and 2021, respectively.
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
| 1) | Identify
the contract with a customer. |
| 2) | Identify
the performance obligations in the contract. |
| 3) | Determine
the transaction price. |
| 4) | Allocate
the transaction price to the performance obligations in the contract. |
| 5) | Recognize
revenue when (or as) the entity satisfies a performance obligation. |
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.
Wholesale
policies:
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an
additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth
of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%)
discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off
retail.
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense
Retail
policies of e-commerce:
Returns.
We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes
that may be made which result in the shipment of incorrect products to you will also be accepted for return.
Shipping.
Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or
shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit
time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays
caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory
amounts. Orders are shipped to customers by the companies as ordered on their websites.
Out
of Stock. We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may
be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any
products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior
to shipping.
Cash
and Cash Equivalents
The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021,
the Company had $0 in excess of the FDIC insured limit.
Inventories
Inventories
are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials
and assembly items.
Derivative
Liabilities
A
derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company
entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features
that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments
within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out
basis.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $202,144
and $531,525 at December 31, 2022 and 2021, respectively.
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities.
The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the years ended December 31, 2022 and 2021:
Schedule
of Change in Derivative Liability
Balance, December 31, 2020 | |
$ | 437,549 | |
| |
| | |
Issuance of new derivative liabilities | |
| 1,077,756 | |
Conversions | |
| (489,279 | ) |
Change in fair market value of derivative liabilities | |
| (494,501 | ) |
| |
| | |
Balance, December 31, 2021 | |
| 531,525 | |
| |
| | |
Issuance of new derivative liabilities | |
| 674,971 | |
Conversions | |
| (713,229 | ) |
Change in fair market value of derivative liabilities | |
| (291,123 | ) |
Balance, December 31, 2022 | |
$ | 202,144 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Use
of Estimates
Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.
Comprehensive
Loss
Comprehensive
loss for the periods reported was comprised solely of the Company’s net loss.
Net
Loss Per Share
Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential
common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.
Depreciation
and Amortization
Depreciation
is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight
line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $10,946 and $6,772,
respectively.
Intangible
Assets
Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $11,295,
respectively.
Long-lived
Assets
In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.
Shipping
and Handling
The
Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within
general administrative expenses.
Advertising
Advertising
costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $4,132 and $0, respectively.
Research
and Development
Research
and Development costs are expensed as incurred. Research and Development expenses were $1,441,128 and $794,750 for the years ended December
31, 2022 and 2021, respectively.
Income
Taxes
The
Company accounts for income taxes under ASC 7”0 “Income Tax”s,” which codified SFAS 10”, “Accounting
for Income Ta”es” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB
Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740,
the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment
occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not
realize tax assets through future operations.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
Stock-Based
Compensation
Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.
Leases
On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $8,612 as of December 31, 2022.
Note
3 – Restricted cash
Included
in current assets is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2023,
and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.
Note
4 – Prepaid expense and other current assets
Prepaid
expenses and other current assets consist of the following:
Schedule
of Prepaid Expenses and Other Current Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Prepaid consulting | |
$ | 148,550 | | |
$ | 930,893 | |
Insurance | |
| 1,141 | | |
| 987 | |
Prepaid costs | |
| 62,661 | | |
| 27,427 | |
Total | |
$ | 212,352 | | |
$ | 959,307 | |
Note
5 – Fixed assets
Fixed
assets consist of the following:
Schedule
of Fixed Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Land | |
$ | 235,223 | | |
$ | 235,223 | |
Vehicles | |
| 50,514 | | |
| 50,514 | |
Computer hardware | |
| 6,135 | | |
| 5,935 | |
Office furniture and equipment | |
| 7,912 | | |
| 7,912 | |
Shipping and other equipment | |
| 1,575 | | |
| 1,575 | |
Total | |
| 301,359 | | |
| 301,159 | |
Accumulated depreciation | |
| (28,281 | ) | |
| (17,135 | ) |
Property and equipment, net | |
$ | 273,078 | | |
$ | 284,024 | |
Depreciation
expense was $10,946 and $6,772 for the years ended December 31, 2022 and 2021, respectively.
Note
6 – Other assets
Other
assets consist of the following:
Schedule
of Other Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Prepaid consulting | |
$ | 7,537 | | |
$ | 108,673 | |
Deposit | |
| 4,123 | | |
| 39,823 | |
Licenses, net | |
| 3,002,960 | | |
| 129,075 | |
Total | |
$ | 3,014,620 | | |
$ | 277,571 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:
Schedule of Net Licenses
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Licenses | |
$ | 3,261,122 | | |
$ | 153,552 | |
Accumulated amortization | |
| (258,162 | ) | |
| (24,477 | ) |
Licenses, net | |
$ | 3,002,960 | | |
$ | 129,075 | |
Amortization
expense for the years ended December 31, 2022 and 2021 was $233,685 and $24,477, respectively.
As
of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December
31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy),
and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived
from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain
injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI
as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.
On
February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties
worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021.
Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390
shares of common stock,
valued at $0.0208
per share, for the EPLA,
with a final value of the license being recorded at $3,107,570.
The Patent expires December
31, 2032. The Exclusive
Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade
and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over
the 10
year life of the Patent.
As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement.
The agreement is until March
24, 2027. The Company
has made an initial payment of $200,000.
Within six months, the Company will make a second payment of $1.8
million. The agreement
is in default and the initial paymentof $200,000 was expensed to research & development.
Note
7 – Convertible notes payable
Convertible Notes Payable
At
various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts
totaling $544,000
with third parties for which the proceeds were used for operations. The Company received net proceeds of $505,000,
and a $39,000
original issuance discount was recorded. The convertible promissory notes incur interest at a rate of 10%
per annum and mature
on dates ranging from January 1, 2023 to December 5, 2023. The
convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion
price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s
common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is
defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the
convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which
the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
The Company was required to reserve at December 31, 2022 a total of 267,136,056
common shares in connection with these promissory notes.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
7 – Convertible notes payable (continued)
At
various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts
totaling $572,250
with third parties for which the proceeds were used for operations. The Company received net proceeds of $538,750,
and a $33,500
original issuance discount was recorded. The convertible promissory notes incur interest at rates ranging from 10%
to 12%
per annum and mature
on dates ranging from January 25, 2022 to December 15, 2022. The
convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion
price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the
Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to
prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of
principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default
provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest
increasing by 150%. The Company was required to reserve at December 31, 2021 total of 95,273,690
common shares in connection with these promissory notes.
Derivative
liabilities
These
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the
number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion
feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability.
The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event
and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting
period.
For
the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting
in initial liabilities totaling $674,971. Since the fair value of the derivative was in excess of the proceeds received, a full discount
to convertible notes payable and a day one loss on derivative liabilities of $171,245 was recorded during the year ended December 31,
2022. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion
prices ranging from $0.0058 to $0.0143, the closing stock price of the Company’s common stock on the dates of valuation ranging
from $0.008 to $0.0272, an expected dividend yield of 0%, expected volatilities ranging from 148%-216%, risk-free interest rate ranging
from 0.48% to 4.77%, and an expected term of one year.
During
the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $774,176 were converted into 68,193,798
shares of common stock, of which 4,054,054 are yet to be issued as of December 31, 2022. At each conversion date, the Company recalculated
the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair
market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative
liability as compared to the portio of the convertible note converted was recorded as a loss or gain on derivative liabilities. During
the year ended December 31, 2022, the Company recorded $39,770 to gain on derivative liabilities. The derivative liabilities were revalued
using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0038 to $0.016, the closing
stock price of the Company’s common stock on the dates of valuation ranging from $0.006 to $0.026, an expected dividend yield
of 0%, expected volatility ranging from 63% to 191%, risk-free interest rates ranging from 0.51% to 4.74%, and expected terms ranging
from 0.44 to 0.50 years.
On
December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $202,144 resulting in a gain of $291,123
for the year ended December 31, 2022 related to the change in fair value of the derivative liabilities. The derivative liabilities were
revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.0038, the closing stock price
of the Company’s common stock on the date of valuation of $0.006, an expected dividend yield of 0%, expected volatility ranging
from 96% to 120%, risk-free interest rate of 4.71%, and an expected term ranging from 0.49 to 0.93 years.
For
the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting
in initial liabilities totaling $1,077,756. Since the fair value of the derivative was in excess of the proceeds received, a full discount
to convertible notes payable and a day one loss on derivative liabilities of $539,006 was recorded during the year ended December 31,
2021. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion
prices ranging from $0.0039 to $0.0351, the closing stock price of the Company’s common stock on the dates of valuation ranging
from $0.0217 to $0.0540, an expected dividend yield of 0%, expected volatilities ranging from 197%-264%, risk-free interest rate ranging
from 0.05% to 0.29%, and an expected term of one year.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
7 – Convertible notes payable (Continued)
During
the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $529,735 were converted into 21,690,671
shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible
note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative
liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended
December 31, 2021, the Company recorded $489,279 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes
option pricing model with the following assumptions: conversion prices ranging from $0.0136 to $0.035, the closing stock price of the
Company’s common stock on the dates of valuation ranging from $0.022 to $0.057, an expected dividend yield of 0%, expected
volatility ranging from 125% to 251%, risk-free interest rates ranging from 0.06% to 0.29%, and expected terms ranging from 0.48 to 0.50
years.
On
December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $531,525 resulting in a gain of
$494,501 for the year ended December 31, 2021 related to the change in fair value of the derivative liabilities. The derivative liabilities
were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0123 to
$0.0127, the closing stock price of the Company’s common stock on the date of valuation of $0.029, an expected dividend yield
of 0%, expected volatility ranging from 165% to 218%, risk-free interest rate of 0.39%, and an expected term ranging from 0.53 to 0.96
years.
The
Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to
the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $593,463 and $541,612 to
interest expense, respectively. As of December 31, 2022, discounts of $175,063 remained for which will be amortized through December
2023.
Note
8 – Notes payable-related parties
Notes Payable-Related Party
Notes
payable-related parties consist of:
Schedule
of Notes Payable Related Parties
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
| |
$ | - | | |
$ | 2,356 | |
Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 | |
$ | - | | |
$ | 2,356 | |
| |
| | | |
| | |
One notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019 | |
| 29,090 | | |
| 27,577 | |
| |
| | | |
| | |
One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues | |
| 534,448 | | |
| 534,544 | |
| |
| | | |
| | |
Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 | |
| 124,800 | | |
| 118,400 | |
| |
| | | |
| | |
Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity date of April 20, 2019 | |
| 30,334 | | |
| 282,334 | |
| |
| 988,672 | | |
| 965,211 | |
| |
| | | |
| | |
| |
$ | 988,672 | | |
$ | 965,211 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
9 – Related party transactions
As
of December 31, 2019 and 2018, the Company had accrued officers’ salary of $439,534
and $663,100,
respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t
accrue interest and will be paid as 0.5%
of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments
for the years ended December 31, 2022 and 2021 was $97 and $101, respectively.
In
2021, we issued 7,544,848 shares of common stock for $239,800 of accrued salaries to one officer of the Company under a Restricted Stock
Award.
On
June 18, 2021, we issued 2,000,000 shares of common stock, to one officer and one director of the Company under a Restricted Stock Award
for $94,600.
On
November 30, 2021, we issued 7,000,000
shares of common stock to four officers and one director under a Restricted Stock Award for $224,000.
In
2022, we issued 4,812,259 shares of common stock for $67,399 of accrued salaries to one officer of the Company under a Restricted Stock
Award.
On
April 5, 2022, we issued 7,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock
Award for $175,700.
On
September 8, 2022, we issued 4,000,000 shares of common stock to one officer and one director under a Restricted Stock Award for $46,400.
On
November 2, 2022, we issued 3,000,000 shares of common stock to one director under a Restricted Stock Award for $29,700.
On
December 30, 2022, we committed to issue 14,000,000 shares of common stock, to four officers and one director of the Company under a
Restricted Stock Award for $84,000, which were subsequently issued on January 3, 2023.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
10 – Income taxes
The
Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision
for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows:
Schedule of Income tax Expense
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Expected income tax at statutory rate | |
$ | (709,666 | ) | |
$ | (621,735 | ) |
State tax | |
| (101,347 | ) | |
| 168 | |
Permanent differences | |
| 405,376 | | |
| 404,872 | |
Other | |
| - | | |
| (71,992 | ) |
Change in valuation allowance | |
| 406,437 | | |
| 289,487 | |
Provision for income taxes | |
$ | 800 | | |
$ | 800 | |
The
significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:
Schedule of Deferred Tax Assets and Liabilities
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Net operating loss carry-forward | |
$ | 2,364,249 | | |
$ | 1,957,812 | |
Valuation allowance | |
| (2,364,249 | ) | |
| (1,957,812 | ) |
Net deferred tax asset | |
$ | - | | |
$ | - | |
The
Company has Federal net operating loss carryforwards of approximately $9.4 million and $7.5 million as of December 31, 2022 and 2021,
respectively. The Company has state net operating loss carryforwards of approximately $7.4 million and $5.5 million as of December 31,
2022 and 2021, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately
$5 million expires beginning in fiscal 2032. Net operating loss carrforwards incurred after 2018 are carried on indefinitely.
As
of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly,
there are no recognized tax benefits at December 31, 2022 and 2021.
The
Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction.
The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently
is not under examination by any tax authority.
Note
11 – Equity
Our
authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value
$0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences,
privileges and restrictions of which shall be established by our board of directors. As of December 31, 2022, we have 2,617,390,830 shares
of common stock and 2 preferred shares issued and outstanding.
In
2021, we issued 4,850,075 shares of common stock for an investment in the Company’s Private Placement of $285,500.
In
2021, we issued 21,000,000 shares of common stock, valued at $858,900 for consulting services.
In
2021, we issued 8,341,723 shares of common stock, valued at $239,799 for salaries.
In
2021, we issued 1,500,000 shares of common stock, valued at $58,900 for land development.
In
2021, we issued 21,690,671 shares of common stock for the conversion of convertible notes of $1,019,014.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
11 – Equity (continued)
In
2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.
In
2022, we issued 32,412,577 shares of common stock, valued at $691,520 for consulting services.
In
2022, we committed to issue 3,000,000 shares of common stock, valued at $18,000 for consulting services, which were issued on January
3, 2023.
In
2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.
In
2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.
In
2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.
In
2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.
In
2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $15,000, which were issued on
January 3, 2023.
Note
12 – Legal proceedings
From
time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods.
However,
as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a
material adverse effect on our financial condition or results of operations.
Note
13 – Commitments and Contingencies
Effective
March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists
of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2023.
During
the year ended December 31, 2022 and 2021, the Company incurred rent expense of $25,044 and $22,768.
The
lease will expire in 2023. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company). Maturities
of Leases were:
Future
minimum lease payments as of December 31, 2022 are as follows:
Schedule of Future Minimum Lease Payments
For the year ending December 31, | |
| |
| |
| | |
2023 | |
$ | 8,612 | |
Effective
November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.
Note
14 – Subsequent events
On
January 3, 2023, we issued 4,054,054 shares of common stock for the partial conversion of $15,000 for convertible note dated June 27,
2022.
On
January 3, 2023, we issued 17,000,000 shares of common stock, valued at $0.006 per share, for consulting services.
On
January 4, 2023, we issued 10,052,083 shares of common stock for the complete conversion of $36,188 for convertible note dated June
27, 2022.
On
January 9, 2023, we issued 4,081,632 shares of common stock for $20,000 of accrued salaries.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
14 – Subsequent events (continued)
On
January 9, 2023, we issued 4,000,000 shares of common stock, valued at $0.049 per share, for consulting services.
On
February 6, 2023, we issued 6,060,606 shares of common stock for the partial conversion of $20,000 for convertible note dated August
2, 2022.
On
February 7, 2023, we issued 11,386,719 shares of common stock for the complete conversion of $36,438 for convertible note dated August
2, 2022.
On
February 21, 2023, we issued 60,224,825 shares of common stock, valued at $0.00216 per share, for an investment in the Company’s
Private Placement.
On
or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval,
and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with the right to vote,
pursuant to Nevada Revised Statutes Section NRS 78.215, has approved a one-time dividend, to be awarded to stockholders of TSOI in subsidiary
Campbell Neurosciences, Inc., a Delaware corporation (“CNSI”). To receive the dividend by future election you must hold TSOI
common at the market close of April 7, 2023. The dividend rate of conversion shall be for every share of TSOI common you will receive
0.0034 shares of CNSI.
TSOI,
which owns 15,660,000 (31%) of the shares of CNSI common stock, would like to issue a dividend consisting of 10,000,000 shares of its
holdings in CNSI to TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April
7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for
Ninety (90) days from the Dividend Offer Date.
A
letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance
letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed
copy to be returned with acceptance.
Required
forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely.
In
accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements
were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.
PART
II
INFORMATION
NOT REQUIRED IN THE PROSPECTUS
Other
Expenses of Issuance and Distribution
The
following is an itemized statement of the estimated amounts of all expenses payable by us in connection with the registration of the
common stock, other than underwriting discounts and commissions. All amounts are estimates except the SEC registration fee.
Securities and Exchange Commission - Registration Fee (1)(2) | |
$ | 1,102.00 | |
State filing Fees | |
$ | 500.00 | |
EDGARizing Costs | |
$ | 500.00 | |
Accounting Fees and Expenses | |
$ | 1,000.00 | |
Legal Fees and Expenses | |
$ | 10,000.00 | |
Miscellaneous | |
$ | 0.00 | |
Total | |
$ | 13,102.00 | |
Note
1: These fees, other than the Registration Fee, are calculated based on the dollar amount of the securities offered and the number of
issuances and, accordingly, cannot be estimated at this time.
Note
2: Note: The difference in registration fees stated in the recently filed S-3 on 9/27/2022 and the S-1 filed on October 31, 2022, represents
the change in registration fee rate that was put into effect October 1, 2022.
None
of the expenses of the offering will be paid by the selling security holders.
Indemnification
of Directors and Officers
Article
6 of our Articles of Incorporation exculpates our directors and officers from certain monetary liabilities. Article 6 of our Articles
of Incorporation provides that we shall indemnify all directors (and all persons serving at our request as a director or officer of another
corporation) to the fullest extent permitted by Nevada law.
Further
pursuant to Article 6, the expenses of the indemnified person incurred in defending a civil suit or proceeding must be paid by us as
incurred and in advance of the final disposition of the action, suit, or proceeding under receipt of an undertaking by or on behalf of
the indemnified person to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not
entitled to be indemnified by us.
The
foregoing indemnification obligations could result in us incurring substantial expenditures, which we may be unable to recoup. These
provisions and resultant costs may also discourage us from bringing a lawsuit against directors and officers for breaches of their fiduciary
duties even though such actions, if successful, might otherwise benefit us and our stockholders.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling
the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is therefore unenforceable.
Recent
Sales of Unregistered Securities
There
have been no recent sales of unregistered securities during the relevant time period prior to this registration and Prospectus.
Undertakings
The
undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers, or sales are being made, a post-effective amendment to this registration statement to:
(i)
Include any prospectus required by section 10(a)(3) of the Securities Act;
(ii)
Reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high and of the estimated maximum offering range
may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee”
table in the effective registration statement.
(iii)
Include any material or changed information with respect to the plan of distribution not previously disclosed in the registration statement
or an material change to such information in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4)
Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into
the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of
sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part
of the registration statement or made in any such document immediately prior to such date of first use.
(5)
That, for the purpose of determining liability under the Securities Act to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus, supplemental prospectus, or prospectus of the undersigned registrant relating to the offering required to
be filed pursuant to Rule 424 of Regulation C of the Securities Act;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(6)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC
such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
[Balance
of Page Intentionally Left Blank]
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the San Diego County, California, on January 4, 2024.
|
Therapeutic Solutions International, Inc. |
|
|
|
|
By: |
/s/:
Timothy G. Dixon |
|
|
Timothy
G. Dixon, CEO |
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates stated.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/:
Timothy G. Dixon |
|
|
|
|
Timothy
G. Dixon |
|
Chairman,
President & CEO (Principal Executive Officer) |
|
January
4, 2024 |
/s/:
Thomas Ichim |
|
|
|
|
Thomas
Ichim, PhD |
|
Director |
|
January
4, 2024 |
[OUTSIDE
BACK COVER]
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
[A Nevada Corporation]
701
Wild Rose Lane
Elk
City, Idaho 83525
760-295-7208
January
3, 2024
PROSPECTUS
Up
to 300,000,000 Additional Shares of Common Stock
Total
Registered Shares up to 313,367,703
Until
September 19, 2024, all dealers that effect transactions in our shares, whether or not participating in this offering, may be required
to deliver a Prospectus pursuant to the securities Purchase Agreement.
(1)
See the “Securities Purchase Agreement” description under the Prospectus Summary and the “Plan of Distribution”
for a more detailed explanation of the identity, rights, obligation, and terms and conditions for the purchase of securities by the selling
shareholder.
Exhibit 5.1
![](https://www.sec.gov/Archives/edgar/data/1419051/000149315224001075/ex5-1_001.jpg)
![](https://www.sec.gov/Archives/edgar/data/1419051/000149315224001075/ex5-1_002.jpg)
Exhibit 15.1
Exhibit 21.1
Exhibit
23.1
![](https://www.sec.gov/Archives/edgar/data/1419051/000149315224001075/ex23-1_001.jpg)
CONSENT
OF INDEPENDENT REGISTERED ACCOUNTING FIRM
We
consent to the inclusion in this Registration Statement to Form S-1, Amendment 1 of our audit report dated March 29, 2023, with respect
to the consolidated balance sheets of Therapeutic Solutions International, Inc. and subsidiaries as of December 31, 2022 and 2021, and
the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for each of the years in the
two-year period ended December 31, 2022.
Our
report relating to those financial statements includes an emphasis of matter paragraph regarding substantial doubt as to the Company’s
ability to continue as a going concern.
We
also consent to the reference to us under the heading “Experts” in such Registration Statement.
![](https://www.sec.gov/Archives/edgar/data/1419051/000149315224001075/ex23-1_002.jpg)
Spokane,
Washington
January
4, 2024
v3.23.4
Cover
|
9 Months Ended |
Sep. 30, 2023 |
Entity Addresses [Line Items] |
|
Document Type |
POS AM
|
Amendment Flag |
true
|
Amendment Description |
We
initially registered on Form S-1 (File No. 333-268070) (i) the issuance and sale of up to 555,000,000 shares of our Common Stock, par
value $0.0001 per share (“Common Stock) offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933 and pursuant to a securities purchase agreement which provides the right to an aggregate gross proceeds of up to $10.0 million
from the sale of our Common Stock to the selling shareholder, GHS Investments, LLC (“GHS”) (the “GHS Purchase Agreement”)
entered into on September 19, 2022. The S-1, as amended, became effective February 15, 2023.
|
Entity Registrant Name |
Therapeutic
Solutions International, Inc.
|
Entity Central Index Key |
0001419051
|
Entity Tax Identification Number |
45-1226465
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
701
Wild Rose Lane
|
Entity Address, City or Town |
Elk
City
|
Entity Address, State or Province |
ID
|
Entity Address, Postal Zip Code |
83525
|
City Area Code |
760
|
Local Phone Number |
295-7208
|
Entity Filer Category |
Non-accelerated Filer
|
Entity Small Business |
true
|
Entity Emerging Growth Company |
false
|
Business Contact [Member] |
|
Entity Addresses [Line Items] |
|
Entity Address, Address Line One |
5348
Vegas Dr.
|
Entity Address, City or Town |
Las
Vegas
|
Entity Address, State or Province |
NV
|
Entity Address, Postal Zip Code |
89108
|
City Area Code |
702
|
Local Phone Number |
871-8678
|
Contact Personnel Name |
EastBiz.com,
Inc.
|
X |
- DefinitionDescription of changes contained within amended document.
+ References
+ Details
Name: |
dei_AmendmentDescription |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
dei_EntityAddressesLineItems |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Condensed Consolidated Balance Sheets - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Current assets: |
|
|
|
Cash and cash equivalents |
$ 90,138
|
$ 18,040
|
$ 94,036
|
Restricted cash |
|
11,003
|
10,223
|
Accounts receivable |
21,764
|
25,398
|
16,613
|
Inventory |
26,418
|
42,428
|
39,817
|
Prepaid expenses and other current assets |
42,661
|
212,352
|
959,307
|
Total current assets |
180,981
|
309,221
|
1,119,996
|
Property and equipment, net |
377,076
|
273,078
|
284,024
|
Right-of-use asset |
131,818
|
8,612
|
34,184
|
Other assets |
2,784,502
|
3,014,620
|
277,571
|
Total assets |
3,474,377
|
3,605,531
|
1,715,775
|
Current liabilities: |
|
|
|
Accrued expenses and other current liabilities |
601,446
|
531,783
|
487,208
|
Lease liability |
26,786
|
8,612
|
25,374
|
Convertible notes payable, net of discount of $175,063 and $225,800, at December 31, 2022 and 2021, respectively |
46,139
|
65,187
|
79,200
|
Derivative liabilities |
292,699
|
202,144
|
531,525
|
Total current liabilities |
2,053,239
|
2,210,237
|
2,496,415
|
LONG TERM LIABILITIES |
|
|
|
Notes payable, net of current portion |
6,810
|
10,507
|
15,532
|
Lease liability, net of current portion |
105,032
|
|
8,810
|
TOTAL LIABILITIES |
2,165,081
|
2,220,744
|
2,520,757
|
Commitments and contingencies |
|
|
|
Shareholders’ Equity (Deficit): |
|
|
|
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 2 shares and 0 shares issued and outstanding at December 31, 2022 and 2021, respectively |
|
|
|
Common stock, $0.001 par value; 3,500,000,000 shares authorized; 2,617,390,830 and 2,311,123,860 shares issued and outstanding at December 31, 2022 and 2021, respectively. |
3,450,666
|
2,617,392
|
2,311,125
|
Additional paid-in capital |
17,282,608
|
16,334,129
|
10,899,139
|
Shares to be issued |
13,074
|
126,324
|
|
Subscription receivable |
(21,000)
|
(21,000)
|
(21,000)
|
Accumulated deficit |
(19,414,380)
|
(17,672,058)
|
(13,994,246)
|
Total shareholders’ equity (deficit) |
1,310,968
|
1,384,787
|
(804,982)
|
Non-controlling interest |
(1,672)
|
|
|
Total shareholders’ equity - Therapeutic Solutions International, Inc. |
1,309,296
|
1,384,787
|
(804,982)
|
Total liabilities and shareholders’ equity (deficit) |
3,474,377
|
3,605,531
|
1,715,775
|
Nonrelated Party [Member] |
|
|
|
Current liabilities: |
|
|
|
Accounts payable-related parties |
374,459
|
401,992
|
394,035
|
Notes payable-related parties, net |
4,638
|
4,638
|
4,071
|
Related Party [Member] |
|
|
|
Current liabilities: |
|
|
|
Accounts payable-related parties |
7,206
|
7,209
|
9,791
|
Notes payable-related parties, net |
$ 699,866
|
$ 988,672
|
$ 965,211
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebtCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3
+ Details
Name: |
us-gaap_DerivativeLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesNoncurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_MinorityInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_RestrictedCash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15
Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16
Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionNote received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2
+ Details
Name: |
us-gaap_StockholdersEquityNoteSubscriptionsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.4
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Statement of Financial Position [Abstract] |
|
|
|
Debt instrument, unamortized discount, current |
$ 157,861
|
$ 175,063
|
$ 225,800
|
Preferred stock, par value |
$ 0.001
|
$ 0.001
|
$ 0.001
|
Preferred stock, shares authorized |
5,000,000
|
5,000,000
|
5,000,000
|
Preferred stock, shares issued |
2
|
2
|
0
|
Preferred stock, shares outstanding |
2
|
2
|
0
|
Common stock, par value |
$ 0.001
|
$ 0.001
|
$ 0.001
|
Common stock, shares authorized |
5,500,000,000
|
5,500,000,000
|
3,500,000,000
|
Common stock, shares, issued |
3,450,665,355
|
2,617,390,830
|
2,311,123,860
|
Common stock, shares, outstanding |
3,450,665,355
|
2,617,390,830
|
2,311,123,860
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of debt discount to be amortized within one year or within the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscountCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Condensed Consolidated Statements of Operations - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Statement [Abstract] |
|
|
|
|
|
|
Net sales |
$ 25,730
|
$ 74,541
|
$ 75,161
|
$ 198,188
|
$ 206,767
|
$ 145,956
|
Cost of goods sold |
7,052
|
8,790
|
26,217
|
33,437
|
79,440
|
42,544
|
Gross profit |
18,678
|
65,751
|
48,944
|
164,751
|
127,327
|
103,412
|
Operating expenses: |
|
|
|
|
|
|
General and administrative |
127,204
|
204,838
|
359,948
|
388,561
|
491,928
|
138,710
|
Salaries, wages, and related costs |
111,220
|
110,108
|
335,699
|
336,926
|
444,865
|
436,555
|
Consulting fees |
20,150
|
88,158
|
142,907
|
317,284
|
432,033
|
264,540
|
Legal and professional fees |
68,560
|
106,795
|
229,952
|
266,158
|
397,302
|
773,203
|
Research and development |
148,879
|
275,071
|
410,146
|
1,177,123
|
1,441,128
|
794,750
|
Total operating expenses |
476,013
|
784,970
|
1,478,652
|
2,486,052
|
3,207,256
|
2,407,758
|
Loss from operations |
(457,335)
|
(719,219)
|
(1,429,708)
|
(2,321,301)
|
(3,079,929)
|
(2,304,346)
|
Other income (expense): |
|
|
|
|
|
|
Loss on derivative liabilities |
(2,336)
|
(26,867)
|
21,939
|
(136,583)
|
(131,475)
|
(539,006)
|
Change in fair value of derivative liabilities |
(60,124)
|
(32,205)
|
(93,836)
|
233,303
|
291,123
|
494,501
|
Interest expense |
(83,062)
|
(167,371)
|
(327,135)
|
(512,761)
|
(646,089)
|
(611,794)
|
Other expense |
|
|
|
|
(110,642)
|
|
Gain on extinguishment of debt |
|
|
85,546
|
|
|
|
Total other income (expense) |
(145,522)
|
(226,443)
|
(313,486)
|
(416,041)
|
(597,083)
|
(656,299)
|
LOSS BEFORE PROVISION FOR INCOME TAXES |
(602,857)
|
(945,662)
|
(1,743,194)
|
(2,737,342)
|
(3,677,012)
|
(2,960,645)
|
Provision for income taxes |
|
800
|
800
|
800
|
800
|
800
|
Net loss before non-controlling interest |
(602,857)
|
(946,462)
|
(1,743,994)
|
(2,738,142)
|
17,300,000
|
|
Loss attributable to non-controlling interest |
(816)
|
|
(1,672)
|
|
|
|
Net loss |
$ (602,041)
|
$ (946,462)
|
$ (1,742,322)
|
$ (2,738,142)
|
$ (3,677,812)
|
$ (2,961,445)
|
Net loss per share - basic |
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
Net loss per share - diluted |
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
$ (0.00)
|
Weighted average shares outstanding - basic |
3,286,909,395
|
2,565,663,048
|
2,987,459,958
|
2,501,116,667
|
2,528,062,958
|
2,263,126,970
|
Weighted average shares outstanding - diluted |
3,286,909,395
|
2,565,663,048
|
2,987,459,958
|
2,501,116,667
|
2,528,062,958
|
2,263,126,970
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_DerivativeGainLossOnDerivativeNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_GainLossOnDerivativeInstrumentsNetPretax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_LegalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
+ Details
Name: |
us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
+ Details
Name: |
us-gaap_ProfessionalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)
|
Preferred Stock [Member]
Series A Preferred Stock [Member]
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Shares To Be Issued [Member] |
Subscription Receivable [Member] |
Retained Earnings [Member] |
Noncontrolling Interest [Member] |
Total |
Balance at Dec. 31, 2020 |
|
$ 2,233,742
|
$ 7,041,960
|
|
$ (21,000)
|
$ (11,032,801)
|
|
$ (1,778,099)
|
Balance, shares at Dec. 31, 2020 |
|
2,233,741,391
|
|
|
|
|
|
|
Common stock issued for services |
|
$ 21,000
|
837,900
|
|
|
|
|
858,900
|
Common stock issued for services, shares |
|
21,000,000
|
|
|
|
|
|
|
Common stock issued for prepaid fees |
|
$ 20,000
|
1,452,450
|
|
|
|
|
1,472,450
|
Common stock issued for prepaid fees, shares |
|
20,000,000
|
|
|
|
|
|
|
Common stock issued for salaries |
|
$ 8,342
|
231,457
|
|
|
|
|
239,799
|
Common stock issued for salaries, shares |
|
8,341,723
|
|
|
|
|
|
|
Common stock issued for cash |
|
$ 4,850
|
280,649
|
|
|
|
|
285,499
|
Common stock issued for cash, shares |
|
4,850,075
|
|
|
|
|
|
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities |
|
$ 21,691
|
508,044
|
|
|
|
|
529,735
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares |
|
21,690,671
|
|
|
|
|
|
|
Common stock issued for land development |
|
$ 1,500
|
57,400
|
|
|
|
|
58,900
|
Common stock issued for land development, shares |
|
1,500,000
|
|
|
|
|
|
|
Relief of derivative liabilities |
|
|
489,279
|
|
|
|
|
489,279
|
Net loss |
|
|
|
|
|
(2,961,445)
|
|
(2,961,445)
|
Balance at Dec. 31, 2021 |
|
$ 2,311,125
|
10,899,139
|
|
(21,000)
|
(13,994,246)
|
|
(804,982)
|
Balance, shares at Dec. 31, 2021 |
|
2,311,123,860
|
|
|
|
|
|
|
Common stock issued for services |
|
$ 25,303
|
482,775
|
|
|
|
|
508,078
|
Common stock issued for services, shares |
|
25,302,577
|
|
|
|
|
|
|
Common stock issued for prepaid fees |
|
$ 11,000
|
231,320
|
|
|
|
|
242,320
|
Common stock issued for prepaid fees, shares |
|
11,000,000
|
|
|
|
|
|
|
Common stock issued for salaries |
|
$ 1,034
|
28,965
|
|
|
|
|
29,999
|
Common stock issued for salaries, shares |
|
1,034,482
|
|
|
|
|
|
|
Common stock issued for cash |
|
$ 44,500
|
400,500
|
|
|
|
|
445,000
|
Common stock issued for cash, shares |
|
44,500,000
|
|
|
|
|
|
|
Common stock issued for license |
|
$ 149,402
|
2,958,168
|
|
|
|
|
3,107,570
|
Common stock issued for license, shares |
|
149,402,390
|
|
|
|
|
|
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities |
|
$ 41,700
|
901,732
|
|
|
|
|
943,432
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares |
|
41,700,228
|
|
|
|
|
|
|
Common stock issued for land development |
|
$ 4,000
|
46,400
|
|
|
|
|
50,400
|
Common stock issued for land development, shares |
|
4,000,000
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
(2,738,142)
|
|
(2,738,142)
|
Net loss |
|
|
|
|
|
|
|
(2,738,142)
|
Balance at Sep. 30, 2022 |
|
$ 2,588,064
|
15,948,999
|
|
(21,000)
|
(16,732,388)
|
|
1,783,675
|
Balance, shares at Sep. 30, 2022 |
|
2,588,063,537
|
|
|
|
|
|
|
Balance at Dec. 31, 2021 |
|
$ 2,311,125
|
10,899,139
|
|
(21,000)
|
(13,994,246)
|
|
(804,982)
|
Balance, shares at Dec. 31, 2021 |
|
2,311,123,860
|
|
|
|
|
|
|
Common stock issued for services |
|
$ 32,413
|
557,107
|
102,000
|
|
|
|
691,520
|
Common stock issued for services, shares |
|
32,412,577
|
|
|
|
|
|
|
Common stock issued for prepaid fees |
|
$ 11,000
|
231,320
|
|
|
|
|
242,320
|
Common stock issued for prepaid fees, shares |
|
11,000,000
|
|
|
|
|
|
|
Common stock issued for salaries |
|
$ 4,812
|
62,587
|
|
|
|
|
67,399
|
Common stock issued for salaries, shares |
|
4,812,259
|
|
|
|
|
|
|
Common stock issued for cash |
|
$ 44,500
|
400,500
|
|
|
|
|
445,000
|
Common stock issued for cash, shares |
|
44,500,000
|
|
|
|
|
|
|
Common stock issued for license |
|
$ 149,402
|
2,958,168
|
|
|
|
|
3,107,570
|
Common stock issued for license, shares |
|
149,402,390
|
|
|
|
|
|
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities |
|
$ 64,140
|
1,225,308
|
24,324
|
|
|
|
1,313,772
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares |
|
64,139,744
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
17,300,000
|
Net loss |
|
|
|
|
|
(3,677,812)
|
|
(3,677,812)
|
Issuance of preferred stock |
|
|
|
|
|
|
|
|
Issuance of preferred stock, shares |
2
|
|
|
|
|
|
|
|
Balance at Dec. 31, 2022 |
|
$ 2,617,392
|
16,334,129
|
126,324
|
(21,000)
|
(17,672,058)
|
|
1,384,787
|
Balance, shares at Dec. 31, 2022 |
2
|
2,617,390,830
|
|
|
|
|
|
|
Balance at Jun. 30, 2022 |
|
$ 2,552,228
|
15,467,138
|
|
(21,000)
|
(15,785,926)
|
|
2,212,440
|
Balance, shares at Jun. 30, 2022 |
|
2,552,228,460
|
|
|
|
|
|
|
Common stock issued for services |
|
$ 9,303
|
91,575
|
|
|
|
|
100,878
|
Common stock issued for services, shares |
|
9,302,577
|
|
|
|
|
|
|
Common stock issued for prepaid fees |
|
$ 5,000
|
88,500
|
|
|
|
|
93,500
|
Common stock issued for prepaid fees, shares |
|
5,000,000
|
|
|
|
|
|
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities |
|
$ 17,533
|
255,386
|
|
|
|
|
272,919
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares |
|
17,532,500
|
|
|
|
|
|
|
Common stock issued for land development |
|
$ 4,000
|
46,400
|
|
|
|
|
50,400
|
Common stock issued for land development, shares |
|
4,000,000
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
(946,462)
|
|
(946,462)
|
Net loss |
|
|
|
|
|
|
|
(946,462)
|
Balance at Sep. 30, 2022 |
|
$ 2,588,064
|
15,948,999
|
|
(21,000)
|
(16,732,388)
|
|
1,783,675
|
Balance, shares at Sep. 30, 2022 |
|
2,588,063,537
|
|
|
|
|
|
|
Balance at Dec. 31, 2022 |
|
$ 2,617,392
|
16,334,129
|
126,324
|
(21,000)
|
(17,672,058)
|
|
1,384,787
|
Balance, shares at Dec. 31, 2022 |
2
|
2,617,390,830
|
|
|
|
|
|
|
Common stock issued for services |
|
$ 47,757
|
136,654
|
(98,250)
|
|
|
|
86,161
|
Common stock issued for services, shares |
|
47,757,394
|
|
|
|
|
|
|
Common stock issued for salaries |
|
$ 4,082
|
15,918
|
|
|
|
|
20,000
|
Common stock issued for salaries, shares |
|
4,081,632
|
|
|
|
|
|
|
Common stock issued for cash |
|
$ 445,180
|
232,198
|
|
|
|
|
677,378
|
Common stock issued for cash, shares |
|
445,180,614
|
|
|
|
|
|
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities |
|
$ 276,255
|
525,878
|
(15,000)
|
|
|
|
787,133
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares |
|
276,254,885
|
|
|
|
|
|
|
Common stock issued for land development |
|
$ 60,000
|
36,000
|
|
|
|
|
96,000
|
Common stock issued for land development, shares |
|
60,000,000
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
(1,742,322)
|
(1,672)
|
(1,743,994)
|
Common stock issued by subsidiary for services |
|
|
1,831
|
|
|
|
|
1,831
|
Net loss |
|
|
|
|
|
|
|
(1,742,322)
|
Balance at Sep. 30, 2023 |
|
$ 3,450,666
|
17,282,608
|
13,074
|
(21,000)
|
(19,414,380)
|
(1,672)
|
1,309,296
|
Balance, shares at Sep. 30, 2023 |
2
|
3,450,665,355
|
|
|
|
|
|
|
Balance at Jun. 30, 2023 |
|
$ 3,134,045
|
17,181,978
|
9,324
|
(21,000)
|
(18,812,339)
|
(856)
|
1,491,152
|
Balance, shares at Jun. 30, 2023 |
2
|
3,134,044,074
|
|
|
|
|
|
|
Common stock issued for services |
|
$ 1,757
|
1,054
|
3,750
|
|
|
|
6,561
|
Common stock issued for services, shares |
|
1,757,394
|
|
|
|
|
|
|
Common stock issued for prepaid fees |
|
|
|
|
|
|
|
|
Common stock issued for salaries |
|
|
|
|
|
|
|
|
Common stock issued for cash |
|
$ 175,089
|
13,937
|
|
|
|
|
189,026
|
Common stock issued for cash, shares |
|
175,089,179
|
|
|
|
|
|
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities |
|
$ 79,775
|
49,639
|
|
|
|
|
129,414
|
Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities, shares |
|
79,774,708
|
|
|
|
|
|
|
Common stock issued for land development |
|
$ 60,000
|
36,000
|
|
|
|
|
96,000
|
Common stock issued for land development, shares |
|
60,000,000
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
(602,041)
|
(816)
|
(602,857)
|
Common stock issued by subsidiary for services |
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
(602,041)
|
Balance at Sep. 30, 2023 |
|
$ 3,450,666
|
$ 17,282,608
|
$ 13,074
|
$ (21,000)
|
$ (19,414,380)
|
$ (1,672)
|
$ 1,309,296
|
Balance, shares at Sep. 30, 2023 |
2
|
3,450,665,355
|
|
|
|
|
|
|
X |
- DefinitionAdjustments to additional paid in capital subsidiary for services.
+ References
+ Details
Name: |
TSOI_AdjustmentsToAdditionalPaidInCapitalSubsidiaryForServices |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionRelief of Derivative Liabilities.
+ References
+ Details
Name: |
TSOI_ReliefOfDerivativeLiabilities |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period common stock issued for land development.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodCommonStockIssuedForLandDevelopment |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period common stock issued for land development shares.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodCommonStockIssuedForLandDevelopmentShares |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares for license.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesForLicense |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for prepaid fees, shares.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesForPrepaidFees |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares for salaries.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesForSalaries |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock Issued During Period Shares New Issues Preferred Stock.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesNewIssuesPreferredStock |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value for license.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValueForLicense |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for prepaid fees.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValueForPrepaidFees |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock Issued During Period Value New Issues Preferred Stock.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValueNewIssuesPreferredStock |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period values for salaries.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValuesForSalaries |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15
Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16
Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.4
Condensed Consolidated Statements of Cash Flows - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
194 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Sep. 30, 2023 |
Cash flows from operating activities |
|
|
|
|
|
|
|
Net loss |
$ (602,041)
|
$ (946,462)
|
$ (1,742,322)
|
$ (2,738,142)
|
$ (3,677,812)
|
$ (2,961,445)
|
$ (19,400,000)
|
Net loss |
(602,857)
|
(946,462)
|
(1,743,994)
|
(2,738,142)
|
17,300,000
|
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
Stock-based compensation to consultants |
|
|
|
311,078
|
380,820
|
397,750
|
|
Stock-based compensation to related parties |
|
|
86,161
|
197,000
|
310,700
|
461,150
|
|
Loss on derivative liabilities |
2,336
|
26,867
|
(21,939)
|
136,583
|
131,475
|
539,006
|
|
Change in fair value of derivative liabilities |
60,124
|
32,205
|
93,836
|
(233,303)
|
(291,123)
|
(494,501)
|
|
Gain on extinguishment of debt |
|
|
(85,546)
|
|
|
|
|
Amortization of prepaid stock-based compensation |
|
|
112,971
|
868,089
|
951,748
|
480,135
|
|
Amortization of debt discount |
|
|
299,267
|
461,058
|
593,463
|
541,612
|
|
Patent amortization |
|
|
222,581
|
191,192
|
233,685
|
11,295
|
|
Depreciation |
|
|
8,161
|
3,489
|
10,946
|
6,772
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable |
|
|
3,634
|
(25,769)
|
(8,785)
|
(14,172)
|
|
Inventory |
|
|
16,010
|
(5,126)
|
(2,611)
|
(34,418)
|
|
Prepaid expenses and other current assets |
|
|
69,595
|
73,807
|
174,364
|
64,777
|
|
Right-of-use asset |
|
|
23,038
|
19,113
|
25,572
|
24,792
|
|
Accounts payable |
|
|
(27,535)
|
(30,051)
|
15,166
|
91,557
|
|
Accounts payable - related parties |
|
|
(3)
|
(2,552)
|
(9,791)
|
2,581
|
|
Accrued expenses and other current liabilities |
|
|
117,538
|
139,405
|
169,451
|
188,979
|
|
Lease liability |
|
|
(23,038)
|
(19,113)
|
(25,572)
|
(24,792)
|
|
Net cash used in operating activities |
|
|
(849,263)
|
(653,242)
|
(1,018,304)
|
(718,922)
|
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(16,158)
|
|
|
(260,565)
|
|
Deposits |
|
|
|
|
|
4,015
|
|
Purchase of license |
|
|
|
(200,000)
|
|
|
|
Issuance of note receivable |
|
|
(3,507)
|
|
|
|
|
Net cash used in investing activities |
|
|
(19,665)
|
(200,000)
|
|
(256,550)
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
Payments on notes payable to related party |
|
|
(17)
|
(2,444)
|
(2,453)
|
(4,799)
|
|
Proceeds from notes payable to related party |
|
|
5,609
|
|
|
|
|
Proceeds from convertible notes payable |
|
|
250,750
|
415,000
|
505,000
|
538,750
|
|
Payments on notes payable |
|
|
(3,697)
|
(3,324)
|
(4,459)
|
(2,068)
|
|
Proceeds from sale of common stock |
|
|
677,378
|
445,000
|
445,000
|
285,499
|
|
Net cash provided by financing activities |
|
|
930,023
|
854,232
|
943,088
|
817,382
|
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
|
61,095
|
990
|
(75,216)
|
(158,090)
|
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
29,043
|
104,259
|
104,259
|
262,349
|
|
Cash, cash equivalents and restricted cash at end of period |
90,138
|
105,249
|
90,138
|
105,249
|
29,043
|
104,259
|
90,138
|
Supplemental cash flow information: |
|
|
|
|
|
|
|
Cash paid for interest |
|
|
2,475
|
2,357
|
3,173
|
3,312
|
|
Cash paid for income taxes |
|
|
|
800
|
800
|
800
|
|
Non-cash investing and financing transactions: |
|
|
|
|
|
|
|
Original issuance discount on convertible notes payable |
|
|
32,500
|
30,500
|
39,000
|
33,500
|
|
Debt discount recorded in connection with derivative liability |
|
|
249,565
|
415,000
|
503,726
|
538,750
|
|
Common stock issued in conversion of convertible notes payable and interest |
|
|
787,133
|
943,431
|
1,313,772
|
1,019,014
|
|
Property and equipment purchased with note payable |
|
|
|
|
|
21,671
|
|
Common stock issued for prepaid fees |
|
|
1,831
|
242,320
|
242,320
|
1,472,450
|
|
Common stock issued for accrued salaries |
|
|
20,000
|
29,999
|
67,399
|
239,799
|
|
Accrued interest added to principal |
|
|
11,148
|
19,436
|
25,914
|
25,912
|
|
Common stock issued for license |
|
|
|
3,107,570
|
3,107,570
|
|
|
Common stock issued for land development |
|
|
96,000
|
50,400
|
|
58,900
|
|
Right of use asset and lease liability |
|
|
146,244
|
|
|
|
|
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: |
|
|
|
|
|
|
|
Cash and cash equivalents |
90,138
|
94,246
|
90,138
|
94,246
|
18,040
|
94,036
|
90,138
|
Restricted cash |
|
11,003
|
|
11,003
|
11,003
|
10,223
|
|
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows: |
$ 90,138
|
$ 105,249
|
$ 90,138
|
$ 105,249
|
$ 29,043
|
$ 104,259
|
$ 90,138
|
X |
- DefinitionAccrued interest added to principal.
+ References
+ Details
Name: |
TSOI_AccruedInterestAddedToPrincipal |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmortization of prepaid stock based compensation.
+ References
+ Details
Name: |
TSOI_AmortizationOfPrepaidStockBasedCompensation |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for accrued salaries value.
+ References
+ Details
Name: |
TSOI_CommonStockIssuedForAccruedSalariesValue |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for license value.
+ References
+ Details
Name: |
TSOI_CommonStockIssuedForLicenseValue |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for prepaid fees value.
+ References
+ Details
Name: |
TSOI_CommonStockIssuedForPrepaidFeesValue |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in right of use asset.
+ References
+ Details
Name: |
TSOI_IncreaseDecreaseInRightOfUseAsset |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPayments for proceeds from notes receivable.
+ References
+ Details
Name: |
TSOI_PaymentsForProceedsFromNotesReceivable |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockAmountIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionOriginalDebtAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_DerivativeGainLossOnDerivativeNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe fair value of assets acquired in noncash investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_FairValueOfAssetsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_GainLossOnDerivativeInstrumentsNetPretax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow for receipts of deposits classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_ProceedsFromOtherDeposits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_RestrictedCash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe fair value of stock issued in noncash financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_StockIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SupplementalCashFlowElementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Organization and Business Description
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
Organization and Business Description |
Note
1 – Organization and Business Description
Therapeutic
Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007, under the name Friendly
Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto
Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.
Business
Description
Currently
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one’s immune system.
Activating
one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.
TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
and for daily health.
Nutraceutical
Division – TSOI has been producing high quality nutraceuticals. Its current flagship product, QuadraMune®, is a multi-patented
synergistic blend of pterostilbene, sulforaphane, epigallocatechin-3-gallate, and thymoquinone. QuadraMune has been shown to increase Natural
Killer Cell activity and healthy Cytokine production.
Regenerative
Medicine – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
The
stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability. Subsequent to this acquisition the Company has filed an additional 22 patents on this population of unique mesenchymal
like stromal cells.
Immunotherapies
TSOI
has a large portfolio of immunotherapies that range from dendritic cell vaccines for cancers to parkinson’s disease developed on
our StemVacs platform.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Management
does not expect existing cash as of September 30, 2023, to be sufficient to fund the Company’s operations for at least twelve months
from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumed
the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of September 30, 2023,
the Company has incurred losses totaling $19.4 million since inception, has not yet generated material revenue from operations, and will
require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue
as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as
a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its
obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating
costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings,
debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required
to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments
to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the
Company be unable to continue as a going concern.
|
Note
1 – Organization and Business Description
Therapeutic
Solutions International, Inc. (“TSI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto
Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011 the Company changed its name from Friendly Auto Dealers,
Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation.
Business
Description
Currently,
the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to
upregulate (make more active) or downregulate (make less active) one’s immune system.
Activating
one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections
and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and
allergic reactions.
TSOI
is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury,
lung pathologies, and for daily health.
Cellular
Division – TSOI obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic
traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
The
stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and
neurogenic ability.
Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and
is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression,
depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment
to enhance receptivity of regenerative cells such as stem cells. On March 4, 2021 the Company received an IND Serial # 27377 for a clinical
trial of 10 patients with CTE.
On
August 4th, 2021, the Company announced clearance from the Food and Drug Administration (FDA) to initiate a Phase III pivotal
trial for registration of the Company’s JadiCell™ universal donor stem cell as a treatment for COVID-19 associated
lung failure under IND # 19757. In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types
of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, the JadiCell™ was shown to be 100% effective
in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the
ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
In
addition, the Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™
resulted in enhanced activity of a type of immunological cell called “natural killer” cells, otherwise known as “NK
cells.”
The
Company has also developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells
called dendritic cells in a manner so that upon injection they reprogram the body’s NK cells.
Most
recently the Company announced filing of a patent for a new hybrid cell created by the Company capable of training the immune system
to kill blood vessels feeding cancer, but sparing healthy blood vessels. These discoveries are an extension of previous findings from
the Company showing that StemVacs is capable of suppressing new blood vessel production.
On
May 9, 2022, the Company filed an Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Using JadiCell™ Universal Donor Adult Stem Cells under IND Serial # 28508.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Management
does not expect existing cash as of December 31, 2022 or as of March 31, 2023 to be sufficient to fund the Company’s operations
for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going
concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business.
As of December 31, 2022, the Company has incurred losses totaling $17.3 million since inception, has not yet generated material revenue
from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s
ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability
to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing
to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to
finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital
through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable
terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements
do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Basis of presentation and significant accounting policies
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Basis of presentation and significant accounting policies |
Note
2 – Basis of presentation and significant accounting policies
Basis
of Presentation
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries,
and its 68% owned subsidiary Res Nova Bio, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
No material activity in any subsidiaries.
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
|
1) |
Identify
the contract with a customer. |
|
|
|
|
2) |
Identify
the performance obligations in the contract. |
|
|
|
|
3) |
Determine
the transaction price. |
|
|
|
|
4) |
Allocate
the transaction price to the performance obligations in the contract. |
|
|
|
|
5) |
Recognize
revenue when (or as) the entity satisfies a performance obligation. |
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
Revenue is adjusted based on an estimate of the expected returns based on historical rates. Our
estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we
consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel
as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision
for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s
revenues in the accompanying financial statements.
Wholesale
policies:
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional
Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned
products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the
aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense
Retail
policies of e-commerce:
Shipping.
Shipping Time — Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed
or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or
transit time offered to the customer by this site or other parties only as an estimate. We encourage the customer to order in a timely
fashion to avoid delays caused by shipping or product availability. Fulfillment mistakes that may be made which result in the shipment
of incorrect products to the customer will also be accepted for return.
Out
of Stock. We will ship the customer’s product as it becomes available. Usually, products ship by the next business day. However,
there may be times when the product the customer had ordered is out-of-stock, which will delay fulfilling the customer’s order.
We will keep the customer informed of any products that the customer had ordered that are out-of-stock and unavailable for immediate
shipment. The Customer may cancel their order at any time prior to shipping.
Cash
and Cash Equivalents
The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2023 and December
31, 2022, the Company had $0 and $0 in excess of the FDIC insured limit.
Inventories
Inventories
are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials
and assembly items.
Derivative
Liabilities
A
derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the
Company entered into certain debt financing transactions in fiscal 2023 and 2022, as disclosed in Note 7 containing certain
conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to
properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments
indexed to our common shares on a first-in-first-out basis.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $292,699
and $202,144 at September 30, 2023 and December 31, 2022, respectively.
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of September 30, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative
liabilities. The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the three months ended September 30, 2023:
Schedule
of Change in Derivative Liability
Balance, December 31, 2022 | |
$ | 202,144 | |
Issuance of new derivative liabilities | |
| 328,433 | |
Conversions | |
| (331,714 | ) |
Change in fair market value of derivative liabilities | |
| 93,836 | |
Balance, September 30, 2023 | |
$ | 292,699 | |
Use
of Estimates
Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.
Comprehensive
Loss
Comprehensive
loss for the periods reported was comprised solely of the Company’s net loss.
Non-Controlling
Interests
Non-controlling
interests disclosed within the consolidated statement of operations represent the minority ownership’s 32% share of net losses
of Res Nova Bio, Inc. incurred during the nine months ended September 30, 2023.
Net
Loss Per Share
Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of September 30, 2023, and 2022, a total of 1,259,591,300 and 211,919,728, respectively,
potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would
be antidilutive.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Depreciation
and Amortization
Depreciation
is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line
method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2023, and 2022 was $8,161 and $3,489,
respectively.
Intangible
Assets
Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2023, and 2022 was $222,581 and
$191,192, respectively.
Long-lived
Assets
In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.
Research
and Development
Research
and Development costs are expensed as incurred. Research and Development expenses were $410,146 and $1,177,123 for the nine months ended
September 30, 2023, and 2022, respectively.
Income
Taxes
The
Company accounts for income taxes under ASC 740 “Income Taxes,” which codified SFAS 109, “Accounting for
Income Taxes” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No.
109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided
for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
Stock-Based
Compensation
Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.
Leases
On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $131,818 as of September 30, 2023.
Recently
Issued Accounting Pronouncements
In
August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
(“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models
for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result,
more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion
features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use
of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using
either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller
reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those
fiscal years. The accounting guidance has been adopted with no significant financial statement impact.
Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company’s financial statement presentation or disclosures.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
|
Note
2 – Basis of presentation and significant accounting policies
Basis
of Presentation
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any
subsidiaries.
Accounts
Receivable
Accounts
receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require
collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including
the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability
to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts
receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful
accounts.
The
Company recorded an allowance for doubtful accounts of $6,807 as of both December 31, 2022 and 2021, respectively.
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
| 1) | Identify
the contract with a customer. |
| 2) | Identify
the performance obligations in the contract. |
| 3) | Determine
the transaction price. |
| 4) | Allocate
the transaction price to the performance obligations in the contract. |
| 5) | Recognize
revenue when (or as) the entity satisfies a performance obligation. |
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.
Wholesale
policies:
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an
additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth
of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%)
discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off
retail.
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense
Retail
policies of e-commerce:
Returns.
We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes
that may be made which result in the shipment of incorrect products to you will also be accepted for return.
Shipping.
Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or
shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit
time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays
caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory
amounts. Orders are shipped to customers by the companies as ordered on their websites.
Out
of Stock. We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may
be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any
products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior
to shipping.
Cash
and Cash Equivalents
The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021,
the Company had $0 in excess of the FDIC insured limit.
Inventories
Inventories
are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials
and assembly items.
Derivative
Liabilities
A
derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company
entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features
that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments
within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out
basis.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $202,144
and $531,525 at December 31, 2022 and 2021, respectively.
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities.
The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the years ended December 31, 2022 and 2021:
Schedule
of Change in Derivative Liability
Balance, December 31, 2020 | |
$ | 437,549 | |
| |
| | |
Issuance of new derivative liabilities | |
| 1,077,756 | |
Conversions | |
| (489,279 | ) |
Change in fair market value of derivative liabilities | |
| (494,501 | ) |
| |
| | |
Balance, December 31, 2021 | |
| 531,525 | |
| |
| | |
Issuance of new derivative liabilities | |
| 674,971 | |
Conversions | |
| (713,229 | ) |
Change in fair market value of derivative liabilities | |
| (291,123 | ) |
Balance, December 31, 2022 | |
$ | 202,144 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Use
of Estimates
Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.
Comprehensive
Loss
Comprehensive
loss for the periods reported was comprised solely of the Company’s net loss.
Net
Loss Per Share
Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential
common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.
Depreciation
and Amortization
Depreciation
is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight
line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $10,946 and $6,772,
respectively.
Intangible
Assets
Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $11,295,
respectively.
Long-lived
Assets
In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.
Shipping
and Handling
The
Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within
general administrative expenses.
Advertising
Advertising
costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $4,132 and $0, respectively.
Research
and Development
Research
and Development costs are expensed as incurred. Research and Development expenses were $1,441,128 and $794,750 for the years ended December
31, 2022 and 2021, respectively.
Income
Taxes
The
Company accounts for income taxes under ASC 7”0 “Income Tax”s,” which codified SFAS 10”, “Accounting
for Income Ta”es” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB
Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740,
the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment
occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not
realize tax assets through future operations.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
Stock-Based
Compensation
Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.
Leases
On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $8,612 as of December 31, 2022.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
+ Details
Name: |
us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Prepaid expense and other current assets
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Prepaid Expense And Other Current Assets |
|
|
Prepaid expense and other current assets |
Note
3 – Prepaid expense and other current assets
Prepaid
expenses and other current assets consist of the following:
Schedule of Prepaid Expenses and Other Current Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Prepaid consulting | |
$ | 16,939 | | |
$ | 148,550 | |
Insurance | |
| 1,601 | | |
| 1,141 | |
Prepaid costs and other | |
| 24,121 | | |
| 62,661 | |
Total | |
$ | 42,661 | | |
$ | 212,352 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
|
Note
4 – Prepaid expense and other current assets
Prepaid
expenses and other current assets consist of the following:
Schedule
of Prepaid Expenses and Other Current Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Prepaid consulting | |
$ | 148,550 | | |
$ | 930,893 | |
Insurance | |
| 1,141 | | |
| 987 | |
Prepaid costs | |
| 62,661 | | |
| 27,427 | |
Total | |
$ | 212,352 | | |
$ | 959,307 | |
|
X |
- DefinitionDeferred Costs Capitalized Prepaid and Other Assets [Text Block]
+ References
+ Details
Name: |
TSOI_DeferredCostsCapitalizedPrepaidAndOtherAssetsTextBlock |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
TSOI_DisclosurePrepaidExpenseAndOtherCurrentAssetsAbstract |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Fixed assets
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Abstract] |
|
|
Fixed assets |
Note
4 – Fixed assets
Fixed
assets consist of the following:
Schedule of Fixed Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Land | |
$ | 347,381 | | |
$ | 235,223 | |
Vehicles | |
| 50,514 | | |
| 50,514 | |
Computer hardware | |
| 6,135 | | |
| 6,135 | |
Office furniture and equipment | |
| 7,912 | | |
| 7,912 | |
Shipping and other equipment | |
| 1,575 | | |
| 1,575 | |
Total | |
| 413,517 | | |
| 301,359 | |
Accumulated depreciation | |
| (36,441 | ) | |
| (28,281 | ) |
Property and equipment, net | |
$ | 377,076 | | |
$ | 273,078 | |
Depreciation
expense was $8,161 and $3,489 for the nine months ended September 30, 2023, and 2022, respectively.
|
Note
5 – Fixed assets
Fixed
assets consist of the following:
Schedule
of Fixed Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Land | |
$ | 235,223 | | |
$ | 235,223 | |
Vehicles | |
| 50,514 | | |
| 50,514 | |
Computer hardware | |
| 6,135 | | |
| 5,935 | |
Office furniture and equipment | |
| 7,912 | | |
| 7,912 | |
Shipping and other equipment | |
| 1,575 | | |
| 1,575 | |
Total | |
| 301,359 | | |
| 301,159 | |
Accumulated depreciation | |
| (28,281 | ) | |
| (17,135 | ) |
Property and equipment, net | |
$ | 273,078 | | |
$ | 284,024 | |
Depreciation
expense was $10,946 and $6,772 for the years ended December 31, 2022 and 2021, respectively.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Other assets
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Other assets |
Note
5 – Other assets
Other
assets consist of the following:
Schedule of Other Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Prepaid consulting | |
$ | - | | |
$ | 7,537 | |
Deposit | |
| 4,123 | | |
| 4,123 | |
Licenses, net | |
| 2,780,379 | | |
| 3,002,960 | |
Total | |
$ | 2,784,502 | | |
$ | 3,014,620 | |
As
of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December
31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy),
and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived
from US Patent No.: 9,803,176 B2.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:
Schedule of Net Licenses
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
License | |
$ | 3,261,122 | | |
$ | 3,261,122 | |
Accumulated amortization | |
| (480,743 | ) | |
| (258,162 | ) |
Licenses, net | |
$ | 2,780,379 | | |
$ | 3,002,960 | |
Amortization
expense for the nine months ended September 30, 2023, and 2022 was $222,581 and $191,192.
|
Note
6 – Other assets
Other
assets consist of the following:
Schedule
of Other Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Prepaid consulting | |
$ | 7,537 | | |
$ | 108,673 | |
Deposit | |
| 4,123 | | |
| 39,823 | |
Licenses, net | |
| 3,002,960 | | |
| 129,075 | |
Total | |
$ | 3,014,620 | | |
$ | 277,571 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:
Schedule of Net Licenses
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Licenses | |
$ | 3,261,122 | | |
$ | 153,552 | |
Accumulated amortization | |
| (258,162 | ) | |
| (24,477 | ) |
Licenses, net | |
$ | 3,002,960 | | |
$ | 129,075 | |
Amortization
expense for the years ended December 31, 2022 and 2021 was $233,685 and $24,477, respectively.
As
of June 1, 2019, we entered into a license agreement, which will be amortized over the life of the Patent. The Patent expires December
31, 2032. The Exclusive Patent License to the Jadi Cell is for use under the designated areas of CTE (Chronic Traumatic Encephalopathy),
and TBI (Traumatic Brain Injury). The Jadi Cell is an cGMP grade and Research grade manufactured allogenic mesenchymal stem cells derived
from US Patent No.: 9,803,176 B2. Forward looking the Company intends to file an Investigational New Drug Application (IND) for brain
injured patients who have been intensively cared for and mechanically ventilated due to covid-19 illness and a second IND for CTE/TBI
as well in keeping with the spirit of the licensing agreement to advance the Jadi Cell through to FDA Approval for CTE/TBI.
On
February 9, 2021, the Company issued a Convertible Promissory Note (CPN) to JadiCell LLC that was never fully executed while the parties
worked to finalize the agreement that resulted in an Exclusive Patent License Agreement (EPLA) being executed on September 15, 2021.
Finally, a Settlement Agreement was entered into on February 23, 2022. On February 23, 2022, we issued 149,402,390
shares of common stock,
valued at $0.0208
per share, for the EPLA,
with a final value of the license being recorded at $3,107,570.
The Patent expires December
31, 2032. The Exclusive
Patent License to the Jadi Cell is for use under the designated areas of all applicable Lung Pathology. The Jadi Cell is an cGMP grade
and Research grade manufactured allogenic mesenchymal stem cells derived from US Patent No.: 9,803,176 B2 and will be amortized over
the 10
year life of the Patent.
As of March 25, 2022, we entered into a asset transfer and license agreement, which will be amortized over the life of the agreement.
The agreement is until March
24, 2027. The Company
has made an initial payment of $200,000.
Within six months, the Company will make a second payment of $1.8
million. The agreement
is in default and the initial paymentof $200,000 was expensed to research & development.
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
+ Details
Name: |
us-gaap_OtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Notes Payable-Related Party
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Debt Disclosure [Abstract] |
|
|
Notes Payable-Related Party |
Note
6 - Notes Payable-Related Party
At
September 30, 2023 and December 31, 2022, the Company has unsecured interest-bearing demand notes outstanding to certain officers and
directors amounting to $694,257 and $988,672 respectively. Interest accrued on these notes during the nine months ended September 30,
2023, and 2022 was $3,956 and $12,956, respectively.
|
Note
8 – Notes payable-related parties
Notes Payable-Related Party
Notes
payable-related parties consist of:
Schedule
of Notes Payable Related Parties
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
| |
$ | - | | |
$ | 2,356 | |
Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 | |
$ | - | | |
$ | 2,356 | |
| |
| | | |
| | |
One notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019 | |
| 29,090 | | |
| 27,577 | |
| |
| | | |
| | |
One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues | |
| 534,448 | | |
| 534,544 | |
| |
| | | |
| | |
Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 | |
| 124,800 | | |
| 118,400 | |
| |
| | | |
| | |
Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity date of April 20, 2019 | |
| 30,334 | | |
| 282,334 | |
| |
| 988,672 | | |
| 965,211 | |
| |
| | | |
| | |
| |
$ | 988,672 | | |
$ | 965,211 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Convertible Notes Payable
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Debt Disclosure [Abstract] |
|
|
Convertible Notes Payable |
Note
7 – Convertible Notes Payable
At
various times during the nine months ended September 30, 2023, the Company entered into convertible promissory notes with principal amounts
totaling $283,250 with a third party for which the proceeds were used for operations. The Company received net proceeds of $250,750,
and an $32,500 original issuance discount was recorded. The convertible promissory notes incur interest at 10% per annum and mature on
dates ranging from April 11, 2024, to September 29, 2024. The convertible promissory notes are convertible to shares of the Company’s
common stock 180 days after issuance. The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices
of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay
the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the
default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company
was required to reserve at September 30, 2023 a total of 1,259,591,300 common shares in connection with these promissory notes.
Derivative
liabilities
These
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number
of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented
an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability
is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes
in the derivative liability fair value are reported in operating results each reporting period.
For
the notes issued during the nine months ended September 30, 2023, the Company valued the conversion feature on the date of issuance resulting
in an initial liability of $628,437. Since the fair value of the derivative was in excess of the proceeds received, a full discount to
convertible notes payable and a day one loss on derivative liabilities of $78,868 was recorded during the nine months ended September
30, 2023. Upon issuance, the Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $0.0008 to $0.0034, the closing stock price of the Company’s common stock on the date of valuation
ranging from $0.0011 to $0.006, an expected dividend yield of 0%, expected volatility ranging from 124% to 160%, risk-free interest rate
ranging from 4.67% to 5.46%, and an expected term of one year.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
During
the nine months ended September 30, 2023, convertible notes with principal and accrued interest balances totaling $338,577
were converted into 218,504,885
shares of common stock. At each conversion date,
the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection
with the change in fair market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata
portion of the derivative liability as compared to the portion of the convertible note converted was recorded as a loss or gain on derivative
liabilities. During the nine months ended September 30, 2023, the Company recorded $100,807
to gain on derivative liabilities in connection
with these conversions. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions:
conversion prices ranging from $0.0008
to $0.004,
the closing stock price of the Company’s common stock on the date of valuation ranging from $0.001
to $0.006,
an expected dividend yield of 0%,
expected volatility ranging from 110%
to 193%,
risk-free interest rates ranging from 4.55%
to 5.37%,
and expected terms of 0.48
to 0.50
years.
On
September 30, 2023, the derivative liabilities on the remaining convertible notes were revalued at $292,699 resulting in a gain of $93,836
for the nine months ended September 30, 2023, related to the change in fair value of the derivative liabilities. The derivative liabilities
were revalued using the Black-Scholes option pricing model with the following assumptions: exercise prices of $0.0008, the closing stock
price of the Company’s common stock on the date of valuation of $0.002, an expected dividend yield of 0%, expected volatility ranging
from 157% to 175%, risk-free interest rate of 5.46%, and an expected term ranging from 0.53 to 1 years.
The
Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to
the effective interest method. During the nine months ended September 30, 2023, and 2022, the Company amortized $299,268 and $461,058
to interest expense, respectively. As of September 30, 2023, discounts of $157,861 remained which will be amortized through September
2024.
|
Note
7 – Convertible notes payable
Convertible Notes Payable
At
various times during the year ended December 31, 2022, the Company entered into convertible promissory notes with principal amounts
totaling $544,000
with third parties for which the proceeds were used for operations. The Company received net proceeds of $505,000,
and a $39,000
original issuance discount was recorded. The convertible promissory notes incur interest at a rate of 10%
per annum and mature
on dates ranging from January 1, 2023 to December 5, 2023. The
convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion
price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s
common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is
defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the
convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which
the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
The Company was required to reserve at December 31, 2022 a total of 267,136,056
common shares in connection with these promissory notes.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
7 – Convertible notes payable (continued)
At
various times during the year ended December 31, 2021, the Company entered into convertible promissory notes with principal amounts
totaling $572,250
with third parties for which the proceeds were used for operations. The Company received net proceeds of $538,750,
and a $33,500
original issuance discount was recorded. The convertible promissory notes incur interest at rates ranging from 10%
to 12%
per annum and mature
on dates ranging from January 25, 2022 to December 15, 2022. The
convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion
price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the
Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to
prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of
principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default
provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest
increasing by 150%. The Company was required to reserve at December 31, 2021 total of 95,273,690
common shares in connection with these promissory notes.
Derivative
liabilities
These
convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the
number of common stock we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion
feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability.
The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event
and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting
period.
For
the notes issued during the year ended December 31, 2022, the Company valued the conversion features on the date of issuance resulting
in initial liabilities totaling $674,971. Since the fair value of the derivative was in excess of the proceeds received, a full discount
to convertible notes payable and a day one loss on derivative liabilities of $171,245 was recorded during the year ended December 31,
2022. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion
prices ranging from $0.0058 to $0.0143, the closing stock price of the Company’s common stock on the dates of valuation ranging
from $0.008 to $0.0272, an expected dividend yield of 0%, expected volatilities ranging from 148%-216%, risk-free interest rate ranging
from 0.48% to 4.77%, and an expected term of one year.
During
the year ended December 31, 2022, convertible notes principal plus their accrued interest totaling $774,176 were converted into 68,193,798
shares of common stock, of which 4,054,054 are yet to be issued as of December 31, 2022. At each conversion date, the Company recalculated
the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair
market value. In addition, the fair value of the shares of common stock issued in excess or deficit of the pro-rata portion of the derivative
liability as compared to the portio of the convertible note converted was recorded as a loss or gain on derivative liabilities. During
the year ended December 31, 2022, the Company recorded $39,770 to gain on derivative liabilities. The derivative liabilities were revalued
using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0038 to $0.016, the closing
stock price of the Company’s common stock on the dates of valuation ranging from $0.006 to $0.026, an expected dividend yield
of 0%, expected volatility ranging from 63% to 191%, risk-free interest rates ranging from 0.51% to 4.74%, and expected terms ranging
from 0.44 to 0.50 years.
On
December 31, 2022, the derivative liabilities on the remaining convertible notes were revalued at $202,144 resulting in a gain of $291,123
for the year ended December 31, 2022 related to the change in fair value of the derivative liabilities. The derivative liabilities were
revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.0038, the closing stock price
of the Company’s common stock on the date of valuation of $0.006, an expected dividend yield of 0%, expected volatility ranging
from 96% to 120%, risk-free interest rate of 4.71%, and an expected term ranging from 0.49 to 0.93 years.
For
the notes issued during the year ended December 31, 2021, the Company valued the conversion features on the date of issuance resulting
in initial liabilities totaling $1,077,756. Since the fair value of the derivative was in excess of the proceeds received, a full discount
to convertible notes payable and a day one loss on derivative liabilities of $539,006 was recorded during the year ended December 31,
2021. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion
prices ranging from $0.0039 to $0.0351, the closing stock price of the Company’s common stock on the dates of valuation ranging
from $0.0217 to $0.0540, an expected dividend yield of 0%, expected volatilities ranging from 197%-264%, risk-free interest rate ranging
from 0.05% to 0.29%, and an expected term of one year.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
7 – Convertible notes payable (Continued)
During
the year ended December 31, 2021, convertible notes principal plus their accrued interest totaling $529,735 were converted into 21,690,671
shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible
note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative
liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the year ended
December 31, 2021, the Company recorded $489,279 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes
option pricing model with the following assumptions: conversion prices ranging from $0.0136 to $0.035, the closing stock price of the
Company’s common stock on the dates of valuation ranging from $0.022 to $0.057, an expected dividend yield of 0%, expected
volatility ranging from 125% to 251%, risk-free interest rates ranging from 0.06% to 0.29%, and expected terms ranging from 0.48 to 0.50
years.
On
December 31, 2021, the derivative liabilities on the remaining five convertible notes were revalued at $531,525 resulting in a gain of
$494,501 for the year ended December 31, 2021 related to the change in fair value of the derivative liabilities. The derivative liabilities
were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0123 to
$0.0127, the closing stock price of the Company’s common stock on the date of valuation of $0.029, an expected dividend yield
of 0%, expected volatility ranging from 165% to 218%, risk-free interest rate of 0.39%, and an expected term ranging from 0.53 to 0.96
years.
The
Company amortizes the discounts over the term of the convertible promissory notes using the straight line method which is similar to
the effective interest method. During the years ended December 31, 2022 and 2021, the Company amortized $593,463 and $541,612 to
interest expense, respectively. As of December 31, 2022, discounts of $175,063 remained for which will be amortized through December
2023.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-term debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
+ Details
Name: |
us-gaap_LongTermDebtTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Equity
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Equity [Abstract] |
|
|
Equity |
Note
8 – Equity
Our
authorized capital stock consists of an aggregate of 5,505,000,000 shares, comprised of 5,500,000,000 shares of common stock, par value
$0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences,
privileges, and restrictions of which shall be established by our board of directors. As of September 30, 2023, we have 3,450,665,355
shares of common stock and 2 shares preferred shares issued and outstanding.
Our
non-controlling interest’s authorized capital stock consists of an aggregate of 505,000,000 shares, comprised of 500,000,000 shares
of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time
to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of September
30, 2023, we have 18,308,333 shares of common stock and 0 shares preferred shares issued and outstanding.
In
2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.
In
2022, we issued 32,412,577 shares of common stock, valued at $691,520 for consulting services.
In
2022, we committed to issue 3,000,000 shares of common stock, valued at $18,000 for consulting services, which were issued on January
3, 2023.
In
2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.
In
2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.
In
2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.
In
2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.
In
2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $15,000, which were issued on
January 3, 2023.
In
2023, we issued 445,180,614 shares of common stock for an investment in the Company’s Private Placement of $677,378.
In
2023, we issued 47,757,394 shares of common stock, valued at $86,161 for consulting services.
In
2023, we issued 4,081,632 shares of common stock, valued at $20,000 for salaries.
In
2023, we issued 276,254,885 shares of common stock for the conversion of convertible notes of $787,133.
In
2023, we issued 60,000,000 shares of common stock, valued at $96,000 for land development.
On
August 4, 2022, the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to
Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall
be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on
all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all
issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination,
on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock
shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall
vote together with the holders of Common Stock as a single class.
On
August 9, 2022, we issued 2 shares of preferred shares, valued at 0.001 per share.
During
the nine months ended September 30, 2023, the Company’s subsidiary, Res Nova Bio, Inc., issued shares of its common stock to third
parties which represented 32% ownership of the subsidiary as of September 30, 2023. Net loss attributable to the noncontrolling interest
during the nine months ended September 30, 2023, was $1,672, which netted against the value of the non-controlling interest in equity.
The allocation of net loss was presented in the consolidated statement of operations.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
|
Note
11 – Equity
Our
authorized capital stock consists of an aggregate of 3,505,000,000 shares, comprised of 3,500,000,000 shares of common stock, par value
$0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences,
privileges and restrictions of which shall be established by our board of directors. As of December 31, 2022, we have 2,617,390,830 shares
of common stock and 2 preferred shares issued and outstanding.
In
2021, we issued 4,850,075 shares of common stock for an investment in the Company’s Private Placement of $285,500.
In
2021, we issued 21,000,000 shares of common stock, valued at $858,900 for consulting services.
In
2021, we issued 8,341,723 shares of common stock, valued at $239,799 for salaries.
In
2021, we issued 1,500,000 shares of common stock, valued at $58,900 for land development.
In
2021, we issued 21,690,671 shares of common stock for the conversion of convertible notes of $1,019,014.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
11 – Equity (continued)
In
2022, we issued 44,500,000 shares of common stock for an investment in the Company’s Private Placement of $445,000.
In
2022, we issued 32,412,577 shares of common stock, valued at $691,520 for consulting services.
In
2022, we committed to issue 3,000,000 shares of common stock, valued at $18,000 for consulting services, which were issued on January
3, 2023.
In
2022, we issued 4,812,259 shares of common stock, valued at $67,399 for salaries.
In
2022, we issued 149,402,390 shares of common stock, valued at $3,107,570 for a license.
In
2022, we issued 11,000,000 shares of common stock, valued at $242,320 for prepaid fees.
In
2022, we issued 64,139,744 shares of common stock for the conversion of convertible notes of $1,313,772.
In
2022, we committed to issue 4,054,054 shares of common stock for the conversion of convertible notes of $15,000, which were issued on
January 3, 2023.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Subsequent events
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Subsequent Events [Abstract] |
|
|
Subsequent events |
Note
9 – Subsequent events
On October 2, 2023, we issued 2,500,000 valued at $0.0015 per share, for consulting services.
On
October 5, 2023, we issued 35,702,240 shares of common stock for an investment in the Company’s Private Placement of $34,274.
On
October 13, 2023, we filed an amendment of the articles of incorporation to increase the authorized shares from 4,505,000,000 to 5,505,000,000,
which include 5,500,000,000 of common stock and 5,000,000 of preferred stock.
On
October 13, 2023, we issued 46,832,386 shares of common stock for the complete conversion of $41,212 for convertible note dated April
11, 2023.
On
October 16, 2023, we issued 60,000,000 shares of common stock for $90,000 of accrued salaries.
On
October 16, 2023, we issued 65,000,000 valued at $0.0015 per share, for consulting services.
On
October 25, 2023, we issued 75,749,443 shares of common stock for an investment in the Company’s Private Placement of $78,779.
In
accordance with ASC 855, the Company has analyzed its operations subsequent to November 17, 2022, through the date these financial statements
were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.
|
Note
14 – Subsequent events
On
January 3, 2023, we issued 4,054,054 shares of common stock for the partial conversion of $15,000 for convertible note dated June 27,
2022.
On
January 3, 2023, we issued 17,000,000 shares of common stock, valued at $0.006 per share, for consulting services.
On
January 4, 2023, we issued 10,052,083 shares of common stock for the complete conversion of $36,188 for convertible note dated June
27, 2022.
On
January 9, 2023, we issued 4,081,632 shares of common stock for $20,000 of accrued salaries.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
14 – Subsequent events (continued)
On
January 9, 2023, we issued 4,000,000 shares of common stock, valued at $0.049 per share, for consulting services.
On
February 6, 2023, we issued 6,060,606 shares of common stock for the partial conversion of $20,000 for convertible note dated August
2, 2022.
On
February 7, 2023, we issued 11,386,719 shares of common stock for the complete conversion of $36,438 for convertible note dated August
2, 2022.
On
February 21, 2023, we issued 60,224,825 shares of common stock, valued at $0.00216 per share, for an investment in the Company’s
Private Placement.
On
or about March 21, 2023, the Board of Directors of Therapeutic Solutions International, Inc. (“TSOI”), by unanimous approval,
and with the unanimous approval of the Preferred A Stock holders representing at least 51% of all shareholders with the right to vote,
pursuant to Nevada Revised Statutes Section NRS 78.215, has approved a one-time dividend, to be awarded to stockholders of TSOI in subsidiary
Campbell Neurosciences, Inc., a Delaware corporation (“CNSI”). To receive the dividend by future election you must hold TSOI
common at the market close of April 7, 2023. The dividend rate of conversion shall be for every share of TSOI common you will receive
0.0034 shares of CNSI.
TSOI,
which owns 15,660,000 (31%) of the shares of CNSI common stock, would like to issue a dividend consisting of 10,000,000 shares of its
holdings in CNSI to TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April
7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for
Ninety (90) days from the Dividend Offer Date.
A
letter will be mailed to every shareholder of record details of how to accept the Dividend Offer and a fully pre-paid return acceptance
letter containing the necessary information for issuance. In addition, a Shareholder’s Rights Agreement will be enclosed, an executed
copy to be returned with acceptance.
Required
forms and documents shall be filed with FINRA describing the identity of the parties and the Dividend Offer timely.
In
accordance with ASC 855, the Company has analyzed its operations subsequent to December 31, 2022 through the date these financial statements
were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Commitments and Contingencies
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Commitments and Contingencies Disclosure [Abstract] |
|
|
Commitments and Contingencies |
Note
10 – Commitments and Contingencies
Effective
March 22, 2023, the Company entered into a sixth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists
of approximately 1,700 square feet and the amendment is for a term of 60 months and expires on April 30, 2028. Total rent expense for
the nine months ended September 30, 2023, and 2022 is $18,988 and $18,783, respectively.
The
lease will expire in 2028. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company).
|
Note
13 – Commitments and Contingencies
Effective
March 1, 2020, the Company entered into a fifth amendment to a Lease Agreement for property located in Oceanside, CA. The lease consists
of approximately 1,700 square feet and the amendment is for a term of 36 months and expires on April 30, 2023.
During
the year ended December 31, 2022 and 2021, the Company incurred rent expense of $25,044 and $22,768.
The
lease will expire in 2023. The weighted average discount rate used for this lease is 5% (average borrowing rate of the Company). Maturities
of Leases were:
Future
minimum lease payments as of December 31, 2022 are as follows:
Schedule of Future Minimum Lease Payments
For the year ending December 31, | |
| |
| |
| | |
2023 | |
$ | 8,612 | |
Effective
November 8, 2019, the Company entered into a royalty agreement with one of the officers, refer to Note 9.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Restricted cash
|
12 Months Ended |
Dec. 31, 2022 |
Cash and Cash Equivalents [Abstract] |
|
Restricted cash |
Note
3 – Restricted cash
Included
in current assets is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2023,
and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.
|
X |
- References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Related party transactions
|
12 Months Ended |
Dec. 31, 2022 |
Related Party Transactions [Abstract] |
|
Related party transactions |
Note
9 – Related party transactions
As
of December 31, 2019 and 2018, the Company had accrued officers’ salary of $439,534
and $663,100,
respectively. One of the officers settled with the company for a note payable that is unsecured on November 8, 2019 and doesn’t
accrue interest and will be paid as 0.5%
of revenues. This decreased accrued officers’ salary. The note is still outstanding as of December 31, 2022 and 2021. Payments
for the years ended December 31, 2022 and 2021 was $97 and $101, respectively.
In
2021, we issued 7,544,848 shares of common stock for $239,800 of accrued salaries to one officer of the Company under a Restricted Stock
Award.
On
June 18, 2021, we issued 2,000,000 shares of common stock, to one officer and one director of the Company under a Restricted Stock Award
for $94,600.
On
November 30, 2021, we issued 7,000,000
shares of common stock to four officers and one director under a Restricted Stock Award for $224,000.
In
2022, we issued 4,812,259 shares of common stock for $67,399 of accrued salaries to one officer of the Company under a Restricted Stock
Award.
On
April 5, 2022, we issued 7,000,000 shares of common stock, to four officers and one director of the Company under a Restricted Stock
Award for $175,700.
On
September 8, 2022, we issued 4,000,000 shares of common stock to one officer and one director under a Restricted Stock Award for $46,400.
On
November 2, 2022, we issued 3,000,000 shares of common stock to one director under a Restricted Stock Award for $29,700.
On
December 30, 2022, we committed to issue 14,000,000 shares of common stock, to four officers and one director of the Company under a
Restricted Stock Award for $84,000, which were subsequently issued on January 3, 2023.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Income taxes
|
12 Months Ended |
Dec. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
Income taxes |
Note
10 – Income taxes
The
Company is subject to United States federal and state income taxes at an approximate rate of 30%. The reconciliation of the provision
for income taxes at the United States federal statutory rate compared to the Company’s income tax expense as reported is as follows:
Schedule of Income tax Expense
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Expected income tax at statutory rate | |
$ | (709,666 | ) | |
$ | (621,735 | ) |
State tax | |
| (101,347 | ) | |
| 168 | |
Permanent differences | |
| 405,376 | | |
| 404,872 | |
Other | |
| - | | |
| (71,992 | ) |
Change in valuation allowance | |
| 406,437 | | |
| 289,487 | |
Provision for income taxes | |
$ | 800 | | |
$ | 800 | |
The
significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:
Schedule of Deferred Tax Assets and Liabilities
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Net operating loss carry-forward | |
$ | 2,364,249 | | |
$ | 1,957,812 | |
Valuation allowance | |
| (2,364,249 | ) | |
| (1,957,812 | ) |
Net deferred tax asset | |
$ | - | | |
$ | - | |
The
Company has Federal net operating loss carryforwards of approximately $9.4 million and $7.5 million as of December 31, 2022 and 2021,
respectively. The Company has state net operating loss carryforwards of approximately $7.4 million and $5.5 million as of December 31,
2022 and 2021, respectively. The net operating loss carryforwards are available to offset taxable income in future years, of which approximately
$5 million expires beginning in fiscal 2032. Net operating loss carrforwards incurred after 2018 are carried on indefinitely.
As
of and for the years ended December 31, 2022 and 2021, management does not believe the Company has any uncertain tax positions. Accordingly,
there are no recognized tax benefits at December 31, 2022 and 2021.
The
Company is subject to tax in the United States and files tax returns in the U.S. Federal jurisdiction and California state jurisdiction.
The Company is subject to U.S. Federal, state and local income tax examinations by tax authorities starting in 2019. The Company currently
is not under examination by any tax authority.
|
X |
- DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Legal proceedings
|
12 Months Ended |
Dec. 31, 2022 |
Commitments and Contingencies Disclosure [Abstract] |
|
Legal proceedings |
Note
12 – Legal proceedings
From
time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated
litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or
injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods.
However,
as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a
material adverse effect on our financial condition or results of operations.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
+ Details
Name: |
us-gaap_LegalMattersAndContingenciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Basis of presentation and significant accounting policies (Policies)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Basis of Presentation |
Basis
of Presentation
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
|
Basis
of Presentation
The
consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”). In the opinion of the Company’s management, the consolidated financial statements include all adjustments,
which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the
periods presented.
|
Principles of Consolidation |
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc., its wholly owned subsidiaries,
and its 68% owned subsidiary Res Nova Bio, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
No material activity in any subsidiaries.
|
Principles
of Consolidation
The
accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. No material activity in any
subsidiaries.
|
Revenue Recognition |
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
|
1) |
Identify
the contract with a customer. |
|
|
|
|
2) |
Identify
the performance obligations in the contract. |
|
|
|
|
3) |
Determine
the transaction price. |
|
|
|
|
4) |
Allocate
the transaction price to the performance obligations in the contract. |
|
|
|
|
5) |
Recognize
revenue when (or as) the entity satisfies a performance obligation. |
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
Revenue is adjusted based on an estimate of the expected returns based on historical rates. Our
estimate of the provision for returns is based upon our most recent historical experience of actual customer returns. Additionally, we
consider other factors when estimating our current period return provision, including levels of inventory in our distribution channel
as well as significant market changes which may impact future expected returns, and make adjustments to our current period provision
for returns when it appears product returns may differ from our original estimates. These returns have not been significant to the Company’s
revenues in the accompanying financial statements.
Wholesale
policies:
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional
Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned
products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the
aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense
Retail
policies of e-commerce:
Shipping.
Shipping Time — Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed
or shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or
transit time offered to the customer by this site or other parties only as an estimate. We encourage the customer to order in a timely
fashion to avoid delays caused by shipping or product availability. Fulfillment mistakes that may be made which result in the shipment
of incorrect products to the customer will also be accepted for return.
Out
of Stock. We will ship the customer’s product as it becomes available. Usually, products ship by the next business day. However,
there may be times when the product the customer had ordered is out-of-stock, which will delay fulfilling the customer’s order.
We will keep the customer informed of any products that the customer had ordered that are out-of-stock and unavailable for immediate
shipment. The Customer may cancel their order at any time prior to shipping.
|
Revenue
Recognition
The
Company recognizes revenue in accordance with ASC 606,”Revenue from Contracts with Customers” (“ASC 606”). In
accordance with ASC 606, the Company applies the following methodology to recognize revenue:
| 1) | Identify
the contract with a customer. |
| 2) | Identify
the performance obligations in the contract. |
| 3) | Determine
the transaction price. |
| 4) | Allocate
the transaction price to the performance obligations in the contract. |
| 5) | Recognize
revenue when (or as) the entity satisfies a performance obligation. |
ASC
606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount
that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally
satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which
the customer obtains control of the product or service.
Returns.
We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship.
Wholesale
policies:
Delivery.
The Goods shall be deemed delivered when Buyer has accepted delivery at the above-referenced location. The shipping method shall
be determined by Seller, but Buyer will not be responsible for shipping costs.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
Purchase
Price & Payments. Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an
additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth
of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%)
discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off
retail.
Inspection
of Goods & Rejection. Buyer is entitled to inspect the Goods upon delivery. If the Goods are unacceptable for any reason, Buyer
must reject them at the time of delivery up to five (5) business days from the date of delivery. If Buyer has not rejected the Goods
within five (5) business days from the date of delivery, Buyer shall have waived any right to reject that specific delivery of Goods.
In the event Buyer rejects the Goods, Buyer shall allow Seller a reasonable time to cure the deficiency. A reasonable time period shall
be determined by industry standards for the particular Goods, as well as the Seller and Buyer.
Risk
of Loss. Risk of loss will be on the Seller until the time when the Buyer accepts delivery. Seller shall maintain any and all necessary
insurance in order to insure the Goods against loss at Seller’s own expense
Retail
policies of e-commerce:
Returns.
We will gladly accept the return of products that are defective due to defects in manufacturing and/or workmanship. Fulfillment mistakes
that may be made which result in the shipment of incorrect products to you will also be accepted for return.
Shipping.
Shipping Time –Most orders will ship the next business day, provided the product ordered is in stock. Orders are not processed or
shipped on Saturday or Sunday, except by prior arrangement. We cannot guarantee when an order will arrive. Consider any shipping or transit
time offered to you by this site or other parties only as an estimate. We encourage you to order in a timely fashion to avoid delays
caused by shipping or product availability. Shipping for Amazon and Walmart are shipped to the fullfillment centers based on inventory
amounts. Orders are shipped to customers by the companies as ordered on their websites.
Out
of Stock. We will ship your product as it becomes available. Usually, products ship by the next business day. However, there may
be times when the product you have ordered is out-of-stock, which will delay fulfilling your order. We will keep you informed of any
products that you have ordered that are out-of-stock and unavailable for immediate shipment. You may cancel your order at any time prior
to shipping.
|
Cash and Cash Equivalents |
Cash
and Cash Equivalents
The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At September 30, 2023 and December
31, 2022, the Company had $0 and $0 in excess of the FDIC insured limit.
|
Cash
and Cash Equivalents
The
Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Financial
instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each
institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021,
the Company had $0 in excess of the FDIC insured limit.
|
Inventories |
Inventories
Inventories
are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials
and assembly items.
|
Inventories
Inventories
are stated at lower of cost (using the first-in, first-out method, “FIFO”) or market. Inventories consist of purchased materials
and assembly items.
|
Derivative Liabilities |
Derivative
Liabilities
A
derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the
Company entered into certain debt financing transactions in fiscal 2023 and 2022, as disclosed in Note 7 containing certain
conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to
properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments
indexed to our common shares on a first-in-first-out basis.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $292,699
and $202,144 at September 30, 2023 and December 31, 2022, respectively.
|
Derivative
Liabilities
A
derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap,
option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other
contracts and for hedging activities.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
As
a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company
entered into certain debt financing transactions in fiscal 2022 and 2021, as disclosed in Note 5, containing certain conversion features
that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments
within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out
basis.
The
classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during
a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on
the number of times a contract may be reclassified.
Instruments
classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification)
and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $202,144
and $531,525 at December 31, 2022 and 2021, respectively.
|
Fair Value of Financial Instruments |
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of September 30, 2023 and December 31, 2022, the Company has level 3 fair value calculations on derivative
liabilities. The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the three months ended September 30, 2023:
Schedule
of Change in Derivative Liability
Balance, December 31, 2022 | |
$ | 202,144 | |
Issuance of new derivative liabilities | |
| 328,433 | |
Conversions | |
| (331,714 | ) |
Change in fair market value of derivative liabilities | |
| 93,836 | |
Balance, September 30, 2023 | |
$ | 292,699 | |
|
Fair
Value of Financial Instruments
The
Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount
of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.
Fair
value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an
orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on
assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed
by level within the following fair value hierarchy:
Level
1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level
2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability
through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level
3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing
the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent
in the inputs to the model.
When
determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable
market data is not available. As of December 31, 2021 and 2020, the Company has level 3 fair value calculations on derivative liabilities.
The table below reflects the results of our Level 3 fair value calculations:
The
following is the change in derivative liability for the years ended December 31, 2022 and 2021:
Schedule
of Change in Derivative Liability
Balance, December 31, 2020 | |
$ | 437,549 | |
| |
| | |
Issuance of new derivative liabilities | |
| 1,077,756 | |
Conversions | |
| (489,279 | ) |
Change in fair market value of derivative liabilities | |
| (494,501 | ) |
| |
| | |
Balance, December 31, 2021 | |
| 531,525 | |
| |
| | |
Issuance of new derivative liabilities | |
| 674,971 | |
Conversions | |
| (713,229 | ) |
Change in fair market value of derivative liabilities | |
| (291,123 | ) |
Balance, December 31, 2022 | |
$ | 202,144 | |
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
|
Use of Estimates |
Use
of Estimates
Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.
|
Use
of Estimates
Estimates
were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could
differ materially from those estimates.
|
Comprehensive Loss |
Comprehensive
Loss
Comprehensive
loss for the periods reported was comprised solely of the Company’s net loss.
|
Comprehensive
Loss
Comprehensive
loss for the periods reported was comprised solely of the Company’s net loss.
|
Non-Controlling Interests |
Non-Controlling
Interests
Non-controlling
interests disclosed within the consolidated statement of operations represent the minority ownership’s 32% share of net losses
of Res Nova Bio, Inc. incurred during the nine months ended September 30, 2023.
|
|
Net Loss Per Share |
Net
Loss Per Share
Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of September 30, 2023, and 2022, a total of 1,259,591,300 and 211,919,728, respectively,
potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would
be antidilutive.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
NOTES
TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September
30, 2023
|
Net
Loss Per Share
Basic
loss per share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding
during the period of computation. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased
to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such
additional common shares were dilutive. Since we had net losses for all the periods presented, basic and diluted loss per share are the
same, and additional potential common shares have been excluded as their effect would be antidilutive.
As
of December 31, 2022 and 2021, a total of 267,136,056 and 95,273,690, respectively, potential
common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive.
|
Depreciation and Amortization |
Depreciation
and Amortization
Depreciation
is calculated using the straight-line method over the estimated useful lives of the assets. Amortization is computed using the straight-line
method over the term of the agreement. Depreciation expense for the nine months ended September 30, 2023, and 2022 was $8,161 and $3,489,
respectively.
|
Depreciation
and Amortization
Depreciation
is calculated using the straight line method over the estimated useful lives of the assets. Amortization is computed using the straight
line method over the term of the agreement. Depreciation expense for the years ended December 31, 2022 and 2021 was $10,946 and $6,772,
respectively.
|
Intangible Assets |
Intangible
Assets
Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the nine months ended September 30, 2023, and 2022 was $222,581 and
$191,192, respectively.
|
Intangible
Assets
Intangible
assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized
in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized
over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the
carrying amount may not be recoverable. Amortization expense for the years ended December 31, 2022 and 2021 was $233,685 and $11,295,
respectively.
|
Long-lived Assets |
Long-lived
Assets
In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.
|
Long-lived
Assets
In
accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed
on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the
sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured
as the excess of the carrying amount of the asset over its estimated fair value.
|
Research and Development |
Research
and Development
Research
and Development costs are expensed as incurred. Research and Development expenses were $410,146 and $1,177,123 for the nine months ended
September 30, 2023, and 2022, respectively.
|
Research
and Development
Research
and Development costs are expensed as incurred. Research and Development expenses were $1,441,128 and $794,750 for the years ended December
31, 2022 and 2021, respectively.
|
Income Taxes |
Income
Taxes
The
Company accounts for income taxes under ASC 740 “Income Taxes,” which codified SFAS 109, “Accounting for
Income Taxes” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No.
109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided
for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.
|
Income
Taxes
The
Company accounts for income taxes under ASC 7”0 “Income Tax”s,” which codified SFAS 10”, “Accounting
for Income Ta”es” and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB
Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and
liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740,
the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment
occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not
realize tax assets through future operations.
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC.
Consolidated
Notes to Financial Statements
December
31, 2022
Note
2 – Basis of presentation and significant accounting policies (Continued)
|
Stock-Based Compensation |
Stock-Based
Compensation
Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.
|
Stock-Based
Compensation
Compensation
expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the
equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to
expand the scope of Topic 718 to include share-based payments issued to nonemployees. The effective date for public companies is for
fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the effective
date is fiscal years beginning after December 15, 2019. The Company adopted during the year ended December 31, 2018 for which there was
no impact on the consolidated financial statements. The Company issues shares for multiyear consulting agreements which are restricted
and nonrefundable shares.
|
Leases |
Leases
On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $131,818 as of September 30, 2023.
|
Leases
On
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance
sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02
became effective for the Company in the first quarter of 2019 and was adopted on a modified retrospective transition basis for leases
existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company
recorded a Right-of-use asset and a Lease Liability of $8,612 as of December 31, 2022.
|
Recently Issued Accounting Pronouncements |
Recently
Issued Accounting Pronouncements
In
August 2020, the FASB issued ASU 2020-06, Debt —Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts
in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
(“ASU 2020-06”). This update simplifies the accounting for certain convertible instruments by removing the separation models
for convertible debt with a cash conversion feature and for convertible instruments with a beneficial conversion feature. As a result,
more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion
features. Additionally, this update amends the diluted earnings per share calculation for convertible instruments by requiring the use
of the if-converted method. The treasury stock method is no longer available. Entities may adopt the requirements of ASU 2020-06 using
either a full or modified retrospective approach, and it is effective for public businesses, excluding entities eligible to be smaller
reporting companies, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all
other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those
fiscal years. The accounting guidance has been adopted with no significant financial statement impact.
Management
does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material
impact on the Company’s financial statement presentation or disclosures.
|
|
Accounts Receivable |
|
Accounts
Receivable
Accounts
receivable are stated at amounts due from customers, net of an allowance for doubtful accounts, and the Company generally does not require
collateral. As a general policy, the Company determines an allowance for doubtful accounts by considering a number of factors, including
the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability
to pay its obligation to the Company, and the condition of the general economy and industry as a whole. The Company writes off accounts
receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful
accounts.
The
Company recorded an allowance for doubtful accounts of $6,807 as of both December 31, 2022 and 2021, respectively.
|
Shipping and Handling |
|
Shipping
and Handling
The
Company recognizes shipping and handling billed to customers as a component of net revenues, and the cost of shipping and handling within
general administrative expenses.
|
Advertising |
|
Advertising
Advertising
costs are expensed as incurred. Advertising expense for the years ended December 31, 2022 and 2021 were $4,132 and $0, respectively.
|
X |
- DefinitionNonControlling Interests [Policy Text Block]
+ References
+ Details
Name: |
TSOI_NonControllingInterestsPolicyTextBlock |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShipping and Handling Costs [Policy Text Block]
+ References
+ Details
Name: |
TSOI_ShippingAndHandlingCostsPolicyTextBlock |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for advertising cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for comprehensive income.
+ References
+ Details
Name: |
us-gaap_ComprehensiveIncomePolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1
+ Details
Name: |
us-gaap_ConsolidationPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7
+ Details
Name: |
us-gaap_DerivativesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for earnings per share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3
+ Details
Name: |
us-gaap_EarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 60 -Paragraph 1 -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1
+ Details
Name: |
us-gaap_FairValueOfFinancialInstrumentsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_IntangibleAssetsFiniteLivedPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details
Name: |
us-gaap_InventoryPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1
+ Details
Name: |
us-gaap_LesseeLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
+ Details
Name: |
us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue from contract with customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15
+ Details
Name: |
us-gaap_TradeAndOtherAccountsReceivablePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Basis of presentation and significant accounting policies (Tables)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Accounting Policies [Abstract] |
|
|
Schedule of Change in Derivative Liability |
The
following is the change in derivative liability for the three months ended September 30, 2023:
Schedule
of Change in Derivative Liability
Balance, December 31, 2022 | |
$ | 202,144 | |
Issuance of new derivative liabilities | |
| 328,433 | |
Conversions | |
| (331,714 | ) |
Change in fair market value of derivative liabilities | |
| 93,836 | |
Balance, September 30, 2023 | |
$ | 292,699 | |
|
The
following is the change in derivative liability for the years ended December 31, 2022 and 2021:
Schedule
of Change in Derivative Liability
Balance, December 31, 2020 | |
$ | 437,549 | |
| |
| | |
Issuance of new derivative liabilities | |
| 1,077,756 | |
Conversions | |
| (489,279 | ) |
Change in fair market value of derivative liabilities | |
| (494,501 | ) |
| |
| | |
Balance, December 31, 2021 | |
| 531,525 | |
| |
| | |
Issuance of new derivative liabilities | |
| 674,971 | |
Conversions | |
| (713,229 | ) |
Change in fair market value of derivative liabilities | |
| (291,123 | ) |
Balance, December 31, 2022 | |
$ | 202,144 | |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3
+ Details
Name: |
us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Prepaid expense and other current assets (Tables)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Prepaid Expense And Other Current Assets |
|
|
Schedule of Prepaid Expenses and Other Current Assets |
Prepaid
expenses and other current assets consist of the following:
Schedule of Prepaid Expenses and Other Current Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Prepaid consulting | |
$ | 16,939 | | |
$ | 148,550 | |
Insurance | |
| 1,601 | | |
| 1,141 | |
Prepaid costs and other | |
| 24,121 | | |
| 62,661 | |
Total | |
$ | 42,661 | | |
$ | 212,352 | |
|
Prepaid
expenses and other current assets consist of the following:
Schedule
of Prepaid Expenses and Other Current Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Prepaid consulting | |
$ | 148,550 | | |
$ | 930,893 | |
Insurance | |
| 1,141 | | |
| 987 | |
Prepaid costs | |
| 62,661 | | |
| 27,427 | |
Total | |
$ | 212,352 | | |
$ | 959,307 | |
|
X |
- References
+ Details
Name: |
TSOI_DisclosurePrepaidExpenseAndOtherCurrentAssetsAbstract |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Fixed assets (Tables)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Abstract] |
|
|
Schedule of Fixed Assets |
Fixed
assets consist of the following:
Schedule of Fixed Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Land | |
$ | 347,381 | | |
$ | 235,223 | |
Vehicles | |
| 50,514 | | |
| 50,514 | |
Computer hardware | |
| 6,135 | | |
| 6,135 | |
Office furniture and equipment | |
| 7,912 | | |
| 7,912 | |
Shipping and other equipment | |
| 1,575 | | |
| 1,575 | |
Total | |
| 413,517 | | |
| 301,359 | |
Accumulated depreciation | |
| (36,441 | ) | |
| (28,281 | ) |
Property and equipment, net | |
$ | 377,076 | | |
$ | 273,078 | |
|
Fixed
assets consist of the following:
Schedule
of Fixed Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Land | |
$ | 235,223 | | |
$ | 235,223 | |
Vehicles | |
| 50,514 | | |
| 50,514 | |
Computer hardware | |
| 6,135 | | |
| 5,935 | |
Office furniture and equipment | |
| 7,912 | | |
| 7,912 | |
Shipping and other equipment | |
| 1,575 | | |
| 1,575 | |
Total | |
| 301,359 | | |
| 301,159 | |
Accumulated depreciation | |
| (28,281 | ) | |
| (17,135 | ) |
Property and equipment, net | |
$ | 273,078 | | |
$ | 284,024 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Other assets (Tables)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Schedule of Other Assets |
Other
assets consist of the following:
Schedule of Other Assets
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Prepaid consulting | |
$ | - | | |
$ | 7,537 | |
Deposit | |
| 4,123 | | |
| 4,123 | |
Licenses, net | |
| 2,780,379 | | |
| 3,002,960 | |
Total | |
$ | 2,784,502 | | |
$ | 3,014,620 | |
|
Other
assets consist of the following:
Schedule
of Other Assets
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Prepaid consulting | |
$ | 7,537 | | |
$ | 108,673 | |
Deposit | |
| 4,123 | | |
| 39,823 | |
Licenses, net | |
| 3,002,960 | | |
| 129,075 | |
Total | |
$ | 3,014,620 | | |
$ | 277,571 | |
|
Schedule of Net Licenses |
Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:
Schedule of Net Licenses
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
License | |
$ | 3,261,122 | | |
$ | 3,261,122 | |
Accumulated amortization | |
| (480,743 | ) | |
| (258,162 | ) |
Licenses, net | |
$ | 2,780,379 | | |
$ | 3,002,960 | |
|
Prepaid
consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount above
consists of the following:
Schedule of Net Licenses
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Licenses | |
$ | 3,261,122 | | |
$ | 153,552 | |
Accumulated amortization | |
| (258,162 | ) | |
| (24,477 | ) |
Licenses, net | |
$ | 3,002,960 | | |
$ | 129,075 | |
|
X |
- DefinitionSchedule Of Net Licenses [Table Text Block]
+ References
+ Details
Name: |
TSOI_ScheduleOfNetLicensesTableTextBlock |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
+ Details
Name: |
us-gaap_ScheduleOfOtherAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Restricted cash (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Cash and Cash Equivalents [Abstract] |
|
Schedule of Notes Payable Related Parties |
Notes
payable-related parties consist of:
Schedule
of Notes Payable Related Parties
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
| |
$ | - | | |
$ | 2,356 | |
Note payable – Scientific Advisory Board Member, unsecured, including interest at 10% per annum, with a maturity date of December 31, 2019 | |
$ | - | | |
$ | 2,356 | |
| |
| | | |
| | |
One notes payable – Chief Executive Officer, unsecured, including interest at 8% and 10% per annum, respectively, with maturity date of December 31, 2019 | |
| 29,090 | | |
| 27,577 | |
| |
| | | |
| | |
One note payable – Chief Executive Officer, unsecured, no interest, paid from a % of revenues | |
| 534,448 | | |
| 534,544 | |
| |
| | | |
| | |
Note payable – Chief Financial Officer, unsecured, including interest at 8% per annum, with a maturity date of December 31, 2019 | |
| 124,800 | | |
| 118,400 | |
| |
| | | |
| | |
Three notes payable – Business Advisory Board Member, unsecured, including interest at 8% and 10% per annum, convertible into common stock at $0.005 and $0.004, respectively, with maturity date of April 20, 2019 | |
| 30,334 | | |
| 282,334 | |
| |
| 988,672 | | |
| 965,211 | |
| |
| | | |
| | |
| |
$ | 988,672 | | |
$ | 965,211 | |
|
X |
- DefinitionNotes Payable Related Parties [Table Text Block]
+ References
+ Details
Name: |
TSOI_NotesPayableRelatedPartiesTableTextBlock |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Income taxes (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
Income Tax Disclosure [Abstract] |
|
Schedule of Income tax Expense |
Schedule of Income tax Expense
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Expected income tax at statutory rate | |
$ | (709,666 | ) | |
$ | (621,735 | ) |
State tax | |
| (101,347 | ) | |
| 168 | |
Permanent differences | |
| 405,376 | | |
| 404,872 | |
Other | |
| - | | |
| (71,992 | ) |
Change in valuation allowance | |
| 406,437 | | |
| 289,487 | |
Provision for income taxes | |
$ | 800 | | |
$ | 800 | |
|
Schedule of Deferred Tax Assets and Liabilities |
The
significant components of deferred income tax assets and liabilities at December 31, 2022 and 2021 are as follows:
Schedule of Deferred Tax Assets and Liabilities
| |
December 31, 2022 | | |
December 31, 2021 | |
| |
| | |
| |
Net operating loss carry-forward | |
$ | 2,364,249 | | |
$ | 1,957,812 | |
Valuation allowance | |
| (2,364,249 | ) | |
| (1,957,812 | ) |
Net deferred tax asset | |
$ | - | | |
$ | - | |
|
X |
- DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Paragraph 12 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Organization and Business Description (Details Narrative) - USD ($)
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
194 Months Ended |
Aug. 04, 2021 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Sep. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
|
|
|
|
|
|
Entity incorporation date |
|
|
|
Aug. 06, 2007
|
|
Aug. 06, 2007
|
|
|
Net income loss |
|
$ 602,041
|
$ 946,462
|
$ 1,742,322
|
$ 2,738,142
|
$ 3,677,812
|
$ 2,961,445
|
$ 19,400,000
|
Unusual or infrequent item, description |
the JadiCell™ was shown to be 100% effective
in saving the lives of COVID-19 patients under the age of 85 in a double-blind placebo controlled clinical trial with patients in the
ICU on a ventilator. In patients over the age of 85 the survival rate was 91%.
|
|
|
|
|
|
|
|
Net loss |
|
$ (602,857)
|
$ (946,462)
|
$ (1,743,994)
|
$ (2,738,142)
|
$ 17,300,000
|
|
|
X |
- DefinitionDate when an entity was incorporated
+ References
+ Details
Name: |
dei_EntityIncorporationDateOfIncorporation |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the nature of an event or transaction that is unusual in nature or infrequent in occurrence, or both.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483613/220-20-50-1
+ Details
Name: |
us-gaap_UnusualOrInfrequentItemNatureOfEventOrTransaction |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Schedule of Change in Derivative Liability (Details) - USD ($)
|
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Accounting Policies [Abstract] |
|
|
|
Beginning Balance |
$ 202,144
|
$ 531,525
|
$ 437,549
|
Issuance of new derivative liabilities |
328,433
|
674,971
|
1,077,756
|
Conversions |
(331,714)
|
(713,229)
|
(489,279)
|
Change in fair market value of derivative liabilities |
93,836
|
(291,123)
|
(494,501)
|
Ending Balance |
$ 292,699
|
$ 202,144
|
$ 531,525
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Basis of presentation and significant accounting policies (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Payments description |
|
|
Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional
Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000 worth of aforementioned
products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%) discount up to the
aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off retail.
|
|
Seller agrees to sell the Goods to Buyer for Fifty Percent (50%) off Sellers listed retail price (see Exhibit
A). Seller will provide an invoice to Buyer at the time of delivery. All invoices must be paid, in full, within thirty (30) days. Any
balances not paid within thirty (30) days will be subject to a five percent (5%) late payment penalty. In the event Buyer exceeds the
aggregate of $500,000.00 worth of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an
additional Five Percent (5%) discount up to the aggregate of $750,000.00. In the event Buyer exceeds the aggregate of $750,000.00 worth
of aforementioned products having been purchased, delivered, and paid for, Buyer will be entitled to an additional Five Percent (5%)
discount up to the aggregate of $1,500,000.00. All future sales after initial $1,500,000 in aggregate purchases will be sold at 60% off
retail.
|
|
Cash, FDIC insured amount |
$ 250,000
|
|
$ 250,000
|
|
$ 0
|
$ 0
|
Cash, uninsured amount |
0
|
|
0
|
|
0
|
|
Derivative liabilities |
292,699
|
|
$ 292,699
|
|
$ 202,144
|
$ 531,525
|
Antidilutive securities excluded from computation of earnings per share |
|
|
1,259,591,300
|
211,919,728
|
267,136,056
|
95,273,690
|
Depreciation expense |
|
|
$ 8,161
|
$ 3,489
|
$ 10,946
|
$ 6,772
|
Amortization expense |
|
|
222,581
|
191,192
|
233,685
|
11,295
|
Research and development expense |
148,879
|
$ 275,071
|
410,146
|
$ 1,177,123
|
1,441,128
|
794,750
|
Right-of-use asset |
131,818
|
|
131,818
|
|
8,612
|
34,184
|
Lease liability |
$ 131,818
|
|
$ 131,818
|
|
8,612
|
|
Allowance for doubtful accounts |
|
|
|
|
6,807
|
6,807
|
Advertising expense |
|
|
|
|
4,132
|
$ 0
|
Maximum [Member] |
|
|
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Cash, FDIC insured amount |
|
|
|
|
$ 250,000
|
|
Res Nova Bio Inc [Member] |
|
|
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
|
|
Equity Method Investment, Ownership Percentage |
32.00%
|
|
32.00%
|
|
|
|
X |
- DefinitionWholesale purchase price and payments description.
+ References
+ Details
Name: |
TSOI_WholesalePurchasePriceAndPaymentsDescription |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1
+ Details
Name: |
us-gaap_AdvertisingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of allowance for credit loss on accounts receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
+ Details
Name: |
us-gaap_CashFDICInsuredAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.
+ References
+ Details
Name: |
us-gaap_CashUninsuredAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3
+ Details
Name: |
us-gaap_DerivativeLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TSOI_ResNovaBioIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Prepaid Expense And Other Current Assets |
|
|
|
Prepaid consulting |
$ 16,939
|
$ 148,550
|
$ 930,893
|
Insurance |
1,601
|
1,141
|
987
|
Prepaid costs |
24,121
|
62,661
|
27,427
|
Total |
$ 42,661
|
$ 212,352
|
$ 959,307
|
X |
- References
+ Details
Name: |
TSOI_DisclosurePrepaidExpenseAndOtherCurrentAssetsAbstract |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrepaid consulting current.
+ References
+ Details
Name: |
TSOI_PrepaidConsultingCurrent |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_PrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
+ Details
Name: |
us-gaap_PrepaidInsurance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.4
Schedule of Fixed Assets (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Property, Plant and Equipment [Line Items] |
|
|
|
Total |
$ 413,517
|
$ 301,359
|
$ 301,159
|
Accumulated depreciation |
(36,441)
|
(28,281)
|
(17,135)
|
Property and equipment, net |
377,076
|
273,078
|
284,024
|
Land [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Total |
347,381
|
235,223
|
235,223
|
Vehicles [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Total |
50,514
|
50,514
|
50,514
|
Computer Equipment [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Total |
6,135
|
6,135
|
5,935
|
Office Furniture And Equipment [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Total |
7,912
|
7,912
|
7,912
|
Shipping And Other Equipment [Member] |
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
Total |
$ 1,575
|
$ 1,575
|
$ 1,575
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=TSOI_OfficeFurnitureAndEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=TSOI_ShippingAndOtherEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Schedule of Other Assets (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
|
Prepaid consulting |
|
$ 7,537
|
$ 108,673
|
Deposit |
4,123
|
4,123
|
39,823
|
Licenses, net |
2,780,379
|
3,002,960
|
129,075
|
Total |
$ 2,784,502
|
$ 3,014,620
|
$ 277,571
|
X |
- DefinitionPrepaid consulting, noncurrent.
+ References
+ Details
Name: |
TSOI_PrepaidConsultingNoncurrent |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DepositsAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.4
Schedule of Net Licenses (Details) - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
|
Licenses |
$ 3,261,122
|
$ 3,261,122
|
$ 153,552
|
Accumulated amortization |
(480,743)
|
(258,162)
|
(24,477)
|
Licenses, net |
$ 2,780,379
|
$ 3,002,960
|
$ 129,075
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.4
Other assets (Details Narrative) - USD ($)
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Mar. 25, 2022 |
Feb. 23, 2022 |
Sep. 30, 2023 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
Amortization expenses |
|
|
|
$ 222,581
|
$ 191,192
|
$ 233,685
|
$ 11,295
|
Amortization expenses |
|
|
|
|
|
233,685
|
24,477
|
Stock Issued During Period, Value, New Issues |
|
|
$ 189,026
|
677,378
|
445,000
|
$ 445,000
|
$ 285,499
|
Payments to Acquire Intangible Assets |
|
|
|
|
$ 200,000
|
|
|
Exclusive Patent License Agreement [Member] | Convertible Promissory Note [Member] |
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
Stock Issued During Period, Shares, New Issues |
|
149,402,390
|
|
|
|
|
|
Share Price |
|
$ 0.0208
|
|
|
|
|
|
Stock Issued During Period, Value, New Issues |
|
$ 3,107,570
|
|
|
|
|
|
Patent Expire date |
|
Dec. 31, 2032
|
|
|
|
|
|
Finite-Lived Intangible Assets, Remaining Amortization Period |
|
10 years
|
|
|
|
|
|
Assets Transfer And License Agreement [Member] |
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
Amortized Life |
Mar. 24, 2027
|
|
|
|
|
|
|
Assets Transfer And License Agreement [Member] | Initial Payment [Member] |
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
Payments to Acquire Intangible Assets |
$ 200,000
|
|
|
|
|
|
|
Assets Transfer And License Agreement [Member] | Second Payment [Member] |
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
Payments to Acquire Intangible Assets |
$ 1,800,000
|
|
|
|
|
|
|
X |
- DefinitionAmortized Life of Agreement.
+ References
+ Details
Name: |
TSOI_AmortizedLifeOfAgreement |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPatent Expires Agreement Date.
+ References
+ Details
Name: |
TSOI_PatentExpiresAgreementDate |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquireIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=TSOI_ExclusivePatentLicenseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=TSOI_ConvertiblePromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=TSOI_AssetsTransferAndLicenseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=TSOI_InitialPaymentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_StatementScenarioAxis=TSOI_SecondPaymentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
X |
- DefinitionIncrease for accrued, but unpaid interest on the debt instrument for the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentIncreaseAccruedInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_OfficersAndDirectorsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Convertible Notes Payable (Details Narrative)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2023
USD ($)
$ / shares
shares
|
Sep. 30, 2022
USD ($)
|
Dec. 31, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Debt original issuance discount |
|
|
$ 250,750
|
$ 415,000
|
$ 505,000
|
$ 538,750
|
Derivative liabilities |
$ 292,699
|
|
292,699
|
|
202,144
|
531,525
|
Gain loss on derivative liabilities |
(60,124)
|
$ (32,205)
|
(93,836)
|
233,303
|
291,123
|
494,501
|
Amortization of interest expenses |
|
|
299,267
|
461,058
|
593,463
|
541,612
|
Convertible Promissory Note [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Debt discount |
$ 157,861
|
|
157,861
|
|
|
|
Amortization of interest expenses |
|
|
299,268
|
$ 461,058
|
|
|
Convertible Notes Payable [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Debt discount |
|
|
|
|
175,063
|
|
Interest expenses |
|
|
|
|
593,463
|
541,612
|
Derivative [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative issuance liability |
|
|
628,437
|
|
674,971
|
1,077,756
|
Loss on derivative liability |
|
|
$ 78,868
|
|
$ 171,245
|
$ 539,006
|
Derivative [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.0008
|
|
0.0008
|
|
0.0058
|
0.0039
|
Derivative [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.0034
|
|
0.0034
|
|
0.0143
|
0.0351
|
Derivative [Member] | Measurement Input, Share Price [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.0011
|
|
0.0011
|
|
0.008
|
0.0217
|
Derivative [Member] | Measurement Input, Share Price [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.006
|
|
0.006
|
|
0.0272
|
0.0540
|
Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
0
|
|
0
|
|
0
|
0
|
Derivative [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
1.24
|
|
1.24
|
|
148
|
197
|
Derivative [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
1.60
|
|
1.60
|
|
216
|
264
|
Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
4.67
|
|
4.67
|
|
0.48
|
0.05
|
Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
5.46
|
|
5.46
|
|
4.77
|
0.29
|
Derivative [Member] | Measurement Input, Expected Term [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input term |
|
|
1 year
|
|
1 year
|
1 year
|
Convertible Promissory Note [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Debt principal amount |
$ 283,250
|
|
$ 283,250
|
|
$ 544,000
|
$ 572,250
|
Debt original issuance discount |
|
|
250,750
|
|
505,000
|
538,750
|
Debt discount |
$ 32,500
|
|
$ 32,500
|
|
$ 39,000
|
$ 33,500
|
Interest rate percentage |
10.00%
|
|
10.00%
|
|
10.00%
|
|
Debt maturity date description |
|
|
mature on
dates ranging from April 11, 2024, to September 29, 2024
|
|
mature
on dates ranging from January 1, 2023 to December 5, 2023
|
mature
on dates ranging from January 25, 2022 to December 15, 2022
|
Debt conversion description |
|
|
The conversion price per share is equal to 63% of the average of the three (3) lowest trading prices
of the Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay
the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the
default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
|
|
The
convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion
price per share is equal to a percentage of 63% of the average of the three (3) lowest trading prices of the Company’s
common stock during the fifteen (15) trading days immediately preceding the applicable con’ersion date. The trading price is
defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the
convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance
plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which
the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%.
|
The
convertible promissory notes are convertible to shares of the Company’s common stock 180 days after issuance. The conversion
price per share is equal to apercentage ranging from 61% to 63% of the average of the three (3) lowest trading prices of the
Company’s common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading
price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to
prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of
principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default
provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest
increasing by 150%.
|
Common shares reserve | shares |
1,259,591,300
|
|
1,259,591,300
|
|
267,136,056
|
95,273,690
|
Convertible Promissory Note [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Interest rate percentage |
|
|
|
|
|
10.00%
|
Convertible Promissory Note [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Interest rate percentage |
|
|
|
|
|
12.00%
|
Convertible Notes [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Loss on derivative liability |
|
|
|
|
$ 39,770
|
|
Principal and accrued interest |
|
|
$ 338,577
|
|
|
|
Debt conversion of convertible shares | shares |
|
|
218,504,885
|
|
68,193,798
|
21,690,671
|
Derivative, Gain on Derivative |
|
|
$ 100,807
|
|
|
|
Debt conversion of convertible shares, value |
|
|
|
|
$ 774,176
|
$ 529,735
|
Common stock, subscribed and issued | shares |
|
|
|
|
4,054,054
|
|
Additional paid in capital on convertible debt features |
|
|
|
|
|
$ 489,279
|
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.0008
|
|
0.0008
|
|
0.0038
|
0.0136
|
Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.004
|
|
0.004
|
|
0.016
|
0.035
|
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.001
|
|
0.001
|
|
0.006
|
0.022
|
Convertible Notes [Member] | Measurement Input, Share Price [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.006
|
|
0.006
|
|
0.026
|
0.057
|
Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
0
|
|
0
|
|
|
0
|
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
1.10
|
|
1.10
|
|
63
|
125
|
Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
1.93
|
|
1.93
|
|
191
|
251
|
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
4.55
|
|
4.55
|
|
0.51
|
0.06
|
Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
5.37
|
|
5.37
|
|
4.74
|
0.29
|
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input term |
|
|
5 months 23 days
|
|
5 months 8 days
|
5 months 23 days
|
Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input term |
|
|
6 months
|
|
6 months
|
6 months
|
Remaining Convertible Notes [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liabilities |
$ 292,699
|
|
$ 292,699
|
|
$ 202,144
|
$ 531,525
|
Gain loss on derivative liabilities |
|
|
$ 93,836
|
|
$ 291,123
|
$ 494,501
|
Remaining Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
|
|
|
|
|
0.0123
|
Remaining Convertible Notes [Member] | Measurement Input, Conversion Price [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
|
|
|
|
|
0.0127
|
Remaining Convertible Notes [Member] | Measurement Input, Share Price [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.002
|
|
0.002
|
|
0.006
|
0.029
|
Remaining Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
0
|
|
0
|
|
0
|
0
|
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
1.57
|
|
1.57
|
|
96
|
165
|
Remaining Convertible Notes [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
1.75
|
|
1.75
|
|
120
|
218
|
Remaining Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
5.46
|
|
5.46
|
|
4.71
|
0.39
|
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Minimum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input term |
|
|
6 months 10 days
|
|
5 months 26 days
|
6 months 10 days
|
Remaining Convertible Notes [Member] | Measurement Input, Expected Term [Member] | Maximum [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input term |
|
|
1 year
|
|
11 months 4 days
|
11 months 15 days
|
Remaining Convertible Notes [Member] | Measurement Input, Exercise Price [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input | $ / shares |
0.0008
|
|
0.0008
|
|
0.0038
|
|
Convertible Notes Payable [Member] | Derivative [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
|
|
|
|
Debt Instrument [Line Items] |
|
|
|
|
|
|
Derivative liability, measurement input |
|
|
|
|
0
|
|
X |
- DefinitionDebt Conversion Original Debt Amount.
+ References
+ Details
Name: |
TSOI_DebtConversionOriginalDebtAmount |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 51 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482663/740-10-55-51
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesSubscribedButUnissued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
+ Details
Name: |
us-gaap_DebtConversionDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtInstrumentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase in the fair value of derivatives recognized in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_DerivativeGainOnDerivative |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3
+ Details
Name: |
us-gaap_DerivativeLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of decrease in the fair value of derivatives recognized in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_DerivativeLossOnDerivative |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_GainLossOnDerivativeInstrumentsNetPretax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6
+ Details
Name: |
us-gaap_InterestExpenseDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for cost incurred directly with the issuance of a derivative security.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_PaymentsOfDerivativeIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=TSOI_ConvertiblePromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=TSOI_ConvertiblePromissoryNoteMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=TSOI_ConvertibleNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=TSOI_RemainingConvertibleNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Equity (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
Oct. 25, 2023 |
Oct. 13, 2023 |
Oct. 05, 2023 |
Mar. 21, 2023 |
Feb. 21, 2023 |
Feb. 07, 2023 |
Feb. 06, 2023 |
Jan. 09, 2023 |
Jan. 04, 2023 |
Jan. 03, 2023 |
Aug. 04, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Aug. 09, 2022 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate authorized capital |
|
|
|
|
|
|
|
|
|
|
|
5,505,000,000
|
|
5,505,000,000
|
|
3,505,000,000
|
|
|
Common Stock, Shares Authorized |
|
5,500,000,000
|
|
|
|
|
|
|
|
|
|
5,500,000,000
|
|
5,500,000,000
|
|
5,500,000,000
|
3,500,000,000
|
|
Common stock, par value |
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
$ 0.001
|
|
$ 0.001
|
$ 0.001
|
|
Preferred Stock, Shares Authorized |
|
5,000,000
|
|
|
|
|
|
|
|
|
|
5,000,000
|
|
5,000,000
|
|
5,000,000
|
5,000,000
|
|
Common stock, shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
3,450,665,355
|
|
3,450,665,355
|
|
2,617,390,830
|
2,311,123,860
|
|
Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
2
|
|
2
|
|
2
|
0
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
$ 189,026
|
|
$ 677,378
|
$ 445,000
|
$ 445,000
|
$ 285,499
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
6,561
|
$ 100,878
|
86,161
|
508,078
|
691,520
|
858,900
|
|
Common stock issued for salaries |
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
29,999
|
67,399
|
239,799
|
|
Common stock issued for license |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,107,570
|
3,107,570
|
|
|
Common stock issued for prepaid fees |
|
|
|
|
|
|
|
|
|
|
|
|
93,500
|
|
242,320
|
242,320
|
1,472,450
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
$ 129,414
|
$ 272,919
|
$ 787,133
|
$ 943,432
|
$ 1,313,772
|
$ 529,735
|
|
Preferred stock, voting rights |
|
|
|
|
|
|
|
|
|
|
the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to
Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall
be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on
all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all
issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination,
on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock
shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall
vote together with the holders of Common Stock as a single class
|
|
|
|
|
|
|
|
Preferred stock, shares issued |
|
|
|
|
|
|
|
|
|
|
|
2
|
|
2
|
|
2
|
0
|
2
|
Preferred stock, par value |
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
$ 0.001
|
|
$ 0.001
|
$ 0.001
|
$ 0.001
|
Equity, Attributable to Noncontrolling Interest |
|
|
|
|
|
|
|
|
|
|
|
$ 1,672
|
|
$ 1,672
|
|
|
|
|
Common stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,500,000,000
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
15,660,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
4,000,000
|
|
17,000,000
|
|
|
|
|
|
|
|
|
Land Development [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,500,000
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 58,900
|
|
Res Nova Bio Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Method Investment, Ownership Percentage |
|
|
|
|
|
|
|
|
|
|
|
32.00%
|
|
32.00%
|
|
|
|
|
Convertible Notes Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of convertible notes |
|
|
|
|
|
|
|
|
|
4,054,054
|
|
|
|
276,254,885
|
|
64,139,744
|
21,690,671
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
$ 15,000
|
|
|
|
$ 787,133
|
|
$ 1,313,772
|
$ 1,019,014
|
|
Convertible Notes Payable [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of convertible notes |
|
46,832,386
|
|
|
|
11,386,719
|
6,060,606
|
|
10,052,083
|
4,054,054
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
$ 41,212
|
|
|
|
$ 36,438
|
$ 20,000
|
|
$ 36,188
|
$ 15,000
|
|
|
|
|
|
|
|
|
Land Development [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of convertible notes |
|
|
|
|
|
|
|
|
|
|
|
|
|
60,000,000
|
|
|
|
|
Prepaid Fees [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,000,000
|
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 242,320
|
|
|
Common stock issued for prepaid fees, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,000,000
|
|
|
Common stock issued for prepaid fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 242,320
|
|
|
Salaries [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,812,259
|
8,341,723
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 67,399
|
$ 239,799
|
|
Common stock issued for salaries, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
4,081,632
|
|
4,812,259
|
|
|
Common stock issued for salaries |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20,000
|
|
$ 67,399
|
|
|
Land Development [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for salaries |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 96,000
|
|
|
|
|
Consulting Services [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,412,577
|
21,000,000
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 691,520
|
$ 858,900
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
3,000,000
|
|
|
|
47,757,394
|
|
32,412,577
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
$ 18,000
|
|
|
|
$ 86,161
|
|
$ 691,520
|
|
|
Consulting Services [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
18,000
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
License [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
149,402,390
|
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,107,570
|
|
|
Common stock issued for license, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
149,402,390
|
|
|
Common stock issued for license |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,107,570
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
445,180,614
|
|
44,500,000
|
4,850,075
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 677,378
|
|
$ 445,000
|
$ 285,500
|
|
Private Placement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
75,749,443
|
|
35,702,240
|
|
60,224,825
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash |
$ 78,779
|
|
$ 34,274
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
5,500,000,000
|
|
5,500,000,000
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
175,089,179
|
|
445,180,614
|
44,500,000
|
44,500,000
|
4,850,075
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
$ 175,089
|
|
$ 445,180
|
$ 44,500
|
$ 44,500
|
$ 4,850
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
1,757,394
|
9,302,577
|
47,757,394
|
25,302,577
|
32,412,577
|
21,000,000
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
$ 1,757
|
$ 9,303
|
$ 47,757
|
$ 25,303
|
$ 32,413
|
$ 21,000
|
|
Common stock issued for salaries, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
4,081,632
|
1,034,482
|
4,812,259
|
8,341,723
|
|
Common stock issued for salaries |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,082
|
$ 1,034
|
$ 4,812
|
$ 8,342
|
|
Common stock issued for license, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
149,402,390
|
149,402,390
|
|
|
Common stock issued for license |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 149,402
|
$ 149,402
|
|
|
Common stock issued for prepaid fees, shares |
|
|
|
|
|
|
|
|
|
|
|
|
5,000,000
|
|
11,000,000
|
11,000,000
|
20,000,000
|
|
Common stock issued for prepaid fees |
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,000
|
|
$ 11,000
|
$ 11,000
|
$ 20,000
|
|
Conversion of convertible notes |
|
|
|
|
|
|
|
|
|
|
|
79,774,708
|
17,532,500
|
276,254,885
|
41,700,228
|
64,139,744
|
21,690,671
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
$ 79,775
|
$ 17,533
|
$ 276,255
|
$ 41,700
|
$ 64,140
|
$ 21,691
|
|
Noncontrolling Interest [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate authorized capital |
|
|
|
|
|
|
|
|
|
|
|
505,000,000
|
|
505,000,000
|
|
|
|
|
Common Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
500,000,000
|
|
500,000,000
|
|
|
|
|
Common stock, par value |
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
Preferred Stock, Shares Authorized |
|
|
|
|
|
|
|
|
|
|
|
5,000,000
|
|
5,000,000
|
|
|
|
|
Common stock, shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
18,308,333
|
|
18,308,333
|
|
|
|
|
Preferred stock, shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for salaries |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for license |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for prepaid fees |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionCommon Stock Share authorized.
+ References
+ Details
Name: |
TSOI_CommonStockShareAuthorized |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionStock issued during period shares for license.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesForLicense |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for prepaid fees, shares.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesForPrepaidFees |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period shares for salaries.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodSharesForSalaries |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value for license.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValueForLicense |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCommon stock issued for prepaid fees.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValueForPrepaidFees |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period values for salaries.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValuesForSalaries |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.
+ References
+ Details
Name: |
us-gaap_CapitalUnitsAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_MinorityInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_PreferredStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=TSOI_LandDevelopmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TSOI_ResNovaBioIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=TSOI_LandDevelopmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=TSOI_PrepaidFeesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=TSOI_SalariesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=TSOI_LandDevelopmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=TSOI_ConsultingServicesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=us-gaap_LicenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Subsequent events (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Oct. 25, 2023 |
Oct. 16, 2023 |
Oct. 13, 2023 |
Oct. 05, 2023 |
Oct. 02, 2023 |
Mar. 21, 2023 |
Feb. 21, 2023 |
Feb. 07, 2023 |
Feb. 06, 2023 |
Jan. 09, 2023 |
Jan. 04, 2023 |
Jan. 03, 2023 |
Aug. 04, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 189,026
|
|
$ 677,378
|
$ 445,000
|
$ 445,000
|
$ 285,499
|
Capital Units, Authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
5,505,000,000
|
|
5,505,000,000
|
|
3,505,000,000
|
|
Common stock, shares authorized |
|
|
5,500,000,000
|
|
|
|
|
|
|
|
|
|
|
5,500,000,000
|
|
5,500,000,000
|
|
5,500,000,000
|
3,500,000,000
|
Preferred stock, shares authorized |
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
5,000,000
|
|
5,000,000
|
|
5,000,000
|
5,000,000
|
Conversion of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 129,414
|
$ 272,919
|
$ 787,133
|
$ 943,432
|
$ 1,313,772
|
$ 529,735
|
Right of voting |
|
|
|
|
|
|
|
|
|
|
|
|
the Board of Directors designated “Series A Preferred Stock” and caused to be filed a Certificate of Designation
pursuant to NRS 78.1955 with the State of Nevada, and upon approval the Board has issued One (1) share of Series A Preferred Stock to
Thomas E. Ichim, and One (1) share of Series A Preferred Stock to Timothy G. Dixon. The Holder of the Series A Preferred Stock shall
be entitled to vote on all matters subject to a vote or written consent of the holders of the Corporation’s Common Stock, and on
all such matters, the share of Series A Preferred Stock shall be entitled to that number of votes equal to the number of votes that all
issued and outstanding shares of Common Stock and all other securities of the Corporation are entitled to, as of any such date of determination,
on a fully diluted basis, plus One Million (1,000,000) votes, it being the intention that the Holder(s) of the Series A Preferred Stock
shall have effective voting control of the Corporation, on a fully diluted basis. The Holder(s) of the Series A Preferred Stock shall
vote together with the holders of Common Stock as a single class
|
|
|
|
|
|
|
Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital Units, Authorized |
|
|
4,505,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital Units, Authorized |
|
|
5,505,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
445,180,614
|
|
44,500,000
|
4,850,075
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 677,378
|
|
$ 445,000
|
$ 285,500
|
Convertible Notes Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of common stock, shares |
|
|
|
|
|
|
|
|
|
|
|
4,054,054
|
|
|
|
276,254,885
|
|
64,139,744
|
21,690,671
|
Conversion of common stock |
|
|
|
|
|
|
|
|
|
|
|
$ 15,000
|
|
|
|
$ 787,133
|
|
$ 1,313,772
|
$ 1,019,014
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
15,660,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued for consulting services |
|
|
|
|
|
|
|
|
|
4,000,000
|
|
17,000,000
|
|
|
|
|
|
|
|
Shares issued price per share |
|
|
|
|
|
|
|
|
|
$ 0.049
|
|
$ 0.006
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Campbell Neurosciences Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend conversion rate |
|
|
|
|
|
$ 0.0034
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock shares percentage |
|
|
|
|
|
31.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock divident |
|
|
|
|
|
10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend, description |
|
|
|
|
|
TSOI shareholders at a ratio of 0.00365 shares of CNSI stock for each one (1) share owned in TSOI stock as of April
7, 2023 (“Dividend Offer”) on April 8, 2023 (“Dividend Offer Date”). The Dividend Offer will remain open for
Ninety (90) days from the Dividend Offer Date
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividend offer date |
|
|
|
|
|
Apr. 07, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Preferred Class A [Member] | Director [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Right of voting |
|
|
|
|
|
Preferred A Stock holders representing at least 51% of all shareholders with the right to vote
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Accrued Salaries [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
4,081,632
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash |
|
|
|
|
|
|
|
|
|
$ 20,000
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash, shares |
75,749,443
|
|
|
35,702,240
|
|
|
60,224,825
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for cash |
$ 78,779
|
|
|
$ 34,274
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares issued price per share |
|
|
|
|
|
|
$ 0.00216
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Consulting Services [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of common stock, shares |
|
65,000,000
|
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock issued for consulting services per share |
|
$ 0.0015
|
|
|
$ 0.0015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Convertible Notes Payable [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of common stock, shares |
|
|
46,832,386
|
|
|
|
|
11,386,719
|
6,060,606
|
|
10,052,083
|
4,054,054
|
|
|
|
|
|
|
|
Conversion of common stock |
|
|
$ 41,212
|
|
|
|
|
$ 36,438
|
$ 20,000
|
|
$ 36,188
|
$ 15,000
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Accrued Salaries [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of common stock, shares |
|
60,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion of common stock |
|
$ 90,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionDividend Conversion Rate.
+ References
+ Details
Name: |
TSOI_DividendConversionRate |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionStock issued during period value conversion of convertible securities per share.
+ References
+ Details
Name: |
TSOI_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesPerShare |
Namespace Prefix: |
TSOI_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.
+ References
+ Details
Name: |
us-gaap_CapitalUnitsAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_CommonStockDividendsShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate the dividend to be paid was declared, in YYYY-MM-DD format.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
+ Details
Name: |
us-gaap_DividendsPayableDateDeclaredDayMonthAndYear |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescribes the declaration as being a special dividend (over and above the normal dividend); as the annual, semi-annual, quarterly dividend, or other normal periodic dividend; or as some other type of dividend.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DividendsPayableNature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_PreferredStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=TSOI_CampbellNeurosciencesIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_DirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=TSOI_AccruedSalariesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=TSOI_ConsultingServicesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=TSOI_AccruedSalariesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Commitments and Contingencies (Details Narrative)
|
|
9 Months Ended |
12 Months Ended |
Mar. 22, 2023
ft²
|
Sep. 30, 2023
USD ($)
|
Sep. 30, 2022
USD ($)
|
Dec. 31, 2022
USD ($)
ft²
|
Dec. 31, 2021
USD ($)
|
Commitments and Contingencies Disclosure [Abstract] |
|
|
|
|
|
Area of land | ft² |
1,700
|
|
|
1,700
|
|
Lease contract term |
60 months
|
|
|
36 months
|
|
Lease expiration date |
Apr. 30, 2028
|
|
|
Apr. 30, 2023
|
|
Payment for rent | $ |
|
$ 18,988
|
$ 18,783
|
$ 25,044
|
$ 22,768
|
Operating lease discount rate |
|
5.00%
|
|
5.00%
|
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format.
+ References
+ Details
Name: |
us-gaap_LeaseExpirationDate1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseTermOfContract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCash payments to lessor's for use of assets under operating leases.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForRent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.4
Schedule of Notes Payable Related Parties (Details) - Related Party [Member] - USD ($)
|
Sep. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Short-Term Debt [Line Items] |
|
|
|
Notes payable related party, current |
$ 699,866
|
$ 988,672
|
$ 965,211
|
Notes payable related party, non-current |
|
988,672
|
965,211
|
Notes Payable One [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Notes payable related party, current |
|
|
2,356
|
Notes Payable Two [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Notes payable related party, current |
|
29,090
|
27,577
|
Notes Payable Three [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Notes payable related party, current |
|
534,448
|
534,544
|
Notes Payable Four [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Notes payable related party, current |
|
124,800
|
118,400
|
Notes Payable Five [Member] |
|
|
|
Short-Term Debt [Line Items] |
|
|
|
Notes payable related party, current |
|
$ 30,334
|
$ 282,334
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableThreeMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Schedule of Notes Payable Related Parties (Details) (Parenthetical) - $ / shares
|
12 Months Ended |
Dec. 31, 2022 |
Dec. 31, 2021 |
Scientific Advisory Board [Member] | Notes Payable One [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
10.00%
|
|
Debt maturity date |
Dec. 31, 2019
|
|
Scientific Advisory Board [Member] | Notes Payable One [Member] | Related Party [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
|
10.00%
|
Debt maturity date |
|
Dec. 31, 2019
|
Chief Executive Officer [Member] | Notes Payable Two [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt maturity date |
Dec. 31, 2019
|
|
Chief Executive Officer [Member] | Notes Payable Two [Member] | Minimum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
8.00%
|
|
Chief Executive Officer [Member] | Notes Payable Two [Member] | Maximum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
10.00%
|
|
Chief Executive Officer [Member] | Notes Payable Two [Member] | Related Party [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt maturity date |
|
Dec. 31, 2019
|
Chief Executive Officer [Member] | Notes Payable Two [Member] | Related Party [Member] | Minimum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
|
8.00%
|
Chief Executive Officer [Member] | Notes Payable Two [Member] | Related Party [Member] | Maximum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
|
10.00%
|
Chief Financial Officer [Member] | Notes Payable Four [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
8.00%
|
|
Debt maturity date |
Dec. 31, 2019
|
|
Chief Financial Officer [Member] | Notes Payable Four [Member] | Related Party [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
|
8.00%
|
Debt maturity date |
|
Dec. 31, 2019
|
Business Advisory Board [Member] | Notes Payable Five [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt maturity date |
Apr. 20, 2019
|
|
Business Advisory Board [Member] | Notes Payable Five [Member] | Minimum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
8.00%
|
|
Share price |
$ 0.004
|
|
Business Advisory Board [Member] | Notes Payable Five [Member] | Maximum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
10.00%
|
|
Share price |
$ 0.005
|
|
Business Advisory Board [Member] | Notes Payable Five [Member] | Related Party [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt maturity date |
|
Apr. 20, 2019
|
Business Advisory Board [Member] | Notes Payable Five [Member] | Related Party [Member] | Minimum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
|
8.00%
|
Share price |
|
$ 0.004
|
Business Advisory Board [Member] | Notes Payable Five [Member] | Related Party [Member] | Maximum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Debt interest percentage |
|
10.00%
|
Share price |
|
$ 0.005
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_ScientificAdvisoryBoardMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableFourMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_BusinessAdvisoryBoardMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=TSOI_NotesPayableFiveMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
X |
- References
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_RestrictedCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionDescription of nature and provision of restriction as to withdrawal or usage on cash, classified as current.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-7
+ Details
Name: |
us-gaap_RestrictedCashCurrentNatureOfRestrictionDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.4
Related party transactions (Details Narrative) - USD ($)
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
Dec. 30, 2022 |
Nov. 02, 2022 |
Sep. 08, 2022 |
Apr. 05, 2022 |
Nov. 30, 2021 |
Jun. 18, 2021 |
Sep. 30, 2023 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction, Rate |
|
|
|
|
|
|
|
|
|
0.50%
|
|
|
|
Number of common stock issued, value |
|
|
|
|
|
|
$ 189,026
|
$ 677,378
|
$ 445,000
|
$ 445,000
|
$ 285,499
|
|
|
Related Party [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments |
|
|
|
|
|
|
|
|
|
$ 97
|
$ 101
|
|
|
Officer [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued Salaries, Current |
|
|
|
|
|
|
|
|
|
|
|
$ 439,534
|
$ 663,100
|
One Officers [Member] | Restricted Stock [Member] | Accrued Salaries [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock issued |
|
|
|
|
|
|
|
|
|
4,812,259
|
7,544,848
|
|
|
Number of common stock issued, value |
|
|
|
|
|
|
|
|
|
$ 67,399
|
$ 239,800
|
|
|
One Officer And One Director [Member] | Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock issued |
|
|
4,000,000
|
|
|
2,000,000
|
|
|
|
|
|
|
|
Number of common stock issued, value |
|
|
$ 46,400
|
|
|
$ 94,600
|
|
|
|
|
|
|
|
Four Officer And One Director [Member] | Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock issued |
14,000,000
|
|
|
7,000,000
|
7,000,000
|
|
|
|
|
|
|
|
|
Number of common stock issued, value |
$ 84,000
|
|
|
$ 175,700
|
$ 224,000
|
|
|
|
|
|
|
|
|
Four Officer One Director [Member] | Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock issued |
|
3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
Number of common stock issued, value |
|
$ 29,700
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedSalariesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from parties in nontrade transactions, classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=srt_OfficerMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_OneOfficersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=TSOI_AccruedSalariesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_OneOfficerAndOneDirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_FourOfficerAndOneDirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=TSOI_FourOfficerOneDirectorMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.4
Schedule of Income tax Expense (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Tax Disclosure [Abstract] |
|
|
|
|
|
|
Expected income tax at statutory rate |
|
|
|
|
$ (709,666)
|
$ (621,735)
|
State tax |
|
|
|
|
(101,347)
|
168
|
Permanent differences |
|
|
|
|
405,376
|
404,872
|
Other |
|
|
|
|
|
(71,992)
|
Change in valuation allowance |
|
|
|
|
406,437
|
289,487
|
Provision for income taxes |
|
$ 800
|
$ 800
|
$ 800
|
$ 800
|
$ 800
|
X |
- DefinitionAmount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.4
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
|
Dec. 31, 2022 |
Dec. 31, 2021 |
Income Tax Disclosure [Abstract] |
|
|
Net operating loss carry-forward |
$ 2,364,249
|
$ 1,957,812
|
Valuation allowance |
(2,364,249)
|
(1,957,812)
|
Net deferred tax asset |
|
|
X |
- DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwards |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2
+ Details
Name: |
us-gaap_DeferredTaxAssetsValuationAllowance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.4
X |
- DefinitionNet Operating Loss Carryforwards are Available to Offset Taxable Income.
+ References
+ Details
Name: |
TSOI_NetOperatingLossCarryforwardsAreAvailableToOffsetTaxableIncome |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNet Operating Loss Carryforwards Expiration Description.
+ References
+ Details
Name: |
TSOI_NetOperatingLossCarryforwardsExpirationDescription |
Namespace Prefix: |
TSOI_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8
+ Details
Name: |
us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.4
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2023 to Aug 2024